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Abstract 
Background: The green tea and pomegranate polyphenols epigallocatechin gallate 
(EGCG) and ellagic acid (EA) have previously demonstrated anti-atherosclerotic 
effects and inhibition of VEGFR-2 phosphorylation in cell models. Vascular 
endothelial growth factor (VEGF) injection into animal models induced 
atherosclerosis. This thesis aims to investigate whether polyphenols which potently 
inhibit VEGF-induced VEGFR-2 phosphorylation at physiological concentrations in 
vitro will be able to inhibit VEGF-induced atherosclerotic development in vivo. 
Methods: The inhibition of VEGF-induced VEGFR-2 phosphorylation in Human 
umbilical vein endothelial cells (HUVECs) by EGCG, punicalagin, EA and the 
urolithins was investigated. The effect of 1.8 g/kg EGCG and EA dietary 
supplementation on VEGF-induced atherosclerosis was investigated in the ApoE-/- 
mouse model.  
Results: EGCG, EA and punicalagin inhibited 50 % VEGF activity, quantified by 
VEGFR-2 phosphorylation in HUVECs, at 96, 310, and 49 nM. EA metabolism 
reduced the VEGF inhibitory activity. EGCG and EA significantly inhibited VEGFR-2 
phosphorylation at physiological concentrations, predominantly through 
interactions with the VEGF ligand. 3 weekly intraperitoneal injections of VEGF into 
mice did not induce atherosclerosis. EGCG and EA dietary supplementation did not 
affect plaque size but induced small increases in circulating LDL and total 
cholesterol compared to controls. EGCG and EA injection reduced plaque thickness 
but not overall size. It was shown that foetal calf serum reduced the polyphenol-
mediated inhibition of VEGF activity. 
Conclusions: The data in this thesis suggest that (1) multiple injections of VEGF does 
not induce atherosclerotic plaque growth in the ApoE-/- mouse model under the 
study conditions, (2) a mixture of EGCG and EA had no significant effect on the 
growth of atherosclerotic plaques when supplemented into the diet of ApoE-/- mice, 
and (3) serum proteins limit the ability of polyphenols to inhibit VEGFR-2 
phosphorylation. These results therefore suggest it is unlikely EGCG and EA reduce 
atherosclerosis by inhibiting the VEGF ligand in vivo.  
III  
 
Table of Contents 
Abstract ............................................................................................................................ II 
List of figures .................................................................................................................... X 
List of tables .................................................................................................................. XIII 
Abbreviations ................................................................................................................. XV 
Symbols ....................................................................................................................... XVIII 
List of publications ........................................................................................................ XIX 
Acknowledgements ...................................................................................................... XXII 
Chapter 1 ............................................................................................................. 1 
General Introduction ........................................................................................... 1 
1.1 Summary of thesis aims ............................................................................... 2 
1.2 Classification of polyphenols ....................................................................... 2 
1.3 Polyphenol dietary intake ............................................................................ 2 
1.4 Polyphenol metabolism ............................................................................. 12 
1.4.1  Green tea polyphenol metabolism ........................................................... 12 
1.4.2  Pomegranate polyphenol metabolism ...................................................... 14 
1.5 Bioavailability of polyphenols .................................................................... 17 
1.5.1  Bioavailability of green tea polyphenols ................................................... 17 
1.5.2  Bioavailability of pomegranate polyphenols ............................................ 18 
1.6 Pathology of atherosclerosis ..................................................................... 19 
1.7 Impact of dietary polyphenols on CVD ...................................................... 22 
1.7.1  Epidemiological and dietary intervention studies .................................... 22 
1.7.2  Polyphenol intervention trials in animals ................................................. 23 
1.8 The VEGF protein ....................................................................................... 30 
1.9 The different VEGFA isoforms ................................................................... 30 
1.10 The VEGF receptors ................................................................................... 31 
1.10.1  VEGF receptor 1 ........................................................................................ 32 
1.10.2  VEGF receptor 2 ........................................................................................ 32 
IV  
 
1.10.3  VEGF receptor 3 ........................................................................................ 33 
1.11 The stimulated VEGFR-2 signalling pathway ............................................. 34 
1.11.1 Tyrosine 951, 1054 and 1059 signalling ..................................................... 34 
1.11.2 Tyrosine 1175 signalling ............................................................................. 35 
1.11.3  Tyrosine 1214 signalling ............................................................................ 36 
1.12 Disease relevance of VEGF signalling......................................................... 40 
1.12.1  Diseases currently treated by anti-VEGF medication ............................... 40 
1.12.2  Side effects of anti-VEGF treatments ........................................................ 41 
1.12.3  Association of VEGF with cardiovascular disease ..................................... 41 
1.12.4  The role of VEGF in atherosclerosis ........................................................... 43 
1.13 VEGF signalling within the atherosclerotic plaque .................................... 44 
1.14 Effect of polyphenols on VEGF signalling .................................................. 46 
1.14.1  Polyphenol effects on VEGF gene and protein expression ....................... 46 
1.14.2  Polyphenol effects on VEGFR-2 phosphorylation ...................................... 47 
1.14.3  Polyphenol effects on downstream VEGF signalling partners .................. 48 
1.15 Effect of polyphenols on VEGF associated physiological responses ......... 49 
1.15.1  Polyphenol effects on VEGF associated cell signalling in vitro.................. 49 
1.15.2  Polyphenol effects on angiogenesis in vitro.............................................. 49 
1.15.3  Polyphenol effect on angiogenesis ex vivo ................................................ 50 
1.15.4  Polyphenol effects on angiogenesis in vivo .............................................. 51 
1.16 Objectives for the thesis ............................................................................ 52 
Chapter 2 ........................................................................................................... 53 
In vitro inhibition of VEGF stimulated VEGFR-2 phosphorylation by dietary 
polyphenols ....................................................................................................... 53 
2.1  Abstract ...................................................................................................... 54 
2.2  Introduction ............................................................................................... 55 
2.2.1 The VEGF protein ....................................................................................... 55 
2.2.2 The VEGF/VEGFR-2 signalling pathway ......................................................... 55 
V  
 
2.2.3 Bioavailability of green tea and pomegranate polyphenols.......................... 56 
2.2.4 Effect of polyphenols on VEGF signalling ...................................................... 59 
2.2.5 Objectives ................................................................................................... 60 
2.3 Material and methods .............................................................................................. 61 
2.3.1 Subculture of HUVECs ................................................................................... 61 
2.3.2 Culture of cells in 6 well plates for treatment ............................................... 61 
2.3.3. Determining the IC50 of a polyphenol treatment on VEGFR-2 
phosphorylation in HUVECs ....................................................................... 62 
2.3.4 Determining where the polyphenol acts to elicit any observed inhibitory 
effects. ....................................................................................................... 63 
2.3.5 Quantification of the absolute protein concentration of cell lysates ........... 64 
2.3.6 Determining the amount of VEGF receptor phosphorylation in HUVECs 
following cell treatments ........................................................................... 66 
2.3.7 Statistical analysis .......................................................................................... 66 
2.4 Results ...................................................................................................................... 67 
2.4.1 The green tea polyphenol epigallocatechin gallate effectively inhibits VEGFR-
2 signalling in HUVECs ............................................................................... 67 
2.4.2 The pomegranate polyphenol punicalagin effectively inhibits VEGFR-2 
signalling in HUVECs .................................................................................. 67 
2.4.3 The pomegranate polyphenol ellagic acid effectively inhibits VEGFR-2 
signalling in HUVECs .................................................................................. 70 
2.4.4 The inhibition capacity of the pomegranate derived microbial metabolites 
on p-VEGFR-2 ............................................................................................. 70 
2.4.5 Conjugation of metabolites causes loss of inhibitory capacity ..................... 77 
2.4.6 Green tea and pomegranate polyphenols elicit their anti-VEGFR-2 
phosphorylation activity by acting primarily on the VEGF ligand. ............ 77 
2.5 Discussion ................................................................................................................. 81 
2.5.1  Green tea polyphenol inhibition of VEGF signalling ................................. 82 
2.5.2  Pomegranate polyphenol inhibition of VEGF signalling ............................ 85 
VI  
 
2.5.3  Mechanism of action for polyphenol inhibition of VEGF signalling .......... 88 
2.6 Conclusion ................................................................................................................ 90 
Chapter 3 ........................................................................................................... 91 
Quantifying atherosclerosis in the VEGF injected ApoE-/- mouse following 
epigallocatechin gallate and ellagic acid intervention ......................................... 91 
3.1  Abstract ...................................................................................................... 92 
3.2  Introduction ............................................................................................... 93 
3.2.1 Atherosclerosis progression ....................................................................... 93 
3.2.2 Role of angiogenesis and VEGF in atherosclerosis progression .................... 94 
3.2.3 Polyphenol effects on VEGF and angiogenesis .......................................... 95 
3.2.4 The effect of green tea and pomegranate polyphenols on CVD ................... 97 
3.2.5 Objectives ...................................................................................................... 98 
3.3 Material and methods ............................................................................................ 100 
3.3.1 Animal diet production ................................................................................ 100 
3.3.2 Animal condition and experimental design ................................................. 100 
3.3.3 Monitoring of body weight and pellet consumption .................................. 101 
3.3.4 Intraperitoneal injection of VEGF, mouse serum albumin or VEGF/PP 
combination ............................................................................................. 102 
3.3.5 Quantification of VEGF activity of injection treatments ............................. 103 
3.3.6 Terminal anaesthesia and tissue collection ................................................. 103 
3.3.7 Quantification of atherosclerotic lesions in aortic arch .............................. 104 
3.3.8 Quantification of plasma lipid levels ........................................................... 108 
3.3.9 Quantification of polyphenols in plasma ..................................................... 108 
3.3.10 Quantification of polyphenols in animal diet ............................................ 113 
3.3.11 Statistical analysis ...................................................................................... 113 
3.4 Results .................................................................................................................... 115 
3.4.1 Body weights and daily diet intake of the animals ...................................... 115 
3.4.2 Quantifying EGCG and EA content of the manufactured pellets ................ 115 
VII  
 
3.4.3 Effect of injection solutions on VEGFR-2 phosphorylation of HUVECs ....... 120 
3.4.4 Quantification of atherosclerotic plaque in aortic sinus following 
intervention ............................................................................................. 120 
3.4.5 Quantification of plasma lipids .................................................................... 128 
3.4.6 Quantification of polyphenols in the plasma .............................................. 132 
3.5 Discussion ............................................................................................................... 134 
3.5.1 Was the VEGF active upon injection? ...................................................... 134 
3.5.2 Did cholesterol induction impact the result? .......................................... 135 
3.5.3 Was the plaque susceptible to angiogenesis induction? ......................... 136 
3.5.4 Impact of EGCG dietary intake on atherosclerosis .................................. 136 
3.5.5 Impact of EA dietary intake on atherosclerosis ....................................... 138 
3.5.6 Could plaque vulnerability be altered by VEGF injection?....................... 139 
3.5.7 Impact of treatments on plasma lipid levels ............................................ 140 
3.6  Conclusions ............................................................................................. 142 
Chapter 4 ......................................................................................................... 144 
Serum proteins abolish the strong inhibitory effect of EGCG and EA on HUVEC 
VEGF signalling ................................................................................................ 144 
4.1  Abstract .................................................................................................... 140 
4.2  Introduction ............................................................................................. 141 
4.2.1  Polyphenol inhibition of VEGF signalling ................................................ 141 
4.2.2  Polyphenol inhibition of VEGF induced angiogenesis ............................. 142 
4.2.3  Interaction between polyphenols and proteins...................................... 144 
4.2.4  Implications of polyphenol interactions with proteins ........................... 146 
4.2.5  Objectives ................................................................................................ 147 
4.3 Material and methods ............................................................................................ 148 
4.3.1 Determining effect of EGCG on ex vivo angiogenesis in the aortic ring 
assay ........................................................................................................ 148 
4.3.2 Subculture of HUVECs .............................................................................. 140 
VIII  
 
4.3.3 Culture of cells in 6 well plates for treatment ......................................... 140 
4.3.4 Determining the effect of serums proteins of polyphenol inhibition of 
VEGF signalling ......................................................................................... 140 
4.3.5 Determining the polyphenol inhibition of VEGF signalling following longer 
incubation of VEGF/PP complex with FCS ............................................... 142 
4.3.6  Cell lysis ................................................................................................... 142 
4.3.7  Quantification of the absolute protein concentration of cell lysates ..... 144 
4.3.8  Determining the amount of VEGF receptor phosphorylation in HUVECs 
following cell treatments ......................................................................... 144 
4.3.9 Statistical analysis .................................................................................... 144 
4.4 Results .................................................................................................................... 145 
4.4.1 EGCG was unable to inhibit VEGF-induced new vessel growth in aortic ring 
assay ........................................................................................................ 145 
4.4.2  Potent inhibition of VEGF signalling by epigallocatechin gallate does not 
occur in the presence of FCS ................................................................... 145 
4.4.3 Potent inhibition of VEGF signalling by ellagic acid does not occur in the 
presence of FCS ....................................................................................... 147 
4.4.4 Combinations of EGCG and EA treatment does not improve VEGF inhibition 
capacity of the polyphenols in presence of FCS ...................................... 147 
4.4.5 VEGF regains VEGFR-2 phosphorylating activity over time in the presence of 
FCS following complete inhibition by EGCG/EA ...................................... 151 
4.4.6 Sustained VEGF activity in the presence of FCS, EGCG and EA in vitro ....... 151 
4.5 Discussion ............................................................................................................... 154 
4.5.1 Polyphenol inhibition in the aortic ring assay .......................................... 154 
4.5.2 Effect of FCS on polyphenol inhibition of VEGF signalling after 5 minutes
 ................................................................................................................. 156 
4.5.3 Effect of FCS on polyphenol inhibition of VEGF signalling over longer 
duration ................................................................................................... 157 
4.6 Conclusions............................................................................................................. 161 
 
IX  
 
Chapter 5 ......................................................................................................... 162 
Discussion ....................................................................................................... 162 
5.1  Summary of main findings ...................................................................... 163 
5.2 Do higher circulating VEGF levels increase pathological angiogenesis? . 164 
5.3 Can polyphenols that inhibit VEGF signalling by interacting with VEGF in 
vitro inhibit pathological angiogenesis by binding to VEGF in vivo? ............................ 167 
5.4 What are the wider implications of the influence of serum proteins to the 
field of polyphenol research? ...................................................................................... 170 
5.5 Summary of recommendations for future work ..................................... 172 
5.5.1 Further interpretation of animal intervention in chapter 3 .................... 172 
5.5.2 Alternative animal intervention trials to investigate hypothesis ............ 174 
5.5.3 Further investigation into polyphenol-protein interactions .................... 175 
 
 
  
X  
 
List of figures 
Chapter 1 
Figure 1.1: The basic structures of the main polyphenol classes. ............................... 4 
Figure 1.2: The main structures of the flavonoid subclasses ....................................... 5 
Figure 1.3: The chemical structures of green tea catechins. ..................................... 13 
Figure 1.4: The conversion of punicalagin to ellagic acid .......................................... 15 
Figure 1.5: The route of microbial metabolite production from ellagic acid. ........... 16 
Figure 1.6: The morphological features of atherosclerotic disease .......................... 25 
Figure 1.7: VEGF stimulated VEGFR-2 signalling from the phosphorylated tyrosine 
951, 1054 and 1059 residues ..................................................................................... 37 
Figure 1.8: VEGF stimulated VEGFR-2 signalling from the phosphorylated tyrosine 
1175 residue ............................................................................................................... 38 
Figure 1.9: VEGF stimulated VEGFR-2 signalling from the phosphorylated tyrosine 
1214 residue ............................................................................................................... 39 
Chapter 2 
Figure 2.1: Structures and metabolic path production of the microbial metabolites 
of ellagic acid, the urolithins, and their glucuronides................................................ 58 
Figure 2.2: An overview of the work flow required to determine an IC50 value 
described in section 2.3.3 .......................................................................................... 63 
Figure 2.3: An overview of the work flow required to determine where the 
polyphenol elicits its inhibitory activity as described in section 2.3.4 ....................... 65 
Figure 2.4:.EGCG inhibition of VEGF induced VEGFR-2 phosphorylation .................. 68 
Figure 2.5: Punicalagin inhibition of VEGF induced VEGFR-2 phosphorylation......... 69 
Figure 2.6: Ellagic acid inhibition of VEGF induced VEGFR-2 phosphorylation ......... 72 
Figure 2.7: Urolithin D inhibition of VEGF induced VEGFR-2 phosphorylation ......... 73 
Figure 2.8: Urolithin C inhibition of VEGF induced VEGFR-2 phosphorylation .......... 74 
Figure 2.9: Urolithin A inhibition of VEGF induced VEGFR-2 phosphorylation ......... 75 
Figure 2.10: Urolithin B inhibition of VEGF induced VEGFR-2 phosphorylation ........ 76 
Figure 2.11: VEGF induced VEGFR-2 phosphorylation after pre-mixing with urolithin 
A glucuronide ............................................................................................................. 78 
XI  
 
Figure 2.12: VEGF induced VEGFR-2 phosphorylation after pre-mixing with urolithin 
B glucuronide ............................................................................................................. 79 
Figure 2.13: The VEGF Induced VEGFR-2 phosphorylation following VEGF and 
polyphenol combined treatment or independent treatment of HUVECs ................. 80 
Figure 2.14: Diagram of the possible locations where the polyphenol are eliciting 
the VEGF inhibitory effects ........................................................................................ 88 
Chapter 3 
Figure 3.1: Representative cryosections stained with Oil Red O and haemotoxylin 
across the aortic sinus from one mouse. ................................................................. 105 
Figure 3.2: Example of the aortic sinus with labelled morphological features ....... 106 
Figure 3.3: Diagrammatic representation of plaque size measurements. .............. 107 
Figure 3.4: Mouse body weight progression during study depending on injection 
type (A) or diet type (B)............................................................................................ 116 
Figure 3.5: The average daily pellet consumption per mouse of the two experimental 
diets. ......................................................................................................................... 117 
Figure 3.6: Ellagic acid content in the manufactured experimental diets ............... 118 
Figure 3.7: EGCG content in the manufactured experimental diets ....................... 119 
Figure 3.8: The VEGFR-2 phosphorylation in HUVECs stimulated with the VEGF, MSA 
and VEGF/PP injections diluted to 25 ng/ml. ........................................................... 121 
Figure 3.9: The atherosclerotic plaque area as a percentage of the total area of the 
lumen at baseline, week 3 and week 6 post first injections. ................................... 122 
Figure 3.10: The atherosclerotic plaque area in µm2 at baseline, week 3 and week 6 
post first injections. .................................................................................................. 123 
Figure 3.11: The atherosclerotic plaque circumferential expansion as a percentage 
of the total lumen circumference at baseline, week 3 and week 6 post first 
injections. ................................................................................................................. 124 
Figure 3.12: The atherosclerotic plaque circumferential expansion in µm at baseline, 
week 3 and week 6 post first injections. .................................................................. 125 
Figure 3.13: The atherosclerotic plaque maximal thickness in µm at baseline, week 3 
and week 6 post first injections. .............................................................................. 126 
XII  
 
Figure 3.14: The atherosclerotic plaque area, plaque circumference, and maximal 
plaque thickness for all mice at baseline, week 3 and week 6 post first injection. . 127 
Figure 3.15: The plasma total cholesterol levels in mmol/l at baseline, week 3 and 
week 6 post first injections. ..................................................................................... 129 
Figure 3.16: The plasma LDL cholesterol levels in mmol/l at baseline, week 3 and 
week 6 post first injections. ..................................................................................... 130 
Figure 3.17: The plasma triglyceride levels in mmol/l at baseline, week 3 and week 6 
post first injections. .................................................................................................. 131 
Chapter 4 
Figure 4.1: A visual representation of the experimental procedure described in 
section 4.3.1. ............................................................................................................ 140 
Figure 4.2: A visual representation of the experimental procedure described in 
section 4.3.4. ............................................................................................................ 141 
Figure 4.3: A visual representation of the experimental procedure described in 
section 4.3.5. ............................................................................................................ 143 
Figure 4.4: Effect of EGCG and epicatechin (EC), on VEGF induced new microvessel 
growth in the aortic ring assay ................................................................................. 146 
Figure 4.5: Effect of FCS on EGCG inhibition of VEGF induced VEGFR-2 
phosphorylation ....................................................................................................... 148 
Figure 4.6: Effect of FCS on EA inhibition of VEGF induced VEGFR-2 phosphorylation
 .................................................................................................................................. 149 
Figure 4.7: Effect of FCS on EA and EGCG combined inhibition of VEGF induced 
VEGFR-2 phosphorylation ......................................................................................... 150 
Figure 4.8: Effect of FCS on EA and EGCG combined inhibition of VEGF induced 
VEGFR-2 phosphorylation over time ........................................................................ 152 
Figure 4.9: The loss of VEGFR-2 phosphorylation activity of VEGF over time in cell 
culture media ........................................................................................................... 153 
Chapter 5 
Figure 5.1: Diagrammatic representation of the mechanism of action for polyphenol 
inhibition of VEGF signalling reported in this thesis ................................................ 155 
  
XIII  
 
List of tables 
Chapter 1 
Table 1.1: Estimated daily polyphenol consumption (mg/day) and dietary sources of 
different countries or regions ...................................................................................... 6 
Table 1.2: Summary of the associations between polyphenols in the diet and 
reduced cardiovascular risk or events ....................................................................... 26 
Table 1.3: Table summarising the current literature on the anti-atherosclerotic 
effect of polyphenol rich products and extracts in the ApoE-/- mouse model ......... 28 
Table 1.4: Table summarising the current literature on the anti-atherosclerotic 
effects of individual polyphenol compounds in the ApoE-/- mouse model .............. 29 
Table 1.5: A summary of the different VEGF isoforms, the genetic differences 
between those isoforms and their physiological properties. .................................... 33 
Chapter 2 
Table 2.1: Summary of IC50 values achieved for inhibition of VEGF-induced VEGFR-2 
phosphorylation by polyphenols ............................................................................... 84 
Chapter 3 
Table 3.1: Outline of diet type, injection type, and number of animals per time point 
in each treatment if the animal intervention trial ................................................... 101 
Table 3.2: List of potential compounds searched for in mice plasma samples to be 
found in plasma following epigallocatechin gallate consumption, their molecular 
formula and the molecular mass (Mr)...................................................................... 109 
Table 3.3: List of potential compounds searched for in mice plasma samples to be 
found in plasma following ellagic acid consumption, their molecular formula and 
the molecular mass (Mr). ......................................................................................... 111 
Table 3.4: A summary of the transformation used to conduct statistical analysis on 
the data for total cholesterol, LDL cholesterol, triglycerides and calculated HDL 
cholesterol ................................................................................................................ 114 
Table 3.5 Table demonstrating all EA metabolites found at quantifiable 
concentrations in the plasma of the mice fed an EGCG and EA supplemented diet 
and their concentration in nmol/L as quantified by HPLC/QTOF-MS. ..................... 133 
XIV  
 
Table 3.6: Table demonstrating all EA metabolites found in the plasma of the mice 
fed an EGCG and EA supplemented diet and their relative areas in comparison to a 
chrysin standard as measured by HPLC/QTOF-MS. ................................................. 133 
Chapter 4 
Table 4.1: Summary of polyphenol interactions with plasma proteins ................... 145 
 
  
XV  
 
Abbreviations 
AKT   Protein kinase B 
ApoE-/-  Apolipoprotein E double knockout 
Axl   Tyrosine-protein kinase receptor UFO 
BAECs   Bovine aortic endothelial cells 
BCA   Bicinchoninic acid 
B-Raf   B-Raf proto-oncogene 
BSA   Bovine serum albumin 
CAM   Chorioallantoic membrane 
Ca2+   Calcium 
C-ABL   Abelson murine leukemia viral oncogene homolog 1 
Cmax   Maximal plasma concentration  
COMT   Catechol-o-methyltransferase 
CVD   Cardiovascular disease 
DAD   Diode-array detection 
DAG   Diacylglycerol 
DMEM   Dulbecco’s modified Eagle’s media 
EA   Ellagic acid 
EC   Epicatechin 
ECG   Epicatechin gallate 
ECM   Extracellular matrix 
EGC   Epigallocatechin 
EGCG   Epigallocatechin gallate 
eNOS   Endothelial nitric oxide synthase 
FAK   Focal adhesion kinase 
FCS   Foetal calf serum 
Fyn   Proto-oncogene tyrosine-protein kinase Fyn 
HDL   High density lipoprotein 
HIF1α   Hypoxia inducible factor 1 alpha 
HPLC   High performance liquid chromatography 
HRP   Horseradish peroxidase  
XVI  
 
HSA   Human serum albumin 
HSP90   Heat shock protein 90 
HUVECs  Human umbilical vein endothelial cells 
Grb2   Growth factor receptor-bound protein 2 
IDL   Intermediate density lipoprotein 
IP3   Inostinol-3-phosphate 
I.P.   Intraperitoneal 
IPR   IP3 receptor 
IQGAP1  Ras GTPase-activating-like protein IQGAP1 
I.V.   Intravenous 
LCMS   Liquid-chromatography mass spectrometry 
LDL   Low density lipoprotein 
LDLR-/-  Low density lipoprotein receptor double knockout 
MAPK   Mitogen activated protein kinase 
MMP   Matrix metalloproteinases 
MSA   Mouse serum albumin 
NaPi   Sodium phosphate buffer 
Nck-1   NCK adaptor protein 1 
NO   Nitric oxide 
NRP   Neuropilin co-receptor 
PAF   Platelet-activating factor 
PAK-2   p21-activated kinase 2 
PBS   Phosphate buffered saline 
PDGF   Platelet derived growth factor 
PDIA3   Protein disulfide isomerase isoformA3 
PI3K   Phosphoinositide 3-kinase  
PIP2   Phosphatidylinositol 4,5-bisphosphate 
PKC   Protein kinase C 
Plc-γ   Phospholipase C gamma 
PMSF   Phenylmethanesulfonyl fluoride 
Puni.   Punicalagin 
Raf   Rapidly accelerated fibrosarcoma 
XVII  
 
ROCK   RhoA kinase 
ROS   Reactive oxygen species 
SAPK2   Serine/threonine-protein kinase SAPK2 
Sck   Shc-related adaptor protein 
Shb   SH2 domain-containing adapter protein B 
Src   Proto-oncogene tyrosine-protein kinase Src 
SULT   Sulfotransferases 
TMB   3, 3’, 5, 5’-Tetramethylbenzidine 
TSAd   T-cell specific adapter protein 
UGT   Uridine 5'-diphospho-glucuronosyltransferase 
Uro   Urolithin 
VEGF   Vascular endothelial growth factor 
VEGFR   Vascular endothelial growth factor receptor 
vLDL   Very low density lipoprotein 
WHO   World Health Organisation 
  
XVIII  
 
Symbols 
CO2   Carbon dioxide 
cm2   Centimetre squared 
g   Gram 
h   Hour 
kDa   Kilodalton  
kg   kilogram 
mg   Milligram 
ml   millilitre 
mM   Millimolar 
ng   Nanogram 
nM   nanomolar 
nmol/L   Nanomole per litre 
v:v   volume per volume 
Y   Tyrosine 
µg   Microgram 
µm   Micrometre 
µm2   Micrometre squared 
µM   Micromolar 
µl   Microlitre 
°C   Degrees Celsius 
%   Percent 
  
XIX  
 
List of publications  
Research Journals 
R.L. Edwards, P. Needs, S. Robinson, F.A. Tomás Barberán, P.A. Kroon, Can dietary 
polyphenols prevent cardiovascular disease by inhibiting vegf-dependent 
angiogenesis in atherosclerosis?, Atherosclerosis, Volume 235, Issue 2, August 
2014, Page e95, ISSN 0021-9150 
Edwards, R. L. and Kroon, P. A. (2014) Inhibition of VEGF Signaling by Polyphenols in 
Relation to Atherosclerosis and Cardiovascular Disease, in Recent Advances in 
Polyphenol Research, Volume 4 (eds A. Romani, V. Lattanzio and S. Quideau), John 
Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118329634.ch9 
In preparation: Edwards RL, Vauzour D, Kroon PA. Three consecutive weekly 
injections of VEGFA does not increase the size of aortic sinus atherosclerotic 
plaques in ApoE-/- mice on an atherogenic diet. Target journal: Atherosclerosis. 
In preparation: Edwards RL, Vauzour D, Garcia-Villalba R, Tomas-Barberan FA, 
Kroon PA. 6 weeks dietary supplementation with epigallocatechin gallate and 
ellagic acid in ApoE-/- mice fed an atherogenic diet does not reduce atherosclerotic 
plaque size or circulating cholesterol concentrations. Target journal: The Journal of 
Nutrition.  
In preparation: Edwards RL, Needs PW, Tomas-Barberan FA, Kroon PA. Comparison 
of the inhibition of VEGF-induced VEGFR2 activation by punicalagin and ellagic acid 
with their urolithin microbial metabolites and human phase-2 conjugates. Target 
journal: Molecular Nutrition and Food Research. 
Posters 
Rebecca L. Edwards, Paul Needs, Stephen Robinson, Francisco A. Tomás Barberán, 
Paul A. Kroon. Can dietary polyphenols prevent cardiovascular disease by inhibiting 
VEGF-dependent angiogenesis in atherosclerosis? IFR Student Science Showcase, 
June 2014. 
XX  
 
Rebecca L. Edwards, Paul Needs, Stephen Robinson, Francisco A. Tomás Barberán, 
Paul A. Kroon. Can dietary polyphenols prevent cardiovascular disease by inhibiting 
VEGF-dependent angiogenesis in atherosclerosis? European Atherosclerosis Society 
82nd Annual Congress. May 2014 
Rebecca L. Edwards, Paul A. Kroon. Can dietary polyphenols prevent cardiovascular 
disease by inhibiting VEGF-dependent angiogenesis in atherosclerosis? John Innes 
Centre Annual Science Meeting. October 2013 
Can Dietary Polyphenols Reduce Atherosclerosis through Inhibition of VEGF Induced 
Angiogenesis? Rebecca Edwards, Ben Kirkup, Paul Kroon. IFR student Science 
Showcase. May 2013 
Oral presentations 
Edwards RL, Kroon PA. Pomegranate polyphenols and their metabolites interact 
with VEGF to inhibit VEGFR-2 phosphorylation. Food Bioactives and Health 
Conference. September 2016 
Edwards RL, Kroon PA. Can polyphenols target angiogenesis in atherosclerosis? IFR 
Coffee Break Science. November 2015  
Edwards RL, Kroon PA. Progress update on BACCHUS project WP5, Task 5.3.2. 4th 
European Union FP7 BACCHUS project meeting. November 2015 
Edwards RL, Kroon PA. Potent inhibition of VEGF activity by pomegranate 
polyphenols: A novel mechanism for the atheroprotective effects observed in 
epidemiology. IFR student Science Showcase. September 2015 
Edwards RL, Kroon PA. Potent inhibition of VEGF activity by polyphenols: A novel 
mechanisms for the atheroprotective effects of polyphenols. International 
Conference on Polyphenol and Health. October 2015 
Edwards RL, Kroon PA. Can dietary polyphenols prevent cardiovascular disease by 
inhibiting VEGF-dependent angiogenesis in atherosclerosis? IFR Food and Health ISP 
Annual Meeting. March 2014 
XXI  
 
Edwards RL, Kroon PA. Progress update on BACCHUS project WP5, Task 5.3.2. 3rd 
European Union FP7 BACCHUS project meeting. February 2014 
Edwards RL, Kroon PA. Progress update on BACCHUS project WP5, Task 5.3.2. 2nd 
European Union FP7 BACCHUS project meeting. June 2013 
Other  
Edwards RL, Kroon PA. BACCHUS Month 48 project interim report update on 
progress towards deliverable 5.5. September 2016 
Edwards RL, Kroon PA. BACCHUS Month 36 project interim report update on 
progress towards deliverable 5.5. September 2015 
Edwards RL. Awarded best presentation prize at the IFR student Science Showcase 
for the talk titled: Potent inhibition of VEGF activity by pomegranate polyphenols: A 
novel mechanism for the atheroprotective effects observed in epidemiology. 
September 2015 
Edwards RL, Kroon PA. BACCHUS Month 18 project interim report update on 
progress towards deliverable 5.5. March 2014 
 
 
  
XXII  
 
Acknowledgements 
I would like to express my sincere gratitude to Dr Paul Kroon for his support and 
guidance throughout my PhD studentship and for trusting me to make this project a 
success. I would also like to thank the European Union and The Institute of Food 
Research for providing the funding. The opportunities for travel and networking 
within the BACCHUS project were above expectation and I feel privileged to have 
had the opportunity to meet and hold interesting discussion with the project 
partners. To my supervisory team, Nathalie Juge and Nigel Belshaw, thank you for 
your honest thoughts and excellent contributions to the project as it progressed. I 
also wish to thank the Kroon research group who have been there to answer my 
questions, both basic and complex. In particular I would like to thank Dr Paul Needs 
for his patience, scientific discussions, as well as the non-work related 
conversations which kept a smile on my face. I would also like to thank Professor 
Jeremy Spencer and Professor Keith Waldron for examining this thesis. 
I owe a big thank you to Dr David Vauzour. Not only were you a fantastic 
collaborator but a good friend throughout my PhD. Without your wisdom and 
advice (and the long days in the animal facility) the animal intervention trial would 
have been a much harder challenge. I also owe thanks to the staff within the animal 
facility, as well as Noemi Tejera-Hernandez, Sebastian Achterfeldt, and Mark 
Winterbone for your support at the points in the animal intervention trial where 
one pair of hands was just simply not enough.  
A PhD studentship is an excellent catalyst for friendship. To Lizzie Thursby, Dan 
Lock, Sarah Clements and Alistair Walsham who have shared in the ups and downs 
that inevitably come hand in hand with a PhD, you guys are blooming lovely and I 
couldn’t have asked for a better group of people to experience it all with. I feel 
lucky to also call a number of people in the wider IFR community my friends and I 
thank each and every one of them for our times together. Your support has meant 
the world to me and I will remember our morning coffees, lunchtime chats, breaks, 
nights out, and nights in with fondness.  
XXIII  
 
To my family, who have supported and continue to support my decisions. Thank 
you for understanding the short visits, the missed family events, the lack of contact 
when I’ve been busy, and the fact I couldn’t be there to support you at your difficult 
times. I promise to make this up to you in the years to come. To my brother, Alex, 
you have a way of reminding me to not take myself too seriously and it’s made me 
a better person because of it. To my wonderful mum and dad: this thesis is here 
because of your belief in me. My whole life you have encouraged me to strive for 
improvement, always work hard, and aim to go above and beyond what is 
necessary. I couldn’t have asked for better parents and thank you from the bottom 
of my heart for your support.  
Finally, to Sebastian, of all the things I could have gained from my time in Norwich 
meeting you was the most unexpected and wonderful. Thank you for always being 
there for me and for being so honest, kind, and caring. I look forward to taking my 
next steps into a new and exciting career with you by my side.  
 
 
 
  
 
 
 
 
Chapter 1 
 
General Introduction 
  
 
Chapter 1 
2  
 
1.1 Summary of thesis aims 
The data presented in this thesis surrounds the central investigation into the effects 
of dietary polyphenols on vascular endothelial growth factor (VEGF) induced VEGF 
receptor 2 (VEGFR-2) phosphorylation, and the impact this could have on 
pathological angiogenesis. The specific aims for the project were 1) to investigate if 
and how dietary polyphenols could inhibit VEGF induced VEGFR-2 phosphorylation 
in HUVECs, 2) to determine whether the polyphenols which elicit potent inhibition 
of VEGF-induced VEGFR-2 phosphorylation could, in turn, inhibit VEGF induced 
atherosclerosis. The purpose of this general introduction is to provide an overall 
understanding of the background to the project and will provide detailed 
information about polyphenols, VEGF and its associated signalling and the 
relevance of both of these to cardiovascular atherosclerotic disease.  
1.2 Classification of polyphenols 
Polyphenols are a group of phytochemicals produced in a wide variety of plants, 
including fruits and vegetables. There is a large variety of polyphenols with ranging 
complexity each containing varying numbers of 6 carbon phenol ring structures and 
side groups (Cheynier, 2005). In general polyphenols can be classified as flavonoids, 
phenolic acids, lignans and stilbenes, although many polyphenols do not fall into 
any of these classifications (D'Archivio et al., 2007, Manach et al., 2004). An 
overview of the basic structure of the polyphenol classes can be seen in Figure 1.1. 
The predominant polyphenols consumed in the diet are flavonoids, although in high 
fibre, coffee or citrus diets this balance may shift (Clifford, 1999). Flavonoids can be 
further classified, for example into flavanols, flavonols, flavones, flavanones, 
isoflavones, and anthocyanins. A summary of the main flavonoid sub-classes can be 
seen in Figure 1.2. 
1.3 Polyphenol dietary intake 
A number of studies have estimated the average intake of dietary polyphenols to 
determine the most widely consumed classes of polyphenols. Polyphenol intake 
varies depending on the country where the data is collected. This is due to the 
varying cultural preferences, for example within Japan isoflavone consumption is 
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higher than in other countries due to the frequent consumption of soy products 
(Arai et al., 2000) while consumption of fruits may be higher in the diet of people 
from Mediterranean Europe versus non-Mediterranean Europe (Zamora-Ros et al., 
2016, Murphy et al., 2014). Variation in total polyphenol consumption data also 
varies greatly due to limited data reported in some studies. For example, two 
reports from Finland focussed on flavonols/flavones (Hirvonen et al., 2000) and 
flavonoids (Knekt et al., 2002) intake found the daily dose of these compounds was 
8 and 24.2 mg/day respectively. However, another study reported on the intake of 
a much larger range of polyphenols and estimated a daily total polyphenol dose of 
863 mg/day (Ovaskainen et al., 2008). 75 % of the total polyphenol intake was 
phenolic acids which were not investigated in the 2 earlier reports. It has been 
identified that many global populations eat under 5 portions of fruit or vegetables 
per day which correlated with lower polyphenol consumption (Murphy et al., 2014), 
suggesting that daily polyphenol intake could increase with adherence to dietary 
recommendations. Globally, non-alcoholic beverages and specifically tea and coffee 
provide a large proportion of the daily polyphenol intake. In many countries ranging 
from Brazil (Miranda et al., 2016) to Finland (Ovaskainen et al., 2008) the phenolic 
acids, predominantly hydroxycinnamic acids, are the largest contributor to daily 
polyphenol intake. Where reported, the prevalent hydoxycinnamic acid in the diet 
was 5-caffeoylquinic acid (Miranda et al., 2016, Grosso et al., 2014) or its aglycone 
caffeic acid (Ovaskainen et al., 2008) with coffee being the main food source. In 
comparison to other European countries the UK has a higher intake of polyphenols 
from consumption of tea rather than coffee (Zamora-Ros et al., 2016), perhaps 
explaining the observation that flavanols are the predominant polyphenol in the UK 
diet (Yahya et al., 2016). When tea and coffee were taken out of consideration the 
hydroxycinnamic acids were once again the predominant class of polyphenol in the 
UK diet with potato, pears, tomato, carrot, “ready-to-cook” sauces, and soups 
identified as the sources (Yahya et al., 2016). For a summary of the data please see 
Table 1.1. 
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Hydroxycinnamic acid backbone
Flavonoid backbone
 Stlibene backbone Lignan backbone
Hydroxybenzoic acid backbone
 
Figure 1.1: The basic structures of the main polyphenol classes.   
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Figure 1.2: The main structures of the flavonoid subclasses  
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Table 1.1: Estimated daily polyphenol consumption (mg/day) and dietary sources of different countries or regions  
Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
Australia 454 mg/day Anthocyanidins (2.6 mg/day) 
Flavanols (422.5 mg/day) 
Flavanones (6.94 mg/day) 
Flavones (0.53 mg/day) 
Flavonols (20.69 mg/day) 
Malvidin (1.56 mg/day) 
Thearubigins (213.04 mg/day) 
Hesperetin (4.75 mg/day) 
Apigenin (0.45 mg/day) 
Quercetin (12.53 mg/day) 
Tea, citrus fruits, 
grapes 
(Johannot 
and 
Somerset, 
2006) 
Brazil 349 mg/day Hydroxyinnamic acids (281.2 
mg/day) 
Hydroxybenzoic acids (3.4 mg/day) 
Flavanones (16.1 mg/day) 
Flavonols (14.6 mg/day) 
Flavanols (11.4 mg/day) 
Anthocyanins (6.8 mg/day) 
Flavones (3.6 mg/day) 
Isoflavonoids (1.5 mg/day) 
Lignans (2.3 mg/day) 
Other (8.1 mg/day) 
5-Caffeoylquinic acid (98.7 mg/day) 
Not specified 
Not specified 
Not specified 
Not specified 
Not specified 
Not specified 
Not specified 
Not specified 
4-Ethylguaiacol (0.8 mg/day) 
Coffee, citrus fruits (Miranda et 
al., 2016) 
Europe 
 
 
429 mg/day Flavanols (245 mg/day) 
Anthocyanidins (19 mg/day) 
Flavonols (23 md/day) 
Thearubigins (156 mg/day) 
Cyanidin (9 mg/day) 
Quercetin (14 mg/day) 
Non-alcoholic 
beverages, fruit 
(Vogiatzoglou 
et al., 2015) 
 
 7  
 
Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
 
Europe 
cont. 
Flavanones (14 mg/day) 
Flavones (4 mg/day) 
Proanthocyanidins (124 mg/day) 
Hesperetin (9 mg/day) 
Apigenin (3 mg/day) 
d.p. >10 (42 mg/day) 
 
 
(Vogiatzoglou 
et al., 2015) 
Finland 8 mg/day Flavonols/flavones (8 mg/day) Not specified Not specified (Hirvonen et 
al., 2000) 
 24.2 mg/day Flavonoids (24.2 mg/day) Hesperetin (15.1 mg/day) Citrus fruits, apples (Knekt et al., 
2002) 
 863 mg/day Phenolic acids (641 mg/day) 
Anthocyanidins (47 mg/day) 
Flavanols (5.4 mg/day) 
Flavanones (27 mg/day) 
Isoflavanones (0.9 mg/day) 
Proanthocyanidins (128 mg/day) 
Ellagitannins (12 mg/day) 
Caffeic acid (417 mg/day) 
Cyanidin (23 mg/day) 
Not specified 
Not specified 
Not specified 
d.p. >10 (21 mg/day) 
Not specified 
Coffee/tea, cereals, 
fruits 
(Ovaskainen 
et al., 2008) 
Greece 161 mg/day Flavones (7 mg/day) 
Flavonols (28 mg/day) 
Flavanones (27 mg/day) 
Flavan-3-ols (14 mg/day) 
Anthocyanidins (10 mg/day) 
Isoflavonoids (<0.1 mg/day) 
Apigenin (5 mg/day) 
Quercetin (18 mg/day) 
Hesperetin (19 mg/day) 
Catechin/epicatechin (6 mg/day) 
Cyanidin/delphinidin (4 mg/day) 
Not specified 
Grapes, wine and 
peaches 
(Dilis and 
Trichopoulou, 
2010) 
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Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
Proanthocyanidins (75 mg/day) Not specified 
Italy 
 
Italy cont. 
251 mg/day Proanthocyanidins (96.1 mg/day) 
Flavanols (50.4 mg/day) 
Anthocyanidins (32.9 mg/day) 
Flavanones (24.2 mg/day)  
Flavonols (14.4 mg/day) 
Flavones (1.2 mg/day) 
Isoflavonoids (0.7 mg/day) 
Not specified Fruit, red wine (Ponzo et al., 
2015) 
 
(Ponzo et al., 
2015) 
 348.8 Flavonols (17 mg/day) 
Flavones (0.7 mg/day) 
Flavanones (32.4 mg/day) 
Flavanols (51.2 mg/day) 
Anthocyanidins (144 mg/day) 
Isoflavonoids (23.5 mg/day) 
Lignans (80 mg/day) 
Not specified Seasonal fruits, 
citrus fruits and 
leafy vegetables 
(Pounis et al., 
2016) 
Japan 63.9 mg/day Isoflavonoids (47.2 mg/day) 
Flavonoids (16.7 mg/day) 
Genistein (30.5 mg/day)  
Quercetin (9.3 mg/day) 
Tofu, natto, miso, 
onions 
(Arai et al., 
2000) 
 1492 mg/day Total polyphenols Not specified Coffee, green tea (Taguchi et 
al., 2015) 
Poland 
 
1740.7 mg/day Flavanols (637.3 mg/day) 
Flavonols (106.1 mg/day) 
Gallocatechin (72.6 mg/day) 
Not specified 
Tea, coffee, 
chocolate 
(Grosso et al., 
2014) 
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Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
 
 
 
Poland cont. 
Flavanones (103.8 mg/day) 
Flavones (15.5 mg/day) 
Anthocyanins (29.7 mg/day) 
Isoflavonoids (1.6 mg/day) 
Hydroxybenzoic acids (94.6 mg/day) 
Hydroxycinnamic acids (705.5 
mg/day) 
Lignans (0.6 mg/day) 
Stilbenes (0.2 mg/day) 
Other (41.5 mg/day) 
Not specified 
Not specified  
Hesperidin (28.1 mg/day) 
Not specified 
5-O-galloylquinic acid (60.8 mg/day) 
5-caffeoylquinic acid (224.6 mg/day) 
Not specified 
Not specified 
Not specified 
 
 
 
 
(Grosso et al., 
2014) 
The 
Netherlands 
25.9 mg/day Flavonoid (25.9 mg/day) Quercetin (16.3 mg/day) Tea, onions, apples (Hertog et al., 
1993) 
 50 mg/day Flavonoids (50 mg/day) Epicatechin gallate (16.5 mg/day) Tea, chocolate, 
apples/pears 
(Arts et al., 
2001a) 
 < 1 mg/day Isoflavonoids (0.88 mg/day) Daidzein (0.15 mg/day) Peas/beans, cereal, 
bread 
(Boker et al., 
2002) 
Spain 820 mg/day Phenolic acids (302.7 mg/day) 
Flavanones (132 mg/day) 
Proanthocyanidins (117 mg/day) 
Flavonols (80.4 mg/day) 
Flavones (41.6 mg/day) 
Not specified 
 
 
 
 
Coffee, oranges, red 
wine, apples 
(Tresserra-
Rimbau et al., 
2012) 
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Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
Anthocyanins (38.5 mg/day) 
Flavanols (27.0 mg/day) 
Other (79.7 mg/day) 
 
 
UK 
UK cont. 
1292 mg/day 
 
Flavanols (588.9 mg/day) 
Flavonols (60.7 mg/day) 
Flavanones (24.3 mg/day) 
Anthocyanins (19.9 mg/day) 
Flavones (3.1 mg/day) 
Isoflavonoids (3.2 mg/day) 
Phenolic acids (545 mg/day) 
Other (48.1 mg/day) 
Not specified 
 
Tea, coffee, onion, 
potato, tomato 
(Yahya et al., 
2016) 
 808 mg/day Flavanols (391.5 mg/day) 
Flavonols (55.2 mg/day) 
Flavanones (16.8 mg/day) 
Anthocyanins (18.6 mg/day) 
Flavones (2.4 mg/day) 
Isoflavonoids (1.2 mg/day) 
Phenolic acids (282 mg/day) 
Other (40.5 mg/day) 
Not specified 
 
Tea, coffee, onion, 
potato, tomato 
(Yahya et al., 
2016) 
USA 189.7 mg/day Flavanols (158.4 mg/day) Not specified Tea (Chun et al., 
2007) 
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Country Daily polyphenol 
intake  
Polyphenols analysed  Main polyphenol per class Key food sources Ref.  
 
 
 
 
Flavanones (14.4 mg/day) 
Flavonols (12.9  mg/day) 
Anthocyanidins (3 mg/day) 
Flavones (1.5 mg/day) 
 
 
 
(Chun et al., 
2007) 
USA cont. 207 mg/day Flavonoids (207 mg/day) Not specified Tea (Chun et al., 
2010) 
 < 1 mg/day Isoflavonoids (0.15 mg/day) 
Lignans (0.58 mg/day) 
Genistein (0.07 mg/day) 
Secoisolariciresinol (0.56 mg/day) 
Fruit, grains, berries (de Kleijn et 
al., 2001) 
 57.7 mg/day Proanthocyanidin  d.p. >10 (21 mg/day) Apples, chocolate 
and grapes 
(Gu et al., 
2004) 
 95 mg/day Proanthocyanidin d.p. >10 (28.5 mg/day)  Tea, legumes, and 
wines 
(Wang et al., 
2011) 
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1.4 Polyphenol metabolism  
Polyphenol metabolism can occur through alterations, for example hydrolysis and 
oxidation or conjugation of a side group to the molecule, for example a glucuronide 
or sulfate group. Polyphenol metabolism primarily occurs in the small intestine, 
although further conjugation occurs within the liver (Liu and Hu, 2002, Donovan et 
al., 2001, Crespy et al., 2001, Spencer et al., 1999) and it is thought the majority of 
polyphenols are likely to first undergo microbial alterations before being 
conjugated by the liver (Rechner et al., 2002). Hydrolysis of flavonoid glycosides 
occurs in the upper intestine (Liu and Hu, 2002) with the intestinal epithelial 
hydrolysing enzymes playing a key role (Németh et al., 2003).  
1.4.1  Green tea polyphenol metabolism 
The green tea catechins are a group of flavan-3-ols found in high quantities within 
green tea. The majority of these green tea catechins are gallated while the 
predominant polyphenol in a wide range of green tea cultivars is epigallocatechin 
gallate (EGCG) (Lee et al., 2014, Kerio et al., 2013). The structures of the green tea 
catechins can be seen in Figure 1.3. Epicatechin (EC) has been shown to undergo 
conjugation to a sulfate group via the actions of sulfotransferases SULT1A1 and 
SULT1A3 (Vaidyanathan and Walle, 2002). Liver isolated catechol o-
methyltransferase (COMT) was found to methylate both EGCG and epigallocatechin 
(EGC) although rat derived COMT was more efficient at this action (Lu et al., 2003). 
Rat, but not human, liver fraction efficiently glucuronidated epicatechin 
(Vaidyanathan and Walle, 2002) although it has been suggested that in rats the 
majority of glucuronidation of epicatechin occurs within the intestinal mucosa 
(Piskula and Terao, 1998). Similarly, in mice the majority of EGCG was identified as a 
glucuronide conjugate following pure compound ingestion (Lambert et al., 2003). In 
humans EC appears to be predominantly in the glucuronide conjugated form, 
although sulfates and methyl sulfates have been observed in plasma following 
consumption of high EC containing foods (Actis-Goretta et al., 2012). This being 
said, two isoforms of uridine 5'-diphospho-glucuronosyltransferase (UGT) found in 
humans were unable to glucuronidate EC in vitro (Vaidyanathan and Walle, 2002). 
However, it is important to note that while EC is commonly found in the plasma in a 
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conjugated form, epicatechin gallate (ECG) and epigallocatechin gallate (EGCG) 
have been found unconjugated in plasma (Stalmach et al., 2009, Chow et al., 2001, 
Ullmann et al., 2003). 
It has also been demonstrated that EGCG can be hydrolysed by common 
gastrointestinal bacteria, e.g. Enterobacter aerogenes, to form EGC and gallic acid 
(Takagaki and Nanjo, 2010). Both in vivo feeding of EGCG in rats and in vitro 
incubation of rat cecal bacteria with EGC established the predominant terminal 
metabolite as 5-(3,5-dihydroxyphenyl)-4-hydroxyvaleric acid, although reasonable 
amounts of 5-(3,5-dihydroxyphenyl)-γ-valerolactone was also detected (Takagaki 
and Nanjo, 2010). Cleavage of EGCG to EGC and gallic acid, as well as the conversion 
of EGC to 3', 4', 5'-trihydroxyphenyl-γ-valerolactone was observed following 
incubation of the green tea catechins with ileostomy fluids (Schantz et al., 2010).  
Catechin Epicatechin
EpigallocatechinGallocatechin
Epicatechin gallate Epigallocatechin gallate  
Figure 1.3: The chemical structures of green tea catechins.  
 
Chapter 1 
14  
 
1.4.2  Pomegranate polyphenol metabolism 
Ellagitannins are converted to ellagic acid, first by hydrolysis to form 
hexahydroxydiphenic acid which then undergoes spontaneous lactone formation to 
form ellagic acid (Larrosa et al., 2006) (see Figure 1.4 for diagram). Incubation of an 
ellagitannin with cecal content at the pH found within the small intestine caused 
significant release of ellagic acid (Daniel et al., 1991) while 241 % of ellagic acid was 
recovered from the ileostomy fluid following raspberry consumption (Gonzalez-
Barrio et al., 2010) demonstrating the rapid rate of conversion early within the 
gastrointestinal system. This was confirmed in the Iberian pig model (Espín et al., 
2007). Given the high microbial content of the cecum it was suggested that 
microbes may be performing this action (Daniel et al., 1991) through enzymatic 
hydrolysis (Huang et al., 2007). A number of enzymes have been implicated in this 
action including ellagitannin acyl hydrolase, cellulase, xylanase, and β glucosidase 
(Xu et al., 2014a, Vattem and Shetty, 2003, Huang et al., 2008, Huang et al., 2007). 
Bacteria, particularly Lactobacilli sp., are implicated in the ability to produce tannin 
acyl hydrolases to undertake this hydrolysis action (Vaquero et al., 2004, Osawa et 
al., 2000). It should be noted however that an earlier report found β-glucosidase, 
esterases, and α-amylase did not have an effect on ellagic acid release from a 
raspberry extract, although in this experiment components of the raspberry extract 
inhibited the enzyme activity (Daniel et al., 1991).  
Once ellagic acid has formed it undergoes further hydrolysis by the microbiota 
within the jejunum region of the gastrointestinal tract to produce the urolithins 
(Espín et al., 2007). First the intermediary urolithin, the pentahydroxy-uroltihin M5 
is produced after which the most widely discussed sequential hydrolysis of the 
urolithins proceeds as follows: tetrahydroxy-urolithin D, trihydroxy-urolithin C, 
dihydroxy-urolithin A or isourolithin A, and finally monohydroxy-urolithin B. It 
should be noted that 2 other tetrahydroxy-urolithins (urolithin M6 and urolithin E) 
and 1 other trihydroxy-urolithin (urolithin M7) have been recently identified but are 
thought to be rapidly converted into urolithin A (García-Villalba et al., 2013). See 
Figure 1.5 for a diagram depicting the current understanding about microbial 
conversion of ellagic acid to the urolithins. The predominant urolithin found in 
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circulation is urolithin A. Urolithin B tends to form from isourolithin A rather than 
urolithin A and this has led to the hypothesis that there are three distinct urolithin 
phenotypes based on the terminal urolithins produced by each individual (Tomás-
Barberán et al., 2014). 
Punicalagin
Hexahydroxydiphenic acid
Hydrolysis
Lactone formation
Ellagic acid
 
Figure 1.4: The conversion of punicalagin to ellagic acid  
“Phenotype A” produce only urolithin A metabolites, “phenotype B” produce 
isourolithin A/urolithin B and urolithin A metabolites, and “phenotype 0” none of 
these metabolites. While the research into the bacterial species responsible for the 
production of urolithins is still in its infancy it has been suggested that firmicutes 
species play a role in the metabolism of ellagic acid to the urolithins (García-Villalba 
et al., 2013). Furthermore, urolithin A correlated to the abundance of Gonidobacter 
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in the faeces while Lactobacillus, Leuconostoc and Pediococcus are tentatively 
linked to isourolithin A/urolithin B production. The production of ellagic acid and 
tetrahydroxy-urolithins is tentatively linked to bacteroidetes (Romo-Vaquero et al., 
2015).  
Ellagic acid
Urolithin M5
Urolithin D
Urolithin M6
Urolithin C
Urolithin M7
Isourolithin A
Urolithin A
Isourolithin B
Urolithin E
Urolithin B
 
Figure 1.5: The route of microbial metabolite production from ellagic acid.  
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1.5 Bioavailability of polyphenols 
In 2005 Manach et al. (Manach et al., 2005) undertook a comprehensive review of 
97 bioavailability studies focussed on 18 individual polyphenols commonly found in 
the diet. This review provides an excellent overview of the bioavailability of these 
18 compounds, allowing comparison by normalising the bioavailability to a 50 mg 
aglycone dose. Gallic acid and the isoflavones proved most bioavailable with 
concentrations of up to 4 µM reported in the plasma from a 50 mg dose. The sugar 
moiety attached to flavonoids can significantly alter the bioavailability, for example 
rutin had a much lower Cmax than the quercetin glucoside, most likely due to the 
requirement for cleavage of the rutinoside further down the digestive tract in the 
colon (Hollman et al., 1999). Galloylation of epigallocatechin also significantly 
impacted the bioavailability of the polyphenol reducing the achievable Cmax from a 
50 mg dose from 1.1 µM to 0.12 µM. The least bioavailable compounds identified in 
the review by Manach et al. were the anthocyanins (Cmax 0.03 µM) and the 
proanthocyanadin dimers (Cmax 0.02 µM). 
1.5.1  Bioavailability of green tea polyphenols 
Studies investigating the bioavailability of the predominant green tea catechin, 
EGCG, have reported quite large differences in bioavailability although it has been 
suggested that earlier reports have underestimated due to the lack of consideration 
for the methylated conjugates (Meng et al., 2002). Following ingestion of a 1600 mg 
dose of pure EGCG a peak plasma concentration of 7 µM was found in participants 
(Ullmann et al., 2003) while others reported plasma concentrations in the 
nanomolar range from lower doses. Henning et al. found that following 
consumption of tea containing 193 mg green tea catechins produced an EGCG 
plasma concentration of 174 nM. They also reported that EGCG was more 
bioavailable when given as a green tea supplement instead of tea in the same pool 
of participants, resulting in 326 nM peak EGCG plasma concentrations (Henning et 
al., 2004). It is also interesting to note that the EGCG compounds identified in the 
plasma have been found up to 90 % in the aglycone form (Ullmann et al., 2003, 
Chow et al., 2001, Meng et al., 2002, Lee et al., 2002). Bioavailability studies in 
animals found that gastric delivery of polyphenols at varying doses produced peak 
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plasma concentration of around 31-50 nM (Lambert et al., 2003, Dube et al., 2011a, 
Lambert et al., 2004). However, it has also been shown that green tea catechins can 
be rapidly glucuronidated after entry into the plasma and are found in large 
quantities as phase-2 conjugates (Lambert et al., 2003). All studies demonstrate 
that green tea catechins are highly unstable and are rapidly turned over in the 
body.  
1.5.2  Bioavailability of pomegranate polyphenols  
Reported studies of the bioavailability of ellagitannins and ellagic acid in humans to 
date have mainly focussed from pomegranate food products, while some reports 
use extracts and, at the time of writing, only one study investigated the 
bioavailability of pure ellagic acid. No human bioavailability trial found punicalagin, 
the pomegranate derived ellagitannin, in the plasma of volunteers. It should be 
noted that punicalagin was found at 30 µg/ml in the plasma of rats following 
feeding with a punicalagin supplemented diet but has not been observed in the 
plasma from any other interventions since this trial (Cerda et al., 2003). Ellagic acid 
also has relatively poor bioavailability, with only nanomolar concentrations of 
ellagic acid observed in human plasma of (20-100 nM) following consumption of 
pomegranate products such as juice or extracts (Seeram et al., 2004, Seeram et al., 
2006, Mertens-Talcott et al., 2006). In a study where participants were given a dose 
of pure ellagic acid (40 mg) a higher plasma concentration of 660 nM was reported 
(Hamad et al., 2009). Studies in rats report peak plasma ellagic acid concentrations 
of just over 200 nM following dietary intervention with either pure ellagic acid or 
pomegranate extract (Murugan et al., 2009, Lei et al., 2003) although 
concentrations of up to 16.5 µM have been reported (Cerda et al., 2003). Studies on 
ellagic acid bioavailability in mice either from pomegranate products or pure 
compounds are limited. An early study in 1986 found little to no absorption of 
ellagic acid when incorporated into the diet at a 1 % concentration (Smart et al., 
1986). A later study reported a mean peak plasma concentration of 38 nM when a 
dose of 0.8 mg pomegranate extract was given (Seeram et al., 2007), but research 
remains limited. 
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More recently the microbial metabolites of ellagic acid, the urolithins (Cerda et al., 
2005), have been suggested as the bioactive compounds associated with the health 
benefits of pomegranate products due to the their increased bioavailability over the 
parent compounds (Cerda et al., 2004, González-Sarrías et al., 2015). While a higher 
ellagic acid dose did not increase the plasma concentration of ellagic acid it did 
increase the production of the microbial metabolites, the urolithins (González-
Sarrías et al., 2015). The urolithins differ from one another in the number of 
hydroxyl groups contained in the structure and their position. The Iberian pig model 
has been used extensively to clarify the microbial breakdown of ellagic acid (Espín 
et al., 2007). The microbiota of the small intestine converted ellagic acid into the 
first urolithins however the terminal urolithins, particularly urolithin B, were only 
produced in the large intestine. The requirement of colonic microflora for the 
production of urolithin A and B glucuronides was confirmed in ileostomy patients 
where these compounds were not found in the illeal fluid (Gonzalez-Barrio et al., 
2010). It is suggested that the microbiota composition may play a role in the ability 
of an individual to gain benefit from ellagitannin consumption (Puupponen-Pimiä et 
al., 2013). The uptake of urolithin A, B and C into the intestine tissue was 
reasonable while only small amounts of urolithin D was able to pass into the tissue. 
Quantification of the urolithins in human plasma has shown concentrations 
exceeding 18 µM (Cerda et al., 2004) with urolithin A and B being reported at the 
highest concentrations.  
1.6 Pathology of atherosclerosis 
Atherosclerosis is a disease which has been observed across the world for 
thousands of years (Thompson et al., 2013). The world health organisation (WHO) 
reports that the biggest cause of death globally is cardiovascular disease, and 
primarily ischemic heart disease. In western countries the prevalence of 
atherosclerosis has been linked to age as well as more modern factors such as 
smoking status and obesity (Robinson et al., 2009, Webber et al., 2012).  
The risk of a person developing cardiovascular disease is commonly measured using 
the Framingham cardiac risk scale (D’Agostino et al., 2008). This scale considers a 
number of contributing factors: diabetes mellitus (or other equivalent disease), 
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smoking status, age, gender, total cholesterol levels, HDL cholesterol levels, systolic 
blood pressure and systolic blood pressure after treatment (if applicable). The 
pattern of progression differs between genders with the risk of atherosclerotic 
development in men increasing linearly over time whereas for women the risk 
significantly began to increase from around the age of 50 (Joakimsen et al., 1999). 
These age-related differences observed between the sexes are however lost within 
the very elderly (Sawabe et al., 2006).  
Atherosclerosis is characterised as a thickening of the arterial wall through deposits 
of lipids, LDL cholesterol, smooth muscle cells, foamy macrophages and platelets. 
Atherosclerosis is initiated in adolescence (Strong et al., 1999) but these early 
lesions are thought to not affect lumen size or display any physiological symptoms 
of plaque development and that the lesions can regress (Nissen, 2000). Progression 
of atherosclerosis into an unstable and continuous stage of the disease typically 
occurs beyond the age of 50 [147] although it can occur earlier in certain 
individuals, for example those with a genetic disorder such as familial 
hypercholesterolemia (Lavrencic et al., 1996). Atherosclerosis typically starts at 
regions of differential blood flow rates which are known to alter sheer stress and 
the duration circulating components known to advance atherosclerosis are in these 
regions of the circulatory system, repeatedly demonstrating an ability to gather at 
these regions more readily (Sims, 1985, Ku et al., 1985, Zarins et al., 1983). 
Atherosclerosis begins with an increase in oxidised LDL within the tissue which 
typically accumulates because of high LDL concentration within the blood. It has 
been shown that even in clinically healthy patients that a higher LDL cholesterol 
level is correlated to thicker vessel intima [151]. This build-up results in the release 
of chemokines and monocyte adhesion molecules which attract immune cells to the 
site [148]. These adhesion molecules, such as P-selectin, adhere to the monocytes 
increasing the movement of these cells into the tissue [149]. Once in the intima the 
monocytes mature into macrophages and take up the oxidised LDL through 
phagocytosis forming foam cells. Small collections of foam cells and oxidised LDL 
are known as fatty streaks and can be taken as an early indication of future 
atherosclerosis but, due to the occurrence of regression, is not a diagnosis for the 
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disease itself. Following fatty streak formation the intima of the vessel wall begins 
to thicken, encroaching on the lumen space. Lipids gather in pools within the layers 
of smooth muscle cells and this gathering is associated with increased macrophage 
infiltration and increased apoptosis. A reduction in extracellular matrix proteins also 
occurs and a necrotic core forms (Otsuka et al., 2015). Following lipid pool 
expansion and necrotic core development a fibrous cap across the lesion begins to 
form from fibrous smooth muscle cells with a high collagen content, although the 
mechanism is still poorly understood (Newby and Zaltsman, 1999). These are 
subject to proteolysis, for example from matrix metalloproteinases released from 
macrophages (Shah et al., 1995, Peeters et al., 2011), leaving the cap weakened 
increasing the risk of plaque rupture leaving the LDL cholesterol and foam cell 
enlarged intima exposed, typically forming a thrombus within the vessel. 
Furthermore, as the plaque grows it becomes increasingly vascularised (Hiyama et 
al., 2010). This vascularisation overcomes the hypoxia induced through plaque 
growth (Bjornheden et al., 1999). This increase in vascularisation is also linked to 
the instability of plaques which can lead to plaque rupture and haemorrhage 
(Fleiner et al., 2004, Kolodgie et al., 2007). It is thought that the majority of 
myocardial infarction actually stems from plaque rupture thrombus formation 
instead of total lumen occlusion by the plaque itself [154]. Repeated plaque rupture 
leads to a build-up of fibrous tissue increasing the plaque size [151]. A 
diagrammatic representation of atherosclerosis can be seen in Figure 1.6 while the 
morphological features of the atherosclerotic plaque from the study discussed in 
chapter 3 of this thesis can be seen in Figure 3.2. 
To undertake studies investigating the impact of treatments on atherosclerosis a 
suitable model with a similar plaque progression is required. There are numerous 
cholesterol driven animal models of atherosclerosis such as the LDL receptor 
knockout (LDLR-/-) mouse or high cholesterol diet in other rodents. However, the 
most widely used model is the Apolipoprotein E knockout mouse (ApoE-/-) which 
has reduced clearance of very low density lipoproteins (vLDLs) and intermediary 
density lipoproteins (IDLs) (Meir and Leitersdorf, 2004, Plump et al., 1992). These 
mice develop spontaneous atherosclerosis even on a standard chow diet with the 
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plaque morphology mimicking that of atherosclerotic lesions in humans and other 
species resulting in it being the leading model for investigations into atherosclerosis 
(Reddick et al., 1994, Nakashima et al., 1994). 
1.7 Impact of dietary polyphenols on CVD 
1.7.1  Epidemiological and dietary intervention studies 
The correlation between polyphenols or foods rich in polyphenols and a reduced 
risk in cardiovascular disease (CVD) associated factors has been understood for a 
while. Tea and green tea which are rich in polyphenols including flavan-3-ols have 
frequently been associated with a reduction in risk of myocardial infarction (MI) 
and stroke (Pang et al., 2016, Sesso et al., 2003) as well as a reduction in 
atherosclerosis (Sasazuki et al., 2000, Geleijnse Jm, 1999). Olive oil and the 
Mediterranean diet have also been associated with positive changes in blood 
pressure, lipid profiles and reductions in intima-media thickness (Martinez-Gonzalez 
et al., 2015, Hernaez et al., 2014, Fito et al., 2008). Daily pomegranate juice 
consumption, known to be a rich source of ellagitannins and anthocyanins (Gil et 
al., 2000), was able to reduce stress-induced cardiac ischemia (Sumner et al., 2005). 
While these studies demonstrate a strong link between foods containing large 
amounts of polyphenols and reduced CVD risk, the studies did not go further into 
which compounds were responsible for the effects. However, other studies have 
highlighted the link between certain polyphenols or classes of polyphenols which 
are also associated with reduced risk or occurrence of CVD. A higher consumption 
of flavonoids from a variety of sources has been linked to reduced mortality from 
cardiovascular events including ischemia and improvement in plasma lipid 
parameters (Yochum et al., 1999, Geleijnse et al., 2002, Gorinstein et al., 2006, 
Widmer et al., 2013). The Zupthen elderly study conducted in The Netherlands 
collated information about the diets of over 800 elderly men (aged 65-84) along 
with both CVD mortality data after 5 and 10 years follow up. Both reports found a 
higher flavonoid intake was inversely correlated to general CVD related mortality 
(Hertog et al., 1993) while after 10 years the risk of death specifically from 
myocardial infarction was also reduced in those with a higher flavonoid-containing 
diet (Hertog et al., 1997). In the same cohort an increased consumption of catechin 
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was associated with a reduction in ischemic heart disease (Arts et al., 2001b). 
Association of the flavonoid subclasses with cardiovascular improvements have also 
been investigated. In a Finnish cohort the flavanones and flavones were associated 
with reduced risk of CVD mortality while in the same cohort the flavonols and 
flavan-3-ols were associated with reduced incidence of stroke (Mursu et al., 2008). 
In a larger cohort an increased diet content of quercetin, kaempferol, naringenin 
and hesperetin was associated with reduced ischemia and stroke (Knekt et al., 
2002). A summary of studies reporting an association between polyphenols and 
CVD risk and events can be seen in Table 1.2.Atherosclerosis research samples can 
be difficult or inappropriate to obtain as these require invasive procedures. Critical 
insights into atherosclerosis have come from gross evaluation of arterial plaque in 
post-mortem samples (Webber et al., 2012). Imaging techniques can provide clues 
to the degree of vessel wall thickening (measured as intima media thickness) and 
vessel stiffness (measured as flow mediated dilatation). However, to evaluate 
plaque progression under experimental conditions animal models are useful.  
1.7.2  Polyphenol intervention trials in animals 
Investigations into the anti-atherosclerotic effects of polyphenols have 
predominantly been undertaken with flavonoids although the stilbene resveratrol 
has also been investigated. Naringin and naringenin reduced atherosclerotic plaque 
size in both New Zealand white rabbits and wild type mice fed a high cholesterol 
diet (Lee et al., 2001, Chanet et al., 2012) however naringin diet supplementation 
did not reduce atherosclerotic plaque size in ApoE-/- mice (Chanet et al., 2012). 
Catechin, quercetin, and resveratrol reduced atherosclerotic plaque size by around 
80 % in high cholesterol fed Syrian golden hamsters (Auger et al., 2005). The LDLR-/- 
mouse is also an important model of atherosclerosis and quercetin was reported to 
have potent anti-atherosclerotic effects in this model even after only a short 4 week 
intervention (Leckey et al., 2010). Quercetin also demonstrated anti-atherosclerotic 
effect in the high cholesterol fed New Zealand white rabbit model (Juzwiak et al., 
2005). Ellagic acid limited atherosclerosis progression in high fat diet fed wild type 
mice but not in the ApoE-/- mouse model due to low plaque size in all groups (Ding 
et al., 2014). Arguably the most widely used animal model of atherosclerosis is the 
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ApoE-/- mouse model, and a large amount of the research investigating the anti-
atherosclerotic effects of polyphenols has been undertaken in this model. 
Polyphenol rich food extracts, from products such as green tea, pomegranate, and 
apple peel rich in the polyphenols EGCG, punicalagin, and quercetin have all 
demonstrated strong inhibition of atherosclerosis growth after dietary intervention 
over the experimental period in ApoE-/- mice (Miura et al., 2001, Aviram et al., 
2008, Gonzalez et al., 2015). Other alternative polyphenol rich extracts, such as 
pine bark extract rich in proanthocyanidins have also limited the size of the 
atherosclerotic plaque in the aortic sinus, the region of differential pressure around 
the semi-lunar valves of the aorta near the aortic root, in comparison to controls 
(Sato et al., 2009). A summary of polyphenols rich extracts or products and their 
effects on atherosclerosis plaque size in the ApoE-/- mouse model can be seen in 
Table 1.3. Specific polyphenols have also been investigated for their anti-
atherogenic properties in the ApoE-/- mouse model. EGCG treatment, either in the 
drinking water or through intraperitoneal injection, reduced atherosclerotic plaque 
size in diet-induced accelerated atherosclerosis (Chyu et al., 2004, Yin et al., 2016). 
A mixture of catechin, caffeic acid and resveratrol was also able to significantly 
reduce western-diet accelerated atherosclerosis within the aortic sinus and the 
ascending aorta by up to 40 % (Norata et al., 2007). In this study we cannot 
conclude that any individual polyphenol may be responsible for the observed effect 
however both catechin and caffeic acid phenethyl ester have been independently 
reported to limit atherosclerosis progression in the ApoE-/- mouse (Hishikawa et al., 
2005, Auclair et al., 2009). While diet supplementation with 0.01 % resveratrol was 
able to inhibit atherosclerosis progression by 52 %, in the ApoE*3, a more 
atherosclerosis susceptible ApoE genotype (Berbee et al., 2013), resveratrol has yet 
to be independently tested in the ApoE-/- model. Long term diet supplementation 
of quercetin (Shen et al., 2013) theaflavin (Loke et al., 2010), and the anthocyanin 
metabolite protocatechuic acid (Wang et al., 2010) were also able to inhibit 
atherosclerosis progression. A summary of the anti-atherosclerotic effects of 
individual polyphenols can be found in Table 1.4.  
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Figure 1.6: The morphological features of atherosclerotic disease   
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Table 1.2: Summary of the associations between polyphenols in the diet and reduced cardiovascular risk or events   
Polyphenol 
Source 
Polyphenol Dose Study population No. 
participants 
Outcome at follow up Ref.  
General diet Flavonoid 25.9 m/day Elderly men from The 
Netherlands 
805 Reduced mortality from CVD (Hertog et al., 
1993) 
General diet Flavonoid > 29.9 mg/day Elderly men from The 
Netherlands 
804 Reduced mortality from CVD and 
reduced MI 
(Hertog et al., 
1997) 
General diet Flavonoid 13.9 mg/day Post-menopausal American 
women 
34,492 Reduced risk of CHD mortality  (Yochum et al., 
1999) 
Tea Flavonoid 32.9 mg/day Men and Women from The 
Netherlands ≥55 years old 
4807 Reduced risk of MI (Geleijnse et al., 
2002) 
General diet Flavonols 
Flavones 
Flavan-3-ols 
3.8 mg/day 
0.8 mg/day 
7.2 mg/day 
Greek cohort ≥ 49 years old 
with peripheral arterial 
occlusive disease 
200 Reduced risk of further peripheral 
arterial occlusive disease 
(Lagiou et al., 
2006) 
General diet Flavanone, flavone 
 
Flavonol, flavan-3-ols 
435 mg/day (total 
flavonoids) 
Finnish men without previous 
CHD 
1950 Reduced risk of CVD death 
 
Reduced risk of ischemic stroke 
(Mursu et al., 
2008) 
General diet Flavonol 
Flavone 
18 mg/day 
 
Finnish male smoker aged 50-
69 
25,372 Reduced risk of non-fatal MI (Hirvonen et al., 
2001) 
General diet Luteolin 
Kaempferol 
0.2 mg/day 
1.3 mg/day 
Finish men and women aged 
65-99 
755 Reduced risk of acute MI (Marniemi et 
al., 2005) 
General diet Kaempferol  4.7 mg/day American females aged 30-55  66,360 Reduced risk of CHD (Lin et al., 2007) 
General diet Quercetin 28.6 mg/day (total Elderly men from The 552 Reduced risk of stroke (Keli et al., 
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Polyphenol 
Source 
Polyphenol Dose Study population No. 
participants 
Outcome at follow up Ref.  
flavonoids) Netherlands 1996) 
General diet Quercetin 
 
Kaempferol, 
naringenin, hesperetin 
3.3 mg/day 
 
0.6, 5.1, 15.1 
mg/day 
General population of Finland 10,054 Reduced mortality from cardiac 
ischemia 
Reduced stroke incidence 
(Knekt et al., 
2002) 
General diet Anthocyanidin, 
flavanones 
0.2, 93.7 mg/day Post-menopausal American 
women 
34,489 Reduced risk of CHD, CVD or both (Mink et al., 
2007) 
Tea, apples, 
chocolate 
Catechin 72 mg/day Elderly men from the 
Netherlands 
806 Reduced ischemic heart disease 
mortality 
(Arts et al., 
2001b) 
Olive oil Hydroxytyrosol 
derivatives, flavonoids, 
lignans, 
301 mg/day total 
polyphenols 
American men and women 
over 18 years old with early 
atherosclerosis 
82 Improved endothelial function (Widmer et al., 
2013) 
Red grapefruit Flavonoids, 
anthocyanins 
One per day Polish patients with coronary 
atherosclerosis 
92 Reduced LDL, triglycerides, and 
total cholesterol 
(Gorinstein et 
al., 2006) 
CVD = cardiovascular disease; CHD = coronary heart disease; MI = myocardial infarction; LDL = low-density lipoproteins 
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Table 1.3: Table summarising the current literature on the anti -atherosclerotic effect of polyphenol ric h products and extracts in 
the ApoE-/- mouse model 
GAE = gallic acid equivalent; HF = high fat; HC = high cholesterol 
Diet type 
 
Polyphenol 
containing product  
Main polyphenol Dose/delivery Intervention 
duration 
Location of plaque Effect size (% 
inhibition) 
Ref. 
HF diet  Apple peel Quercetin 20 % in diet 20 weeks Thoracic aorta Not quantified (Gonzalez et 
al., 2015) 
Western diet Cocoa powder Not stated 0.2 % in diet 
2 % in diet 
12 weeks Aortic sinus 47 % 
32 % 
(Guan et al., 
2016) 
Normal diet Pine bark extract Proanthocyanidins 2 % in diet 9 weeks Aortic sinus ~35 % (Sato et al., 
2009) 
HF/HC diet Dealcoholised red wine Not stated 10 % in water 26 weeks Thoracic aorta ~40 % (Waddington 
et al., 2004) 
Western diet Apple polyphenols Not stated 100 mg/kg/day 12 weeks Aortic sinus 61 % (Xu et al., 
2015) 
Normal diet Pomegranate juice Punicalagin/punicalin 200 µg GAE/day 3 months Aortic sinus ~40 % (Aviram et 
al., 2008) 
HF/HC diet Tea extract Epigallocatechin gallate 0.8 g/L in sucrose 14 weeks Aortic sinus 23 % (Miura et al., 
2001) 
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Table 1.4: Table summarising the current literature on the anti -atherosclerotic effects of individual polyphenol compounds in the 
ApoE-/- mouse model 
Diet type 
 
Compound PP dose/delivery Intervention 
duration 
Location of plaque Effect size (% 
inhibition) 
Ref. 
HC diet EGCG 10 mg/kg daily PP I.P. injections 6 weeks Aortic sinus Day 21: 55 % 
Day 42: 73 % 
(Chyu et al., 2004) 
HF diet EGCG 0.8 g/L in water 7 weeks Aortic sinus Not quantified  (Yin et al., 2016) 
Normal diet Catechin 0.02 % in diet 6 weeks Aortic sinus 32 % (Auclair et al., 
2009) 
Normal diet Quercetin 
Theaflavin 
1.3 mg/day in diet 26 weeks Aortic sinus 80 % 
60 % 
(Loke et al., 2010) 
Western diet Catechin + caffeic acid + 
resveratrol 
160 mg/kg body weight/day 8 weeks Aortic sinus 
Ascending aorta 
40 % 
36 % 
(Norata et al., 
2007) 
HF diet Quercetin 0.05 % in diet 14 weeks Aortic sinus 
Thoracic aorta 
20 % 
54 % 
(Shen et al., 2013) 
Normal diet Protocatechuic acid 0.003 % 20 weeks Aortic sinus 42 % (Wang et al., 
2010) 
HF diet Chlorogenic acid 400 mg/kg body weight/day 12 weeks Aortic sinus 52 % (Wu et al., 2014) 
Normal diet Caffeic acid phenethyl 
ester 
30 mg/kg body weight/day 12 weeks Thoracic aorta ~65 % (Hishikawa et al., 
2005) 
PP = polyphenol; I.P = intraperitoneal; HF = high fat; HC = high cholesterol;  
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1.8 The VEGF protein 
Vascular endothelial growth factor (VEGF) is the growth factor primarily responsible 
for angiogenic stimulation in the endothelial cells of humans and other animals 
(Ferrara, 2009). The VEGF protein functions as a dimer of around 45kDa size 
(Ferrara and Henzel, 1989), binding to a family of tyrosine kinase receptors known 
as the VEGF receptors, as well as the co-receptors neuropilin 1 and 2 (NRP1 and 
NRP2) and extracellular complexes such as heparin (Ferrara et al., 2003). There are 
multiple forms of VEGF with VEGFA being the most crucial as it is responsible for 
the majority of angiogenesis signalling and maintenance of vascular health, 
signalling via VEGFR-2 (Shalaby et al., 1995). Neither VEGFA heterozygous or 
homozygous negative mice survive past gestation due to defective formation of the 
vasculature demonstrating the importance of VEGFA in developmental blood vessel 
generation (Carmeliet et al., 1996, Ferrara et al., 1996). Due to its dominant role 
VEGFA is often referred to in the literature simply as VEGF, as will be done in this 
chapter, however a number of other VEGF ligands exist. VEGFB plays some role in 
regulating and maintaining the formed vasculature (Aase et al., 2001, Bellomo et 
al., 2000) and recently has been linked to neurogenesis in rodent models (Sun et al., 
2006). VEGFC and VEGFD predominantly induce lymphangiogenesis through 
signalling via VEGFR-3. VEGFC and VEGFD have been shown to bind to VEGFR-2 
following proteolysis albeit at a lower binding affinity than VEGFA (Joukov et al., 
1997, McColl et al., 2007). Two further biological VEGF proteins have been 
documented, VEGFE and VEGFF, however they are produced by the parapox virus 
(Ogawa et al., 1998) and in eastern cottonmouth snake venom (Yamazaki et al., 
2005) respectively. They are capable of inducing VEGF signalling via VEGFR-2 to 
varying levels of success.  
1.9 The different VEGFA isoforms 
The key VEGF protein, VEGFA, exists as five isoforms, produced from alternative 
splicing of the VEGF gene with one further isoform after proteolysis (Ferrara, 2010). 
These isoforms are VEGF121, VEGF145, VEGF165, VEGF189, and VEGF209, while VEGF110 
can be formed through proteolysis. The number refers to the number of amino 
acids in the protein. Each of these isoforms has a varying ability to induce signalling 
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via the VEGF receptors. The VEGF isoforms which are able to effectively induce the 
VEGF signalling pathway are those with only an intermediate binding affinity for the 
neuropilin co-receptors and the extracellular matrix component heparin. This 
affinity is dependent on inclusion of exon 6 and 7 in the splice variant (Krilleke et 
al., 2009). VEGF121 and VEGF110 lack both exon 6 and 7, are found freely in 
circulation and are poor inducers of VEGF receptor phosphorylation. VEGF189 and 
VEGF209, containing both exon 6 and 7, have a very strong affinity for heparin and 
are rapidly sequestered from circulation. Alternative splicing produces two VEGF 
isoforms with only one of these exons, VEGF145 and VEGF165, including only exon 6 
and 7 respectively (Dehghanian et al., 2014). VEGF145 has specifically been shown to 
bind in a heparin in-dependent manner leading to a tissue specific response in 
corneal endothelial cells (Stalmans et al., 2002). VEGF165 is able to recognise the 
majority of VEGF receptors and co-receptors and is the predominant angiogenic 
circulating VEGF isoform. A summary of the VEGF isoforms is shown in Table 1.5. 
1.10 The VEGF receptors 
The VEGF receptors are a family of tyrosine kinase receptors which have a distinct 
structure. The extracellular domain contains 7 immunoglobulin like domains which 
form the VEGF binding region (Shinkai et al., 1998, Fuh et al., 1998). The 
intracellular region of the receptor consists of multiple domains including, a 
juxtamembrane domain, two kinase domains separated by a kinase insert domain 
and a c-terminus. Until recently, it was thought that upon binding of the VEGF 
ligand a receptor dimer was formed leading to a series of phosphorylation events 
stimulating a variety of downstream signals. However, evidence is now emerging 
that the receptors may be able to form receptor dimers without the presence of 
the VEGF ligand with low levels of activity which only become fully active upon 
VEGF ligand binding and a conformational change in the transmembrane region 
(Sarabipour et al., 2016). Upregulation of ligand independent signalling can occur in 
diabetes mellitus patients due to an increase in reactive oxygen species (ROS) 
generation (Warren et al., 2014). There are 3 main VEGF receptors known as 
VEGFR-1, VEGFR-2 and VEGFR-3 and the receptor dimer pair can be both a homo- 
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or hetero-dimer and each combination produces an individual phosphorylation 
pattern (Nilsson et al., 2010, Neagoe et al., 2005, Cudmore et al., 2012).  
1.10.1  VEGF receptor 1 
VEGFR-1 receptor is stimulated by the VEGFA, VEGFB and platelet derived growth 
factor (PDGF) ligands. VEGFR-1 -/- mice die at embryonic day 8.5-9.0 due to an 
increase in endothelial progenitor cells causing a disorganised vascular network 
(Fong et al., 1995, Fong et al., 1999) suggesting that a lack of VEGFR-1 induces over 
commitment of progenitor cells to endothelial cell formation and not a lack of 
vessel formation. It is thought VEGFR-1 plays more of a regulatory role in 
angiogenesis by sequestering the circulating VEGF, controlling the amount available 
for signalling via VEGFR-2 (Fong et al., 1999, Hiratsuka et al., 1998). VEGFR-1 
tyrosine kinase domain knockout mice, which have the VEGF binding region but do 
not generate the downstream signalling response, develop normal vasculature 
(Hiratsuka et al., 1998) but have impaired VEGF-induced macrophage migration, 
suggesting VEGFR-1 signalling plays a much large role in this function. A soluble 
form of VEGFR-1 has also been shown to behave as a sink for VEGF, reducing its 
mitogenic potential (Kendall and Thomas, 1993) and causing endothelial 
dysfunction in preeclampsia patients (Maynard et al., 2003). Interestingly, 
heterodimers of VEGFR-1 and VEGFR-2 can induce an individual vasodilatory 
response by releasing prostaglandin following activation (Neagoe et al., 2005).  
1.10.2  VEGF receptor 2 
VEGFR-2 is predominantly found as a homodimer and is the primary receptor 
responsible for VEGF stimulated angiogenesis and neoangigoenensis in the body, 
including pathological angiogenesis (Goodlad et al., 2006, Doi et al., 2012) as well as 
the response of endothelial cells to VEGF stimulation in vitro (Endo et al., 2003).The 
importance of VEGFR-2 is demonstrated in knockout mouse studies where VEGFR-2 
-/- mice do not develop past embryonic day 8.5-9.5 due to lack of endothelial cell 
development and lack of blood vessel generation (Shalaby et al., 1995).  
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1.10.3  VEGF receptor 3 
VEGFR-3 has demonstrated a key role in lymphangiogenesis (Dumont et al., 1998) 
and, in contrast to VEGFR-1 and VEGFR-2, VEGFR-3 cannot bind with VEGFA and 
instead binds with VEGFC and VEGFD. The exception to this is with a VEGFR-
2/VEGFR-3 heterodimer which can bind VEGFA, VEGFC and VEGFD. The sites that 
become phosphorylated with VEGFR-2/VEGFR-3 heterodimer activation by a VEGF 
ligand seem to be predominantly associated with kinase regulation however 
evidence does suggest this heterodimer is found at a higher level in the tip cells of 
filopodia and may have a role in angiogenic sprouting (Deng et al., 2015, Nilsson et 
al., 2010).  
Table 1.5: A summary of the different VEGF isoforms, the genetic differences 
between those isoforms and their physiological properties.  
Table originally published by Edwards and Kroon (2013) in Recent Advances in 
Polyphenol Research Volume 4 with permission from  John Wiley and Sons. .  
VEGF 
Isoform 
Exon 
6 
Exon 
7 
Extracellular matrix 
(ECM) binding 
Receptor 
recognition 
Functionality 
121 X X No binding. Found 
in circulation 
VEGFR-2 Poor functionality due to lack of 
heparin binding 
145   X Intermediary 
binding to ECM 
VEGFR-2 Able to activate VEGFR-2 but not 
any other receptors 
165 X    Intermediary 
binding to ECM  
VEGFR-2, 
VEGFR1, 
Neuropilins 
The predominant isoform, with 
intermediary heparin binding 
189     Strong binding to 
ECM 
N/A Rapidly sequestered due to high 
affinity for heparin. Not seen in 
circulation 
209     Strong binding to 
ECM 
N/A Rapidly sequestered due to high 
affinity for heparin. Not seen in 
circulation 
110 X X No binding. Found 
in circulation 
VEGFR-2 Acts as VEGF121 with poor 
functionality due to lack of 
heparin binding 
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1.11 The stimulated VEGFR-2 signalling pathway 
Each phosphorylation site identified on VEGFR-2 has a distinct signalling role 
leading to the range of physiological outcomes that allow for vessel growth, 
permeability, cell survival and migration. Tyrosine 1054 and 1059 residues are 
highly conserved across all 3 VEGF receptors due to their integral role in the kinase 
activation loop. Without activation of these phosphorylation sites only 10% of the 
receptor activation is able to occur, significantly impacting on VEGFR-2 signalling 
capability (Dougher and Terman, 1999). These phosphorylation sites are further 
controlled by the intracellular juxtamembrane region where, if this region in VEGFR-
1 and VEGFR-2 are swapped, VEGFR-2 has reduced receptor kinase activation while 
receptor activity is significantly increased in VEGFR-1, suggesting the 
juxtamembrane region plays a role in the kinase activation (Gille et al., 2000).  
1.11.1  Tyrosine 951, 1054 and 1059 signalling 
The kinase insert domain is also important for VEGF mediated angiogenesis as 
replacing the Y951 in this region with a phenylalanine residue stops Y1175 
phosphorylation associated downstream signalling (Manni et al., 2014) .The 
tyrosine 951 site activates the signalling molecule T-cell specific adapter protein 
(TSAd), leading to membrane bound Src signalling and induced vascular 
permeability (Sun et al., 2012). TSAd stimulation of Src has been shown to lead to 
phosphorylation of another receptor tyrosine kinase, Axl, which stimulates 
phosphorylation of AKT signalling independent of Y1175 phosphorylation (Ruan and 
Kazlauskas, 2012). Src has also been shown to bind to phosphorylated Y1057 (Y1059 
in humans) and leads to phosphorylation of the key angiogenesis Y1173 (Y1175 in 
humans) and facilitates the phosphorylation of IQGAP1 which, in turn leads to b-Raf 
stimulated proliferation in endothelial cells (Meyer et al., 2008). Src also has an 
interesting role in positive feedback following VEGF stimulation where VEGFR-
2+/Src+ intracellular vesicles are mobilised to the cell membrane providing a new 
supply of VEGFR-2 for stimulation with close proximity to the Src binding partner 
(Gampel et al., 2006). A summary of the signalling pathways stimulated by VEGF 
stimulated phosphorylation of the VEGFR-2 tyrosine 951, 1054, and 1059 residues 
can be seen in Figure 1.7 
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1.11.2  Tyrosine 1175 signalling  
Tyrosine 1175 is known to be the key phosphorylation site for the majority of 
angiogenesis signalling by the VEGFR-2 receptor as transgenic mice for mutated 
Y1175 die at embryonic day 8.5-9, in almost an identical manner to mice completely 
deficient in the VEGFR-2 receptor (Sakurai et al., 2005a). Perhaps the dependency 
of functional angiogenesis on stimulation of the VEGFR-2 Y1175 site provides an 
explanation for the large number of regulatory pathways associated with this 
phosphorylation event. The molecule Shb is phosphorylated in a Src dependent 
manner after binding to the phosphorylation Y1175 site and stimulates focal 
adhesion kinase (FAK) phosphorylation (Holmqvist et al., 2004) which mediates 
vascular permeability (Chen et al., 2012). Furthermore, phosphoinositol-3-kinase 
(PI3K) activation is dependent on the presence of FAK (Qi and Claesson-Welsh, 
2001). Considering the presence of Shb has been demonstrated to be important for 
the VEGF stimulated activation of PI3K (Holmqvist et al., 2004) it could be suggested 
that Shb mediates PI3K activity through FAK. PI3K facilitates phosphorylation of Akt 
(Cantley, 2002) which, in turn reduces the activity of apoptotic signalling molecules 
(Cardone et al., 1998, Datta et al., 1997, Trinh et al., 2009). Akt can also 
phosphorylate endothelial nitric oxide synthase (eNOS) (Fulton et al., 1999) to 
stimulate vascular permeability (Duran et al., 2010). The phosphorylated Y1175 site 
also provides the binding site for phospholipase C gamma (Plc-γ) (Sawano et al., 
1997, Takahashi and Shibuya, 1997, Takahashi et al., 2001) and stimulated an 
elevation in intracellular calcium which correlates to the stimulation of mitogen 
activated protein kinase (MAPK) signalling and cell proliferation (McLaughlin and De 
Vries, 2001) and eNOS production of nitric oxide (NO) (Gélinas et al., 2002). 
Furthermore, Plc-γ stimulates the production of inositol-3-phosphate (IP3) and 
diacylglycerol (DAG) which stimulate protein kinase C (PKC) leading to MAPK 
induction of platelet activating factor induced vascular permeability (Sirois and 
Edelman, 1997, Bernatchez et al., 1999) and to increased gene expression and cell 
proliferation (Xia et al., 1996). Sck has also been shown to bind at Y1175 and caused 
a reduction in MAPK phosphorylation although the physiological outcome of this 
has not been further explored (Ratcliffe et al., 2002). A summary of the signalling 
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pathways stimulated by VEGF stimulated phosphorylation of VEGFR-2 tyrosine 1175 
residue can be seen in Figure 1.8. 
1.11.3  Tyrosine 1214 signalling  
Y1214, another C-terminal region tyrosine, has been highlighted as an important 
phosphorylation site for VEGFR-2 signalling. VEGFR-2 stimulation with VEGF and β1 
integrin results in a prolonged phosphorylation at this site. Phosphorylation at 
Y1214 causes recruitment of the protein Fyn while recruitment of Nck occurs in a 
Fyn dependent manner (Lamalice et al., 2006). p21-activated kinase 2 (PAK-2) is 
also phosphorylated in a Fyn and p-Y1214 dependent manner (Lamalice et al., 
2006) to stimulate SAPK2/p38 actin remodelling and endothelial migration 
(Lamalice et al., 2004). Furthermore, Y1214 appears to be important in 
differentiating the signal transduction between matrix bound VEGF and free VEGF 
with matrix bound VEGF associated with a prolonged stimulation of p38 MAPK 
(Chen et al., 2010, Wang et al., 2013). Heat shock protein 90 (HSP90) has also been 
shown to interact with the 130 amino acid residues of the c-terminal end of VEGFR-
2. HSP90 also associates with αvβ3 integrin to stimulate a VEGFR-2-αvβ3 integrin 
dependent activation of FAK through the signalling molecule RhoA and RhoA kinase 
(ROCK) (Le Boeuf et al., 2004) leading to angiogenesis associated cell migration 
(Bryan et al., 2010, Haskell et al., 2003, Avraham et al., 2003). A summary of the 
signalling pathways stimulated by VEGF stimulated phosphorylation of VEGFR-2 
tyrosine 1214 residue can be seen in Figure 1.9. 
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Figure 1.7: VEGF stimulated VEGFR-2 signalling from the phosphorylated 
tyrosine 951, 1054 and 1059 residues  
Edited from Chapter 9 Recent Advances in Polyphenol Research Volume 4; (Edwards and Kroon, 
2014) with permission from John Wiley and Sons. 
Abbreviations: AKT = protein kinase B; Axl = Tyrosine-protein kinase receptor UFO; B-Raf = B-Raf 
proto-oncogene; eNOS = endothelial nitric oxide synthase; FAK = Focal adhesion kinase; IQGAP1 = 
Ras GTPase-activating-like protein IQGAP1; PI3-K = Phosphoinositide 3-kinase; Sck = Shc-related 
adaptor protein; Shb = SH2 domain-containing adapter protein B; Src = Proto-oncogene tyrosine-
protein kinase Src; TSAd = T cell-specific adapter; Y = tyrosine.  
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Figure 1.8: VEGF stimulated VEGFR-2 signalling from the phosphorylated 
tyrosine 1175 residue 
Edited from Chapter 9 Recent Advances in Polyphenol Research Volume 4; (Edwards and Kroon, 
2014) with permission from John Wiley and Sons. 
Abbreviations: AKT = protein kinase B; B-Raf = B-Raf proto-oncogene; C-ABL =Abelson murine 
leukemia viral oncogene homolog 1; Ca2+ = calcium; DAG = diacylglycerol; eNOS = endothelial nitric 
oxide synthase; FAK = Focal adhesion kinase; Grb2 = Growth factor receptor-bound protein 2; IP3 = 
inositol triphosphate; IPR = IP3 receptor; IQGAP1 = Ras GTPase-activating-like protein IQGAP1; 
MAPK = mitogen activated protein kinase; Nck-1 =NCK adaptor protein 1; NO = nitric oxide; PAF = 
Platelet-activating factor; PIP2 = Phosphatidylinositol 4,5-bisphosphate; PI3-K = Phosphoinositide 3-
kinase; PKC = protein kinase C; Plc-γ = Phospholipase C gamma; Raf = rapidly accelerated 
fibrosarcoma; Sck = Shc-related adaptor protein; Shb = SH2 domain-containing adapter protein B; 
Src = Proto-oncogene tyrosine-protein kinase Src; TSAd = T cell-specific adapter; Y = tyrosine 
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Figure 1.9: VEGF stimulated VEGFR-2 signalling from the phosphorylated 
tyrosine 1214 residue 
Edited from Chapter 9 Recent Advances in Polyphenol Research Volume 4; (Edwards and Kroon, 
2014) with permission from John Wiley and Sons. 
Abbreviations: Nck-1 =NCK adaptor protein 1; Fyn = Proto-oncogene tyrosine-protein kinase Fyn; 
PAK-2 = Serine/threonine-protein kinase PAK 2; SAPK2 = Serine/threonine-protein kinase SAPK2; Y = 
tyrosine. 
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1.12 Disease relevance of VEGF signalling 
VEGF signalling and the associated angiogenesis response is necessary in both 
development and regulation of the vascular system (Shalaby et al., 1995, Carmeliet 
et al., 1996, Ferrara et al., 1996). The VEGF signalling pathway is highly controlled 
(Simons et al., 2016) however abnormal regulation of VEGF signalling can lead to 
pathological angiogenesis (Goodlad et al., 2006, Doi et al., 2012, Carmeliet, 2005) or 
vascular dysfunction (Maynard et al., 2003, Robinson et al., 2010).  
1.12.1  Diseases currently treated by anti-VEGF medication 
Upregulation of the VEGF signalling pathway has been identified as a crucial step in 
the development (Mattern et al., 1996, Kopparapu et al., 2013) and metastasis 
(Takahashi et al., 1995, Weis et al., 2004) of numerous cancers. Circulating VEGF 
levels are increased in certain metastatic cancers (Duque et al., 1999) and have 
been suggested as a prognostic factor for certain cancers (Kim et al., 2003). Hypoxia 
caused through rapid tissue expansion is also known to stimulate tumour 
angiogenesis as well as VEGF expression (Liao and Johnson, 2007, De Francesco et 
al., 2013). Upregulation of VEGF signalling (Jensen et al., 2006) in the tumour and 
surrounding stromal cells (Fukumura et al., 1998) also increases tumour 
angiogenesis (Rak et al., 1995). Bevacizumab and ranibizumab (Yang  et al., 2003, 
Saltz et al., 2008, Giantonio et al., 2007), VEGF targeting monoclonal antibody 
treatments, and sorafenib, sunitinib and pazopanib (Bergh et al., 2012, Escudier et 
al., 2009, Cheng et al., 2013, Sternberg et al., 2010), multikinase inhibitors known to 
affect the VEGF receptors, have been found to be highly effective alone and in 
combination therapies at reducing a range of metastatic cancers. VEGF is also 
associated with wet age-related macular degeneration. Unnecessary blood vessel 
generation in the tissues of the eye stimulated by increased VEGF expression 
(Kvanta et al., 1996, Kliffen et al., 1997) results in fibrosis and a loss of vision clarity 
(Friedlander, 2007). The anti-VEGF therapy ranibizumab has been approved for use 
in the NHS for treatment of this VEGF associated macular degeneration (Rosenfeld  
et al., 2006, Brown et al., 2009).  
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1.12.2  Side effects of anti-VEGF treatments 
In recent years there have been reports of side-effects of anti-VEGF therapies. 
However, a recent meta-analysis of intravitreal monoclonal anti-VEGF treatments 
did not associate the treatment with increased CVD events or mortality risk, 
although there was a link with venous thromboembolic events and non-ocular 
haemorrhage (Thulliez et al., 2014). Bevacizumab treatment of cancer has also been 
associated with an increased risk of cardiac ischemia and thromboembolic events 
(Ranpura et al., 2010) while sorafenib is associated with an increased risk of 
hypertension (Wu et al., 2008) although the reason is not understood. This is 
perhaps not overly unexpected as VEGF plays an important role in inducing 
vasodilation and hypotension via NO release (Yang et al., 1996) however it raises 
extra considerations when prescribing the treatment. Anti-VEGF monoclonal 
antibody bevacizumab has been predicted by pharmacokinetic modelling to induce 
higher circulating VEGF levels after intravenous (I.V.) injection, hypothesised to be 
due to reduced VEGF clearance after binding within the monoclonal antibody which 
may explain the thrombotic risk associated with such treatment, although this is 
only identified with Bevacizumab in particular (Stefanini et al., 2010). Furthermore 
the pan-VEGFR tyrosine kinase inhibiting treatments (Ebos et al., 2009) as well as 
VEGFR-2 specific inhibitors (Pàez-Ribes et al., 2009) have been found to accelerate 
tumour metastasis in animal models. There has not been reported increases in 
metastasis in the clinical trials of anti-VEGF treatments although anti-VEGF 
treatment of mice transplanted with human glioblastoma cells had reduced tumour 
blood vessel density but increased hypoxia induced invasion into healthy tissue 
(Keunen et al., 2011) suggesting that further understanding of the effects of VEGF 
inhibition is needed.   
1.12.3  Association of VEGF with cardiovascular disease 
Increasing evidence suggests that growth factors and particularly VEGF or its 
associated signalling pathways contribute to atherosclerosis (Blann et al., 2002, 
Fleisch et al., 1999). Angiogenesis and neovascularisation have been known to play 
a role in cardiovascular disease for some time (Khurana et al., 2005). Under normal 
conditions the inner lining of the artery wall, the intima, is supplied sufficient 
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nourishment without its own specific network of vessels. However, this capacity is 
limited and during atherosclerotic development as the intima expands beyond this 
diffusible distance resulting in a loss of the supply of the necessary compounds for 
growth, including oxygen, to the core of these tissues. This stimulates new blood 
vessel generation from the vasa vasorum, the network of vessels supplying bigger 
vessels, to support the growing plaque (Bjornheden et al., 1999) The generation of 
these vessels is linked with an upregulation of hypoxia inducible factor 1α (HIF1α) 
(Kuwahara et al., 2002), a known activator of VEGF transcription (Hirota and 
Semenza, 2006), and allows for the continual supply of the building blocks of the 
atherosclerotic plaque. In both humans and mice the link between increased 
atherosclerotic disease and vessel wall neovascularisation is demonstrated by an 
increase in blood supply to the aortic tissue correlating to characteristics of 
advancing atherosclerosis, such as necrotic core formation (Hiyama et al., 2010, 
Juan-Babot et al., 2003, Fleiner et al., 2004) and increased risk of plaque 
vulnerability and rupture (Virmani et al., 2005). In the ApoE-/- model known 
angiogenesis inhibitors significantly reduced the atherosclerotic lesion size by up to 
85 % (Moulton et al., 1999). Following a review of plasma VEGF levels in the 
Framingham study participants (the largest continuous CVD epidemiological study 
to date (Dawber et al., 1951)) demonstrated that those in the second and third 
quartiles of plasma VEGF levels had an increased risk of CVD of 34 % and 59 % 
respectively compared to the first quartile (Kaess et al., 2016) although, 
interestingly, in the fourth quartile with the highest VEGF levels this association was 
not observed. Another study concluded VEGF serum concentration could become a 
useful prognostic factor for atherosclerosis due to correlation with CVD risk factors, 
particularly in men (Kimura et al., 2007). Although it is important to note that not all 
studies have observed this strong link (Sandhofer et al., 2009, Alber et al., 2005) an 
increase in intra-plaque VEGF and VEGFR-2 levels have been associated with 
neovascularisation and greater macrophage density of the atherosclerotic plaque 
(Ma et al., 2016, Inoue et al., 1998, Chen et al., 1999). Plasma VEGF levels have also 
been compared with patient angiograms, showing VEGF levels were significantly 
higher in the critical lesion group, but not the non-critical lesion group, when 
compared to the control (Kucukardali et al., 2008). This supports the notion that 
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angiogenesis is important during advancing and dangerous atherosclerosis and may 
offer an explanation why contradictory reports on the relevance of circulating VEGF 
levels are found in the literature when all levels of disease are taken into account. 
Diseases such as type-I diabetes (Iacobellis et al., 2004) and systemic lupus 
erythematosus (SLE) (Colombo et al., 2009) are associated with increased risk of 
CVD and have increased VEGF levels which, in the case of SLE, was associated with 
increased intima media thickness (IMT) of the carotid artery.  
1.12.4  The role of VEGF in atherosclerosis 
Direct evidence of the stimulatory action of VEGF on atherosclerotic plaque growth 
has been observed in ApoE-/- ApoB100-/- mice and New Zealand white rabbits. The 
plaque area in the aortic arch was significantly increased following a single 
intraperitoneal injection of VEGF versus a serum albumin control. The VEGF 
injection also induced greater macrophage infiltration and vascularisation of the 
plaque (Celletti et al., 2001a, Celletti et al., 2001b). Similarly in the ApoE-/- model, 
but not other cholesterol driven atherosclerosis models, adenoviral gene transfer 
caused high systemic VEGF expression levels and induced the progression of 
atherosclerosis (Heinonen et al., 2013). Using the VEGF injected rabbit model, it 
was also demonstrated that the VEGF induced progression of atherosclerotic 
disease could be significantly reduced by paclitaxel and angiostatin treatment 
(Celletti et al., 2002). Together, these reports demonstrate that VEGF, and 
specifically the VEGF165 isoform, is capable of driving atherosclerosis progression by 
increasing the angiogenic potency of vascular tissues, and that anti-angiogenic 
therapies can block the pro-atherosclerotic action of VEGF. Vaccination against 
VEGFR-2 resulted in a 77% reduction in the formation of new lesions and limited 
progression of atherosclerosis by 66% in hypercholesterolaemic models (Hauer et 
al., 2007, Petrovan et al., 2007) suggesting the angiogenic actions of VEGF through 
VEGFR-2 are associated with its atherogenic potential. However, in the ApoE-/- 
mouse model a pan-VEGF receptor inhibitor which blocks not only the actions of 
VEGFR-2 but of VEGFR-1 and VEGFR-3 as well (Winnik et al., 2013) significantly 
increased atherosclerotic plaque area in comparison to controls. Perhaps this is due 
to the key role of VEGF in endothelial maintenance (Horowitz et al., 1997) and 
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blood vessel generation following injury (Couffinhal et al., 1999) as there is a risk 
that complete inhibition of VEGF activity could negatively impact cardiovascular 
health, as has been suggested is the case for anti-VEGF monoclonal treatments for 
other diseases. Nevertheless, these studies demonstrate the need for further 
investigation into the role of VEGF in atherosclerosis but suggest that regulation of 
raised VEGF levels may still be an important avenue of investigation as treatment 
for atherosclerotic disease.  
1.13 VEGF signalling within the atherosclerotic plaque  
VEGF signalling is a necessity for normal vascular health and critical in new vascular 
development (Carmeliet et al., 1996). Given this critical role it is regulated in a 
complex manner with many different cell types being able to secrete VEGF 
(Pertovaara et al., 1994, Taichman et al., 1997, Namiki et al., 1995), including 
macrophages (McLaren et al., 1996). In pathological angiogenesis VEGF signalling 
can be initiated in an autocrine (Soker et al., 2001), paracrine (Villegas et al., 2005) 
or intracrine (Bhattacharya et al., 2016) manner. Circulating VEGF levels are higher 
in patients with severe atherosclerotic lesions (Kucukardali et al., 2008) and VEGF 
levels in tissue are found to be higher in atherosclerotic plaque sites (Ho-Tin-Noe et 
al., 2011) demonstrating that VEGF is not only raised in systemic circulation (Kimura 
et al., 2007, Blann et al., 2002, Fleisch et al., 1999) but also localised within the 
plaque itself. The morphology of atherosclerosis may provide insight into why 
raised VEGF levels are associated with atherosclerotic plaque. One of the earliest 
stages of atherosclerosis development is the build-up of oxidised low density 
lipoprotein (OxLDL) laden macrophages (foam cells) in the artery wall. The uptake 
of OxLDL has been shown to stimulate macrophages to release VEGF protein (Riazy 
et al., 2009) and to cause macrophage associated accumulation of VEGF in the 
atherosclerotic plaque (Ramos et al., 1998, Inoue et al., 2001) even at the early 
stages of plaque formation. Macrophages have also demonstrated a novel role in 
vascular tip cell fusion and therefore creating new vascular networks (Fantin et al., 
2010). A high cholesterol diet is associated with VEGF expressing macrophage 
induction of angiogenesis in atherosclerosis (Hutter et al., 2013). Further 
recruitment of inflammatory cells occurs in atherosclerosis through secretion of 
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chemokines by plaque associated tissues (Wezel et al., 2015). The immune system 
is also plays a role in regulating pathological VEGF-induced angiogenesis in retinal 
vascular related disease with some cases requiring immune suppression and anti-
VEGF treatment to limit angiogenic progression (Sene et al., 2015).  
Hypoxia is also able to induce recruitment of neutrophils to the atherosclerotic 
plaque resulting in pro-angiogenic expression of MMP9 which encourages release 
of VEGF from the extracellular matrix within the plaque (Christoffersson et al., 
2012). Equally hypoxia is known be present within the atherosclerotic plaque as 
HIF1α expression was seen within endothelial cells of lesions in the ApoE-/- mouse 
model (Akhtar et al., 2015). VEGF expression is directly induced by HIF1α as it binds 
to the promoter region of the VEGF gene and directly increases VEGF protein 
expression (Liu et al., 1995).  
Extracellular matrix components form a critical part of developing atherosclerosis, 
for example fibronectin is associated with wound repair in the developing plaque 
and is found in up 80 % of early plaques in humans (Kakolyris et al., 1995). It is also 
capable of acting as a VEGF store and being associated with promotion of new 
vascular networks though orchestrating VEGF gradients (Ruhrberg et al., 2002, 
Stenzel et al., 2011), with critical VEGF-induced branching not occurring when the 
interaction of VEGF and fibronectin is interrupted (Wijelath et al., 2002). 
Furthermore, the circulatory VEGF121 is able to bind to the extracellular matrix in 
acidic conditions as induced in hypoxic tissues (Goerges and Nugent, 2004), and 
could therefore have the potential to upregulate VEGF signalling in fibronectin rich, 
hypoxic conditions (Reynolds et al., 2009). It could be suggested that VEGF activity 
would also be upregulated by the increase in fibronectin, collagen and other 
extracellular components of a growing atherosclerotic plaque, even from the early 
stages of plaque development. 
Platelet aggregation and activation is associated with progressive and unstable 
atherosclerosis (Huo et al., 2003) as well as the release platelet derived VEGF 
(Wartiovaara et al., 1998). Platelet VEGF itself has been identified in the fibrin 
networks of atherosclerotic thrombotic tissues (Arisato et al., 2003) with platelet 
aggregation also resulting in the release of pro-angiogenic compounds such as 
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MMP’s (Sawicki et al., 1997) which have been shown to induce the release of VEGF 
from the fibrinogen network in pathological angiogenesis (Belotti et al., 2003).  
 Furthermore, LDL can bind to VEGFR-1 and stimulate autophosphorylation, 
internalisation and degradation (Usui et al., 2007) while Apolipoprotein B has been 
shown to downregulate VEGFR-1 expression in hyperlipidaemic mice (Avraham-
Davidi et al., 2012). This reduces the VEGFR-1 able to act as a sink for the VEGF 
ligand in epithelium rich in these compounds, as would be found in atherosclerotic 
plaque sites, which may result in more free VEGF available to stimulate VEGFR-2 
associated angiogenic signalling.  
1.14 Effect of polyphenols on VEGF signalling 
1.14.1  Polyphenol effects on VEGF gene and protein expression 
Determining VEGF and VEGF receptor gene and protein expression is one method 
by which the effects of polyphenols on VEGF signalling have been investigated. 
While there are a few reports of an increase in VEGF gene (Lin et al., 2010, 
Nicholson et al., 2010) and protein expression (Oak et al., 2006, Lin et al., 2010) a 
wide variety of polyphenols have demonstrated the opposite effect, eliciting strong 
inhibition of VEGF gene and protein expression, including rutin (Guruvayoorappan 
and Kuttan, 2007), quercetin (Oh et al., 2010, Pratheeshkumar et al., 2012), 
kaempferol (Luo et al., 2012, Luo et al., 2009), delphinidin, resveratrol (Dann et al., 
2009), cyanidin (Oak et al., 2006), and EGCG (Lee et al., 2004, Dann et al., 2009) 
treatment. These studies focus on longer incubation times of between 3 and 24 
hours predominantly in unstimulated cells however stimulation with hypoxic 
conditions, hydrogen peroxide (H2O2), or platelet derived growth factor have also 
been undertaken. The concentrations that have previously demonstrated an effect 
range from 1 - 100 µM. For example, at 30 µM a range of polyphenols all 
demonstrated inhibition of VEGF gene expression in unstimulated MCF-7 breast 
cancer cells following 18 hour treatment, but with a range of efficacies. Quercetin 
was the most effective (74 % inhibition) followed by silibinin (65 %), apigenin (47 
%), morin (43 %), and naringenin (28 %). Conversely, 1 µM quercetin treatment of 
unstimulated HUVECs for 24 hours demonstrated an upregulation of VEGF gene 
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expression although treatment of HUVECs with the same dose of quercetin in 
combination with H2O2 for 24 hours caused a reduction in VEGF gene expression. 
Perhaps this suggests that quercetin inhibition of VEGF gene expression is only 
occurring in conditions where VEGF is upregulated such as cancer cells or after H2O2 
treatment, a known VEGF stimulant (Cisowski et al., 2005). VEGFR-2 protein 
expression has also been shown to be downregulated in unstimulated SW837 
adenocarcinoma cells following 24 hour incubation with 50 µM EGCG (Shimizu et 
al., 2010).  
1.14.2  Polyphenol effects on VEGFR-2 phosphorylation  
A variety of dietary polyphenols can affect VEGFR-2 phosphorylation. Delphinidin, 
cyanidin, the green tea catechins, scopoletin, ellagic acid, and wogonin among 
others have demonstrated inhibition of this key angiogenesis stimulating receptor 
(Huang et al., 2012, Lamy et al., 2006, Wen et al., 2008, Lamy et al., 2002, Lee et al., 
2004, Liu et al., 2008, Neuhaus et al., 2004, Rodriguez et al., 2006, Lu et al., 2008, 
Shimizu et al., 2010, Pan et al., 2011, Cerezo et al., 2015, Moyle et al., 2015). These 
studies all differ in both the polyphenol incubation time which ranged from 5 
minutes – 24 hours and the VEGF stimulation time which ranged from 0 – 10 
minutes. The majority of these studies undertook long duration pre-treatment with 
the polyphenol prior to a short VEGF stimulation. Of the polyphenols tested in this 
manner some effects were observed at comparatively low concentrations, for 
example, delphinidin at 2 µM inhibited around 50 % VEGF stimulated VEGFR-2 
phosphorylation in HUVECs following an 18 hour pre-treatment (Lamy et al., 2006). 
Ellagic acid inhibited 48 % VEGFR-2 phosphorylation in bovine aortic endothelial 
cells (BAECs) at 5 µM for the same pre-treatment duration of 18 hours (Labrecque 
et al., 2005). 60 minute pre-treatment of HUVECs with up to 100 µM EGCG 
significantly reduced the binding of labelled VEGF suggesting this pre-treatment 
blocked this interaction (Kondo et al., 2002) while silico modelling suggested that 
ellagic acid was predicted to bind the VEGFR-2 at the receptor binding region (Wang 
et al., 2012) suggesting a possible mechanism for the polyphenol inhibition of VEGF-
induced VEGFR-2 phosphorylation. More recently however polyphenols have been 
shown to exert potent inhibition of VEGF-induced VEGFR-2 phosphorylation. In 
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these studies the polyphenol was mixed with VEGF for 5 minutes prior to being 
used to treat HUVECs for 5 minutes. The concentration required to elicit 50 % 
inhibition was used as a comparator. Many polyphenols demonstrated inhibition in 
this model at nanomolar or micromolar concentrations. The most potent of these 
were EGCG (88 nM), catechin gallate (94 nM), quercetagetin (96 nM), myrecetin 
(121 nM), epicatechin gallate (160nM), ellagic acid (230 nM), and procyanidin d.p 4 
(280 nM). Furthermore, it was reported that while quercetin was able to inhibit 50 
% VEGF-induced VEGFR-2 phosphorylation at 754 nM all quercetin glycosides tested 
were unable in inhibit at any concentration tested (Cerezo et al., 2015). It was also 
demonstrated that following pre-mixing of VEGF with EGCG, VEGF could not 
recover VEGFR-2 phosphorylation activity even after dialysis suggesting that the 
polyphenol was able to bind to the VEGF ligand to cause the observed inhibition 
(Moyle et al., 2015). This hypothesis was supported through in silico modelling 
which demonstrated a correlation between the predicted strength of binding to 
VEGF and the potency of inhibition of VEGFR-2 phosphorylation (Cerezo et al., 
2015).  
1.14.3  Polyphenol effects on downstream VEGF signalling partners  
The effect of polyphenols on downstream VEGF signalling has also been 
investigated. ERK1/2 and MAPK inhibition is seen after treatment with a variety of 
diet derived polyphenols in vitro either by inhibiting phosphorylation or expression 
(Neuhaus et al., 2004, Luo et al., 2012, Pan et al., 2011, Kim et al., 2007b, Jung et 
al., 2009) although only resveratrol (Lin et al., 2003), ellagic acid (Labrecque et al., 
2005) and EGCG (Neuhaus et al., 2004) have specifically demonstrated inhibition of 
VEGF-induced ERK phosphorylation. Interestingly 20 µM Kaempferol, apigenin or 
luteolin stimulation for differing lengths of time induced phosphorylation of ERK 
although none of these treatments used VEGF to induce phosphorylation (Luo et 
al., 2009, Lamy et al., 2012). NFκB protein levels and activation were observed to be 
lower in cells treated with kaempferol and EGCG respectively (Luo et al., 2012, Kim 
et al., 2007b). Furthermore, 16 weeks dietary intervention with Naringenin in rats 
reduced hepatic expression of NFκB (Subramanian and Arul, 2012). VEGF-
stimulated phosphorylation of AKT and/or eNOS was also shown to be reduced in a 
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concentration dependent manner by EGCG (Rodriguez et al., 2006, Tang et al., 
2003) and scopoletin (Pan et al., 2011) while general inhibition of AKT was 
demonstrated with acacetin, quercetin and kaempferol (Luo et al., 2009, Liu et al., 
2011, Oh et al., 2010).  
1.15 Effect of polyphenols on VEGF associated physiological 
responses 
1.15.1  Polyphenol effects on VEGF associated cell signalling in vitro 
The effect of polyphenols on the key physiological outcomes following VEGF 
stimulation has also been investigated. Cell proliferation can be inhibited by food 
extracts containing polyphenols such as grape seed extract or green tea extract 
(Kojima-Yuasa et al., 2003, Wen et al., 2008, Chen et al., 2011a) although these 
results must be interpreted with caution as there is no way to determine which 
component of the complex extract will be causing the effect. The effect if individual 
polyphenol treatment has also been investigated using for example the tea 
catechins EC, EGC, ECG, and EGCG, among others (Luo et al., 2012, Jung et al., 2009, 
Guruvayoorappan and Kuttan, 2007, Kondo et al., 2002). Naringenin at 1 µM was 
able to significantly reduce mouse aortic smooth muscle cell proliferation following 
3 days of PP treatment (Chanet et al., 2012) while delphinidin and gallic acid have 
both increased the number of cells in cell cycle arrest after VEGF stimulation (Hseu 
et al., 2011, Favot et al., 2003). Cell migration has been inhibited by a wide variety 
of polyphenols e.g. resveratrol, quercetin, and delphinidin (Scoditti et al., 2012, 
Lamy et al., 2006) and decursin and wogonin extracted from plants (Lu et al., 2008, 
Jung et al., 2009). The green tea catechins each demonstrated different potential to 
inhibit VEGF-induced HUVEC migration, mirroring the results from the studies into 
inhibition of VEGFR-2 phosphorylation with the galloylated catechins proving more 
effective (Kondo et al., 2002).  
1.15.2  Polyphenol effects on angiogenesis in vitro 
The tube formation of HUVECs is a popular angiogenesis assay in the literature 
however comes with the limitation that it models vasculogenesis rather than 
angiogenesis. This model seeds vascular cells between two layers of an extracellular 
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matrix allowing them to grow over a set period of time after which the number of 
tubes or branch points is quantified. Scopoletin, delphinidin, resveratrol, and the 
green tea catechins have all been reported to inhibit VEGF-induced tube formation 
in this model (Pan et al., 2011, Lamy et al., 2006, Lin et al., 2003, Liu et al., 2008, 
Tang et al., 2003, Pratheeshkumar et al., 2012) while galloylation of the catechins 
proved an important structural aspect to increase potency (Kondo et al., 2002). 
Resveratrol was a particularly potent inhibitor in this model being able to inhibit 
over 50 % of VEGF induced tube formation at the low concentration of 1 µM (Lin et 
al., 2003). Other polyphenols have also demonstrated an inhibition of unstimulated 
tube formation including delphinidin and the green tea catechins as mentioned 
above (Labrecque et al., 2005, Lamy et al., 2006, Guruvayoorappan and Kuttan, 
2007, Lamy et al., 2002, Kondo et al., 2002, Liu et al., 2008) although it should be 
noted that one study identified ferulic acid as a stimulant of tube formation (Lin et 
al., 2010). Ellagic acid was one of the polyphenols which demonstrated an inhibitory 
effect on endogenous tube formation at a supra-physiological concentration of 5 
µM (Labrecque et al., 2005).  
1.15.3  Polyphenol effect on angiogenesis ex vivo 
The aortic ring assay involves embedding aortic tissue into an extracellular matrix 
and reporting the number of new vessel which grow, typically stimulated by VEGF. 
Quercetin, rutin, resveratrol, and ellagic acid among others (Chen and S. Easton, 
2011, Wang et al., 2012, Pratheeshkumar et al., 2012, Guruvayoorappan and 
Kuttan, 2007, Matsubara et al., 2005) as well as a number of polyphenol rich 
extracts (Lu et al., 2010, Wen et al., 2008, Kang et al., 2013, Daleprane et al., 2012) 
have been able to inhibit new vessel generation from ex vivo aortic tissue. 
Quercetin demonstrated anti-angiogenic at 20 µM concentrations and above 
(Pratheeshkumar et al., 2012) while rutin significantly inhibited angiogenesis at a 25 
µg/ml concentration (Guruvayoorappan and Kuttan, 2007). Catechin however was 
not able to inhibit new vessel generation in the aortic ring assay (Negrão et al., 
2013).  
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1.15.4  Polyphenol effects on angiogenesis in vivo 
The chick chorioallantoic membrane (CAM) assay involves placing the polyphenol 
treatment onto the membrane just beneath a removed portion of the egg shell and 
the numbers of blood vessels or vessel branches are quantified as a measure of 
angiogenesis. Once again polyphenol rich extracts (Maiti et al., 2003, Toi et al., 
2003)  and a range of polyphenols were able to inhibit this angiogenesis (Pan et al., 
2011, Pratheeshkumar et al., 2012, Oh et al., 2010, Hseu et al., 2011, Favot et al., 
2003) with quercetin (Pratheeshkumar et al., 2012) and resveratrol (Brakenhielm et 
al., 2001) demonstrating inhibition of blood vessel formation albeit at high 
concentrations while ellagic acid was able to inhibit 90 % of VEGF stimulated 
angiogenesis in this model at 10 µM concentration (Wang et al., 2012). Another key 
model for in vivo angiogenesis is the matrigel plug assay where a matrigel bolus 
containing the polyphenol in injected into an in vivo incubation site, e.g. the hind 
limb of an animal, and the angiogenesis quantified typically by haemoglobin 
content at the end of the study. Inclusion of three polyphenols found in hops at 10 
µM limited VEGF induced haemoglobin build-up in the matrigel plug (Negrão et al., 
2010). Delphinidin, kaempferol, quercetin, apigenin, and luteolin (Lamy et al., 2006, 
Luo et al., 2009, Pratheeshkumar et al., 2012, Lamy et al., 2008) were all able to 
inhibit vascularisation of the matrigel plug, with apigenin demonstrating around 45 
% inhibition at a 25 µM concentration (Lamy et al., 2008). Following a separate 
experiment where a VEGF and polyphenol loaded pellet into was implanted in the 
eye the conjugate quercetin-3-glucuronide, but not quercetin-3-sulphate, could 
significantly inhibit VEGF induced in vivo angiogenesis (Donnini et al., 2006) 
demonstrating the difference in biological activity that can occur with different 
metabolites of the same polyphenol. In a modified version of this model where 
cancer cell lines are included into the matrigel plug alongside the polyphenol, 
tumour size as well as haemoglobin content has been reported to be inhibited by 
polyphenols. A polyphenol rich cinnamon extract reduced the haemoglobin content 
of the matrigel plug containing adenocarcinoma cells (Lu et al., 2010). Curcumin 
was also able to limit the vessel generation, as measured by haemoglobin content, 
of the same cell line at a 30 µM concentration (Chakraborty et al., 2008). 
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Kaempferol was also efficient at limiting both tumour size (46 %) and haemoglobin 
content (39 %) at 20 µM (Luo et al., 2009). Intraperitoneal (I.P.) injections of 50 
mg/kg ellagic acid reduced tumour volume following implantation of 
adenocarcinoma cell line, although the haemoglobin content of the tumour was not 
measured (Wang et al., 2012).  
1.16 Objectives for the thesis  
Considering the previous literature described in this chapter there are two key aims 
for this thesis. 1) to investigate if and how dietary polyphenols could inhibit VEGF 
induced VEGFR-2 phosphorylation in HUVECs, 2) to determine whether the 
polyphenols which elicit potent inhibition of VEGF induced VEGFR-2 
phosphorylation could, in turn, inhibit VEGF induced atherosclerosis.  
To complete these aims a number of objectives were required to be met. The 
objectives per chapter are outlined below:  
 The objective for chapter 2 is to determine the inhibitory capacity of the 
bioavailable green tea and pomegranate polyphenols on VEGF-induced 
VEGFR-2 phosphorylation at physiological concentrations, including the 
microbial metabolites, the urolithins, which are often overlooked.  
 The objective for chapter 3 is to determine whether VEGF supplementation 
via I.P. injection can induce atherosclerosis in a high cholesterol fed ApoE-/- 
mouse model, and determine the impact of dietary and injected EGCG and 
ellagic acid in this model.  
 The objective for chapter 4 was to explore the ability of polyphenols to 
inhibit VEGF-induced-VEGFR-2 phosphorylation in a more physiological in 
vitro model and understand the impact serum proteins can have on 
polyphenol activity. 
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2.1  Abstract 
VEGF signalling stimulates angiogenesis however upregulation of VEGF signalling is 
also responsible for pathological angiogenesis. Polyphenols can affect VEGF 
signalling however for the most part research is undertaken at supra-physiological 
concentrations, using long incubation times, and overlooking the importance of 
polyphenol metabolites which limit the conclusions which can be drawn.  
In this chapter VEGFR-2 phosphorylation was measured in HUVECs after stimulation 
with VEGF in the presence of a range of concentrations of EGCG, punicalagin or 
ellagic acid (EA) as well as the ellagic acid microbial metabolites urolithin A, B, C and 
D and urolithin A and B glucuronide for 5 minutes. The results were used to 
calculate the concentration required to inhibit 50 % VEGF-induced VEGFR-2 
phosphorylation (IC50) for each polyphenol. Experiments were also conducted 
which determined whether the polyphenols inhibited VEGF-induced VEGFR-2 
phosphorylation through actions on the VEGF ligand or the cell.  
EGCG, punicalagin and ellagic acid were demonstrated as potent and rapid 
inhibitors of VEGF-stimulated VEGFR-2 phosphorylation with IC50 values of 96, 49 
and 310 nM respectively. Moreover, the main pomegranate microbial metabolites, 
the urolithins, were also effective inhibitors. The loss of one hydroxyl group from 
urolithin D, to urolithin C, then urolithin A and finally urolithin B reduced the 
inhibitory activity (IC50 values were 0.2, 3.7, 54, and 251 µM respectively). The 
urolithin glucuronides were ineffective inhibitors at the concentrations tested. It 
was also demonstrated that punicalagin tested elicited their inhibitory effect 
predominantly by interacting with the VEGF ligand and not the cell.  
The data presented in this chapter provides a strong indication that EGCG and EA 
are able to inhibit VEGF-induced VEGFR-2 phosphorylation at physiologically 
relevant concentrations via interactions with the VEGF ligand. Metabolism of the 
urolithin compounds reduces their efficacy at inhibiting VEGF signalling however 
urolithin D and urolithin C could inhibit VEGF signalling at concentrations close to 
those found in the plasma. Both EGCG and EA are viable candidates for further 
investigation into the polyphenol inhibition of pathological angiogenesis. 
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2.2  Introduction 
Chapter 1 outlined the current understanding of the role of VEGF in angiogenesis, 
of angiogenesis in atherosclerosis, and of VEGF in atherosclerosis, as well as the 
current understanding of the effect of polyphenols on these processes. 
Investigations into the effects of polyphenols on VEGF expression and signalling in 
vitro, until recently, have primarily been undertaken at supra-physiological 
concentrations without taking into account bioavailability or the physiologically 
relevant polyphenol metabolites. This chapter will focus on the impact of 
physiologically relevant polyphenols on inhibition of VEGF signalling.  
2.2.1 The VEGF protein 
As described in the general introduction VEGF is the primary growth factor 
responsible for angiogenesis (Ferrara, 2009) through binding to a family of tyrosine 
kinase receptors known as the VEGF receptors, aided by co-receptors and 
extracellular complexes such as heparin (Ferrara et al., 2003). There are multi 
isoforms of VEGF formed through alternative splicing (Krilleke et al., 2009) or 
proteolytic processing (Ferrara, 2010) however this chapter will focus on the 
VEGFA165 (or VEGFA164 in mice) as it is the predominant isoform responsible for 
VEGF signalling and will simply be referred to as VEGF. VEGF phosphorylation of the 
VEGFR-2 dimer pair leading to angiogenesis associated signalling. The focus of this 
chapter is on the activities of VEGFR-2 homodimer receptor pair as it is the primary 
VEGF receptor responsible for the angiogenesis and neoangiogenesis in the body, 
including pathological angiogenesis (Goodlad et al., 2006, Doi et al., 2012) as well as 
being the receptor associated with the response of endothelial cells to VEGF 
stimulation in vitro (Endo et al., 2003). 
2.2.2 The VEGF/VEGFR-2 signalling pathway 
Upon VEGF ligand binding the VEGF receptor dimer pair switch from their inactive 
to active state (Sarabipour et al., 2016). Signal transduction occurs via tyrosine 
phosphorylation sites located along the cytoplasmic domain with each 
phosphorylation site stimulating a distinct set of secondary signalling molecules. 
Tyrosine 1054 and 1059 residues are highly conserved across all 3 VEGF receptors 
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due to their integral role in the kinase activation loop. Without activation of these 
phosphorylation sites only 10% of the receptor activation is able to occur (Dougher 
and Terman, 1999). The tyrosine 951 site is found in the kinase insert domain of the 
receptor. It contributes to Y1175 phosphorylation (Manni et al., 2014) and 
stimulates membrane bound c-SRC signalling (Sun et al., 2012), vascular 
permeability and b-Raf dependent cell proliferation (Matsumoto et al., 2005). 
Phosphorylation at tyrosine 1175 is known to stimulate the majority of 
angiogenesis signalling by the VEGFR-2 receptor, emphasised by experiments where 
a mutation at this site induced embryonic death with a similar phenotype to VEGFR-
2 null mice (Sakurai et al., 2005b). Signalling from this residue stimulates a number 
of pathways including the phosphoinositol-3-kinase (PI3K) pathway (Holmqvist et 
al., 2004), leading to AKT (Cantley, 2002) and eNOS (Fulton et al., 1999) production 
for cell survival and vascular permeability respectively, and the Plc-γ pathway 
leading to altered gene expression and endothelial cell migration (Takahashi et al., 
2001). For an overview of the key angiogenesis associated VEGF-induced VEGFR-2 
signalling pathways see Figure 1.8.  
2.2.3 Bioavailability of green tea and pomegranate polyphenols 
The bioavailability of polyphenols is an important consideration when investigating 
their biological action in relation to health. For the polyphenol to elicit the 
beneficial effect in vivo the polyphenol will need to reach an active concentration at 
the location where the biological effect occurs. VEGFR-2 is a membrane bound 
receptor, with the stimulant VEGF found in circulation. Therefore, when discussing 
the effect of polyphenols on VEGF signalling it is important to relate that to the 
concentration the polyphenol can reach in plasma.  
Investigations into green tea polyphenol bioavailability have provided varying 
results. In humans a high dose (1600 mg) was reported to produce an EGCG plasma 
concentration of 7 µM (Ullmann et al., 2003) while a lower dose of 193 mg green 
tea catechins in tea resulted in 174 nM EGCG maximum concentrations in plasma 
(Cmax) although bioavailability of EGCG appears to be improved when given as a 
supplement (Henning et al., 2004). Interestingly EGCG is the only polyphenol found 
predominantly unconjugated within human plasma following ingestion (Ullmann et 
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al., 2003, Chow et al., 2001, Meng et al., 2002, Lee et al., 2002). However, in mice it 
has been reported that EGCG become rapidly glucuronidated after ingestion 
(Lambert et al., 2003) although EGCG plasma concentrations of 31-50 nM have 
been reported (Lambert et al., 2003, Dube et al., 2011a, Lambert et al., 2004). 
Encapsulation of EGCG in nanoparticles increased the polyphenol bioavailability 1.5-
fold due to increased stability under gastric conditions (Dube et al., 2011b).  
The predominant ellagitannin in pomegranates, punicalagin, is thought to be very 
poorly bioavailable although was found in rat plasma at 30 µg/ml following feeding 
with a 6 % punicalagin supplemented diet (Cerda et al., 2003) but this has not been 
observed in any other species including numerous human intervention trials 
(Seeram et al., 2004, Cerda et al., 2004, Seeram et al., 2006). However the 
polyphenol ellagic acid, which is found in the pomegranate fruit as well as being the 
product of punicalagin hydrolysis, is frequently detected in human plasma with Cmax 
values of 20-100 nM after consumption of pomegranate juice or extracts (Seeram 
et al., 2004, Seeram et al., 2006, Mertens-Talcott et al., 2006). Furthermore feeding 
of pure ellagic acid resulted in higher plasma concentrations of up to 660 nM 
(Hamad et al., 2009). In rats peak plasma ellagic acid concentrations of 16.5 µM 
have been reported (Hamad et al., 2009) although other reports limit this 
concentration to around 200 nM (Murugan et al., 2009, Lei et al., 2003). Research 
into the bioavailability of ellagic acid in mice is limited however one report found it 
in plasma at 38 nM after a 0.8 mg dose (Seeram et al., 2007). However, it has been 
suggested that the microbial metabolite products of ellagic acid, the urolithins, 
reach far greater quantities in the plasma than the parent compounds. The 
concentration of the urolithins in human plasma was reported to exceed 18 µM 
(Cerda et al., 2004) and for this reason the urolithins have been suggested as the 
bioactive compound associated with the health benefits of pomegranate. An 
overview of the ellagic acid metabolism to the main urolithin compounds can be 
seen in Figure 2.1 
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Urolithin D
Urolithin C
Urolithin A
Urolithin B Urolithin B glucuronide
Urolithin A glucuronide
Ellagic acid
 
Figure 2.1: Structures and metabolic path production of the microbial 
metabolites of ellagic acid, the urolithins, and their glucuronides.  
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2.2.4 Effect of polyphenols on VEGF signalling  
Inhibition of VEGFR-2 phosphorylation by a wide variety of polyphenols has been 
reported in a large range of cell types. EGCG and ellagic acid have both 
demonstrated inhibition of VEGFR-2 phosphorylation, receptor tyrosine kinase 
activity and phosphorylation of downstream VEGF signalling partners (Neuhaus et 
al., 2004, Rodriguez et al., 2006, Shimizu et al., 2010, Tang et al., 2003, Labrecque et 
al., 2005). EGCG has also been shown to downregulate VEGF gene expression as 
well as VEGF and VEGFR-2 protein expression. However, these observations were 
made at supra-physiological concentrations with effective treatments typically 
ranging from 10 - 50 µM (Shimizu et al., 2010, Lee et al., 2004, Labrecque et al., 
2005). Ellagic acid has demonstrated VEGF inhibitory properties at sub 10 µM 
concentrations. However, long incubation times were used in these studies may 
have led to polyphenol and VEGF instability over time (Wang et al., 2012). Recently, 
both EGCG and ellagic acid were demonstrated to have strong effects at nanomolar 
concentrations on VEGFR-2 phosphorylation in HUVECs after only 5 minutes of 
treatment (Moyle et al., 2015, Cerezo et al., 2015). In an earlier study in silico 
modelling predicted ellagic acid may elicit its VEGF signalling inhibition by binding 
the ATP binding region of VEGFR-2 (Wang et al., 2012). However, Cerezo et al. 
demonstrated a correlation between inhibition of rapid VEGF-stimulated VEGFR-2 
phosphorylation and in silico predicted affinity of the polyphenols for the receptor 
binding region of the VEGF ligand. This suggests that VEGF signalling may be 
affected through polyphenol interactions with the VEGF ligand itself (Cerezo et al., 
2015). 
Studies into the effect of polyphenol metabolites on VEGF signalling are limited. 
Metabolism of polyphenols occurs in a number of ways. The phase-II metabolites, 
quercetin-3-glucuronide and quercetin-3-sulphate, had opposing inhibitory and 
stimulatory activities on the VEGF signalling pathway (Donnini et al., 2006). The 
effects of the microbial metabolites are also an important to consider, especially as 
the inter-individual differences in microbiota may account for the variability in 
results or effects. For example, the anti-proliferative effects of the urolithins 
observed in a number of cancer cells lines was significantly reduced through 
Chapter 2 
60 
 
glucuronidation (González-Sarrías et al., 2014) demonstrating the importance of 
understanding the effects of metabolism and not just the polyphenols found in the 
diet. The effect of any microbial metabolites on VEGF signalling has yet to be 
investigated however it is well documented that research into the bioactivity of 
metabolites is necessary but currently lacking (Selma et al., 2009, Del Rio et al., 
2010). 
2.2.5 Objectives 
The main objectives of this chapter are: 1) to identify polyphenols which 
demonstrate potent inhibition of VEGF-induced VEGFR-2 phosphorylation in 
HUVECs; 2) to determine whether the inhibition of VEGF-induced VEGFR-2 
phosphorylation could be achieved at a biologically relevant concentrations; 3) to 
identify a possible mode of action for polyphenols which elicit potent inhibition of 
VEGF-induced VEGFR-2 in HUVECs; and 4) to determine whether metabolism can 
alter the efficacy of VEGF signalling inhibition.  
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2.3 Material and methods 
2.3.1 Subculture of HUVECs  
All HUVECs subculture and growth was undertaken in EGM-2 full media which is the 
EBM-2 basal media (CC-3156, Lonza Group Ltd.) with all growth aliquots added (CC-
4176, Lonza Group Ltd.). The EGM-2 media will henceforth be known as ‘full 
media’. HUVECs aliquots were thawed in a water bath at 37°C. The aliquot was 
pipetted into warmed full media and thoroughly mixed using 10ml stripettes after 
which, the cell suspension was added drop by drop to the centre of a warmed T75 
or T175 flask (Sarstedt Ltd.) to a density of 3500 cells per cm2. The wells were 
incubated at 37 °C, 5 % CO2 in a Heracell 150i incubator (Thermo Scientific) until 
reaching 80-90 % confluency with the media changed every two days. The cells 
were then removed from the flask by adding trypsin, incubating at 37 °C, 5 % CO2 
for 0.5-1 minute, tapping the sides of the flask to dislodge any stuck cells, and 
washing the flask surface with warmed full media. The trypsinised cell suspension 
was moved to a centrifuge tube. The cells were then spun at 250 x g for 5 minutes 
and the supernatant was carefully removed. The cells were resuspended in 1 ml of 
cryo-SFM freezing media (Promocell) and counted using a Reichert bright-line 
haemocytometer (Sigma Aldrich) under a 10 x magnification on an Olympus CK2 
inverted microscope, after which the total cell density was calculated. The 
remaining cell solution was diluted to the correct cell density as required for its 
planned use in Cryo-SFM, aliquoted into cryovials, and gently frozen in a Mr. Frosty 
cryocontainer (Nalgene, Thermo Fisher Scientific) filled with isopropanol at -80°C. 
After 24 hours the cells were transferred to liquid nitrogen for long term storage. 
2.3.2 Culture of cells in 6 well plates for treatment 
HUVECs were thawed in a water bath at 37°C. The aliquot was pipetted into 
warmed full media and thoroughly mixed using 10ml stripettes, after which 2 ml of 
the cell suspension was added drop by drop to the centre of each well of two 
warmed 6 well plates (Greiner BioOne Ltd) to a density of 3500 cells per cm2. The 
plates were incubated at 37°C, 5% CO2 in a Heracell 150i incubator (Thermo 
Scientific) and media was changed every 2 days until 100% confluency was 
achieved. 
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2.3.3. Determining the IC50 of a polyphenol treatment on VEGFR-2 
phosphorylation in HUVECs 
EBM-2 basal endothelial medium lacking all growth components and FCS (CC-3156, 
Lonza Group Ltd.) was supplemented with Gentamycin/Amphotericin and was 
stored at 4°C for up to one month. From here on in this media will be referred to as 
simply ‘basal media’. Stocks of polyphenols were diluted in DMSO (Sigma Aldrich) to 
a concentration of 1000 x higher than required in the cell treatments and stored at -
20 °C until required. Stocks of recombinant human VEGF165 (300-035S, Reliatech) 
were made from 20 µg lyophilised VEGF reconstituted in phosphate buffered saline 
(PBS) supplemented with 0.2% bovine serum albumin (BSA) to a concentration of 
50 µg/ml. The aliquot of VEGF was defrosted on ice and added to the relevant 
treatments at a concentration of 1:2000 to give a final VEGF concentration of 25 
ng/ml. The polyphenol stocks were added to the appropriate treatments at a 
1:1000 ratio and allowed to mix with the VEGF for 5 minutes at room temperature. 
DMSO was added as a vehicle control to the treatments without polyphenols. 
Confluent HUVECs grown in 6 well plates (Greiner BioOne Ltd.) were washed twice 
with 2 ml PBS warmed to 37 °C. After the 5 minute pre-mixing of the VEGF and 
polyphenol the treatments were added to the appropriate wells and incubated at 
37 °C, 5% CO2 for 5 minutes. The cells were then washed with 2 ml ice cold PBS 
twice after which 50 µl cell lysis buffer supplemented with 1mM 
Phenylmethanesulfonyl fluoride solution (PMSF) according to manufacturer’s 
instructions (#9803, Cell Signalling Technology, Inc). Plates were kept at 4 °C for a 
minimum of 15 minutes after which cells were scraped (541070, Greiner BioOne 
Ltd.) and the lysates collected. Each lysate was vortexed for 20 seconds, three times 
at maximum speed with breaks on ice between each vortex. The lysates were then 
centrifuged for 10 minutes at 13,000 x g at 4 °C and the supernatant was collected 
in a separate tube. A 5 µl aliquot of each sample was taken prior to freezing to use 
to determine the total protein concentration in each sample. The sample and 5 µl 
aliquot were frozen and stored at -80 °C until analysis could be performed. An 
overview of the workflow for this assay can be seen in Figure 2.2. 
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Figure 2.2: An overview of the work flow required to determine an IC50 
value described in section 2.3.3  
2.3.4 Determining where the polyphenol acts to elicit any observed 
inhibitory effects. 
As before stocks of polyphenols and recombinant human VEGF165 (300-035S, 
Reliatech) were made as described earlier in section 2.3.3. The concentration of 
polyphenols used in these experiments was determined as a strongly inhibitory 
concentration based upon the data from the IC50 experiments. One treatment was 
designed to treat the cells first with the polyphenol, followed by an independent 
VEGF treatment (named ‘independent’ treatments). The cells requiring 
independent treatment were washed twice with warmed PBS after which the 
appropriate wells were treated with basal media supplemented with the 
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polyphenol to the required concentration at 1:1000 dilution and the cells were 
incubated for 5 minutes at 37 °C, 5% CO2. VEGF was added to the treatment media 
requiring VEGF supplementation in a 1:2000 ratio to concentration of 25 ng/ml. 
One volume of VEGF only supplemented media was to be used for the independent 
treatment after the 5 minute polyphenol only treatment was complete. Another 
volume of VEGF supplemented media was mixed with the polyphenol for 5 minutes 
to create a treatment where the VEGF and polyphenol are added to the cells in a 
pre-mixed manner (‘combined’ treatment). DMSO was added as a vehicle control to 
the treatments without polyphenols. After the polyphenol only independent 5 
minute treatment was complete all cells were washed with warmed PBS twice and 
2 ml of either the VEGF only or VEGF and polyphenol treatments were added to the 
‘independent’ and ‘combined’ treated cells respectively and incubated at 37°C, 5% 
CO2 for 5 minutes. Following this final incubation all wells were washed with 2 ml 
ice cold PBS twice. Cells were lysed with 50 µl cell lysis buffer supplemented with 
1mM PMSF (9803, Cell Signalling Technology Inc., New England Biolabs), scraped, 
and the lysates collected. Each lysate was vortexed for 20 seconds three times at 
maximum speed with breaks on ice between each vortex. The lysates were then 
centrifuged for 10 minutes at 13,000 x g at 4 °C and the supernatant was collected 
in a separate tube. A 5 µl aliquot of each sample was taken prior to freezing to use 
to determine the total protein concentration in each sample. An overview of the 
workflow for this assay Is shown in Figure 2.3. 
2.3.5 Quantification of the absolute protein concentration of cell lysates  
To quantify the total protein a sample the bicinchoninic acid (BCA) assay was used. 
For each BCA assay a BSA calibration curve ranging from 0 mg/ml to 1 mg/ml was 
set up. 55 µl of sodium phosphate buffer (NaPi) buffer was added to each of the 5 
µl experimental samples. 25 µl of each sample were transferred to two wells of a 96 
well plate in duplicate. A solution of Bicinchoninic acid and copper II sulphate in a 
ratio of 50:1 v:v. was made and 200 µl of this was added to each of the wells 
containing sample. The plate was left at 37 °C for 30 minutes to complete the 
reaction after which the plate was immediately read using a FluorStar OPTIMA 
spectrophotometer (BMG Labtech) at 450nm.  
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Figure 2.3: An overview of the work flow required to determine where the 
polyphenol elicits its inhibitory activity as described in section 2.3.4   
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2.3.6 Determining the amount of VEGF receptor phosphorylation in 
HUVECs following cell treatments 
An enzyme linked immunosorbent assay (ELISA) kit was used (7335, New England 
Biolabs) to determine the amount of tyrosine 1175 (Y1175) VEGFR-2 
phosphorylation in the cell lysates. ELISAs were run according to the manufacturer’s 
instructions. Briefly, the samples were diluted in MilliQ water to the same total 
protein concentration in a volume of 110 µl. The samples were diluted 1:1 with the 
sample diluent provided to give a total volume of 220 µl. 100 µl of each sample was 
added per well of a mouse anti-VEGFR-2 antibody pre-coated ELISA plate. The 
plates were sealed and stored overnight at 4 °C. The following morning the wells 
washed four times with 1x wash buffer. 100 µl of the rabbit anti-phosphorylated 
Y1175-VEGFR-2 primary antibody was added to each well and the plates were 
sealed and incubated at 37 °C for 1 h. Following this the plates washed a further 
four times with 1x wash buffer. 100 µl of the anti-rabbit HRP-linked secondary 
antibody was added to each well, the plates were sealed and incubated at 37 °C for 
30 minutes after which the plates were again washed four times with 1x wash 
buffer. 100 µl TMB substrate solution was added to each well, the plates were 
sealed and incubated for 10 minutes at 37 °C. Following this incubation 100 µl STOP 
solution was added directly to the TMB substrate and the plates were read 
immediately at 450nm-540 nm on a FluorStar OPTIMA spectrophotometer (BMG 
Labtech). The percentage VEGFR-2 phosphorylation in comparison to a VEGF 
stimulated sample was calculated. 
2.3.7 Statistical analysis  
The VEGFR-2 phosphorylation percentages of each treatment group in comparison 
to the VEGF positive control were plotted into both a bar chart and line graphs 
using the GraphPad Prism software. Any statistical difference between the groups 
was determined by ANOVA with a Tukey post-hoc test comparing all sample groups 
to one another. The IC50 was calculated following logarithmic transformation and 
non-linear regression analysis of the data. The IC50 is the half way point between 
the bottom and top plateaus of the curve of the transformed data   
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2.4 Results 
2.4.1 The green tea polyphenol epigallocatechin gallate effectively inhibits 
VEGFR-2 signalling in HUVECs 
As shown previously (Moyle et al., 2015) treatment of HUVECs with VEGF that has 
been pre-mixed with EGCG at 1 µM for 5 minutes prior to treatment strongly 
inhibits VEGFR-2 phosphorylation. This experiment was replicated to confirm the 
same observation could be made. EGCG at both a 0.1 µM and 1µM concentration 
significantly inhibited the VEGF-induced VEGFR-2 phosphorylation after 5 minute 
treatment with EBM-2 media containing pre-mixed VEGF (25 ng/ml) and EGCG. 
There was also a significant decrease in VEGFR-2 phosphorylation when treating 
HUVECs with VEGF pre-mixed with the higher EGCG concentration of 1 µM in 
comparison to the 0.1 µM concentration, suggesting a higher concentration of 
EGCG is able to more strongly reduce VEGF stimulated VEGFR-2 phosphorylation 
(Figure 2.4). Following non-linear regression analysis of the transformed data an 
IC50 value of 96 nM (95% CI 91.1 nM to 102 nM) was calculated. 
2.4.2 The pomegranate polyphenol punicalagin effectively inhibits VEGFR-
2 signalling in HUVECs 
The primary ellagitannin in pomegranates, punicalagin was pre-mixed with VEGF 
(25 ng/ml) in EBM-2 basal media at varying concentrations. 0.01µM did not show a 
decrease in VEGFR-2 phosphorylation in comparison to VEGF only stimulated cells. 
All other concentrations tested resulted in a significant reduction in VEGFR-2 
phosphorylation, with increasing concentrations of punicalagin corresponding to a 
greater decrease in VEGFR-2 phosphorylation in comparison to a VEGF only 
stimulated control (Figure 2.5). Following transformation of the data to a 
logarithmic scale and undertaking of a non-linear regression analysis the IC50 of 
punicalagin was estimated as 49 nM (95% CI 43.0 µM to 57.3 µM).   
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Figure 2.4:.EGCG inhibition of VEGF induced VEGFR-2 phosphorylation  
EBM-2 media was supplemented with 25 ng/ml VEGF plus either 0.1 or 1 µM EGCG and allowed to 
mix for 5 minutes. The supplemented media was then used to stimulate HUVECs for 5 minutes at 37 
°C, after which the total protein was extracted and the amount of phosphorylated VEGFR-2 
determined. Bars represent means ± standard deviation of % p-VEGFR-2 in comparison to the VEGF 
only stimulated control. *** p ≤ 0.001 as compared to the VEGF stimulated control; n = 4.  
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Figure 2.5: Punicalagin inhibition of VEGF induced VEGFR -2 phosphorylation  
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of punicalagin 
(range: 0.01-0.2µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. *** p ≤ 0.001 as compared to the VEGF 
stimulated control; .n = 5.  
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2.4.3 The pomegranate polyphenol ellagic acid effectively inhibits VEGFR-
2 signalling in HUVECs 
Ellagic acid is a compound found both in pomegranate products and is also a 
primary breakdown product of punicalagin. The IC50 of EA on VEGFR-2 
phosphorylation in HUVECs had previously been estimated to be 0.230 (95% CI 
0.214-0.247) (Cerezo et al., 2015). Figure 2.6 shows the VEGF-induced VEGFR-2 
phosphorylation achieved in the presence of increasing concentrations of ellagic 
acid in this experiment. A significantly reduced p-VEGFR-2 percentage is observed 
following treatment with VEGF pre-mixed with EA at 0.15 µM or higher and as the 
concentration of the EA increases the VEGF stimulated VEGFR-2 phosphorylation 
decreases. Following transformation of the data to a logarithmic scale and 
undertaking of a non-linear regression analysis the relative IC50 of ellagic acid from 
this data was determined as 0.31 µM (95% CI 0.1614 µM to 0.5950 µM).  
2.4.4 The inhibition capacity of the pomegranate derived microbial 
metabolites on p-VEGFR-2  
Following ingestion of pomegranate the predominant metabolites, formed by 
microbial metabolism, are the urolithin compounds. The VEGFR-2 phosphorylation 
inhibition capabilities of these metabolites, determined by IC50 where possible, 
were tested using the same in vitro protocol as for EGCG, punicalagin, and EA. 
Urolithin D, the initial tetra-hydroxy microbial metabolite, demonstrated a potent 
inhibitory effect on p-VEGFR-2 at all concentrations tested. Nearly complete 
inhibition of VEGFR-2 phosphorylation was seen following pre-mixing of the VEGF 
with urolithin D at a concentration of 3 µM (Figure 2.7). Following transformation of 
the data to a logarithmic scale and undertaking of a non-linear regression analysis 
the relative IC50 of urolithin D was determined as 0.20 µM (95% CI 0.106 µM to 
0.357 µM).  
Urolithin C is a tri-hydroxy compounds and follows urolithin D in the metabolism 
pathway. Urolithin C was tested at four different concentrations (2, 4, 8, and 16 
µM) to determine the IC50 for VEGFR-2 phosphorylation inhibition in the assay 
(Figure 2.8). All tested concentrations significantly reduced the percentage VEGFR-2 
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phosphorylation at Y1175 in comparison to a VEGF stimulated control with near 
complete inhibition occurring following co-treatment with both 8 µM urolithin C (3 
% p-VEGFR-2) and 16 µM urolithin C (0.6 % p-VEGFR-2). Following transformation of 
the data to a logarithmic scale and undertaking of a non-linear regression analysis 
the relative IC50 of urolithin C was determined as 3.70 µM (95% CI 3.40 µM to 4.01 
µM). 
Urolithin A is a di-hydroxy compound which appears after urolithin C and D in the 
plasma after consumption of pomegranates. Using the in vitro assay to investigate 
the effect of urolithin A on VEGF stimulated VEGFR-2 phosphorylation it was shown 
that urolithin A had a reduced ability to inhibit this signalling in comparison to the 
previously tested urolithins. Significant inhibition of VEGF-induced VEGFR-2 
phosphorylation was observed following pre-mixing of the VEGF with 40 and 60 µM 
urolithin A. Complete inhibition of p-VEGFR-2 could not be achieved at any of the 
concentration tested (Figure 2.9). Following transformation of the data to a 
logarithmic scale and undertaking of a non-linear regression analysis the relative 
IC50 of urolithin A was determined as 54.0 µM (95% CI 45.6 µM to 63.8 µM). 
Urolithin B is a mono-hydroxy compound and, along with urolithin A, is a terminal 
urolithin produced through metabolism of pomegranate polyphenols. Urolithin B 
was tested at a range of concentrations (20, 60, 90, and 120 µM) up to a level that 
exceeded the expected plasma concentration following high amounts of 
pomegranate ingestion. 20 and 60 µM did not significantly inhibit VEGF induced 
VEGFR-2 phosphorylation while pre-mixing the VEGF with 90 and 120 µM urolithin 
B resulted in a small but significant decrease in VEGFR-2 phosphorylation (Figure 
2.10). An IC50 value is difficult to accurately interpret from the results as no 
treatment with urolithin B was able to reduce the VEGFR-2 phosphorylation to 
below 50 %. However, following transformation and non-linear regression analysis 
an IC50 of 251 µM was determined with a wide 95 % confidence interval (131 to 
484 µM).  
 
  
Chapter 2 
72 
 
 
Figure 2.6: Ellagic acid inhibition of VEGF induced VEGFR -2 phosphorylation 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of EA (range: 
0.075-0.6 µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. * p ≤ 0.05, *** p ≤ 0.001 as compared 
to the VEGF stimulated control; n = 4.   
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Figure 2.7: Urolithin D inhibition of VEGF induced VEGFR-2 phosphorylation 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin D 
(range: 0.1-3 µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. * p ≤ 0.05, *** p ≤ 0.001 as compared 
to the VEGF stimulated control; n = 6.   
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Figure 2.8: Urolithin C inhibition of VEGF induced VEGFR -2 phosphorylation 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin C 
(range: 2-16 µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. * p ≤ 0.05, *** p ≤ 0.001 as compared 
to the VEGF stimulated control; n = 6. 
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Figure 2.9: Urolithin A inhibition of VEGF induced VEGFR -2 phosphorylation 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin A 
(range: 10-60 µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. *** p ≤ 0.001 as compared to the VEGF 
stimulated control; n = 6. 
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Figure 2.10: Urolithin B inhibition of VEGF induced VEGFR -2 phosphorylation  
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin B 
(range: 20-120 µM) and allowed to mix for 5 minutes. The supplemented media was then used to 
stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted and the 
amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation of % p-
VEGFR-2 in comparison to the VEGF only stimulated control. ** p ≤ 0.01, *** p ≤ 0.001 as compared 
to the VEGF stimulated control; n = 6.   
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2.4.5 Conjugation of metabolites causes loss of inhibitory capacity 
In vivo urolithin D and C can be found in the plasma but are relatively rapidly 
converted to urolithin A and B which are the terminal urolithins. Urolithin A-
glucuronide and urolithin B-glucuronide are produced by the liver through 
conjugation and are found in comparatively high quantities in the plasma. Urolithin 
A and B glucuronide were investigated for their VEGFR-2 phosphorylation inhibition 
capacity using the same model as for the unconjugated polyphenols. Structures of 
urolithin A-glucuronide and urolithin B-glucuronide can be seen in Figure 2.1. 
Following pre-mixing of VEGF with urolithin A-glucuronide or urolithin B-
glucuronide at a wide range of concentrations (10-150 µM) there was no significant 
inhibition of VEGF-induced VEGFR-2 phosphorylation at any concentrations tested 
(Figure 2.11 and Figure 2.12) for either compound. Due to a complete lack in 
inhibitory capacity in this model an IC50 could not be determined for comparison.  
2.4.6 Green tea and pomegranate polyphenols elicit their anti-VEGFR-2 
phosphorylation activity by acting primarily on the VEGF ligand.  
It has previously been reported that EGCG is capable of inhibiting VEGFR-2 
phosphorylation by interacting with the VEGF ligand (Moyle et al., 2015). To test 
this, an experiment was conducted where the VEGF and polyphenol are either pre-
mixed for 5 minutes prior to treatment, named ‘Combined’ treatment, or where the 
cells are treated with the polyphenol only for 5 minutes followed by a second 5 
minute VEGF only stimulation, called ‘independent’ treatment. As expected the 
‘combined’ treatments, where VEGF was pre-mixed with EGCG, punicalagin or EA (1 
µM) or urolithin D and C (10 µM) for 5 minutes, resulted in near complete inhibition 
of VEGF-induced p-VEGFR-2. In the ‘independent’ treatment which underwent a 5 
minute polyphenol only treatment followed by 5 minute VEGF stimulation little to 
no inhibition of VEGF-induced VEGFR-2 phosphorylation was observed (0-10 %). 
Interestingly, punicalagin, EA, and urolithin D only treatment of the cell 
(‘independent’ treatment) resulted in around 10% VEGFR-2 phosphorylation 
inhibition without coming into contact with the VEGF ligand. This suggests this 
small effect was caused by actions on the cells directly (Figure 2.13).   
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Figure 2.11: VEGF induced VEGFR-2 phosphorylation after pre-mixing with 
urolithin A glucuronide 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin A - 
glucuronide (range: 10-150 µM) and allowed to mix for 5 minutes. The supplemented media was 
then used to stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted 
and the amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation 
of % p-VEGFR-2 in comparison to the VEGF only stimulated control; n = 6.  
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Figure 2.12: VEGF induced VEGFR-2 phosphorylation after pre-mixing with 
urolithin B glucuronide 
EBM-2 media was supplemented with 25 ng/ml VEGF plus varying concentrations of urolithin B - 
glucuronide (range: 10-150 µM) and allowed to mix for 5 minutes. The supplemented media was 
then used to stimulate HUVECs for 5 minutes at 37 °C, after which the total protein was extracted 
and the amount of phosphorylated VEGFR-2 determined. Bars represent means ± standard deviation 
of % p-VEGFR-2 in comparison to the VEGF only stimulated control; n = 6. 
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Figure 2.13: The VEGF Induced VEGFR-2 phosphorylation following VEGF and 
polyphenol combined treatment or independent treatment of HUVECs  
All dietary sourced polyphenol with complete or near-complete inhibition of p-VEGFR-2 inhibition at 
1 µM were investigated for their mode of action. All urolithin compounds with complete or near-
complete inhibition of p-VEGFR-2 at 10 µM were also investigated for the mode of action. VEGF and 
the polyphenol were either pre-mixed for 5 minutes prior to treatment of cells for 5 minutes 
(combined) or the polyphenol only in EBM-2 media was added to the cell for 5 minutes 
(independent) after which the cells were washed and stimulated with VEGF only for 5 minutes. Total 
protein was extracted and VEGFR-2 phosphorylation determined by ELISA. ** p ≤ 0.01, *** p ≤ 0.001 
as compared to a VEGF only stimulated sample. †††  p ≤ 0.001 between independent and combined 
treatments with the same polyphenol; n = 4.   
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2.5 Discussion 
The data presented in this chapter confirms the previous observation that the 
green tea polyphenol EGCG and the pomegranate polyphenol ellagic acid are strong 
inhibitors of VEGF stimulated VEGFR-2. It is also the first time it has been shown 
that: 1) the predominant pomegranate polyphenol, punicalagin, is a strong inhibitor 
of VEGF-induced VEGFR-2 phosphorylation; 2) Microbial metabolites of ellagic acid 
are able to inhibit VEGF-induced VEGFR-2 phosphorylation; 3) all processes of 
punicalagin metabolism, be it hydrolysis, microbial, or conjugation reduce the 
potency of inhibition in this model; 4) where tested, the potent inhibition of VEGF-
stimulated VEGFR-2 phosphorylation by green tea and pomegranate polyphenols 
was predominantly through interaction with the VEGF ligand and not the cell.  
Inhibition of VEGF signalling has an important role in clinical treatment of 
conditions such as cancer and wet-related macular degeneration (Massin et al., 
2010, Ferrara et al., 2005) and VEGF has been linked to the progression of diseases 
such as atherosclerosis (Celletti et al., 2001a, Celletti et al., 2001b). However, side-
effects from current anti-VEGF treatments are starting to emerge (Kamba and 
McDonald, 2007) such as increased venous thromboembolic events (Thulliez et al., 
2014). Dietary intervention may provide an alternative to such treatments given 
they can inhibit VEGF-induced VEGFR-2 phosphorylation at biologically relevant 
concentrations in vitro and have been found to be non-toxic in high doses 
(Isbrucker et al., 2006, Cerdá et al., 2003, Tasaki et al., 2008). 
It was previously demonstrated that EGCG and ellagic acid were able to effectively 
inhibit VEGFR-2 phosphorylation without significantly altering the total VEGFR-2 
protein level (Labrecque et al., 2005, Lamy et al., 2002), as well as inhibiting the 
phosphorylation of VEGF associated downstream signalling partners such as AKT, 
eNOS and ERK. However, these experiments used supra-physiological 
concentrations to demonstrate the effects on cell signalling pathways, as well as 
long incubation times. Treatments with supra-physiological concentrations can 
provide an indication as to which polyphenols may be more efficient inhibitors of 
the VEGF signalling pathway but if the concentrations used cannot be achieved in 
the plasma, the physiological effects are not relevant to an in vivo setting. Equally, 
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polyphenols are known to be unstable under cell culture conditions to a lesser or 
greater extent (Xiao and Hogger, 2015) Therefore, as they didn’t analyse the 
treatment media it cannot be determined whether the effect is due to the original 
polyphenol or its breakdown components. Longer incubations of EGCG are also 
known to make a number of changes to cell media which has the potential to 
influence the conclusions from the experiment (Tao et al., 2014). Furthermore, 
phosphorylation is a rapid event (Fearnley et al., 2016) therefore longer incubation 
times when discussing phosphorylation inhibition may not be the most suitable 
study design. More recently data has been emerging on the direct effect of a 
variety of polyphenols to rapidly inhibit VEGF-induced VEGFR-2 phosphorylation. 
Following a 5 minute pre-mixing of the VEGF with the polyphenol the cells are 
stimulated for 5 minutes with the mixture and the VEGFR-2 phosphorylation 
quantified. Given VEGFR-2 phosphorylation peaks at 5-10 minutes post stimulation 
(Fearnley et al., 2016) this represents the immediate effects of polyphenols on 
VEGF signalling. In these studies, both EGCG and ellagic acid were shown to be 
strong inhibitors with IC50 values of 88 nM and 230 nM concentration respectively 
(Cerezo et al., 2015, Moyle et al., 2015).  
2.5.1  Green tea polyphenol inhibition of VEGF signalling 
The data presented in this chapter used the same premixed VEGF and polyphenol 5 
minute treatment as described above (Cerezo et al., 2015, Moyle et al., 2015). A 
summary of the IC50 values reported in this chapter can be seen in Table 2.1. EGCG 
was able to inhibit 50 % of VEGFR-2 phosphorylation at 96 nM, a similar value to 
that achieved previously (88 nM) (Cerezo et al., 2015), demonstrating that the 
HUVECs were an effective, operator independent reporter of VEGF stimulated 
VEGFR-2 phosphorylation. The potent inhibition of VEGFR-2 phosphorylation 
achieved with EGCG is at a much lower concentration than previously reported. 
Lamy et. al. (Lamy et al., 2002) reported near complete inhibition of p-VEGFR-2 
following 10 µM EGCG pre-treatment for 24 hours. However, the inhibition 
observed in the study by Lamy et. al. is not directly comparable due to the long 
incubation times, the fact that a pan-tyrosine phosphorylation of VEGFR-2 
immunoprecipitated protein was used for quantification, and that the EGCG was 
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only able to elicit its effect via actions on the cell and never came into contact with 
the VEGF ligand. However, it suggests that EGCG and the degradation products do 
have a role in sustained inhibition of pan VEGF receptor phosphorylation.  
Bioavailability is an important consideration when discussing in vitro observations if 
they are to be considered relevant to an in vivo setting, although translational 
research plays another key role in this conclusion. Henning et. al. compared the 
plasma concentrations achieved following a similar dose in green tea, black tea and 
a green tea extract (193.3., 230.8, 213.6 mg respectively). It demonstrated that 
EGCG was able to reach plasma concentrations of 174, 218, and 326 nM 
respectively following green tea, black tea and green tea extract intake suggesting 
that the source of the polyphenol contributed to the plasma concentration 
achieved (Henning et al., 2004). Other studies have looked at the bioavailability of 
the pure compound EGCG, at doses ranging from 50-1600 mg (Chow et al., 2001, 
Ullmann et al., 2003, Henning et al., 2005) with the highest dose being reported to 
induce around 7 µM, a highly effective concentration for inhibiting VEGF induced 
VEGFR-2 phosphorylation in the in vitro model presented in this chapter. However, 
without further supplementation to the diet these concentrations are unlikely to 
appear in human plasma through dietary intake alone. It is also important to note 
that EGCG is often found predominantly as an aglycone in plasma (Ullmann et al., 
2003, Chow et al., 2001, Meng et al., 2002, Lee et al., 2002). Therefore it can be 
concluded that EGCG has the potential to reach concentrations within the plasma 
which have been demonstrated in this chapter to significantly inhibit VEGF-induced 
VEGFR-2 phosphorylation. Given that EGCG is also the predominant catechin found 
in green tea (El-Shahawi et al., 2012, Lee et al., 2014) it seems a sensible candidate 
polyphenol to further investigate the potential for polyphenol inhibition of 
pathological VEGF signalling in vivo. 
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Table 2.1: Summary of IC50 values achieved for inhibition of VEGF -induced 
VEGFR-2 phosphorylation by polyphenols  
Polyphenol 
name 
Structure 
No -OH 
groups 
IC50  
 
Location of 
inhibition action 
EGCG 
 
8 96 nM 
100 % VEGF 
ligand  
Punicalagin  
 
17 49 nM 
90 % VEGF 
ligand 
 
10 % cell 
Ellagic acid 
 
4 310 nM 
90 % VEGF 
ligand 
 
10 % cell 
Urolithin D 
 
4 200 nM 
87 % VEGF 
ligand 
 
13 % cell 
Urolithin C 
 
3 3.7 µM 
100 % VEGF 
ligand 
Urolithin A 
 
2 54 µM Not measured 
Uroliothin B 
 
1 251 µM Not measured 
Urolithin A-glc 
 
5 
No 
inhibition 
Not measured 
Urolithin B-glc 
 
4 
No 
inhibition 
Not measured 
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2.5.2  Pomegranate polyphenol inhibition of VEGF signalling 
The number of reports discussing the effects of pomegranate derived polyphenol 
on VEGF signalling inhibition is very limited. Where effects on VEGF signalling and 
its physiological responses have been investigated this has been primarily 
undertaken with pomegranate extract and, to a much more limited degree, with 
ellagic acid. VEGF protein secretion was reduced over 48 hrs following treatment 
with pomegranate extract but no measure of receptor expression or activation 
were performed (Sartippour et al., 2008). Pomegranate oil and fermented 
pomegranate both inhibited VEGF protein expression in a variety of cell types 
suggesting pomegranates have anti-VEGF potential, although phosphorylation 
status of VEGFR-2 was not measured (Toi et al., 2003). Also, as the treatment was 
with an extract and not individual compounds it is not known which component in 
the pomegranate extract caused the observed effect. In another experiment Bovine 
Aortic Endothelial Cells (BAECs) stimulated with VEGF for 1 minute after pre-
treatment with ellagic acid at 5 and 10 µM for 24 hrs showed a significant reduction 
in VEGFR-2 phosphorylation. In the same assay phosphorylation of the downstream 
signalling molecule ERK was significantly reduced at 10 µM treatment (Labrecque et 
al., 2005). Considering VEGFR-2 phosphorylation peaks at 5-10 minutes post 
stimulation (Fearnley et al., 2016), 1 minute is a relatively short VEGF stimulation 
time, perhaps limiting the effect size achievable. A long pre-treatment time, 24 
hours in this study, could lead to a change in the polyphenol profile in the media 
making conclusions about particular polyphenols difficult (Xiao and Hogger, 2015). 
For example in the caco-2 cell culture model, following 24 hours incubation with 
ellagic acid, the predominant compounds found in the media were dimethyl ellagic 
acid and dimethyl ellagic acid glucuronide, although free ellagic acid was still 
detected (Larrosa et al., 2006). Equally, it is difficult to compare the inhibitory 
capability as this study only models the polyphenol eliciting its effect via actions on 
the cell and does not come into contact with the VEGF ligand. The data presented in 
this chapter suggests that the pomegranate polyphenols punicalagin and ellagic 
acid have a rapid inhibitory effect on VEGFR-2 phosphorylation via action on the 
VEGF ligand itself. Following 5 minute stimulation with a pre-mixed treatment of 
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VEGF and the polyphenol, punicalagin was able to inhibit 50% of phosphorylation at 
49 nM, more potent than any polyphenol reported to date. Ellagic acid was also a 
strong inhibitor of VEGF-induced VEGFR-2 phosphorylation albeit the effect was less 
potent than that of punicalagin with an IC50 value of 310 nM. This IC50 value for 
ellagic acid is similar to that previously reported by Cerezo et. al. of 230 nM (Cerezo 
et al., 2015).  
The pomegranate polyphenol punicalagin has been found in the plasma of rats at 
concentrations up to 30 µg/ml. However, punicalagin has not been found in the 
plasma of any other species (Cerdá et al., 2003). Ellagic acid, which is found in the 
fruit itself and is a metabolite of punicalagin, is regularly reported to be found in 
plasma following pomegranate, pomegranate extract, and pure ellagic acid 
ingestion. Ellagic acid is also found in a wide variety of other foods such as walnuts 
and raspberries (Daniel et al., 1989). Predominantly the bioavailability studies in 
humans focus on interventions with ellagitannin containing foods or extracts. It has 
been suggested that both pomegranate juice and pomegranate extract induce a 
similar ellagic acid plasma concentration of 106 – 112 nM following intervention 
when the ellagitannin and ellagic acid profile is similar (ET 318 mg, EA 25 mg 
pomegranate juice; ET 330.4mg, EA 21.6mg pomegranate extract) (Seeram et al., 
2004, Mertens-Talcott et al., 2006). In another study where 40 mg of ellagic acid 
only was fed to participants in the form of a capsule, over 6 times as much ellagic 
acid (662 nM) was detected in plasma (Hamad et al., 2009). This study suggests that 
feeding pure ellagic acid may elicit a larger EA Cmax comparative to pomegranate or 
EA/ellagitannin combination intervention. However, more recently González-Sarrías 
et. al. demonstrated that EA plasma bioavailability is not changed when the EA dose 
is significantly increased with the low dose (279 mg ET, 25 mg EA) giving a EA 
plasma concentration of 74.8 nM while the high dose (130 mg punicalagin, 524 mg 
EA) resulted in an EA plasma concentration of 64.1 nM (González-Sarrías et al., 
2015). Another study by Seeram et. al. also demonstrates ellagic acid is capable of 
reasonable plasma concentrations following a similar polyphenol dose containing 
318 mg ellagitannins and 12 mg ellagic acid. In this study the ellagic acid peak 
plasma concentration was 60 nM (Seeram et al., 2006), which is very similar to the 
Chapter 2 
87 
 
concentrations achieved by González-Sarrías et. al. These studies demonstrate that 
ellagic acid has the potential to reach concentrations in plasma which were 
reported in this chapter to be significantly inhibitory of VEGF induced VEGFR-2 
phosphorylation in vitro. This suggests, should the inhibitory effect be translatable 
to an in vivo setting, that EA could reach a concentration capable of inhibiting an 
effect.  
Metabolism and bioavailability of ellagic acid metabolites must also be taken into 
account. Urolithin D and urolithin C with tetra- or tri-hydroxy groups respectively, 
are more hydrophilic and therefore less likely to pass through the epithelial barrier 
and into the plasma (Tammela et al., 2004), although urolithin C (Cerda et al., 2004) 
has been seen at reasonable concentration and urolithin C and D glucuronides were 
previously reported at high concentrations in plasma (79 and 87 µM respectively) 
(Pfundstein et al., 2014). However, urolithin A and B appear to be readily absorbed 
from the GI tract (Espín et al., 2007). The results presented in this chapter 
demonstrate that there is a negative impact of metabolism, be it hydrolysis or 
conjugation, on the ability of the polyphenol to inhibit VEGF-induced VEGFR-2 
phosphorylation. Urolithin D was a potent inhibitor with an IC50 comparable to that 
of ellagic acid. However, urolithin D is thought to be readily metabolised to the 
consequent urolithins (Espín et al., 2007, Cerda et al., 2004). Urolithin C, which was 
shown to reach a up to a 1.8 µM concentration in plasma (Cerda et al., 2004), 
demonstrated significant inhibition in vitro of VEGF-induced VEGFR-2 at a similar 
concentration of 2 µM in this chapter. Urolithin A and B are only able to 
significantly inhibit VEGF induced VEGFR-2 phosphorylation at much higher 
concentrations than have been reported to date in vivo. However, urolithin 
quantification following intake of a high dose ellagic acid or punicalagin has not yet 
been conducted so it is unclear whether higher in vivo concentrations of the 
urolithins is achievable. The total urolithin concentration following dietary 
intervention has been shown to be as high as 18.6 µM and the inhibitory capacity of 
a combination of urolithins has not been investigated in this chapter, so the 
potential for a cumulative or collaborative inhibitory effect of urolithin treatment is 
unknown. However, in relation to whether the pomegranate polyphenols may be 
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able to inhibit VEGFR-2 phosphorylation in vivo it may be suggested that, while 
urolithin C has the potential to reach a similar dose to the 2 µM in vitro inhibitory 
dose, ellagic acid is the only pomegranate polyphenol which demonstrated potent 
inhibition of VEGF-induced VEGFR-2 at doses previously observed in plasma.  
2.5.3  Mechanism of action for polyphenol inhibition of VEGF 
signalling 
A further aim for this chapter was to identify a possible mechanism of action for the 
observed polyphenol inhibition of VEGF-induced VEGFR-2. The polyphenol could 
have elicited its inhibitory effects via 3 ways: 1) inhibition by interacting with the 
VEGF ligand; 2) interacting with the extracellular region of receptor or co-receptors 
or 3) inhibiting the VEGFR-2 tyrosine kinase activity intracellularly. Please see Figure 
2.14 for a visual representation of these possible mechanisms of action.   
 
Figure 2.14: Diagram of the possible locations where the polyphenol are 
eliciting the VEGF inhibitory effects 
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Wang et. al. (Wang et al., 2012) observed inhibition of VEGFR-2 phosphorylation in 
HUVECs following 24 hr treatment with 5 and 10 µM treatment with ellagic acid 
and that the in vitro VEGFR-2 tyrosine kinase activity was strongly inhibited by 
ellagic acid with an IC50 of 25.8 nM. However, VEGFR-2 is a transmembrane 
receptor and the in vitro tyrosine kinase model assesses the effect on the VEGFR-2 
protein in a free state. Considering the kinase domain of VEGFR-2 is intracellular 
this may explain the discrepancy between the strong inhibition elicited in the in 
vitro kinase assay which was not replicated in VEGFR-2 phosphorylation inhibition 
in a whole cell model. Through in silico modelling they hypothesised that this 
inhibition occurred due to interactions of ellagic acid with the ATP binding region of 
the VEGF-2 (intracellular location) but no demonstration that ellagic acid was 
entering the cell was provided limiting this conclusion. In contrast, Cerezo et. al 
(Cerezo et al., 2015) suggested that the polyphenols capable of inhibiting VEGFR-2 
phosphorylation in the 5 minute model could exert their effect through interactions 
with the VEGF ligand. In silico modelling predicted that the inhibitory polyphenols 
were all able to bind to VEGF dimer close to the receptor binding site. Moreover, 
there was a strong correlation (r = 0.9445) between the predicted binding affinities 
and the IC50 value determined in the cell culture model. While the in silico model is 
a very simple binding prediction, with only a 1:1 VEGF (dimer):polyphenol input 
parameter it can be a useful tool for predicting a possible mode of action for further 
investigation. In 2002 Kondo et. al. demonstrated for the first time that a 
polyphenol was able to reduce the amount of tagged VEGF bound to HUVECs by 
around 40% following a 30 minute pre-treatment with EGCG (Kondo et al., 2002) 
and more recently it was reported that binding of tagged VEGF to HUVECs was 
reduced by 20% following 40 µM EGCG treatment (Moyle et al., 2015). Both of 
these papers suggest that EGCG has the potential to inhibit VEGFR-2 signalling 
through interactions with either the extracellular receptor domain to reduce 
VEGF/VEGFR-2 coupling or to the VEGF ligand. In this chapter it was demonstrated 
that all the polyphenols tested were required to interact with the VEGF ligand to be 
able to elicit the potent inhibition VEGF induced VEGFR-2 phosphorylation. 
Treatment of the cells with EGCG and urolithin C independently prior to VEGF 
stimulation did not result in any reduction of VEGFR-2 phosphorylation, 
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demonstrating that inhibition by these polyphenols can only occur when the 
polyphenol and VEGF are able to come into contact. A higher concentration was not 
tested as this was deemed supra-physiological. Treatment of the cells with 
punicalagin, ellagic acid and urolithin D independently prior to VEGF stimulation 
resulted in only 10 % inhibition of VEGFR-2 phosphorylation suggesting once again 
the potent inhibition of VEGF-induced VEGFR-2 phosphorylation only occurs when 
the polyphenol and VEGF can interact, although some inhibition through 
receptor/cell interactions can occur. Perhaps the in silico modelling by Wang et. al 
identifying the ATP binding region of the VEGFR-2 as a binding location of ellagic 
acid suggests a justification of this 10 % for ellagic acid. However, it demonstrates 
that the polyphenols are required to interact with the VEGF ligand to result in the 
potent and rapid inhibition of VEGF signalling discussed in this chapter.  
2.6 Conclusion  
The results presented in this chapter demonstrate that: 1) the dietary derived 
polyphenol EGCG, punicalagin and ellagic acid are able to potently inhibit VEGF-
induced VEGFR-2 phosphorylation at nanomolar concentrations; 2) EGCG and 
ellagic acid were able to inhibit VEGF-induced VEGFR-2 phosphorylation at 
biologically relevant concentrations 3) metabolism of the pomegranate polyphenols 
reduced the inhibitory effect on VEGF-induced VEGFR-2 phosphorylation 4) all 
polyphenols demonstrating potent inhibition of VEGF-induced VEGFR-2 
phosphorylation did so primarily through interactions with the VEGF ligand. 
Considering that EGCG and ellagic acid have demonstrated potent and rapid 
inhibition of VEGF-induced VEGFR-2 phosphorylation at concentrations that can be 
found in plasma, both EGCG and ellagic acid are good candidates for further 
investigation into the potential health benefits from polyphenol inhibition of VEGF 
signalling. This will be explored in the next chapter, which will focus on the ability of 
EGCG and ellagic acid to inhibit VEGF-induced atherosclerosis in the ApoE-/- mouse 
model.   
  
 
 
 
 
 
Chapter 3 
 
Quantifying atherosclerosis in the 
VEGF injected ApoE-/- mouse 
following epigallocatechin gallate and 
ellagic acid intervention  
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3.1  Abstract 
Intake of green tea and pomegranate products is associated with cardiovascular 
improvements. Angiogenesis is associated with atherosclerosis progression while 
intraperitoneal VEGF injection in animals increased atherosclerotic plaque size. The 
aim of this chapter is to investigate whether dietary intake of EGCG and EA can 
inhibit VEGF-induced and VEGF-independent atherosclerotic progression. 
ApoE-/- mice received 3 weekly intraperitoneal injections of either 2 µg/kg body 
weight VEGF or mouse serum albumin (MSA) alongside feeding either a 1.8 g/kg 
pellet weight EGCG and EA supplemented or a control (non-supplemented) diet. 
Atherosclerotic plaque was quantified in the aortic sinus by histological analysis and 
cholesterol was measured using a biochemical analyser. 
All mice developed significant increases in all parameters of plaque size over time in 
association with the atherogenic diet. Neither 3 weekly intraperitoneal VEGF 
injections nor diet type caused a significant change in plaque size in comparison to 
controls. Injection of VEGF + EGCG and EA resulted in reduced plaque thickness but 
did not alter overall plaque size in comparison to VEGF only injected animals. Total 
and LDL cholesterol plasma levels were significantly higher in the mice fed the 
EGCG and EA supplemented diet, regardless of injection type. VEGF injection was 
associated with reduced plasma triglycerides while polyphenol injection was 
associated with increased plasma triglycerides, although not at all time points.  
In conclusion, 3 times 2 µg/kg body weight VEGF injections did not increase 
atherosclerosis plaque progression above MSA injected mice in the ApoE-/- model 
fed an atherogenic diet. Furthermore, EGCG and EA dietary supplementation at 1.8 
g/kg pellet weight did not reduce atherosclerosis in the ApoE-/- model, irrelevant of 
injection type, and caused a small increase in plasma total cholesterol and LDL 
cholesterol levels however these levels were not significantly increased in 
comparison to baseline plasma lipid measurements. As the polyphenol dose of 
these compounds used was lower than in previous experiments where an anti-
atherosclerotic effect was observed it suggests that lower doses may not be 
effective, at least in hypercholesterolaemic models.   
Chapter 3 
93 
 
3.2  Introduction 
In chapter 2 it was demonstrated that the predominant polyphenols in both green 
tea and pomegranates were able to inhibit VEGF-induced VEGFR-2 phosphorylation. 
Two of these potent polyphenols, EGCG and EA, were able to significantly inhibit 
VEGF-induced VEGFR-2 phosphorylation at biologically relevant concentrations. 
Furthermore, these polyphenols elicited their inhibitory action primarily through 
interacting with the VEGF ligand and not the VEGF receptor or cell. In this chapter 
the current research into the role of VEGF in atherosclerotic progression will be 
discussed while the aim of this chapter is to identify whether the potent inhibition 
of VEGF-induced VEGFR-2 phosphorylation by EGCG and EA observed in vitro can be 
translated into in vivo inhibition of VEGF-induced atherosclerosis. 
3.2.1 Atherosclerosis progression  
Atherosclerosis causes symptomatic disease by reducing blood flow to the tissue 
either through direct narrowing of the artery (plaque growth) or plaque rupture 
causing a blood clot (thrombus) which can occlude at the location of the plaque or 
travel through the vascular network to another location. The atherosclerotic plaque 
can also weaken the artery which can increase the risk of aneurysm and vessel 
rupture. For a diagrammatic overview please see Figure 1.6. 
Atherosclerosis starts with a thickening of the vessel wall through accumulation of 
smooth muscle cells and lipid laden macrophages, leading to fatty streaks in the 
aortic tissue. These further develop into large extracellular lipid pools causing 
significant growth of the lesion beyond the diffusion barrier leading to oxygen 
starvation and necrosis at the core. Fibrous cap formation and calcification also 
occur and new blood vessels are generated to supply the growing plaque. Increased 
vascularisation of the plaque leads to further instability of the vessel wall and an 
increased risk of plaque rupture and thrombus formation (Insull, 2009, Stary et al., 
1995).  
The ApoE-/- mouse model has a reduced ability to clear vLDL and LDL cholesterol 
from circulation and develops atherosclerosis, including the phases of disease 
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progression, in a similar manner to humans making the genotype an ideal model for 
investigating the disease (Nakashima et al., 1994, Pendse et al., 2009).  
3.2.2 Role of angiogenesis and VEGF in atherosclerosis progression 
As with cancer the growing atherosclerotic plaque requires the generation of new 
blood vessels, which are not required in healthy tissue, to continue the disease 
progression (Chen et al., 1999), stimulated through hypoxia associated signalling 
(Kuwahara et al., 2002). Histological analysis directly correlates the number of 
microvessels in the atherosclerotic plaque with the degree of severity of 
atherosclerosis, including the uptake of foam cells, tissue necrosis (Hiyama et al., 
2010), intra-plaque haemorrhage, thrombosis, fibrous cap formation (Hiyama et al., 
2010) and calcification (Demer and Tintut, 2008). Hypoxic signalling is known to 
upregulate the expression of VEGF, suggesting a critical role of VEGF in the 
atherosclerosis related angiogenesis (Hirota and Semenza, 2006). Furthermore, a 
correlation between circulating VEGF levels and critical lesion formation has been 
reported, while VEGF levels have been shown to be associated with increased risk 
of CVD (Kaess et al., 2016, Kimura et al., 2007), although not in all studies 
(Sandhofer et al., 2009, Alber et al., 2005). Increased VEGF, VEGFR-1 and VEGFR-2 
expression, as well as higher microvessel density, has also been observed in 
atherosclerotic regions of arteries (Inoue et al., 1998). It was also shown that direct 
injection of VEGF into animal models induced atherosclerotic plaque growth by up 
to 10-fold (Celletti et al., 2001a, Celletti et al., 2001b). Vaccination against VEGFR-2 
inhibited atherosclerotic progression (Hauer et al., 2007). However, another study 
in the same model reported inhibition of pan-VEGF receptor activity stimulated 
atherosclerosis progression. This may suggest that, while inhibition of angiogenesis 
associated VEGF signalling can have a limiting effect on atherosclerosis progression, 
that inhibition of all VEGF signalling may have the opposite effect. Furthermore, the 
negative side effects associated with anti-VEGF treatment which have emerged 
over the last few years (Tunon et al., 2009) may be mirrored in the ApoE-/- pan-
VEGFR inhibitor study. These studies demonstrate that greater understanding 
about the role of VEGF in atherosclerosis is needed but do suggest that regulation 
of raised VEGF levels could prove to be an important treatment for atherosclerotic 
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disease. Furthermore, given the negative side effects with current anti-VEGF 
treatments, such as increased risk of thrombosis (Thulliez et al., 2014), there is 
room for an alternative therapy. Food bioactives could fulfil this role as they are 
able to be consumed in high amounts with fewer concerns about toxicity.  
3.2.3 Polyphenol effects on VEGF and angiogenesis 
More difficult to ascertain are the in vivo effects of polyphenols on VEGF and in turn 
VEGF associated angiogenesis. This is due to the low levels of naturally circulating 
VEGF and the many interconnected signalling pathways associated with VEGF 
induced angiogenesis in vivo. The majority of the research into the effects of 
polyphenols on VEGF signalling or indeed VEGF-induced angiogenesis has been 
performed using human cell lines, predominantly HUVECs or ex vivo tissue culture 
of aortic tissue from animals.  
EGCG and EA effects on VEGF signalling  
In HUVECs it has been observed that polyphenols can affect VEGF signalling through 
a number of different mechanisms, including alterations to gene and protein 
expression, VEGFR-2 expression or phosphorylation, and on downstream signalling 
events. EGCG has been reported to significantly inhibit VEGF mRNA expression (20 
µM) (Kim et al., 2007a) and protein expression (100 µM) (Dann et al., 2009), VEGFR-
2 protein expression (55 µM) (Shimizu et al., 2010) as well as the binding of labelled 
VEGF to HUVECs at 25 μM (Kondo et al., 2002). EA has been reported to inhibit 
phosphorylation of the downstream signalling partners of VEGFR-2, for example 
PLCγ, ERK and AKT, while EGCG is reported to inhibit phosphorylation of these 
molecules at comparatively low concentrations (2-10 µM) (Labrecque et al., 2005, 
Rodriguez et al., 2006). EGCG and ellagic acid have demonstrated potent and 
specific inhibition of VEGFR-2 phosphorylation following 5 minute treatment when 
the polyphenol and VEGF have been pre-mixed (Moyle et al., 2015, Cerezo et al., 
2015) with the same observation being shown to be repeatable in chapter 2 of this 
thesis. The IC50 values for both EGCG and EA under this 5 minute model reported in 
chapter 2 of this thesis were 96 and 310 nM respectively. The strength of 
polyphenol inhibition also correlated to the predicted binding affinity of the 
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polyphenol for the VEGF ligand (Cerezo et al., 2015). Taking this into account with 
the observation from chapter 2 that the potent inhibition of VEGFR-2 
phosphorylation was not possible if the polyphenol and VEGF did not come into 
contact, it suggests EGCG and ellagic acid inhibit VEGF-induced VEGFR-2 
phosphorylation by interacting with the VEGF ligand.  
EGCG and EA effects on angiogenesis 
To accurately determine whether new vessel formation can be affected there are 
two key in vitro models: 1) HUVECs are seeded into an extracellular matrix and 
stimulated with VEGF [49] +/- polyphenol (DeCicco-Skinner et al., 2014); 2) ex vivo 
aortic tissue is embedded into an extracellular matrix and stimulated to grow with 
VEGF (Baker et al., 2012) +/- polyphenol. Both ellagic acid and EGCG have been 
reported to inhibit tube formation by HUVECs. Ellagic acid has demonstrated anti-
angiogenic effects, with 5 µM treatment inhibiting 38 % (Labrecque et al., 2005) 
and 10 µM inhibiting 85 % (Wang et al., 2012) of tube formation in a VEGF 
unstimulated model. VEGF stimulated tube formation was inhibited by EGCG 
treatment and inhibited both the number of branch points and the tube length in 
this assay at 20 µM (Liu et al., 2008). The aortic ring assay measures the number of 
new microvessels which sprout from the ex vivo aortic tissues in culture under the 
experimental conditions and is a model of arterial angiogenesis. Ellagic acid at 5 µM 
was able to potently inhibit angiogenesis in ex vivo aortic rings after 48-72 hours 
(Wang et al., 2012). EGCG has yet to be tested, however a high dose of catechin did 
not significantly alter the new vessel growth (Negrão et al., 2013). There are also in 
vivo angiogenesis assays such as the chick chorioallantoic membrane (CAM) or 
matrigel plug assay which use the natural blood vessel system of the animal to 
determine if angiogenesis can be stimulated or inhibited by the treatment. An 
extract of green tea catechins, of which EGCG is the predominant polyphenol, at 1 
% (Maiti et al., 2003) and pomegranate extract at doses as low as 0.1 µg (Toi et al., 
2003), as well as pure ellagic acid treatment at 2.5 µM (Wang et al., 2012) were 
able to significantly inhibited angiogenesis in the CAM assay. A number of 
polyphenols have demonstrated anti-angiogenic potential in the matrigel plug 
model including significant effects by 100 µM catechin (Negrão et al., 2013) and 
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EGCG (Li et al., 2013) measured by the amount of haemoglobin content of the plug 
however ellagic acid has yet to be investigated in this manner.  
3.2.4 The effect of green tea and pomegranate polyphenols on CVD 
Epidemiology and human intervention trials 
The association between reduced CVD risk of and increased polyphenol 
consumption has been reported for many years (Hertog et al., 1993, Knekt et al., 
1996, Arts and Hollman, 2005, Lai et al., 2015, Keli et al., 1996, Arts et al., 2001b). A 
recent meta-analysis focussed on the cardiovascular related effects of green tea 
found that higher consumers of green tea had a reduced risk of myocardial 
infarction, stroke, and, in the case of those drinking ≥10 cups a day, a reduced LDL 
level (Pang et al., 2016). Other studies found a significant association between 
green tea consumption and blood pressure reduction, particularly in participants 
with an elevated baseline systolic BP (Khalesi et al., 2014). A review into 133 
polyphenol intervention studies found that cocoa or chocolate and green tea were 
associated with positive effects on CVD risk factors by reducing LDL cholesterol 
levels in participants (Hooper et al., 2012). A number of studies describe 
improvements to blood pressure (Mathew et al., 2012), carotid intima media 
thickness (Aviram et al., 2004) and reduced stress induced ischemia (Sumner et al., 
2005) in response to pomegranate intervention while a meta-analysis of 12 studies 
found no significant effect of on lipid levels (Sahebkar et al., 2016). However, a 
critical evaluation of the intervention trials into pomegranate effects on 
cardiovascular disease highlighted the need for more rigorous and controlled 
interventions with a clear dosing strategy. This clearly suggests caution should be 
used when interpreting the individual study data (Vlachojannis et al., 2015).  
Animal intervention trials 
Animal studies can be used to assess the effects of diets supplemented with 
particular compounds on atherosclerotic plaque morphology and degree of 
atherosclerosis. (Rouanet et al., 2010, Yamakoshi et al., 1999, Loke et al., 2010, 
Kleemann et al., 2011, Shen et al., 2013, Chanet et al., 2012) Mice which drank 
green tea were found to have significantly reduced lipid deposition in the aortic 
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wall (Rouanet et al., 2010) and around 30 % less atherosclerotic plaque compared 
to control groups, with an associated reduction in VEGF expression in the plaque 
itself (Kavantzas et al., 2006). Hyperlipidaemic mice (Miura et al., 2001, Minatti et 
al., 2012) and rabbits (Tijburg et al., 1997) orally supplemented with a green tea 
extract had up to a 35 % reduction in atherosclerosis compared to control groups. 
Equally, intraperitoneal injection of EGCG has been demonstrated to inhibit 
progressive atherosclerosis (Ramesh et al., 2010) although it did not reduce 
established plaque (Chyu et al., 2004). A reduction in lipid deposition in the aortic 
arch caused by EGCG supplementation (35.5 %) was enhanced through nano-
encapsulation of the polyphenol (74.1 %), which might be explained by overcoming 
the low stability of EGCG in vivo (Hong et al., 2014). Supplementation of 
pomegranate juice (Aviram et al., 2008) and pomegranate fruit extracts to the diet 
has demonstrated significant atherosclerotic plaque reduction by around 40 % in 
hypercholesteraemic mice (de Nigris et al., 2007). The pomegranate flowers and 
pomegranate peel contained the most anti-atherogenic compounds (Aviram et al., 
2008). Furthermore, a 2 % ellagic acid supplementation to the diet of diabetic rats 
reduced intimal thickness, lipid deposition, and collagen inclusion in the aortic arch 
(Rani et al., 2013) while 1 % ellagic acid supplementation to the diet of rabbits 
completely negated the atherogenic effects of the cholesterol supplemented diet 
(Yu et al., 2004).  
3.2.5 Objectives  
The aim for this chapter is to determine whether EGCG and EA, two potent 
inhibitors of VEGF-induced VEGFR-2 phosphorylation in vitro, are able to inhibit 
VEGF-induced atherosclerosis in vivo. In previous studies intraperitoneal injection of 
VEGF induced atherosclerosis in both mice and rabbits while dietary intervention 
with EGCG and EA rich foods, or the compounds themselves, inhibited 
atherosclerotic progression. This chapter will present a study investigating whether 
an EGCG and EA supplemented diet can affect atherosclerosis in the ApoE-/- mouse 
which has undergone 3 times VEGF intraperitoneal injection. In a further 
experimental arm the VEGF will be pre-mixed with the polyphenol to determine if 
the in vitro observations can be directly translated to an in vivo environment. 
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This leads to a number of hypothesis: 1) VEGF injection will induce significant 
atherosclerosis above a mouse serum albumin (MSA) injected control; 2) dietary 
supplementation with EGCG and ellagic acid, potent in vitro inhibitors of VEGF-
induced VEGFR-2 phosphorylation, will inhibit VEGF-induced atherosclerosis; 3) 
dietary supplementation with EGCG and EA will be able to limit endogenous VEGF 
signalling associated with atherosclerotic progression; 4) mixing EGCG and EA with 
VEGF prior to intraperitoneal injection will completely ablate any VEGF stimulation 
of atherosclerosis.   
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3.3 Material and methods 
3.3.1 Animal diet production 
Pellets were manufactured by TestDiet (Test Diet Limited, London, UK). EGCG was 
ordered from Toronto Research Chemicals, Canada. EA was ordered from Acros 
Chemicals, Belgium. All additives and complete diets were subject to nutritional 
review by TestDiet specialists. The experimental diet was the TestDiet 57BB Paigen 
diet (15.5 % fat, 1.25 % cholesterol, 0.5 % sodium cholate). For reference, from here 
this diet will be called the ‘basic diet’. EGCG and EA were sent to the manufacturer 
for mixing with the 57BB recipe and this new diet was named by the manufacturer 
as 5W70. Both compounds were added at 1.8 g/kg total pellet weight providing a 
0.18% pellet content of each polyphenol. For reference, from here this diet will be 
called the ‘EGCG/EA diet’. The AIN-93G diet was also produced to be used during 
the acclimatisation period. All pellets underwent a slow drying process to reduce 
the risk of compound breakdown and were sealed in airtight bags then irradiated 
for sterility.  
3.3.2 Animal condition and experimental design  
The experiments described here were conducted in compliance with the European 
Union regulations concerning the protection of experimental animals and with the 
UK Home Office Animals (Scientific Procedures) Act of 1986 under the personal 
licence I181618BE and project licence 80/2533. 
100 mice were delivered in 5 batches aged 3 weeks and were kept in 
acclimatisation on AIN-93G. At age 4 weeks they were switched to the basic diet 
but remained in acclimatisation for a further week. All mice continued on the basic 
diet until aged 8 weeks. 10 mice were culled at 8 weeks for a baseline 
measurement. At 8 weeks of age all non-baseline mice underwent 3 x weekly 
injections of a 2 µg/kg body weight of either VEGF, MSA or VEGF combined with 
EGCG and EA. At the time of the first injection mice either remained on the basic 
diet or were switched to the EGCG/EA diet until they underwent terminal 
anaesthesia. 9 mice from each group were culled at age 11 weeks and a further 9 
from each group at 14 weeks of age (it should be noted 3 mice died prematurely 
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before any intervention and these were not included in the final data). All Mice 
were culled by terminal anaesthesia and cardiac puncture/perfusion. All animals 
were kept in individually ventilated cages in a 22 °C controlled temperature room 
with 55 % humidity and a 12 h light-dark cycle. Bedding was changed every two 
weeks. Cages were checked daily by staff and individual mice were health checked 
and weighed 3 times a week. Following intraperitoneal injection mice were checked 
for signs of inflammation around the injection site. Mice were provided food and 
water ad libitum using the cage hopper and water bottle. See Table 3.1 for study 
overview. 
Table 3.1: Outline of diet type, injection type, and number of animals p er 
time point in each treatment if the animal intervention trial  
Treatment name Diet type 
(4-8 weeks) 
Injection 
type 
Diet type 
(8-14 
weeks) 
No. 
culled at 
8 weeks 
No. 
culled at 
11 weeks 
No. 
culled at 
14 weeks 
Baseline 57BB 
(Paigen diet) 
n/a n/a 10 n/a n/a 
Basic diet + MSA 
injection 
57BB 
(Paigen diet) 
MSA 57BB 
(Paigen diet) 
n/a 8 9 
Basic diet + VEGF 
injection 
57BB 
(Paigen diet) 
VEGF 57BB 
(Paigen diet) 
n/a 9 9 
EGCG/EA diet 
+MSA injection 
57BB 
(Paigen diet) 
MSA 5W70 n/a 9 9 
EGCG/EA diet + 
VEGF injection 
57BB 
(Paigen diet) 
VEGF 5W70 n/a 9 8 
Basic diet + 
VEGF/EGCG/EA 
injection 
57BB 
(Paigen diet) 
VEGF/ 
EGCG/ 
EA 
57BB 
(Paigen diet) 
n/a 9 8 
 
3.3.3 Monitoring of body weight and pellet consumption 
Body weights were measured 3 times a week to monitor animal health and growth. 
The body weights of all animals based on injection type or diet type were combined 
to determine whether there were significant differences in the growth rates 
between treatment types. The body weights from the mice that did not complete 
the intervention were excluded.  
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To determine the daily intake of each diet the pellet consumption was monitored. 
Upon receiving a new diet the cages were changed and the initial pellet weight 
recorded. The pellets in the cage were transferred to a sterilised pot for weighing 
three times a week. Where required the mice were provided with further pellets of 
a recorded weight. It was noticed in week 9 that the mice were shredding their diet 
and creating food stores under the cage bedding, leading to an inaccurate 
assumption of diet intake. From this point forward a once weekly measurement of 
solid and powder diet was undertaken. Briefly, all mice were transferred to a clean 
cage after which the entire bedding, including the shredded diet, was sieved 
through an autoclaved kitchen sieve. This allowed the diet to fall through while the 
bedding remained in the sieve. The diet was weighed and the bedding, diet and 
mice were returned to the home cage.  
3.3.4 Intraperitoneal injection of VEGF, mouse serum albumin or VEGF/PP 
combination 
At age 8, 9, and 10 weeks each mouse underwent an intraperitoneal injection of 
200 µl volume. Briefly, mice were transferred to a clean cage for procedure. Prior to 
injection the VEGF stocks were made to 200 µg/ml concentration while mouse 
serum albumin (MSA) was made to a 40 µg/ml stock concentrations and were 0.22 
µm filter sterilised and stored at -80 until required. Immediately prior to injection a 
final stock solutions of 0.4 µg/ml VEGF and MSA were made up in sterile PBS. Mice 
were weighed on the morning of the injections to give an accurate body weight, 
and an excess of individual injection solution of VEGF and MSA were made to a 
concentration allowing for delivery of 2 µg/kg body weight in a 200 µl volume. Mice 
were injected with 200 µl solution by maintaining a tight scruff, gently tilting the 
animal so the head is lower than the flank, and injecting the full volume into the 
intraperitoneal sack. Upon removal the syringe tip was twisted to seal the wound, 
the mouse was returned to the home cage. The excess injection sample was snap 
frozen on dry ice to be used to determine the VEGF stimulatory capacity of the 
injection sample. The order of mice and cages to be injected was rotated over the 
three repeat injections to remove any impact of injection stability.  
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3.3.5 Quantification of VEGF activity of injection treatments 
HUVECs were grown to confluency to be ready for the day of injection. Samples 
snap frozen at the time of injection were added to EBM-2 media to give a final VEGF 
concentration of 25 ng/ml as was standard in the cell culture experiments in 
chapter 2. A fresh VEGF positive control was also made immediately prior to the 
HUVEC treatment to compare the activity of the VEGF injection samples to. The 
activity of the MSA injection samples at 25 ng/ml was also tested. Each treatment 
was added to a well of confluent HUVECs for 5 minutes at 37°C, 5% CO2 after which 
the cells were lysed and the proteins extracted. Total protein content was 
determined by using the BCA assay (Chapter 2.3.5), the samples were normalised to 
the same total protein content and the VEGFR-2 phosphorylation quantified in 
comparison to the fresh VEGF treatment by ELISA following the manufacturer’s 
instructions as specified in chapter 2.3.6 (7335, Cell Signalling Technology Inc., New 
England Biolabs) 
3.3.6 Terminal anaesthesia and tissue collection 
Mice underwent terminal anaesthesia, cardiac puncture and saline perfusion at age 
8, 11 and 14 weeks. Mice were anaesthetised using isoflurane and anaesthesia was 
maintained until confirmation of death. Complete anaesthesia was confirmed by a 
lack of muscle reflex following a physical pinch, after which the fur, peritoneum and 
diaphragm were cut to allow access to the heart. A 1 ml syringe with a 25 gauge, 
16mm syringe tip was flushed with EDTA saline and was inserted directly into the 
apex of the heart. Once in place the blood was gently removed from the heart in 
time with the heart contractions to remove the total blood. Following blood 
collection the right ventricle was cut and a new syringe containing saline + EDTA 
was inserted into the apex of the heart. The animal was perfused with saline + EDTA 
until the saline came out clear and organ colour indicated no blood remained. 
Death was confirmed by beheading. The blood was spun at 3,500 x g for 10 minutes 
to separate erythrocytes and plasma, and the plasma transferred to a new tube. 
The plasma and the erythrocytes/buffy coat were snap frozen in dry ice. The left 
lateral lobe of the liver, right kidney and the aorta were immediately placed into 
RNALater and stored on wet ice. The heart, including the aortic arch, and the eyes 
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were placed into 4 % paraformaldehyde and stored on wet ice. The brain, spleen, 
intestine and stomach (including faeces), left kidney, lungs, visceral fat and 
remaining lobes of liver were snap frozen in dry ice. For long term storage the 
sample on wet ice were transferred to a -20 °C freezer and the samples on dry ice 
were stored at -80 °C. 
3.3.7 Quantification of atherosclerotic lesions in aortic arch 
Atherosclerotic lesions size was quantified by staining for lipid deposition across the 
aortic sinus. Following fixation the hearts were stored to a 30% sucrose solution for 
up to 1 week at 4 °C. The hearts were cleaned of any other tissue and a cut was 
made with a scalpel to remove the lower half of the heart. After this the heart was 
placed into a 1:1 solution 30% sucrose:optimal cutting temperature (OCT) solution 
for 30 minutes or until the hearts had sunk to bottom of the vessel. The hearts were 
then placed into OCT filled square moulds and snap frozen on dry ice. Serial 5 µm 
cryosections across the aortic sinus were performed on a cryostat (Cryo-Star NX70, 
Thermo Scientific) cooled to -20 °C. Sections began when the start of all three 
valves could be seen or a leaflet of one of the valves become visible, as 
demonstrated in Figure 3.1, and ended when all three valves had disappeared. Each 
section was collected across this region on 12 slides which lead to each slide 
containing serial sections at 60 µm distance from one another. Slide 3 was taken 
and stained with oil red O and haemotoxylin and the morphological features 
observed through this staining can be seen in Figure 3.2. Images of the plaque were 
taken with a colour camera attached to a BX60 Olympus microscope. Quantification 
of atherosclerotic plaque was performed in 3 ways. 1) Atherosclerotic plaque area 
as both the percentage of the total lumen area and area in µm2 of the 
atherosclerotic plaque; 2) Atherosclerotic plaque circumferential expansion as both 
the percentage and distance in µm the plaque expanded along the lumen 
circumference; and 3) the maximal plaque thickness, presented as the distance in 
µm from the lumen wall to the end of the plaque at the thickest portion of plaque. 
All quantification was performed blinded using the imageJ software and a 
diagrammatic representation of how these measurements were undertaken for 
each section can be seen in Figure 3.3.  
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Figure 3.1: Representative cryosections stained with Oil Red O and 
haemotoxylin across the aortic sinus from one mouse.  
The actual size shown in each image is 1.8 mm (width) x 1.3 mm (length).  
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Figure 3.2: Example of the aortic sinus with labelled morphological features   
The actual size shown in the image is 1.8 mm (width) x 1.3 mm (length). . 
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Figure 3.3: Diagrammatic representation of plaque size measurements.   
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3.3.8 Quantification of plasma lipid levels 
Following storage of the plasma at -80 °C the samples were defrosted and total 
cholesterol, LDL cholesterol, and triglycerides were quantified using the Randox RX 
Daytona+ biochemical analyser (Randox Inc., Ireland) using the recommended 
Randox kits for each assay. Prior to initiation of analysis the machine was cleaned, 
primed and calibrated. Briefly, a minimum of 200 µl of plasma was transferred to a 
bioanalyser cup and placed into the sample chamber. The appropriate reagents and 
cleaning solutions were placed into the reagent chamber. For total cholesterol and 
triglyceride analysis only 1 reagent was needed (R1) and quantification was 
performed by colorimetric assay. For LDL cholesterol analysis 2 reagents were 
required (R1 and R2) and quantification was performed through a direct clearance 
method of analysis. 
3.3.9 Quantification of polyphenols in plasma 
Polyphenols were extracted from plasma following the protocol as previously 
described (García-Villalba et al., 2016). Briefly 600 µl acetonitrile:formic acid (98:2 
v:v) was added to 200 µl plasma. 6,7, di-hydroxycoumarin was added to each 
sample to create a 0.1 ppm final concentration once reconstituted. Each sample 
was vortexed for 2 minutes, placed in a sonication bath at room temperature for 10 
minutes. Samples were then centrifuged at 14,000 x g at 4 °C for 10 minutes and 
the supernatant transferred to a 2 ml tube. Samples were evaporated at 45 °C in a 
centrifugal evaporator until only a small amount of reagent remained. Following 
this, samples were dried to complete dryness at room temperature in a centrifugal 
evaporator. High (200 nM) and low (1 µM) QC samples were also extracted 
alongside the samples. Sample tube were made airtight and kept at -20 °C until 
shipping. Samples were shipped to Centro de Edafología y Biología Aplicada del 
Segura-Consejo Superior de Investigaciones Científicas (CEBAS-CSIC) in Murcia for 
analysis. All the dried samples were re-suspended in 100 µL of MeOH and filtered 
through a 0.22 µm PVDF filter before analysis. 0.1 ppm of chrysin was added as 
internal standard immediately prior to LC-MS analysis. Samples were analysed using 
an Agilent 1290 Infinity UPLC system coupled to the 6550 Accurate-Mass 
quadrupole TOF mass spectrometer (Agilent Technologies, Waldbronn, Germany) 
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using an electrospray interface with Jet Stream technology. Briefly, separation was 
performed using a reverse phase Poroshell 120 EC-C18 column (3 × 100 mm, 2.7 
µm; Agilent) operating at 30 °C. Solvent A was water:formic acid (99.9:0.1 v/v) and 
solvent B was acetonitrile:formic acid (99.9:0.1 v/v) using the gradient program as 
follows: 0–3 min, 5–15 % B; 3–11 min, 15–30 % B; 11–15 min, 30–50 % B, 15–21 
min, 50–90 % B, followed by 21- 26 min 5 % B to re-equilibrate the column. The 
flow rate was 0.4 mL/min and the injection volume was 3 µL. The electrospray 
interface conditions were as follows: gas temperature 280 °C, drying gas 9 L/min, 
nebulizer 45 psi, sheath gas temperature 400 °C, sheath gas flow 12 L/min. Spectra 
were acquired in single MS mode with m/z range of 100–1100, negative polarity, 
and an acquisition rate of 1.5 spectra/s. Internal mass calibration by simultaneous 
acquisition of reference ions and mass drift compensation was used for obtaining 
low mass errors. Data were processed using the Mass Hunter Qualitative Analysis 
software (version B.06.00 Agilent Technologies). A list of all potential compounds to 
be found following EGCG or EA consumption which were searched for in the 
analysis can be seen in Table 3.2 and Table 3.3 respectively.   
 
Table 3.2: List of potential compounds searched for in mice plasma samples 
to be found in plasma following epigallocatechin gall ate consumption, their 
molecular formula and the molecular mass (M r).  
Compound Molecular formula Exact mass 
EGC C15H14O7 305.0667 
EGC glcA C21H22O13 481.0988 
EGC sulfate C15H14O10S 385.0235 
Methyl EGC C16H16O7 319.0823 
Methyl EGC glcA C22H24O13 495.1144 
Methyl EGC sulfate  C16H16O10S 399.0391 
EGCG C22H18O11 457.0776 
EGCG glcA C28H26O17 633.1097 
EGCG sulfate C22H18O14S 537.0344 
Methyl EGCG C23H20O11 471.0933 
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Compound Molecular formula Exact mass 
Methyl EGCG glcA C29H28O17 647.1254 
Methyl EGCG sulfate  C23H20O14S 551.0501 
1-trihydroxy- 
phenyl-3-trihydroxyphenylpropan-2-ol 
C15H16O7 307.0823 
1-trihydroxy- 
phenyl-3-trihydroxyphenylpropan-2-ol glcA 
C21H24O13 483.1144 
1-trihydroxy- 
phenyl-3-trihydroxyphenylpropan-2-ol sulfate  
C15H16O10S 339.0391 
1-dihydroxyphenyl-3-tri- 
hydroxyphenylpropan-2-ol 
C15H16O6 291.0874 
1-dihydroxyphenyl-3-tri- 
hydroxyphenylpropan-2-ol glcA 
C21H24O12 467.1195 
1-dihydroxyphenyl-3-tri- 
hydroxyphenylpropan-2-ol sulfate 
C15H16O9S 323.0442 
5-dihydroxyphenyl-4-hydroxyvaleric acid C11H14O5 225.0768 
5-dihydroxyphenyl-4-hydroxyvaleric acid glcA C17H22O11 401.1089 
5-dihydroxyphenyl-4-hydroxyvaleric acid sulfate  C11H14O8S 305.0337 
5-dihydroxyphenyl-γ-valerolactone C11H12O4 207.0663 
5-dihydroxyphenyl-γ-valerolactone glcA C17H20O10 383.0984 
5-dihydroxyphenyl-γ-valerolactone sulfate C11H12O7S 287.0231 
3-dihydroxyphenyl propionic acid C9H10O4 181.0506 
3-dihydroxyphenyl propionic acid glcA C15H18O10 357.0827 
3-dihydroxyphenyl propionic acid sulfate C9H10O7S 261.0074 
4-dehydroxy EGC C15H14O6 289.0718 
4-dehydroxy EGC glcA C15H14O9S 369.0286 
4-dehydroxy EGC sulfate C21H22O12 465.1038 
5-trihydroxyphenyl-4-hydroxyvaleric acid C11H14O6 241.0718 
5-trihydroxyphenyl-4-hydroxyvaleric acid glcA C17H22O12 417.1038 
5-trihydroxyphenyl-4-hydroxyvaleric acid sulfate C11H14O9S 321.0286 
5-trihydroxyphenyl-γ-valerolactone C11H12O5 223.0612 
5-trihydroxyphenyl-γ-valerolactone glcA C17H20O11 399.0933 
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Compound Molecular formula Exact mass 
5-trihydroxyphenyl-γ-valerolactone sulfate C11H12O8S 303.018 
5-dihydroxyphenyl valeric acid C11H14O4 209.0819 
5-dihydroxyphenyl valeric acid glcA C17H22O10 385.114 
5-dihydroxyphenyl valeric acid sulfate C11H14O7S 289.0387 
5-hydroxyphenyl valeric acid C11H14O3 193.087 
5-hydroxyphenyl valeric acid glcA C17H22O9 369.1191 
5-hydroxyphenyl valeric acid sulfate C11H14O6S 273.0438 
5-trihydroxyphenyl valeric acid C11H14O5 225.0768 
5-trihydroxyphenyl valeric acid glcA C17H22O11 401.1089 
5-trihydroxyphenyl valeric acid sulfate C11H14O8S 305.0337 
EGC = epigallocatechin; EGCG = epigallocatechin gallate; GlcA = glucuronide 
 
Table 3.3: List of potential compounds searched for in mice plasma samples 
to be found in plasma following ellagic acid consumption, their molecular 
formula and the molecular mass (M r). 
Compound Molecular formula Exact mass 
UroA glcA C19H16O10 403.0671 
UroA sulfate C13H8O7S 306.9918 
UroA sulfoglcA C19H16O13S 483.0239 
UroA C13H8O4 227.0350 
Methyl UroA C14H10O4 241.0506 
Methyl UroA glcA C20H18O10 417.0827 
Methyl UroA sulfate C14H10O7S 321.0074 
UroB glcA C19H16O9 387.0722 
UroB sulfate C13H8O6S 290.9969 
UroB-sulfoglcA C19H16O12S 467.029 
UroB C13H8O3 211.0401 
UroC glcA C19H16O11 419.062 
UroC sulfate C13H8O8S 322.9867 
UroC sulfoglcA C19H16O14S 499.0188 
UroC C13H8O5 243.0299 
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Compound Molecular formula Exact mass 
Methyl UroC glcA C20H18O11 433.0776 
Methyl UroC sulfate C13H8O8S 322.9867 
Methyl UroC C14H10O5 257.0455 
Dimethyl UroC glcA C21H20O11 447.0933 
Dimethyl UroC C15H12O5 271.0612 
UroM6 glcA C19H16O12 435.0569 
UroM6 sulfate C13H8O9S 338.9816 
UroM6 C13H8O6 259.0248 
Methyl UroM6 glcA C20H18O12 449.0725 
Methyl UroM6 C14H10O6 273.0405 
Dimethyl UroM6 glcA C21H20O12 463.0882 
Dimethyl UroM6 C15H12O6 287.0561 
UroM5 glcA C19H16O13 451.0518 
UroM5 sulfate C13H8O10S 354.9765 
UroM5 C13H8O7 275.0197 
Methyl UroM5 glcA C20H18O13 465.0675 
Methyl UroM5 C14H10O7 289.0354 
Nasutin C14H6O6 269.0092 
Nasutin glcA C20H14O12 445.0412 
EA glcA C20H14O14 477.0311 
EA sulfate C14H6O11S 380.9558 
EA C14H6O8 300.999 
Methyl-EA glcA C21H16O14 491.0467 
Methyl-EA sulfate C15H8O11S 394.9715 
Methyl-EA C15H8O8 315.0146 
Dimethyl-EA glcA C22H18O14 505.0624 
Dimethyl-EA sulfate C16H10O11S 408.9871 
Dimethyl-EA C16H10O8 329.0303 
Uro = urolithin; glcA = glucuronide; sulfoglcA = sulfoglucuronide; EA = ellagic acid 
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3.3.10 Quantification of polyphenols in animal diet  
All diets for analysis were stored in airtight containers at 4 °C until use. A portion of 
both diets were double bagged and ground to a powder using a hammer. 2 g of 
each ground pellet was placed into a separate 50 ml centrifuge tube. A second 2 g 
sample of ‘basic diet’ ground pellet was placed into a third 50 ml centrifuge tube 
where epigallocatechin gallate and ellagic acid were added in methanol at 1.8 mg/g 
each to match the w:w quantities added to the polyphenol supplemented pellets in 
production and samples were dried. The pellets were defatted 3 times in hexane. 
Following drying 10 ml of 5 % formic acid in methanol was added to each sample 
and these were vortexed and left to mix for 1 hour on a shaker at 4 °C. The 10 ml 
solution was then removed to a fresh tube and the extraction process was repeated 
a further 4 times. 1 ml of the sample solution was transferred to HPLC vials. A 
calibration curve of EGCG and EA were made ranging from 100 µg/ml–1 µg/ml, 
giving a good coverage of the anticipated polyphenol concentration in the sample. 
The samples were analysed using a Luna C18 250 x 4.6, 5 µm column on a Agilent 
1100/1200 HPLC-DAD-MS system using a gradient of solvent A (0.1 % aqueous 
formic acid) and solvent B (0.1% formic acid in acetonitrile) with a flow rate of 1 
ml/min and a run time of 40 minutes using the gradient program as follows: 0–10 
min, 5–17 % B; 10–12 min, 17 % B; 12–17 min, 17–25 % B, 17–25 min, 25–35 % B, 
25–30 min, 35–50 % B, 30–35 min, 50–100 % B, 35–40 min 100 % B, 40–41 min 
100–5 % B, 41–45 min 5 % B. Recovery of the polyphenols from the extraction was 
90 % and 92 % for ellagic acid and EGCG respectively. The polyphenol content as 
milligram per gram of pellets was calculated following correction for the polyphenol 
recovery.   
3.3.11 Statistical analysis  
Data underwent standard model diagnostics to assess assumptions of normality in 
the residuals, potential outlier detection and influential data points. Where 
appropriate transformations of the data were undertaken based on box-cox plots to 
provide a normal distribution.  
Body weight, polyphenol content in pellets, VEGF stimulation by injection samples, 
and pellet consumption data were analysed untransformed. Body weight by 
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injection type was analysed using ANOVA analysis. Body weight by diet type and 
pellet consumption data were analysed by t-test. The data for the VEGF stimulation 
activity in the injection samples and the polyphenol content in pellets were 
analysed by ANOVA with Tukey multiple-comparison post-hoc test.  
ANOVA analysis of the plaque size, circumference and thickness was undertaken 
with untransformed data, after which a backwards elimination was conducted. A 
Welch-Satterthwaite t-test on rank transformed data was used to determine 
significance levels of diet or injection type. The effect of the VEGF/EGCG/EA 
injection in comparison to the VEGF only injected group was analysed through a 
Welch-Satterthwaite t-test on rank transformed data.  
Transformations of the plasma lipid data were performed as presented in Table 3.4. 
Backward elimination based on ANOVA analysis was performed and post hoc group 
differences were assessed using Tukey’s honest significant difference (HSD) 
multiple comparison procedure. The effect of the VEGF/EGCG/EA injection in 
comparison to the VEGF only injected group was analysed through a Welch-
Satterthwaite t-test on rank transformed data.  
Table 3.4: A summary of the transformation used to conduct statistical 
analysis on the data for total cholesterol, LDL cholesterol, triglycerides and 
calculated HDL cholesterol  
 
 
 
  
Time Parameter Transformation 
Week 3 Total Chol Square root 
 LDL Square root 
 Trigs Logarithmic  
Week 6 Total Chol Square root 
 LDL Square root 
 Trigs Logarithmic 
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3.4 Results 
3.4.1 Body weights and daily diet intake of the animals  
Body weight and pellet consumption were monitored over the duration of the 
study for welfare purposes and to monitor if there were any differences based on 
intervention. 
Over the study period there were fluctuations in body weight following the 
intraperitoneal injections but this was to be expected and the animals regained the 
weight and continued growth after a couple of days. Neither the injection type 
(Figure 3.4 A) nor the diet type (Figure 3.4 B) had any significant effect on weight 
gain in the mice.  
There was no significant difference in average pellet consumption per mouse per 
day (Figure 3.5). The mice fed the ‘Basic diet’ consumed 2.6 g/mouse/day while the 
mice fed the ‘EGCG/EA diet’ consumed 2.4 g/mouse/day.  
3.4.2 Quantifying EGCG and EA content of the manufactured pellets 
To determine whether any loss of polyphenols in the pellets had occurred through 
the manufacture process quantification of EGCG and ellagic acid in the 
manufactured diets was undertaken. The ‘Basic diet’ contained little to no 
polyphenol while the ‘Basic diet + EGCG/EA’, where polyphenols were added prior 
to extraction, and the ‘EGCG/EA diet’, manufactured with EGCG and EA, had much 
higher level of EGCG and EA (p = <0.001). There was a small loss of 1 % of EA in the 
pellets through manufacture but this was not significant (Figure 3.6). However, 
there was a significant loss of 21.6 % of EGCG in the pellets through manufacture (p 
= < 0.001; Figure 3.7). This equated to the final concentration of 1.78 g/kg ellagic 
acid and 1.41 g/kg EGCG in the manufactured diet fed to the animals and. This 
translated to an average daily dose per mouse of 4.3 mg ellagic acid and 3.4 mg 
EGCG.  
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Figure 3.4: Mouse body weight progression during study depending on injection 
type (A) or diet type (B) . 
The animals were weighed three times a week and the weights recorded against the day since the 
start of the intervention per batch. These were plotted into a line graph and the data is presented as 
mean ± standard deviation. There was no significant difference between either weights dependent 
on injection type or diet type; n = 17 - 35.   
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Figure 3.5: The average daily pellet consumption per mouse of the two 
experimental diets. 
The average pellet consumption per mouse in grams was calculated for both studies across the 
duration of the study. The graph shows the average of these values across all cages and batches for 
each diet type ± standard deviation. There was no significant difference between the daily pellet 
consumption of the two experimental diets; n = 35 - 52.   
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Figure 3.6: Ellagic acid content in the manufactured experimental diets   
The ellagic acid content the manufactured diet in mg/g powdered pellets was determined after 
methanol extraction by HPLC/DAD/LCMS. The ‘Basic pellets’ supplemented with EGCG and EA to a 
1.8 g/kg dose were spiked immediately prior to extraction for comparison. The data is presented as 
mean ± standard deviation after correction for loss during extraction process. The ‘Basic diet’ did not 
contain significant amounts of polyphenols. There was no significant difference in the ellagic acid 
content of the ‘EGCG/EA diet’, manufactured with EGCG and EA to a 1.8 g/kg dose, compared to the 
‘Basic pellet + EGCG/EA’ which were supplemented with 1.8 g/kg polyphenols immediately prior to 
extraction; n = 3.   
Chapter 3 
119 
 
 
Figure 3.7: EGCG content in the manufactured experimental diets  
The EGCG content the manufactured diet in mg/g powdered pellets was determined after methanol 
extraction by HPLC/DAD/LCMS. The ‘Basic pellets’ supplemented with EGCG and EA to a 1.8 g/kg 
dose were spiked immediately prior to extraction for comparison. The data is presented as mean ± 
standard deviation after correction for loss during extraction process. The ‘Basic diet’ did not contain 
significant amounts of polyphenols. There was a significant difference between the EGCG content in 
the ‘EGCG/EA diet’, manufactured with EGCG and EA to a 1.8 g/kg dose, compared to the ‘Basic 
pellet + EGCG/EA’ which were supplemented with 1.8 g/kg polyphenols immediately prior to 
extraction.(*** p = ≤ 0.001). This equated to a 21.6 % loss of EGCG through manufacture; n = 3.   
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3.4.3 Effect of injection solutions on VEGFR-2 phosphorylation of HUVECs  
The injection samples from the animal study were used to treat HUVECS to 
determine whether the VEGF in the sample was able to stimulated VEGFR-2 and 
therefore active upon delivery to the animal. All VEGF injection samples were able 
to significantly stimulate VEGFR-2 phosphorylation in HUVECs (see Figure 3.8Error! 
Reference source not found.). Although there were fluctuations in the VEGF 
stimulatory activity of each individual VEGF injection sample, treatment of HUVECs 
with the VEGF injection samples stimulated, on average, 85 % VEGFR-2 
phosphorylation in comparison to a freshly defrosted VEGF control (p = ≤0.001). 
Limited to no VEGFR-2 phosphorylation was seen in any of the MSA or 
VEGF+EA+EGCG injection samples. 
3.4.4 Quantification of atherosclerotic plaque in aortic sinus following 
intervention 
The degree of atherosclerotic plaque development in the aortic sinus of the animals 
was measured in 3 ways. 1) Atherosclerotic plaque area, presented as both the 
percentage and µm2; 2) Atherosclerotic plaque circumferential expansion, 
presented as both the percentage and µm; and 3) the maximal plaque thickness at 
the thickest portion of plaque, presented in µm (Figure 3.9-Figure 3.13).  
There were no significant differences in plaque area and plaque circumference 
between any of the treatment groups (p = > 0.05). The maximal plaque thickness 
was significantly lower in the ‘basic diet + VEGF/EGCG/EA inj.’ group in comparison 
to the ‘Basic diet + VEGF inj.’ group (p = 0.0213). There were no significant 
differences in maximal plaque thickness between any of the other groups (p = > 
0.05). The data for all treatments at each time point was pooled to determine 
whether the common factor, the high fat and high cholesterol diet, was able to 
induce disease over study duration. There was a significant increase in plaque area, 
circumference and thickness between baseline and 3 weeks post first injection, and 
between 3 weeks and 6 weeks post first injection, showing progression of 
atherosclerosis between each time point (p = 0.001 – 0.0001; Figure 3.14).  
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Figure 3.8: The VEGFR-2 phosphorylation in HUVECs stimulated with the 
VEGF, MSA and VEGF/PP injections diluted to 25 ng/ml.  
A sample of the injection solution used in the animal study was snap frozen in dry ice at time of 
injection. The injection solutions were diluted to a 25 ng/ml VEGF concentration in basal media and 
used to stimulate HUVECs for 5 minutes. A VEGF positive treatment made from a freshly defrosted 
aliquot was used as a comparator. The activity of the injections samples is expressed as a percentage 
of the VEGFR-2 phosphorylation in comparison to this VEGF positive control. Results are plotted as 
mean ± standard deviation The VEGFR-2 stimulating activity of the VEGF injection samples was 
significantly lower than the freshly defrosted VEGF samples. Limited to no stimulation was observed 
by the MSA or VEGF+EA+EGCG injection samples. There was no significant difference between the 
VEGFR-2 phosphorylation activities of the MSA injected samples versus the VEGF+EA+EGCG injected 
samples. *** p = ≤ 0.001; n = 44 – 105.   
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Figure 3.9: The atherosclerotic plaque area as a percentage of the total area 
of the lumen at baseline, week 3 and week 6 post first injections.   
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
atherosclerotic plaque percentage after this 4 week induction. At baseline, 3 weekly injections were 
undertaken and, where required, the animals received an EGCG and EA supplemented diet 
(‘EGCG/EA diet’). The data is presented as the mean ± standard deviation of the percentage plaque 
area to lumen area. The inset graph presents the same data as a progression over time. There was 
no significant difference between any of the treatment at each of the time points; n = 8-9.   
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Figure 3.10: The atherosclerotic plaque area in µm2 at baseline, week 3 and 
week 6 post first injections.  
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
atherosclerotic plaque area (µm
2
) after this 4 week induction. At baseline, 3 weekly injections were 
undertaken and, where required, the animals received an EGCG and EA supplemented diet 
(‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The inset graph presents 
the same data as a progression over time. There was no significant difference between any of the 
treatment at each of the time points; n = 8-9.   
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Figure 3.11: The atherosclerotic plaque circumferential expansion as a 
percentage of the total lumen circumference at baseline, week 3 and week 6 
post first injections.  
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
percentage of atherosclerotic plaque circumferential expansion after this 4 week induction. At 
baseline, 3 weekly injections were undertaken and, where required, the animals received an EGCG 
and EA supplemented diet (‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. 
The inset graph presents the same data as a progression over time. There was no significant 
difference between any of the treatment at each of the time points; n = 8-9.   
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Figure 3.12: The atherosclerotic plaque circumferential  expansion in µm at 
baseline, week 3 and week 6 post first injections.  
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
atherosclerotic plaque circumferential expansion (µm) after this 4 week induction. At baseline, 3 
weekly injections were undertaken and, where required, the animals received an EGCG and EA 
supplemented diet (‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The 
inset graph presents the same data as a progression over time. There was no significant difference 
between any of the treatment at each of the time points; n = 8-9.   
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Figure 3.13: The atherosclerotic plaque maximal thickness in µm at baseline, 
week 3 and week 6 post first injections.   
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
atherosclerotic plaque maximal thickness (µm) after this 4 week induction. At baseline, 3 weekly 
injections were undertaken and, where required, the animals received an EGCG and EA 
supplemented diet (‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The 
inset graph presents the same data as a progression over time. At week 3 there was no significant 
difference between any of the treatments. At week 6 the ‘Basic diet + VEGF/PP inj.’ was significantly 
lower than the ‘Basic diet + VEGF inj.’ group (* p = 0.0213). There were no significant differences 
between any other groups at the week 6 time point; n = 8-9.    
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Figure 3.14: The atherosclerotic plaque area, plaque circumference, and 
maximal plaque thickness for all mice at baseline, week 3 and week 6 post 
first injection.  
All animals were aged 8 weeks at baseline and had undergone 4 weeks induction of atherosclerosis 
with an atherogenic diet. Animals continued on the atherogenic diet until the end of the study and 
at week 3 and week 6 the plaque in the aortic sinus of a subset of animals was measured. 
Atherosclerotic plaque was measured as plaque area in % (A) and µm
2 
(B), plaque circumferential 
expansion in % (C) and µm (D), and maximal plaque thickness in µm (E). The data is presented as the 
mean ± standard deviation. In all measurements there was a significant increase between baseline 
and week 3 and between week 3 and week 6 (** p = <0.01; *** p = <0.001); n = 10 - 44.  
.   
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3.4.5 Quantification of plasma lipids 
Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were quantified 
on the Randox Daytona+ biochemical analyser using the manufacturer’s protocol.  
The values for total cholesterol ranged from 31.6 - 65.7 mmol/L (Figure 3.15) while 
the values for LDL cholesterol ranged from 5.55 - 20.46 mmol/L (Figure 3.16) across 
the study. When comparing the values at 3 weeks post first injection the ‘EGCG/EA 
diet + MSA inj.’ groups had significantly higher total cholesterol and LDL cholesterol 
values than all other groups (p ≤0.05). At 6 weeks post first injection a raised total 
cholesterol (p = 0003) and LDL cholesterol (p = 0.0001) was significantly associated 
with the EGCG and EA supplemented ‘EGCG/EA diet’, regardless of injection type. 
The MSA injection, was also significantly associated with an increased LDL 
cholesterol in comparison to the VEGF injected animals (p = 0.0054). HDL 
cholesterol was below the limit of detection in all samples and could therefore not 
be quantified.  
Triglyceride levels in the plasma were also significantly reduced at 3 weeks post first 
injection in the ‘Basic diet + VEGF inj.’ treatment in comparison to all other 
treatments (p = ≤ 0.05). Furthermore, at 3 weeks post first injection there was a 
significantly higher triglyceride level in the plasma from the ‘Basic diet + VEGF/PP 
inj.’ treated mice in comparison to the plasma triglyceride levels in the ‘Basic diet + 
VEGF inj.’ group (p = 0.0009). At 6 weeks post first injection there was no significant 
difference between the treatment groups in plasma triglyceride levels (Figure 3.17).   
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Figure 3.15: The plasma total cholesterol levels in mmol/l at baseline, week 
3 and week 6 post first injections.   
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
plasma total cholesterol levels after this 4 week induction. At baseline, 3 weekly injections were 
undertaken and, where required, the animals received an EGCG and EA supplemented diet 
(‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The inset graph presents 
the same data as a progression over time. At week 3 post first injection ‘EGCG/EA diet + MSA inj.’ 
treatment was associated with raised total cholesterol (p = ≤ 0.05) in comparison to all other groups 
(a). At week 6 post first injection there was a significant association between higher total cholesterol 
levels and the PP diet in general, irrelevant of injection type (p = 0.0003) (b); n = 8-9.     
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Figure 3.16: The plasma LDL cholesterol levels in mmol/l at baseline, week 3 
and week 6 post first injections.  
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
plasma LDL cholesterol levels after this 4 week induction. At baseline, 3 weekly injections were 
undertaken and, where required, the animals received an EGCG and EA supplemented diet 
(‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The inset graph presents 
the same data as a progression over time. At 3 weeks post first injection the ‘EGCG/EA Diet + MSA 
inj.’ treatment was associated with raised plasma LDL cholesterol (p = ≤ 0.05) in comparison to all 
other groups at this time point (a). At 6 weeks post first injection there was a significant association 
between higher LDL cholesterol levels and the PP diet in general, irrelevant of injection type (p = 
0.0003) (b) and LDL cholesterol and the MSA injection, irrelevant of diet type (p = 0.0054) (c); n = 8-
9.  
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Figure 3.17: The plasma triglyceride levels in mmol/l at baseline, week 3 and 
week 6 post first injections.   
All animals underwent a 4 week an atherogenic diet and the baseline measurement represent 
plasma triglyceride levels after this 4 week induction. At baseline, 3 weekly injections were 
undertaken and, where required, the animals received an EGCG and EA supplemented diet 
(‘EGCG/EA diet’). The data is presented as the mean ± standard deviation. The inset graph presents 
the same data as a progression over time. At 3 weeks post first injection the ‘Basic diet + VEGF inj.’ 
treatment was associated with lower triglyceride levels (p = ≤ 0.05) in comparison to all other groups 
at this time point (a). At week 6 there were no significant differences in plasma triglycerides levels 
between any treatments; n = 8-9.   
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3.4.6 Quantification of polyphenols in the plasma 
The quantification and evaluation of polyphenols in the plasma from the mice was 
performed using a published method (García-Villalba et al., 2016). No EGCG derived 
compounds identified in Table 3.2 were found in any sample, including the quality 
control samples spiked with known concentrations of EGCG and EA, demonstrating 
that the method was not appropriate for analysis of compounds associated with 
EGCG consumption in plasma. It was therefore impossible to determine the plasma 
concentration of EGCG and its metabolites. In all the plasma samples from mice fed 
the ‘Basic diet’ no polyphenol metabolites could be detected. Similarly, no 
polyphenols or metabolites were detected in the plasma samples from mice in the 
‘Basic diet + VEGF/EGCG/EA injection’ treatment group. However, in the plasma 
samples from mice fed the ‘EGCG/EA diet’ there were detectable amounts of a 
variety of the EA derived compounds presented in Table 3.3. Where standards were 
available the compounds were quantified against calibration curves to give an 
accurate concentration. A summary of the compounds quantified using standards 
can be found in Table 3.5. Quantification of the compounds where a standard was 
not available was undertaken by comparing the relative areas to the relative area of 
the known internal standard, chrysin. A summary of these compounds can be seen 
in Table 3.6. It is worth noting that ellagic acid extraction from the QC samples was 
poor, with only 20 % of spiked concentration being quantified in the QC samples.  
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Table 3.5 Table demonstrating all EA metabolites found at quan tifiable concentrations in the plasma of the mice fed an EGCG and 
EA supplemented diet and their concentration in nmol/L as quantified by HPLC/QTOF -MS.  
 
Ellagic acid Uro A-3 glucuronide Uro A sulfate 
Retention time 
(min) 
7.25 6.43 8.11 
Conc. (nmol/L) 12.9 19.5 15.3 
 
 
Table 3.6: Table demonstrating all EA metabolites found in the plasma of the mice fed an EGCG and EA supplemented diet and their 
relative areas in comparison to a chrysin standard as measured by HPLC/QTOF -MS.  
 Methyl-EA Methyl-EA 
glucuronide 
Dimethyl
-EA 
Dimethyl-EA 
glucuronide 
Uro-A 
sulfoglucuronide 
Uro-C 
sulfate 
Uro-C 
glucuronide 
Uro-C 
sulfoglucuronide 
Uro-C 
sulfoglucuronide 
Retention 
time (min) 
9.82 6.91 12.37 7.77 4.68 7.76 6.29 4.76 5.28 
Relative 
area 
4.5 2.5 35.5 67.8 10.8 152.9 92.4 41.4 157.0 
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3.5 Discussion 
The aim of this chapter was to determine whether polyphenols which are capable of 
potent in vitro inhibition of VEGF induced VEGFR-2 phosphorylation could inhibit 
VEGF induced atherosclerosis. The study reported in this chapter was designed to 
investigate a number of hypotheses. 1) VEGF injection will induce significant 
atherosclerosis above a mouse serum albumin (MSA) injected control; 2) Dietary 
supplementation with EGCG and ellagic acid, potent in vitro inhibitors of VEGF-
induced VEGFR-2 phosphorylation, will inhibit VEGF-induced atherosclerosis; 3) 
dietary supplementation with EGCG and EA will be able to limit endogenous VEGF 
signalling associated with atherosclerotic progression; 4) mixing EGCG and EA with 
VEGF prior to intraperitoneal injection will completely ablate any VEGF stimulation 
of atherosclerosis. 
It has previously been demonstrated that intraperitoneal injection of VEGF in both a 
high cholesterol fed New Zealand white rabbit and ApoE-/-ApoB100-/- genetically 
modified mouse model was able to significantly stimulate atherosclerotic plaque 
growth (Celletti et al., 2001a, Celletti et al., 2001b). This suggests that the induction 
of atherosclerotic disease by VEGF was not dependent on genetic 
hypercholesterolemia but that cholesterol induction of the disease may be 
important. However, the work presented in this chapter has shown that 
intraperitoneal injection of VEGF into ApoE-/- mice fed a high fat, high cholesterol 
did not induce atherosclerosis, at least under these study conditions. 
3.5.1 Was the VEGF active upon injection?   
To determine whether the VEGF in the injections was active at time of injection the 
VEGFR-2 phosphorylation capacity of the injections was monitored throughout the 
study. All VEGF injections were active at the time of injection while the MSA and 
VEGF/PP injections were not. It should be noted that, on average, only 85 % of the 
VEGF stimulatory capacity was retained in the VEGF injection samples in comparison 
to a freshly made VEGF control. However, no blood was taken from the mice 
immediately after injection so we cannot conclusively say whether the VEGF reached 
the blood stream. Limited data is present on the capacity for proteins to pass into 
the blood stream following intraperitoneal injection although a study in 2014 
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investigated the distribution of fluorescent labelled mouse serum albumin after 
different routes of injection. Intraperitoneal injection resulted in limited distribution 
at 1 hr and systemic distribution at 3 hour post-injection (Kijanka et al., 2014). Given 
that the in vivo VEGF half-life has been shown to be around 30 minutes (Eppler et al., 
2002), perhaps a delayed systemic distribution limited the effective VEGF dose in 
circulation. However, the injection protocol used in this chapter was identical to that 
used in previous studies where strong induction of atherosclerosis was observed 
following intraperitoneal injection of VEGF (Celletti et al., 2001b). This suggests that 
the dissemination of active VEGF after injection is unlikely to be the cause of the lack 
of atherosclerosis induction observed in this chapter. Furthermore, there were two 
additional VEGF injections undertaken in the discussed study in comparison to 
previous reports providing two more opportunities for VEGF induction of the 
disease. Considering the VEGF was active at time of injection, the similarity of 
injection protocol to previous studies where VEGF induced atherosclerosis, and the 
repeated number of injections to previous reports it can be concluded that the lack 
of disease induction by VEGF it unlikely to be due to inactive or non-functioning 
injections. However, the study design may be improved through use of intravenous 
injection of the VEGF utilising a VEGF expressing adenovirus as previously reported 
(Heinonen et al., 2013). 
3.5.2 Did cholesterol induction impact the result?  
The study presented in this chapter used the ApoE knockout mouse as a model. This 
differs from the ApoE-/-ApoB100-/- used by Celletti et al. The lack of Apolipoprotein E 
in the animal leads to a reduced ability to clear LDL and vLDL cholesterol (Meir and 
Leitersdorf, 2004), leading to high circulating cholesterol levels. The additional 
mutation, ApoB100-/- mice used in the Celletti et al. paper resulted in the animals 
expressing only the Apolipoprotein B48 truncated protein which is incapable of 
binding to the LDL receptor, and therefore clearing the cholesterol it carries, 
inducing further hypercholesterolemia. However, this anticipated difference in 
cholesterol burden between the ApoE-/- and the ApoE-/-ApoB100-/- models was 
overcome by inclusion of an atherogenic diet (AIN57BB, TestDiet) which increased 
the cholesterol dose from 0.25 % used in the Celletti et al. study to 1.25 %. The 
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atherogenic diet did induce atherosclerosis over time and the atherosclerotic plaque 
sizes achieved were similar or slightly larger than to those observed in other studies 
which fed ApoE-/- mice a similar atherogenic diet for a similar duration (Huang et al., 
2015, Cao et al., 2009).  
3.5.3 Was the plaque susceptible to angiogenesis induction? 
Considering angiogenesis plays a role in progressing plaque growth and not initiating 
it (Khurana et al., 2004) it could be suggested that in mice with a smaller level of 
plaque (≤100 µm thickness (Doyle and Caplice, 2007)) diffusion of the molecules can 
occur freely across the tissue without the need for induction of microvessel growth, 
which a supplementation of VEGF would aid. The average value for maximal plaque 
thickness at baseline, and therefore at the time of the first injection in the presented 
study was 61.5 µm, which is within a distance where diffusion should not be limited. 
This provides one explanation as to why the supplementation of VEGF did not induce 
atherosclerosis as VEGF supplementation may not provide the same advantage to 
atherosclerotic plaque growth in this tissue as it would if there was a need for 
microvessel growth. Unfortunately, the data provided in the Celletti et al. paper 
(Celletti et al., 2001b) only reports a normalised to zero baseline maximal plaque 
thickness therefore a comparison cannot be drawn. However, if we compare the 
plaque areas of the control serum albumin sham-injected mice between the study 
presented in this chapter and the Celletti et al. a comparison between the model 
induction of atherosclerosis can be undertaken. In the study presented in this 
chapter the mice in the ‘basic diet + MSA injection’ treatment arm at 3 weeks post 
first injection had an average plaque area of 79,547 µm2 while Celletti et al. reported 
an average plaque area of 64,238 µm2 for the serum albumin injected mice at 3 
weeks post first injection. This slightly larger amount of plaque in the sham-injected 
mice in the study presented in this chapter suggests that induction of baseline 
atherosclerosis was unlikely to be an issue, as the controls in both studies developed 
similar plaque levels.  
3.5.4 Impact of EGCG dietary intake on atherosclerosis 
Another interesting result from this study was the demonstration that EGCG and EA 
supplementation to the diet does not reduce atherosclerotic plaque size, irrelevant 
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of injection type. A number of studies demonstrated that green tea extract, of which 
EGCG is the major component, has anti-atherosclerotic properties with up to around 
35 % reduction in plaque size (Miura et al., 2001, Minatti et al., 2012, Tijburg et al., 
1997, Hong et al., 2014). ApoE-/- mice fed with EGCG in their water at 0.8 g/L 
(estimated 4.8 mg/day (Bachmanov et al., 2002)) for 7 weeks up to the age of 15 
weeks, a similar duration of study and EGCG dose to the 3.4 mg/day presented in 
this chapter. A reduction in atherosclerotic development was observed which was 
attributed to reduced vascular endothelial induced Notch signalling (Yin et al., 2016), 
a known VEGF associated signalling pathway (Jakobsson et al., 2009). Considering a 
loss of EGCG was observed during the manufacture of the pellets it is possible that 
the stability of EGCG may have played a part in the lack of effect in the discussed 
study. The importance of pH, temperature, humidity and oxygen on EGCG 
degradation has been demonstrated previously (Ananingsih et al., 2013) and perhaps 
the experimental cage conditions reduced the EGCG content of the pellets through 
degradation. However, fresh pellets were provided 3 times a week and in a previous 
report it was shown that green tea powder retained up to 95 % of the green tea 
catechins over 112 days of storage under similar conditions to those in the cage (25 
°C and 58 % humidity) suggesting that stability of EGCG in the pellets is unlikely to be 
the reason for the lack of observed effect on plaque size reported in this chapter (Li 
et al., 2011).  
All studies to date which have demonstrated an atherosclerosis inhibitory effect of 
either green tea extract or pure EGCG have had the extract of polyphenol provided 
in the drinking water or through intraperitoneal injection (Chyu et al., 2004, Miura et 
al., 2001, Yin et al., 2016). It has previously been shown in humans that the 
bioavailability of EGCG was affected when the dose was given alongside food, in 
comparison to water alone (Naumovski et al., 2015). This may explain why these 
studies observed an anti-atherosclerotic effect of EGCG while no effect was observed 
in the discussed study where dietary delivery of EGCG was undertaken. 
Unfortunately, we cannot determine whether free EGCG was able to reach the 
plasma of mice in the discussed study due to instability of EGCG during the 
polyphenol plasma extraction procedure, evidenced by the lack of EGCG in quality 
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control samples. Previously, daily injection of 10 mg/kg body weight for 6 weeks 
reduced cuff-induced atherosclerosis by 73 % in comparison to the control group 
(Chyu et al., 2004). In the study described in this chapter, if some free polyphenol 
had been provided in the ‘basic diet + VEGF/EA/EGCG injection’ group it will be 
below the EGCG dose of 36 µg/kg provided in the injection due to the 
VEGF/polyphenol interactions reducing the free EGCG available. In the ‘basic diet + 
VEGF/EA/EGCG injection’ treatment arm the maximal plaque thickness was 
significantly reduced in comparison to the VEGF only injected animals (p = 0.0213). 
This suggests that intraperitoneal delivery of EGCG could limit the progression of 
atherosclerosis however all other measurements of plaque size for this treatment 
group were not significant therefore the result of reduced plaque thickness should 
be treated with caution. The difference between the previously observed inhibitory 
effects of intraperitoneal EGCG injection on plaque size to the data presented in this 
chapter is likely due to the concentration of EGCG used.  
3.5.5 Impact of EA dietary intake on atherosclerosis 
In the presented study the mice were fed with an EA 0.18 % supplemented diet. A 
previous study in rats, albeit with a much higher dose of EA (2 % diet 
supplementation), found reduced intimal thickening and lipid deposition with intimal 
thickness measuring less than 100 µm in EA fed mice. The data presented in this 
chapter demonstrate the maximal plaque thickness in the mice fed an EGCG and EA 
supplemented diet at 3 and 6 weeks post diet change far exceeds this at an average 
of 140 µm and 241 µm respectively. Given that rats have a higher food intake than 
mice this would equate to a much high EA daily dose which may suggest that a 
higher ellagic acid dose is required for plaque reduction, although drawing 
comparisons between rats and mice is not ideal (Rani et al., 2013). Similarly after 1 % 
EA diet supplementation in rabbits only 2 % of the intima contained lipids compared 
to 43 % in the control group showing that strong anti-atherosclerotic effects have 
been observed in two different animal models of disease with a higher EA diet dose 
(Yu et al., 2004). Ellagic acid was detected in the plasma of mice albeit at very low 
levels (12.9 nmol/L). Mice were fed ad libitum up until time of death and the 
concentration of the polyphenols in the plasma will depend on the length of time 
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since the mice last ate which was not able to be monitored. However, the amount of 
ellagic acid quantified in the quality control samples was lower than the spiked dose 
suggesting the plasma concentration of ellagic acid is likely to be underestimated. 
Ellagic acid is known to be poorly soluble (Bala et al., 2005) and this may explain this 
reduced concentration in the quality control samples. If we assume the overall loss 
of ellagic acid through the extraction process is the same as with the quality control 
samples the average ellagic acid content in plasma would be 645 nmol/L, which is in 
a similar range to previous reports in other species (Hamad et al., 2009, Murugan et 
al., 2009, Lei et al., 2003). The analysis of plasma samples presented in this study 
does indicate that ellagic acid and the urolithins are present in plasma following 
ellagic acid consumption. Furthermore, urolithins are present in higher 
concentrations than ellagic acid, while the majority of metabolites appear as phase-II 
conjugates. The amount and type of urolithins produced following EA consumption 
has been reported to be dependent on microbiota (Tomás-Barberán et al., 2014), 
specifically Gordonibacter Spp (Romo-Vaquero et al., 2015). Since urolithin B was not 
detected in any of the mouse plasma samples reported in this thesis, the microbiota 
of the mice appears to be more similar to the human urolithin A producer phenotype 
rather than the human urolithin B/isourolithin A producer phenotype (Tomás-
Barberán et al., 2014). Interestingly, in a recent pomegranate intervention only 
participants with the urolithin B producer phenotype were reported to be 
susceptible to the lipid lowering effects of the pomegranate intervention (Gonzalez-
Sarrias et al., 2016). However, given that ellagic acid and its metabolites were 
detected in the plasma, and that a higher ellagic acid dose previously demonstrating 
anti-atherosclerotic effects, it is likely that one reason for a lack of observed anti-
atherosclerotic effect by ellagic acid consumption in this chapter is due to the lower 
dose of ellagic acid given to the mice.  
3.5.6 Could plaque vulnerability be altered by VEGF injection? 
While the physical amount of atherosclerosis was not changed by VEGF injection or 
dietary supplementation with EA and EGCG, the existing literature evidence suggests 
that the dangerous nature of atherosclerosis is the vulnerability of the plaque, as 
rupture and thrombus formation pose more of a risk than a large but stable plaque 
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(Eliasziw et al., 1994). Increased angiogenesis is a feature of vulnerable plaques, with 
the suggestion that the vulnerable vessel formation may be associated with growth 
factors such as VEGF (Chen et al., 1999, Juan-Babot et al., 2003, Fleiner et al., 2004). 
While the size of the plaque can give an indication of disease level, perhaps plaque 
morphology and vulnerability may be more critical in evaluating the role of VEGF 
injection in atherosclerotic disease. In the presented study measurements to 
investigate plaque vulnerability were not undertaken due to time restrictions but 
further staining for morphology with histological methods such as the Masson’s 
trichrome or Movat’s pentachrome stains to determine incorporation of elastin, 
collagen and fibrinogen (Virmani et al., 2000, Virmani et al., 2006) would be 
beneficial. Equally, von Willebrands factor (Virmani et al., 2005), VEGF (Chen et al., 
1999) or VEGFR-2 staining could provide insight into microvessel density of the 
plaque and angiogenic potential of the disease based on treatment type.  
3.5.7 Impact of treatments on plasma lipid levels 
The levels of plasma cholesterol observed in the study were very high but similar to 
previously reported data. In the presented study total cholesterol values ranged 
from 31.6 – 65.7 mmol/L (or 1222- 2541 mg/dl). Plasma cholesterol levels in ApoE-/- 
mice fed a western type diet (0.25 % cholesterol) have been reported up to 2000 
mg/dL (Getz and Reardon, 2006). Given that the cholesterol load from the diet was 
higher for the discussed study it was expected the total cholesterol and LDL 
cholesterol values exceeded this upper measurement of 2000 mg/dL. It was reported 
in this chapter that HDL could not be quantified in the plasma which matches 
previous observations that ApoE-/- mice fed an atherogenic diet have undetectable 
levels of HDL cholesterol, even compared to a chow diet fed ApoE-/- mouse (Zhang 
et al., 1994). At 3 weeks post first injection total cholesterol (p = 0.0022) and LDL 
cholesterol (p = 0.0005) were significantly higher in the PP diet + MSA injection 
group compared to all other treatment groups. A similar pattern was observed at 6 
weeks post first injection with the PP diet, irrelevant of injection type, causing an 
increase in total cholesterol (p = 0.0003) and LDL cholesterol (p = 0.0001). This is in 
contrast to previous data which demonstrates either no effect of EGCG or EA on 
plasma cholesterol (Chyu et al., 2004, Miura et al., 2001, Ding et al., 2014) or, in the 
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case of ellagic acid, a reducing effect on plasma cholesterol levels (Park and Kang, 
2012) in the ApoE-/- model. In other animal models EGCG has also demonstrated 
lipid lowering activities in high fat models (Chen et al., 2011b, Raederstorff et al., 
2003). There were no studies which demonstrated an induction effect of EA on 
plasma cholesterol although 100 mg/day oral gavage with green tea extract in the 
LDL receptor double knockout mouse model resulted in raised total cholesterol 
levels, although lower triglyceride levels, in comparison to controls (Minatti et al., 
2012). The increase in plasma cholesterol in the EGCG and EA fed mice was not due 
to increased pellet consumption as the average consumption of the ‘EGCG/EA diet’ 
per mouse per day was not significantly different (2.4 g) to the ‘basic diet’ (2.6 g). 
Hepatotoxicity of EGCG has been previously reported following high doses in mice 
(Lambert et al., 2010), with the lethal dose of EGCG for hepatocytes in vitro being 
200 µM (Galati et al., 2006). Liver damage can result in the accumulation of LDL 
cholesterol (Ooi et al., 2005) and could explain the raised cholesterol level if this 
were the case. However previous hepatotoxicity studies of EGCG report a much 
higher dose than used in this study (over 500 mg twice daily) is required before 
hepatotoxic markers are observed (Lambert et al., 2010). Conversely, it has been 
reported that ellagic acid has hepatoprotective effects in vivo (Singh et al., 1999, 
Girish et al., 2009) suggesting that the results observed in this chapter are not due to 
hepatotoxic effects of the polyphenols.  
Another interesting observation is that the ‘diet + VEGF injection’ group had 
significantly lower plasma triglyceride levels at 3 weeks post injection when 
compared to the other groups (P  = < 0.05) and the VEGF injected mice, irrelevant of 
diet type, had reduced plasma LDL cholesterol levels compared to the MSA injected 
groups (p = 0.0054) at 6 weeks post first injection. This suggests that VEGF injection 
may be associated with lipid reducing activities. Previously, plasma cholesterol were 
shown to be raised following injection of a VEGF-A expressing adenovirus into the 
ApoE-/- mouse (Heinonen et al., 2013). However, in female participants in the 
SAPHIR study it was reported that increases in VEGF reduced circulating LDL 
cholesterol levels (Sandhofer et al., 2009). Given the impact that raised LDL 
cholesterol (Jenkins et al., 1978) and triglycerides (Tkác ̆ et al., 1997) can have on 
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atherosclerotic development the observation that VEGF injected mice had lower 
levels of triglycerides and LDL cholesterol can provide an explanation why VEGF 
injection did not induce atherosclerosis in the discussed study. Triglyceride levels 
were also raised in the ‘basic diet + VEGF/EGCG/EA injection’ group in comparison to 
VEGF injected mice at 3 weeks post first injection (p = 0.0009) however this 
observation was not demonstrated at week 6 therefore these differences in 
triglyceride levels may be due to other factors, for example postprandial triglyceride 
elevation (Ueshima et al., 2005).  
Finally, it should also be noted that all plasma cholesterol and triglyceride levels, 
irrelevant of the treatment group, were never significantly raised above the plasma 
cholesterol and triglyceride levels at baseline. Therefore, conclusions about any of 
the treatments increasing plasma lipid levels should be treated with caution.  
3.6  Conclusions 
The study described in this chapter aimed to determine whether EGCG and EA, two 
potent inhibitor of VEGF-induced VEGFR-2 phosphorylation in vitro, are able to 
inhibit VEGF-induced atherosclerosis in vivo.  
The data in this chapter demonstrated that intraperitoneal VEGF injection does not 
induce atherosclerosis in the ApoE-/- mouse model fed an atherogenic diet. 
However, it does not exclude the possibility that other methods of VEGF delivery or 
high systemic VEGF levels would not have a pro-atherogenic effect or that VEGF 
injection may have caused a more unstable, and therefore dangerous, plaque. These 
are interesting avenues for future investigation. A daily dose of 3.4 mg EGCG and 4.3 
mg ellagic acid was not able to reduce atherosclerosis progression in either the VEGF 
or MSA injected animals. This is likely due to the low dose used in this study in 
comparison to other reports. Given VEGF was unable to induce atherosclerosis the 
effect of EGCG and EA on the VEGF in the injection could not be assessed however 
inclusion of EGCG and EA in the injection did result in reduced maximal plaque 
thickness after 6 weeks, although not in overall plaque size reduction. Furthermore, 
EGCG and EA dietary supplementation caused small but significant increases in 
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plasma total cholesterol and LDL cholesterol levels in contradiction to previous 
reports.  
In summary, even though EGCG and EA were potent inhibitors of VEGF-induced 
VEGFR-2 phosphorylation in vitro, this did not translate to a reduction in 
atherosclerotic progression in ApoE-/- mice fed an atherogenic diet. However, 
considering the upregulation of endogenous VEGF associated with atherosclerosis 
and the atherosclerotic plaque tissue this observation is surprising. To further 
investigate this chapter 4 will investigate whether serum proteins can affect the 
interaction of VEGF with EGCG and ellagic acid.  
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Serum proteins abolish the strong 
inhibitory effect of EGCG and EA on 
HUVEC VEGF signalling 
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4.1  Abstract 
In chapter 2 both ellagic acid and EGCG were identified as potent inhibitors of 
VEGF-induced VEGFR-2 activation. However, chapter 3 reports that ellagic acid and 
EGCG dietary supplementation did not affect the atherosclerotic plaque size in 
ApoE-/- mice. Where EGCG and EA were co-injected with VEGF a small reduction in 
plaque thickness was seen however the other measurement of plaque size were 
unaffected. While VEGF-injection did not increase plaque size it was expected that 
endogenous VEGF upregulation would have occurred within the growing plaques 
and that the polyphenols would have the potential to limit atherosclerosis 
progression by acting on endogenous VEGF upregulation. Therefore, the lack of 
atherosclerosis inhibition by EGCG and ellagic acid was further investigated in vitro.  
The ability of EGCG to inhibit VEGF-mediated angiogenesis was assessed in the 
mouse aortic ring assay, where serum is required for tissue growth. Subsequently, 
the effect of FCS presence in the media on the ability of EGCG and EA, 
independently and in combination, to inhibit VEGF-induced VEGFR-2 in HUVECs was 
assessed at the standard 5 minute treatment time and over a longer incubation 
period. EGCG treatment did not inhibit VEGF-induced angiogenic vessel sprouting in 
the aortic ring assay compared to VEGF-only treated rings. Inhibition of VEGF-
induced VEGFR-2 phosphorylation by ellagic acid and EGCG, independently and in 
combination, was completely abolished when FCS was present in the media prior to 
polyphenol addition. Furthermore, it was shown that the VEGFR-2 stimulation 
activity of VEGF which was rendered completely inactive by pre-mixing with ellagic 
acid and EGCG in serum-free medium was recovered over time after serum was 
added to the VEGF/polyphenol mixture. 
The presence of FCS has the ability to cause loss of EGCG and ellagic acid inhibition 
of VEGF-induced VEGFR-2 phosphorylation. Where the FCS is present prior to the 
addition of the polyphenol complete loss of inhibition is seen. Therefore, in a serum 
protein rich environment, such as the blood, EGCG and ellagic acid are unlikely to 
be able to inhibit rapid VEGF-induced VEGFR-2 activation, providing one 
explanation for the lack of observed effects in the animal study in chapter 3.  
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4.2  Introduction 
In the previous chapter it was shown that under the study model conditions used 
the VEGF injection was unable to significantly induce higher levels of atherosclerotic 
disease in the aortic arch of ApoE-/- mice and that the green tea and pomegranate 
polyphenols, epigallocatechin gallate (EGCG) and ellagic acid (EA), were ineffective 
at inhibiting atherosclerosis, even in the sham (MSA) injected mice. Given the 
previous literature discussed in chapter 1 which reports that endogenous VEGF 
upregulation occurs from the early stages of atherosclerotic plaque build-up, EGCG 
and EA had the potential to inhibit this endogenous VEGF signalling through 
interacting with the VEGF ligand to limit atherosclerotic plaque growth. This 
chapter aims to contribute to the interpretation of the lack of observed 
atherosclerosis inhibition in the animal intervention carried out in chapter 3 by 
investigating the impact of inhibitory polyphenols on angiogenesis and the effect of 
serum proteins on the potent inhibition of VEGF stimulated VEGFR-2 
phosphorylation by EGCG and EA in vitro.  
4.2.1  Polyphenol inhibition of VEGF signalling 
As discussed previously inhibition of VEGF signalling has been reported by a wide 
range of polyphenols via a number of mechanisms (Guruvayoorappan and Kuttan, 
2007, Oh et al., 2010, Pratheeshkumar et al., 2012, Luo et al., 2012, Luo et al., 2009, 
Dann et al., 2009, Oak et al., 2006, Subramanian and Arul, 2012, Osada et al., 2004, 
Lee et al., 2004). Early reports into the effects of polyphenols on VEGF signalling 
had demonstrated polyphenols could inhibit VEGFR-2 phosphorylation in both 
unstimulated and VEGF stimulated cells at supra-physiological concentrations (Lee 
et al., 2004, Labrecque et al., 2005, Lamy et al., 2006, Lamy et al., 2002, Teller et al., 
2009, Pratheeshkumar et al., 2012, Neuhaus et al., 2004, Pan et al., 2011, Shimizu 
et al., 2010). The literature also demonstrates that EGCG was able to limit the 
amount of tagged VEGF ligand bound to immobilised VEGFR-2 (Kondo et al., 2002) 
while ellagic acid, through in silico modelling, was predicted to bind to VEGFR-2 at 
the ATP binding site of the receptor limiting VEGFR-2 phosphorylation (Wang et al., 
2012). More recently it has been demonstrated that potent inhibition of VEGFR-2 
phosphorylation by is possible by EGCG and EA is achievable at low nanomolar 
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concentrations (IC50 88 and 230 nM respectively) (Cerezo et al., 2015, Moyle et al., 
2015). Similar results were replicated in chapter 2 of this thesis with IC50 values of 
96 and 310 nM respectively for EGCG and EA inhibition of VEGF-induced VEGFR-2 
phosphorylation after pre-mixing the VEGF and polyphenols. Furthermore, the 
pomegranate derived polyphenol punicalagin and the microbial metabolites 
urolithin D and urolithin C were shown to potently inhibit VEGF-induced VEGFR-2 
phosphorylation at relatively low concentrations of 49nM, 0.2µM and 3.7 µM 
respectively. It was also demonstrated that all the polyphenols tested inhibited 
VEGF-induced VEGFR-2 phosphorylation primarily by interacting with the VEGF 
ligand itself. This supported a previous observation by Moyle et al. who reported 
that the rapid inhibitory action of EGCG on VEGF-induced VEGFR-2 phosphorylation 
was through strong binding of EGCG to the VEGF ligand itself, based on experiments 
where dialysis of the VEGF/PP treatment solution did not result in recovery of VEGF 
activity (Moyle et al., 2015). Additionally, it was reported that the strength of 
inhibition of VEGFR-2 phosphorylation by all polyphenols in this model correlated to 
the predicted binding affinities of the polyphenols to VEGF estimated through in 
silico analysis (Cerezo et al., 2015). Overall, the data thus far suggests that the 
method of rapid inhibition of VEGF signalling by polyphenols at low concentrations 
is due to interactions of the polyphenol with the VEGF ligand, predicted to occur at 
the VEGFR-2 binding regions of the VEGF dimer.  
4.2.2  Polyphenol inhibition of VEGF induced angiogenesis 
There are a number of models used to investigate the effects of polyphenols on 
angiogenesis and VEGF-induced angiogenesis. VEGF-induced vascular endothelial 
cell tube formation has been shown to be inhibited by polyphenols including the 
green tea catechins (Pan et al., 2011, Lamy et al., 2006, Lin et al., 2003, Liu et al., 
2008, Tang et al., 2003, Pratheeshkumar et al., 2012). Treatment with the green tea 
catechins was undertaken at a high dose (100 µM) and it was seen that EGCG and 
ECG were most effective at this dose in comparison to EGC and EC suggesting the 
importance of the galloyl group in this activity (Kondo et al., 2002). In the same 
model 2.5 µM ellagic acid was reported to inhibit VEGF-induced tube formation as 
well as this inhibition being identified as dose-dependent (Wang et al., 2012). The 
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aortic ring assay models aortic angiogenesis. Polyphenol rich extracts (Lu et al., 
2010, Wen et al., 2008, Kang et al., 2013, Daleprane et al., 2012) as well as pure 
polyphenols (Chen and S. Easton, 2011, Wang et al., 2012, Pratheeshkumar et al., 
2012, Guruvayoorappan and Kuttan, 2007, Matsubara et al., 2005) were able to 
inhibit new vessel generation from ex vivo aortic tissue. Ellagic acid in serum free 
media was able to inhibit 70 % new vessel generation after 48-72h treatment at a 
5µM concentration (Wang et al., 2012) however EGCG has yet to be investigated in 
this model. In the chick chorioallantoic membrane once again a range of 
polyphenols were able to inhibit this angiogenesis (Pan et al., 2011, 
Pratheeshkumar et al., 2012, Oh et al., 2010, Hseu et al., 2011, Favot et al., 2003) 
including ellagic acid which was able to inhibit 90 % of VEGF-stimulated 
angiogenesis in this model at 10 µM concentration (Wang et al., 2012). In the in 
vivo matrigel plug assay of angiogenesis cell invasion into the plug was prevented 
by EGCG inclusion at 220 or 440 µM concentrations after 7 days. However, the 
vessel density or branch points were not quantified so the anti-angiogenic potential 
was not measured (Singh et al., 2002). Numerous other polyphenols have 
demonstrated inhibition of blood vessel generation in this model (Lamy et al., 2008, 
Lamy et al., 2006, Pratheeshkumar et al., 2012) as well as limiting pathological 
angiogenesis within a cancer cell and polyphenol laden matrigel plug (Lu et al., 
2010, Chakraborty et al., 2008, Luo et al., 2009). Mice which had undergone daily 
intaperitoneal injections of 50 mg/kg ellagic acid for 25 days had a reduced tumour 
volume following implantation of a plug containing an adenocarcinoma cell line, 
although the haemoglobin content as a marker of angiogenesis was not measured 
in this study (Wang et al., 2012). Overall the data thus far suggests that the 
polyphenols which have demonstrated VEGF signalling inhibition may also have the 
capacity to inhibit VEGF-induced angiogenesis in both simple an complex models. 
Furthermore, the potent and rapid biologically relevant inhibitors of VEGF-induced 
VEGFR-2 phosphorylation, EGCG and ellagic acid, have both previously 
demonstrated anti-angiogenic effects  
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4.2.3  Interaction between polyphenols and proteins 
It has been known for many years that polyphenols are capable of readily 
interacting with proteins. The role of polyphenol and protein interactions was first 
discussed in relevance to the bioavailability and bioactivity of dietary derived 
compounds for example, the impact of milk addition on tea or cocoa polyphenol 
bioavailability and anti-oxidant capacity. The majority of polyphenol-protein 
interactions are non-covalent although the binding affinities do tend to be 
associated with similar structural patterns (Cao et al., 2016, Plet et al., 2015) 
Conversely, quercetin has been shown to selectively and covalently bind human 
serum albumin in the presence of peroxides (Kaldas et al., 2005). However, over the 
last 5 years there has been a boom in published papers discussing the interactions 
between a wide variety of polyphenols and biologically relevant proteins. To date, a 
wide range of polyphenol compounds have been investigated for their interaction 
with blood proteins such as albumin and haemoglobin although the green tea 
catechins, perhaps because of their strong association with cardiovascular 
improvements, have been most widely investigated. Epicatechin exhibited relatively 
low binding constants in comparison to the other green tea catechins although 
polymerisation of the epicatechin into procyanidin increased the binding to BSA 
(Watrelot et al., 2015). The presence of a galloyl moiety in the 3’ position of the C 
ring of green tea catechins inferred up to 100 times greater binding affinity (Minoda 
et al., 2010). In a comparison of binding constants epicatechin gallate (ECG) and 
EGCG were among some of the polyphenols with the strongest binding to BSA 
reported to date (Zinellu et al., 2014) although it should be noted that not all 
polyphenols have been investigated. In another study ellagic acid had a reasonable 
binding constant (8.47 104 L/Mol) and therefore affinity for human serum albumin 
(HSA), although it should be noted that other phenolic acids demonstrated similar 
or higher binding above that observed for ellagic acid (Tang et al., 2013, Tang et al., 
2016, Peng et al., 2016). The binding constant of EGCG to bind to HSA was 
calculated independently at both above (11.0 104 L/Mol) and below (5.81 104 
L/Mol) the value reported for ellagic acid (Ozyurt et al., 2016, Zinellu et al., 2014). It 
is also worth noting that nearly all polyphenols exhibit a higher binding affinity, as 
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measured by binding constant, for human serum albumin over bovine serum 
albumin. This being said in all cases the polyphenol had a higher affinity for serum 
of any kind than for haemoglobin (Ozyurt et al., 2016, Zinellu et al., 2014). This 
suggests that there is specificity with regards to the type of biological protein that 
polyphenols will interact with. Furthermore, modification of the serum albumin, 
such as more glycated HSA in diabetes patients, has been associated with the 
reduced binding affinity for polyphenols (Xu et al., 2014b, Xie et al., 2012), with 
EGCG being among those shown to exhibit this effect (Singha Roy et al., 2016). 
Overall, there is accumulating data that demonstrates polyphenols can bind to 
serum proteins and that specific structural features such as methylation or 
galloylation increase this binding. A summary of polyphenol-serum protein 
interactions can be seen in Table 4.1. 
Table 4.1: Summary of polyphenol interactions with plasma proteins   
Polyphenol name Binding partner 
Binding constant 
(10
4 
L/Mol) 
Ref. 
4-caffeoylquinic 
acid 
Human serum albumin 24.7 (Tang et al., 2016) 
3-caffeoylquinic 
acid 
Human serum albumin 19.7 (Tang et al., 2016) 
5-caffeoylquinic 
acid 
Human serum albumin 10.3 (Tang et al., 2016) 
Resveratrol 
Human serum albumin  
Bovine serum albumin 
Haemoglobin 
74.3 
2.5 
7.4 
(Lu et al., 2007)  
(Bourassa et al., 2010) 
(Lu et al., 2007) 
Rosmarinic acid Human serum albumin 4.29 (Peng et al., 2016) 
Ellagitannin (dp1) Bovine serum albumin 1.84 (Karonen et al., 2015) 
Ellagitannin (dp2) Bovine serum albumin 0.57 (Karonen et al., 2015) 
Ellagitannin (dp3) Bovine serum albumin 0.76 (Karonen et al., 2015) 
Ellagitannin (dp5) Bovine serum albumin 2.32 (Karonen et al., 2015) 
Ellagitannin (dp6) Bovine serum albumin 1.69 (Karonen et al., 2015) 
Ellagitannin (dp8) Bovine serum albumin 1.69 (Karonen et al., 2015) 
Procyanidin dp2 Bovine serum albumin 0.39 (Watrelot et al., 2015) 
Procyanidin dp8 Bovine serum albumin 1.70 (Watrelot et al., 2015) 
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Polyphenol name Binding partner 
Binding constant 
(10
4 
L/Mol) 
Ref. 
EC 
Human serum albumin 
 
Human Haemoglobin 
Bovine serum albumin 
1.40 
1.64 
0.37 
0.046 
0.47 
(Ozyurt et al., 2016) 
(Zinellu et al., 2014) 
(Ozyurt et al., 2016) 
(Watrelot et al., 2015) 
(Zinellu et al., 2014) 
EGC 
Human serum albumin 
 
Human Haemoglobin 
Bovine serum albumin 
0.60 
2.15 
0.24 
0.64 
(Ozyurt et al., 2016) 
(Zinellu et al., 2014) 
(Ozyurt et al., 2016) 
(Zinellu et al., 2014) 
ECG 
Human serum albumin 
Bovine serum albumin 
10.3 
3.37 
(Zinellu et al., 2014) 
(Zinellu et al., 2014) 
EGCG 
Human serum albumin 
 
Bovine serum albumin 
Human Haemoglobin 
5.81 
11.0 
3.68 
1.53 
(Ozyurt et al., 2016) 
(Zinellu et al., 2014) 
(Zinellu et al., 2014) 
(Ozyurt et al., 2016) 
Vescalagin Bovine serum albumin 5.2 (Dobreva et al., 2014) 
Pedunculagin Bovine serum albumin 4.2 (Dobreva et al., 2014) 
Ellagic acid Human serum albumin 8.47 ± 0.52 (Tang et al., 2013) 
Genistein Bovine serum albumin 1.26(+/-0.3 (Bourassa et al., 2010) 
Curcumarin Bovine serum albumin 3.33(+/-0.8) (Bourassa et al., 2010) 
 
4.2.4  Implications of polyphenol interactions with proteins 
The literature has suggested that plasma protein may act as transporters which 
bind to polyphenols increasing the polyphenol concentration in plasma (Lu et al., 
2007). For example, quercetin was reported to bind to haemoglobin after passive 
diffusion into blood cells, with the blood cells acting as reservoirs (Fiorani et al., 
2003). Numerous reports discuss the impact of polyphenol-protein interactions on 
the bioactivity and bioavailability of the polyphenols (Xiao et al., 2011). Some 
reports suggest the concentration of tea or cocoa polyphenols in the plasma is 
unaltered by the addition of milk prior to intake (Keogh et al., 2007, Kyle et al., 
2007). Others report that the antioxidant capacity of the plasma was found to 
decrease, although this was not replicable in vitro (Serafini et al., 1996) and not all 
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reports saw this effect (Reddy et al., 2005). However, it is important to consider 
that this observation appears very method dependent (Bourassa et al., 2013).  
There are reports of polyphenols binding to biologically relevant proteins, altering 
the protein function. The green tea catechins were reported to directly bind and 
modify the protein disulfide isomerase isoformA3 (PDIA3), causing moderate 
inhibition of the protein activity. In this study once again the affinity for the protein 
was higher for galloylated catechins compared to non-galloylated catechins 
(Trnkova et al., 2013). The enzymatic action of porcine pancreatic elastase was 
inhibited by binding with procyanidin, where an increase in the degree of 
polymerisation was associated with an increase in protein action inhibition. (Bras et 
al., 2010). In some cases polyphenols can alter protein activity after binding by 
modifying the protein structure as was the case with the binding of curcumin to 
protein kinase C. The modification was associated with increases in the protein 
activity (Majhi et al., 2010).  
One study reports the effects of serum proteins on a polyphenol-ligand interaction. 
A quinoline appended chalcone derivative was found to exhibit strong inhibition of 
angiotensin converting enzyme (ACE) activity however this inhibition was 
diminished in the presence of BSA (Kumar et al., 2015). At the time of writing this 
was the only research article reporting the influence of serum proteins on the 
interaction of a polyphenol with a biological protein. However, non-protein 
compounds have been found to alter polyphenol-protein interactions. For example, 
Goncalves et al. found that the presence of pectin caused the dissociation of 
previously bound procyanidin-trypsin complex (Goncalves et al., 2011). Although 
limited, the data suggests that polyphenol binding to a ligand can be interrupted by 
external compounds, including serum proteins.   
4.2.5  Objectives 
This chapter aims to determine whether 1) EGCG is able to inhibit VEGF-induced 
angiogenesis under the serum protein rich conditions required for ex vivo aortic 
ring growth; and 2) the presence of FCS can affect the strong inhibition of VEGF-
stimulated VEGFR-2 phosphorylation demonstrated by EGCG and EA in serum-free 
media as reported in chapter 2.    
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4.3 Material and methods 
4.3.1 Determining effect of EGCG on ex vivo angiogenesis in the aortic 
ring assay 
The aortic ring assay was performed as previously reported (Baker et al., 2012).Per 
repeat 3 whole aortas were removed from 8 week old C57BL/6J mice following 
death by rising CO2 and transferred straight to chilled Opti-MEM media (Thermo 
Fisher Scientific, UK) for transport. The aortas were cleaned and cut into 5 mm wide 
rings using microscopy while submerged in Opti-MEM media under sterile 
conditions. The rings were transferred to fresh, sterile Opti-MEM media in a 10 cm 
dish and incubated at 37 °C, 5 % CO2  for 24 hours. The next day 50 µl DMEM 
containing 0.1 mg/ml rat tail collagen was added to each well of a 96 well plate and 
one ring imbedded into each well and the plate was incubated at 37 °C, 5 % CO2  for 
1 hour to set. After the collagen was set each well was fed with 150 µl of the 
treatment solution containing 2.5 % FCS and either no VEGF for a negative control 
(‘VEGF(-)’), VEGF at 30 ng/ml concentration for a VEGF control (‘VEGF (+)’), VEGF at 
30 ng/ml and the EGCG as a treatment (‘VEGF + EGCG’) or VEGF at 30 ng/ml and 
epicatechin (EC) as a negative polyphenol control, considering EC was previously 
unable to inhibit VEGF induced VEGFR-2 phosphorylation (Cerezo et al., 2015) 
(‘VEGF + EC’). Where polyphenol was included with the treatment it was allowed to 
mix in the solution for 5 minutes at room temperature before being added to the 
96 well plate. The media was replaced with freshly prepared media on day 3 and 
day 6. On day 7 the wells were washed with PBS+CaCl2+MgCl2 and fixed with 4 % 
formalin for 30 minutes. The wells were blocked and the endothelial cells were 
stained with 0.1 mg/ml BS1 lectin conjugated to FITC for 24 hours at 4°C. Imaging 
was performed in situ using the AxioVision software on an inverted fluorescence 
microscope (Zeiss) and quantification of microvessels undertaken in a blinded 
manner. A visual representation of the protocol including examples of tissue 
preparation, bright field images of growing tissue, and fluorescent imaging of 
stained tissue used for quantification can be seen in Figure 4.1. 
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Figure 4.1: A visual representation of the experimental pr ocedure described 
in section 4.3.1. 
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4.3.2 Subculture of HUVECs  
HUVECs were subcultured as described earlier in section 2.3.1 in either T75 or T175 
and always seeded to a density of 3500 cells per cm2.  
4.3.3 Culture of cells in 6 well plates for treatment 
HUVECs at passage 5 were grown to 100 % confluency in 6 well plates as described 
previously in section 2.3.2 and always seeded to a density of 3500 cells per cm2.  
4.3.4 Determining the effect of serums proteins of polyphenol inhibition 
of VEGF signalling 
For every well requiring treatment 2.5 ml of basal media was transferred to sterile 
flasks labelled with the treatment and these were warmed in a water bath. A fresh 
aliquot of VEGF was defrosted on ice and added to the relevant treatments at a 
concentration of 1:2000 to give a final VEGF concentration of 25 ng/ml in the VEGF 
positive treatments. Foetal calf serum was added to the treatments requiring FCS 
prior to polyphenol addition at a 2 % concentration (called ‘VEGF/FCS + PP’) after 
which the 1000 x concentrated polyphenol stocks were added to the appropriate 
treatments at a 1:1000 ratio and allowed to mix with the VEGF for 5 minutes at 
room temperature. DMSO was added as a vehicle control to the VEGF negative and 
VEGF positive controls. One treatment (called ‘VEGF/PP + FCS’) allowed the VEGF 
and polyphenol to mix for 5 minutes before the addition of FCS. Confluent HUVECs 
grown in 6 well plates (Greiner BioOne Ltd.) were washed twice with 2 ml PBS 
warmed to 37 °C. After the 5 minute pre-mixing of the VEGF and polyphenol FCS 
was added at 2 % to the ‘VEGF/PP + FCS’ treatment and all treatments were added 
to the appropriate wells and incubated at 37 °C, 5% CO2  for 5 minutes. 2 plates 
were used per experiment and the whole experiment was repeated at least 3 times. 
For a visual representation of the experimental protocol please see Figure 4.2. 
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Figure 4.2: A visual representation of the experimental procedure described 
in section 4.3.4. 
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4.3.5 Determining the polyphenol inhibition of VEGF signalling following 
longer incubation of VEGF/PP complex with FCS 
2 x 20 ml and 1 x 10 ml basal media was transferred to 3 sterile flasks. The 20 ml 
volumes were labelled VEGF/FCS + PP and VEGF/PP + FCS while the 10 ml volume 
was labelled VEGF only. The VEGF was defrosted on ice and added to the relevant 
treatments at a concentration of 1:2000 to give a final VEGF concentration of 25 
ng/ml. FCS was added at a 2 % concentration to the appropriate media (VEGF/FCS + 
PP treatment) prior to the addition of the polyphenol. EGCG and EA stocks were 
added to the appropriate treatments at a 1µM concentration and allowed to mix 
for 5 minutes at room temperature. One treatment (called ‘VEGF/PP + FCS’) 
allowed the VEGF and polyphenols to mix for 5 minutes before the addition of FCS. 
DMSO was added as a vehicle control to the VEGF negative and VEGF positive 
controls. After this 5 minutes and immediately prior to cell treatment FCS was 
added to the ‘VEGF/PP + FCS’ treatment at a 2 % concentration. Treatments were 
added to confluent HUVECs grown in 6 well plates (Greiner BioOne Ltd.) as shown 
in Figure 4.3 and incubated at 37 °C, 5% CO2  for 5 minutes. The VEGF/FCS + PP and 
VEGF/PP + FCS, VEGF only solutions were then incubated between treatments at 37 
˚C and 5 % CO2 and the treatment were repeated using the incubated media at 1 h, 
2 h and 4 h post polyphenol addition. For a visual representation of the 
experimental protocol please see Figure 4.3. 
4.3.6  Cell lysis  
The cells were washed with 2 ml ice cold PBS twice after which 50 µl cell lysis buffer 
supplemented with 1 mM PMSF according to manufacturer’s instructions (#9803, 
Cell Signalling Technology, Inc). Plates were scraped (541070, Greiner BioOne Ltd.) 
and the lysates collected and kept on ice for processing. Each lysate was vortexed 
for 20 seconds, three times at maximum speed with breaks on ice between each 
vortex. The lysates were then centrifuged for 10 minutes at 13,000 x g at 4 °C and 
the supernatant was collected in a separate tube. A 5 µl aliquot of each sample was 
taken prior to freezing to use to determine the total protein concentration in each 
sample. The sample and 5 µl aliquot were frozen and stored at -80 °C until analysis 
could be performed.  
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Figure 4.3: A visual representation of the experimental procedure described 
in section 4.3.5.    
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4.3.7  Quantification of the absolute protein concentration of cell lysates  
To quantify the total protein a sample the bicinchoninic acid (BCA) assay was used 
as described previously in section 2.3.5. Briefly, a BSA calibration curve ranging 
from 0 mg/ml to 1 mg/ml was set up and each experiemtn 5 µl sample was diluted 
in 55 µl of NaPi buffer. The reaction solution of Bicinchoninic acid and copper II 
sulphate in a ratio of 50:1 v:v was added to 25 µl of each sample in duplicate and 
the reaction was incubated at 37 °C for 30 minutes after which it was immediately 
read using a FluorStar OPTIMA spectrophotometer (BMG Labtech) at 450nm.  
4.3.8  Determining the amount of VEGF receptor phosphorylation in 
HUVECs following cell treatments 
An enzyme linked immunosorbent assay (ELISA) kit was used (7335, New England 
Biolabs) to determine the amount of tyrosine 1175 (Y1175) VEGFR-2 
phosphorylation in the cell lysates was used as previously described in section 2.3.6. 
Each experimental sample was performed in duplicate and following completion of 
the ELISA protocol the plates were read immediately at 450nm-540 nm on a 
FluorStar OPTIMA spectrophotometer (BMG Labtech). The percentage VEGFR-2 
phosphorylation in comparison to a VEGF stimulated sample was calculated. 
4.3.9 Statistical analysis 
All samples were compared to the VEGF only stimulated samples and presented as 
a percentage of this value. To determine statistical significance of any differences 
ANOVA with a Tukey post-hoc test was conducted. Results were considered 
significant with a p value of under 0.05.  
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4.4 Results 
4.4.1 EGCG was unable to inhibit VEGF-induced new vessel growth in 
aortic ring assay 
The effect of EGCG treatment in the aortic ring assay was assessed. Epicatechin, a 
polyphenol previously reported as incapable of inhibiting VEGF-induced VEGFR-2 
phosphorylation (Cerezo et al., 2015), was used as a polyphenol control. Treatment 
with 30 ng/ml VEGF + FCS significantly induced more new vessel growth that FCS 
only treatment. Treatment with EGCG + FCS also induced a smaller but significant 
increase in microvessel number. Treatment with VEGF + EGCG and VEGF + EC 
induced a strongly significant increase in number of microvessel in comparison the 
FCS only treatment but did not differ from the VEGF + FCS treatment. EGCG and 
epicatechin, and both the polyphenol treatments were not significantly different to 
the VEGF negative or VEGF positive controls. The variation in the sample was high, 
as is expected with this assay (see Figure 4.4).  
4.4.2  Potent inhibition of VEGF signalling by epigallocatechin gallate does 
not occur in the presence of FCS 
Considering that the addition of FCS to the media as required for aortic ring growth 
may have contributed to the lack of observed inhibition of VEGF-induced 
angiogenesis by EGCG, the effect of FCS in the simpler HUVEC model of VEGF-
induced VEGFR-2 phosphorylation was investigated. Addition of FCS to a VEGF only 
treatment (‘VEGF/FCS’) did not significantly increase the VEGFR-2 phosphorylation 
but did increase the variability. To determine the effect of FCS on this inhibition FCS 
was added to the media either before the pre-mixing of the VEGF and EGCG or after 
this 5 minute period. Where FCS was added to the media prior to the mixing of the 
VEGF and EGCG (‘VEGF/FCS + EGCG’) the VEGF was able to stimulate VEGFR-2 
phosphorylation at a comparable amount to a VEGF only treatment. However when 
the VEGF and EGCG were allowed to mix for 5 minutes prior to the addition of the 
FCS (‘VEGF/PP + FCS’) a comparative inhibition to the VEGF + EGCG treatment was 
achieved after 5 minute treatment (Figure 4.5).  
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Figure 4.4: Effect of EGCG and epicatechin (EC), on VEGF induced new microvessel growth in 
the aortic ring assay 
5 mm thick mouse aortic rings from 8 week old C57BL/6J mice were embedded into collagen and 
grown in 2.5% supplemented Opti-MEM media in the presence or absence of VEGF (30 ng/ml) 
and/or polyphenols (1 µM) for 7 days. The number of new microvessels after this time and a Kruskal-
Wallis ANOVA with Dunns post-test was undertaken. Data is presented as mean ± SD. The results 
were plotted into a bar graph * = p < 0.05; n = 50 - 76.  
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4.4.3 Potent inhibition of VEGF signalling by ellagic acid does not occur in 
the presence of FCS 
As in section 4.4.1 the addition of FCS to a VEGF only (‘VEGF/FCS’) treatment did 
not significantly increase the VEGFR-2 phosphorylation but did increase the 
variability. However, when FCS was present in the media prior to the addition of 
ellagic acid (‘VEGF/FCS + EA’) the VEGF was able to stimulate VEGFR-2 
phosphorylation to the same amount as with the VEGF only treatment. 
Interestingly, the ‘VEGF/EA + FCS’ treatment, where ellagic acid was pre-mixed with 
the VEGF for 5 minutes prior to the addition of FCS to the media, was significantly 
different to both the ’VEGF/FCS +EA’ (p = ≤0.001) and the ‘VEGF/EA’ (p = ≤ 0.05) 
treatments. The VEGF in the ‘VEGF/EA + FCS’ treatment was able to stimulate 
around 28 % of the VEGFR-2 phosphorylation observed in the VEGF only treated 
cells (Figure 4.6).  
4.4.4 Combinations of EGCG and EA treatment does not improve VEGF 
inhibition capacity of the polyphenols in presence of FCS 
The effect of FCS on the inhibition of VEGF-induced VEGFR-2 phosphorylation by a 
combination of 1µM EGCG and ellagic acid was also investigated. As seen before 
FCS addition to a VEGF only (‘VEGF/FCS’) treatment did not significantly increase 
the VEGFR-2 phosphorylation but did increase the variability. When 2 % FCS was 
added to the VEGF supplemented media prior to the addition of the polyphenols 
(‘VEGF/FCS + EA/EGCG’) there was no significant difference in the VEGFR-2 
phosphorylation in comparison to the VEGF only treatments. As seen with EGCG 
only treatment (section 4.4.1; Figure 4.5), when the VEGF and polyphenols were 
pre-mixed for 5 minutes before to the addition of FCS to the treatment 
(‘VEGF/EA/EGCG + FCS’) the VEGFR-2 phosphorylation was completely inhibited 
with no significant difference to the VEGF/EA/EGCG treatment arm (Figure 4.7).   
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Figure 4.5: Effect of FCS on EGCG inhibition of VEGF induced VEGFR-2 phosphorylation  
25 ng/ml VEGF supplemented EBM-2 media (Lonza) was supplemented further with 2% FCS as 
appropriate. EGCG was then added to the appropriate solutions for 5 minutes to mix, after which 
one treatment with VEGF and EGCG only, ‘ VEGF/EGCG + FCS’ had FCS added to 2 % concentration. 
HUVECs were stimulated for 5 minutes at 37 °C, 5 % CO2. Cells were then lysed and total protein 
collected. VEGFR-2 phosphorylation was quantified in samples normalised to the same total protein 
by sandwich ELISA and a percentage phosphorylation in comparison to the VEGF only stimulated 
sample was calculated. These were plotted into a bar graph and a one-way ANOVA with Tukey post-
hoc statistical test performed. *** = p ≥ 0.001; n = 4.   
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Figure 4.6: Effect of FCS on EA inhibition of VEGF induced VEGFR-2 phosphorylation  
25 ng/ml VEGF supplemented EBM-2 media (Lonza) was supplemented further with 2% FCS as 
appropriate. EA was then added to the appropriate solutions for 5 minutes to mix, after which one 
treatment with VEGF and EA only ‘ VEGF/EA + FCS’ had FCS added to 2 % concentration. HUVECs 
were stimulated for 5 minutes at 37 °C, 5 % CO2. Cells were then lysed and total protein collected. 
VEGFR-2 phosphorylation was quantified in samples normalised to the same total protein by 
sandwich ELISA and a percentage phosphorylation in comparison to the VEGF only stimulated 
sample was calculated. These were plotted into a bar graph and a one-way ANOVA with Tukey post-
hoc statistical test performed. *** = p ≤ 0.001; * = p ≤ 0.05; n = 8.  
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Figure 4.7: Effect of FCS on EA and EGCG combined inhibition of VEGF induced VEGFR-2 
phosphorylation  
25 ng/ml VEGF supplemented EBM-2 media (Lonza) was supplemented further with 2% FCS as 
appropriate. EA and EGCG were then added to the appropriate solutions for 5 minutes to mix, after 
which one treatment with VEGF, EA, and EGCG only ‘ VEGF/EA/EGCG + FCS’ had FCS added to 2 % 
concentration. HUVECs were stimulated for 5 minutes at 37 °C, 5 % CO2. Cells were then lysed and 
total protein collected. VEGFR-2 phosphorylation was quantified in samples normalised to the same 
total protein by sandwich ELISA and a percentage phosphorylation in comparison to the VEGF only 
stimulated sample was calculated. These were plotted into a bar graph and a one-way ANOVA with 
Tukey post-hoc statistical test performed. *** = p ≤ 0.001; * = p ≤ 0.05; n = 6.  
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4.4.5 VEGF regains VEGFR-2 phosphorylating activity over time in the 
presence of FCS following complete inhibition by EGCG/EA 
To determine the effect of FCS on EGCG and ellagic acid combined inhibition of 
VEGF-induced VEGFR-2 phosphorylation over time the treatments were repeated as 
in section 4.4.3, stored at 37 °C and 5 % CO2, and at regular time intervals were 
removed to perform a 5 minute treatment on HUVECs. As observed previously after 
5 minutes the treatments where EGCG and ellagic acid were mixed with the VEGF 
before the addition of FCS completely inhibited VEGFR-2 phosphorylation while the 
treatments where the polyphenols were mixed with the VEGF/FCS solution were 
unable to inhibit VEGFR-2 phosphorylation, in fact a small but significant increase in 
p-VEGFR-2 was observed in the ‘VEGF/FCS + EGCG/EA’ treatment at 5 minutes. 
Over time it was observed that the VEGF in the ‘VEGF/EGCG/EA + FCS’ treatment, 
which was completely inhibited at the 5 minute time point, regained activity. This 
increase in VEGF-stimulated VEGFR-2 phosphorylation was only significant however 
after 4 hours (p = ≤ 0.05). The VEGFR-2 phosphorylation of the ‘VEGF/FCS + 
EGCG/EA’ treatment after 1, 2 and 4 hours incubation was significantly lower than 
the same treatment at 5 minutes, although only after 4 hours was this ‘VEGF/FCS + 
EGCG/EA’ treatment significantly different to the VEGF only ‘VEGF (+)’ treatment 
(Figure 4.8).  
4.4.6 Sustained VEGF activity in the presence of FCS, EGCG and EA in vitro  
The VEGFR-2 phosphorylation stimulated by the ‘VEGF/FCS + EGCG/EA’ treatment 
after 1 h, 2 h, and 4 h incubation time was significantly higher than the stimulation 
by the ‘VEGF (+)’ treatment incubated for the same duration. Treatment of cells 
with the ‘VEGF (+)’ media after 4 hours incubation at 37 °C, 5 % CO2 only induced a 
small amount of VEGFR-2 phosphorylation but this was not significantly different to 
the ‘VEGF (-)’ treatment. The ‘VEGF/FCS + EGCG/EA’ treatment retained over 75 % 
VEGFR-2 stimulation activity after the same 4 hour incubation. However, there was 
a smaller but significant decline in VEGF activity over time in the ‘VEGF/FCS + 
EGCG/EA’ treatment with the VEGF-induced VEGFR-2 phosphorylation of this 
treatment being significantly different to the ‘VEGF (+)’ treatment after 4 h 
incubation at 37 °C, 5 % CO2. (Figure 4.9).   
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Figure 4.8: Effect of FCS on EA and EGCG combined inhibition of VEGF induced VEGFR-2 
phosphorylation over time  
A negative control lacking VEGF (‘VEGF (-)’) and a 25 ng/ml VEGF only control (‘VEGF (+)’) were set 
up.  To create the ‘VEGF/FCS + EGCG/EA’ treatment 25 ng/ml VEGF supplemented EBM-2 media was 
supplemented further with 2% FCS, after which 1 µM EA and EGCG were then added for 5 minutes 
to mix. To create the ‘VEGF/EGCG/EA + FCS’ treatment 25 ng/ml VEGF supplemented EBM-2 media 
was supplemented with 1 µM EGCG and EA and allowed to mix for 5 minutes, after it was further 
supplemented with 2% FCS. HUVECs were stimulated with all treatments for 5 minutes at 37 °C, 5 % 
CO2 and the remaining media were left to incubate at 37 °C, 5 % CO2. Periodically at 1, 2, and 4 hours 
after the addition of the polyphenol the media were used to treat HUVEC for 5 minutes at 37 °C, 5 % 
CO2. After each treatment cells were then lysed and total protein collected. VEGFR-2 
phosphorylation was quantified in samples normalised to the same total protein by sandwich ELISA 
and a percentage phosphorylation in comparison to the VEGF only stimulated sample was 
calculated. These were plotted into a bar graph and a one-way ANOVA with Tukey post-hoc 
statistical test performed. *** = p ≤ 0.001; ** = p ≤ 0.01; n = 6.   
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Figure 4.9: The loss of VEGFR-2 phosphorylation activity of VEGF over time in cell culture 
media 
25 ng/ml VEGF supplemented EBM-2 media (Lonza) was supplemented further with 2% FCS as 
appropriate and EA and EGCG were then added to the FCS containing treatments. The treatment 
solutions were incubated at 37 °C, 5 % CO2 until needed. A VEGF only treatment sample was 
incubated for the same duration as a comparison. HUVECs were stimulated for 5 minutes at 37 °C, 5 
% CO2 at 5 minutes, and 1, 2, and 4 hours incubation. After each treatment cells were lysed and 
total protein collected. VEGFR-2 phosphorylation was quantified in samples normalised to the same 
total protein by sandwich ELISA and a percentage phosphorylation in comparison to the VEGF only 
stimulated sample was calculated. These were plotted into a bar graph and a one-way ANOVA with 
Tukey post-hoc statistical test performed. a represent a significant difference to the ‘VEGF (-)’ 
treatment; b represents a significant difference to the ‘VEGF’ 5 min treatment; c represents a 
significantly different to the ‘VEGF’ 1 hr treatment; d represents a significant difference to the ‘VEGF’ 
2hr treatment; e represents a significant difference to the ‘VEGF’ 4 hr treatment; f represents a 
significant difference to the ‘VEGF/FCS + EGCG/EA’ 5 min treatment; n = 6.   
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4.5 Discussion 
In chapter 2 it was identified that both EGCG and ellagic acid were able to potently 
inhibit VEGF-induced VEGFR-2 phosphorylation in HUVECs primarily through 
interactions between the VEGF and the polyphenol. Please see Figure 5.1 for a 
diagrammatic representation of the proposed mechanism of action for the 
inhibition of VEGF-induced VEGFR-2 phosphorylation by polyphenols in serum free 
media. Considering the critical role for angiogenesis in atherosclerosis chapter 3 
investigated the inhibitory effects of the polyphenols on VEGF activity in relevance 
to the progression of atherosclerosis. Although injection of VEGF did not induce 
atherosclerosis in the model it is widely reported that upregulation of endogenous 
VEGF signalling occurs within the atherosclerotic plaque. However, no inhibition of 
atherosclerosis progression was observed in any treatment arm through dietary 
intervention with EGCG and ellagic acid, and only a minimal effect was observed 
when a high dose of EGCG and EA was delivered by intraperitoneal injection. The 
aim of this chapter was to provide an explanation for the lack of observed inhibition 
of the anticipated endogenous VEGF upregulation in atherosclerosis. Firstly, it was 
investigated whether angiogenesis could be inhibited by the potent VEGF inhibitor 
EGCG and, following the lack of inhibitory effect observed in the aortic ring assay, 
whether the interaction of the polyphenols with serum proteins could alter the 
polyphenol inhibition of VEGF-induced VEGFR-2 phosphorylation.  
4.5.1 Polyphenol inhibition in the aortic ring assay 
Through the use of the aortic ring assay it was established that EGCG was not able 
to inhibit angiogenesis and reduce new vessel growth in comparison to the VEGF 
stimulated treatment. EGCG treatment was also not able to significantly alter the 
new vessel generation in comparison to treatment with epicatechin, a polyphenol 
unable to inhibit VEGF induced VEGFR-2 phosphorylation in vitro. The main 
difference between the treatment media used in the HUVEC experiments and that 
used in the aortic ring assay was the presence of 2.5 % FCS as necessary for the 
survival of the aortic ring tissue. It was hypothesised that the presence of serum 
proteins may have interfered with the polyphenol inhibition of VEGF-induced 
VEGFR-2 phosphorylation, given the knowledge that polyphenols are able to bind to 
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a variety of biological proteins (Zinellu et al., 2014, Ozyurt et al., 2016, Soares et al., 
2007). However, considering the aortic ring model required FCS for growth and 
extraction of enough protein from the aortic rings to analyse VEGFR-2 
phosphorylation would require a large amount of tissue, a simpler model of VEGF-
induced VEGFR-2 phosphorylation was needed. Therefore, the HUVEC model, as 
reported in chapter 2, was ideal for investigation of the effect of FCS on polyphenol 
inhibition of VEGF-induced VEGFR-2 phosphorylation.  
 
 
Figure 5.1: Diagrammatic representation of the mechanism of action for 
polyphenol inhibition of VEGF signalling reported in this thesis  
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4.5.2 Effect of FCS on polyphenol inhibition of VEGF signalling after 5 
minutes 
In the HUVEC model EGCG and EA were both able to strongly inhibit VEGF-induced 
VEGFR-2 phosphorylation at 1 µM independently and in combination. For both 
polyphenols, independently and in combination, this inhibitory effect was 
completely lost when the polyphenol was added to the VEGF containing treatment 
already supplemented with FCS. Interestingly, when the VEGF and EGCG were pre-
mixed for 5 minutes prior to the addition of the FCS, the VEGF remained completely 
inactive, at least at this 5 minute time point. This suggests that the FCS was unable 
to affect the interaction between the VEGF and EGCG, which caused the inhibition 
of VEGFR-2 phosphorylation, after this 5 minute incubation (Figure 4.5). When 
ellagic acid was pre-mixed with VEGF prior to the addition of FCS significantly more 
VEGF-induced VEGFR-2 phosphorylation was observed (28 %) than the VEGF + EA 
only treatment after only 5 minutes. This demonstrates that VEGF regains 
significant VEGFR-2 phosphorylating activity after only 5 minutes incubation of the 
VEGF/EA complex with FCS. However, it is of note that a significant amount of 
inhibition is still retained (see Figure 4.6). Without further time points investigating 
EA inhibition alone we cannot conclude whether VEGF would regain more activity if 
the VEGF/EA complex was incubated for a longer time in the presence of FCS. 
This difference between the inhibition capabilities of VEGF by EGCG and ellagic acid 
after 5 minutes incubation with FCS may be due to the binding strength of the 
interaction between the individual polyphenols and the VEGF ligand. While both 
EGCG and ellagic acid are predicted to interact within the ridge on the VEGF dimer 
where the VEGF receptor binding region sits, the binding affinity of EGCG for VEGF 
was higher than that for ellagic acid (change in Gibbs free energy -8.3 kcal/mol for 
EGCG versus -7.5 kcal/mol for ellagic acid) (Cerezo et al., 2015). In other 
experiments the binding constant, as a measure of affinity, of ellagic acid to HSA 
was determined as 8.47 ± 0.52 104 L/Mol (Tang et al., 2013) while EGCG has been 
recorded as having both a higher (Zinellu et al., 2014) and lower (Ozyurt et al., 
2016) binding constant to HSA than ellagic acid (5.81 104 L/Mol and 11.0 104 L/Mol). 
However, on average, EGCG had a similar binding constant to HSA as ellagic acid. 
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Taking into account that data for both compounds on their ability or predicted 
ability to bind to both VEGF and serum albumin it could be suggested that, while 
the ability of both polyphenols to bind to serum albumin may be comparable, EGCG 
maintains a stronger binding affinity to VEGF than ellagic acid. Therefore, ellagic 
acid may be more likely to dissociate from VEGF in the presence of serum albumin 
than EGCG which would explain why EGCG was able to inhibit VEGF signalling in the 
presence of FCS after 5 minutes while VEGF regained 28 % activity following pre-
mixing of the VEGF with ellagic acid under the same conditions. When EGCG and 
ellagic acid were used in combination the results obtained mirrored those achieved 
in the EGCG only experiments demonstrating that there is no impact of the 
polyphenol combination on the inhibitory capabilities of EGCG in the presence of 
FCS after 5 minutes.  
4.5.3 Effect of FCS on polyphenol inhibition of VEGF signalling over 
longer duration 
In further experiments the effect of FCS on EGCG and ellagic acid combined 
inhibition of VEGF-induced VEGFR-2 phosphorylation over time was investigated. 
This provided a greater understanding about the strength of interaction between 
the polyphenols and the VEGF ligand but could also act as an aid to interpretation 
of the results observed in the animal intervention study. Investigating the activity of 
the VEGF in the presence of FCS over time when the VEGF and polyphenol have 
been pre-mixed would provide insight into whether the inhibited VEGF of 
VEGF/EGCG/EA injection treatment arm from the study in chapter 3 would regain 
activity over a longer duration in a protein rich environment. It was clearly 
demonstrated that VEGF regained some ability to stimulate VEGFR-2 
phosphorylation over time with a significant increase in VEGFR-2 phosphorylation in 
the ‘VEGF/EGCG/EA + FCS’ treatment after 4 hours of incubation at 37 °C. This 
suggests that a protein rich environment, in this model FCS supplementation to the 
media, can interfere with the potent inhibition of VEGF by EGCG and ellagic acid 
and that the strength of this interference is dependent on time. It is important to 
note that over 2/3 of VEGF activity remained inhibited after 4 hours and without 
further time points we cannot conclude whether the VEGF would regain more 
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activity, although the trend of the data suggests this may be the case. In the 
experimental arm from the study in chapter 3 where mice ate an EGCG and ellagic 
acid supplemented diet the polyphenol would enter an already protein rich 
environment, the blood, before it would elicit its anti-VEGF effects. Therefore 
investigating the capability of the polyphenols to inhibit VEGF-induced VEGFR-2 
phosphorylation after addition to a serum protein rich environment over time 
would provide information on whether a polyphenol could elicit inhibitory effects 
after dietary supplementation. The VEGFR-2 phosphorylation activity of VEGF in the 
‘VEGF/FCS + EGCG/EA’ treatment was reduced over time however given the 
instability of VEGF in culture media (Figure 4.9), the loss of VEGF stimulated VEGFR-
2 phosphorylation could simply be an artefact of VEGF instability or degradation 
and not the polyphenol exerting an inhibitory effect. In future studies quantifying 
the VEGF protein in the media at the time of treatment could provide an insight 
into whether the observed effects were indeed just VEGF degradation or evidence 
of the polyphenol being able to elicit an inhibitory effect after a longer incubation.  
The addition of FCS and polyphenols to the media increased the VEGF stability over 
the 4 hour period investigated. While it has previously been demonstrated that 
increased stability of VEGF correlates with serum protein concentration there is no 
previous literature describing the binding of VEGF to serum albumin. In mice 
genetically altered to express recombinant human VEGF the yield of the VEGF 
protein was higher when human serum albumin was co-expressed (Baur et al., 
2005) suggesting that the albumin in the FCS could play a role in the increased 
stability of VEGF observed in these experiments. It is also known that heparin can 
be found in the circulating blood and therefore in serum (Engelberg, 1961). 
Assuming that the interaction of VEGF with other protein would increase VEGF 
stability heparin is also a known VEGF binding partner (Ashikari-Hada et al., 2005) 
and perhaps increased the stability of the VEGF in the media. However, it has been 
shown previously that VEGF can be sequestered from biospheres depending on the 
serum concentration of the solution but this was not associated with serum-borne 
heparin (Belair et al., 2014) suggesting the VEGF may have an affinity for something 
else in the serum. Interestingly the ability of VEGF to bind to a synthetic binding 
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partner in vitro was also affected by serum protein concentration. This reduction in 
binding was only demonstrated with generalised serum proteins and did not occur 
when an equivalent concentration of pure albumin was used, suggesting other 
proteins present in serum were able to interfere with VEGF binding to its binding 
partner in vitro (Belair and Murphy, 2013). Given that the half-life of VEGF has been 
extended through the addition of a mixture of FCS, EGCG and EA to the media, and 
given that binding of protein therapeutics to a variety of serum proteins has been 
shown to extend the half-life in vivo (Kontermann, 2011) it appears possible that 
the FCS proteins could cause this increased longevity effect. Furthermore, if these 
effects are down to serum protein binding to VEGF perhaps the serum proteins may 
be able to interfere with VEGF binding to the polyphenol. This could explain the lack 
of observed polyphenol inhibition of VEGF signalling when the VEGF and FCS are 
present in the media together prior to polyphenol addition. However, as stated 
before, there is no data at present which demonstrates that VEGF can bind serum 
proteins so further investigation into this would be required. It must also be 
recognised that the polyphenols could be causing this increased longevity of the 
VEGF protein. Polyphenol-protein interactions between ferulic acid with BSA (Ojha 
et al., 2012) and caffeic acid with milk proteins (O'Connell and Fox, 1999) have 
increased the thermal stability of the proteins. It is possible that this may account 
for the sustained VEGF-induced VEGFR-2 phosphorylation observed in the 
‘VEGF/FCS + EGCG/EA’ treatment over the VEGF only treatment. However, if free 
polyphenol was able to bind to VEGF to increase its stability it would be logical to 
assume the VEGF activity would also be inhibited.  
Another explanation for the lack of EGCG and ellagic acid inhibition in the presence 
of FCS is the interaction of serum proteins and the polyphenols (Ozdal et al., 2013). 
Human serum albumin has been shown to increase the stability of polyphenols such 
as the green tea catechins which are usually highly unstable in an aqueous 
environment (Zinellu et al., 2015), with this effect attributed to the binding of 
polyphenols to the HSA (Zinellu et al., 2014). Equally, as described, a large range of 
polyphenols are known to interact with serum albumin with EGCG and ellagic acid 
demonstrating reasonable affinity (Skrt et al., 2012, Bourassa et al., 2010, Dobreva 
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et al., 2014, Zinellu et al., 2014, Tang et al., 2013). A number of papers discuss the 
binding of polyphenols to serum proteins such as albumin as a mechanism by which 
stability and solubility issues in circulation are overcome (Bae et al., 2009, Pantusa 
et al., 2012). However, the literature does not provide an explanation or 
demonstration for how the polyphenols are able to be released from this binding 
and whether they are able to elicit their activity at the required locations. The data 
presented here in this chapter is therefore important as it demonstrates that the 
serum proteins prevented the inhibitory activity of the polyphenol. In the context of 
the animal study the data presented in this chapter presents a plausible suggestion 
that the polyphenols used in the intervention were inactive, at least in the capacity 
of inhibiting VEGF-induced VEGFR-2 phosphorylation, due to interference from 
serum proteins. It is important to remember that the strength of binding of 
polyphenols for serum albumin appears to be species specific (Zinellu et al., 2014) 
so caution must be taken as calf serum, and not mouse serum, was used in the data 
presented in this chapter.  
Considering the potency of inhibition of VEGF-induced VEGFR-2 phosphorylation by 
EGCG and EA in serum free media and comparative lack of inhibitory activity in the 
presence of serum proteins, another important discussion point is raised. The 
majority of research into the biological effects of polyphenols has been undertaken 
in serum-free media conditions, typically to minimise variation between serum 
batches or for cell cycle synchronisation, however this can result in a different 
cellular response to treatment in comparison to non-serum starved cells. For 
examples, serum-starved HUVECs have been demonstrated to be more vulnerable 
to pro-inflammatory insult in comparison to HUVECs maintained in higher serum 
media (Russell and Hamilton, 2014). In another investigation FCS inhibited LPS-
induced nitric oxide and TNF-α expression (Ohki et al., 1999). Considering 
observations such as these and the impact that serum proteins had on the 
inhibitory activity of polyphenols as demonstrated in this chapter it is important 
that further investigation of the relationship between biological proteins and 
polyphenols, and the impact this can have on the bioactivity of the polyphenols is 
undertaken. Furthermore, it would be prudent to use more biologically relevant cell 
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models when investigating the biological activity of polyphenols to determine the 
biological effect, before proceeding to animal intervention trials.  
4.6 Conclusions 
The data presented in this chapter shows that 1) the potent inhibitor of VEGF 
induced VEGFR-2 phosphorylation in serum-free media, EGCG, was not able to 
inhibit VEGF induced angiogenesis under the protein rich conditions of the aortic 
ring assay; 2) the presence of FCS in the treatment media containing VEGF 
prevented EGCG and ellagic acid inhibition of VEGF-induced VEGFR-2 
phosphorylation in HUVECs 3) Addition of FCS to the treatment media resulted in 
the VEGF activity being slowly recovered following complete inhibition of VEGF-
induced VEGFR-2 phosphorylation by mixing with EGCG and ellagic acid. This data 
may provide one explanation for the lack of inhibition of atherosclerosis 
progression by EGCG and ellagic acid observed in chapter 3, considering the 
expected upregulation of endogenous VEGF previously observed in atherosclerotic 
plaques. Taken into the wider context of polyphenol research, this demonstrated 
the difference in research outcomes that can occur in a cellular experiment in the 
presence or absence of FCS and how the biological activity of polyphenols may be 
misinterpreted in experiments using serum-free media. It also suggests that the 
effects of serum proteins should be considered when designing an experiment 
investigating the biological effects of polyphenols and that using a more biologically 
relevant cell culture model may provide improved insight into the biological effects 
of polyphenols.  
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5.1  Summary of main findings 
The overall aims of this PhD project were to 1) to investigate if and how dietary 
polyphenols could inhibit VEGF induced VEGFR-2 phosphorylation in human 
umbilical vein endothelial cells, 2) to determine whether the polyphenols which 
elicit potent inhibition of VEGF induced VEGFR-2 phosphorylation could, in turn, 
inhibit VEGF induced atherosclerosis. The main findings from the thesis are 
summarised below:  
 The most abundant green tea and pomegranate polyphenols, EGCG and 
punicalagin, are potent and rapid inhibitors of VEGF-induced VEGFR-2 
phosphorylation in HUVECs. Metabolism of the pomegranate polyphenol 
punicalagin to ellagic acid, and further metabolism of ellagic acid to the 
urolithin and urolithin glucuronide compounds reduces the efficacy of the 
polyphenols to inhibit VEGF-induced VEGFR-2 phosphorylation in HUVECs.  
 
 EGCG and ellagic acid were able to effectively inhibit VEGF-induced VEGFR-2 
phosphorylation at physiologically relevant concentrations. Urolithin C was 
able to significantly inhibit VEGF induced VEGFR-2 phosphorylation at a 
concentration close to that previously observed in plasma.  
 
 The polyphenols EGCG, punicalagin, ellagic acid, urolithin D and urolithin C 
inhibited VEGF-induced VEGFR-2 phosphorylation primarily through 
interaction with the VEGF ligand and not actions on the cell or receptor.  
 
 3 once weekly intraperitoneal injections of VEGF at 2 µg/kg body weight did 
not stimulate atherosclerotic plaque growth above a serum albumin 
injected control in the ApoE-/- mouse model fed an atherogenic diet after 6 
weeks.  
 
 6 week diet supplementation with 3.4 mg EGCG and 4.3 mg ellagic acid per 
mouse per day in the ApoE-/- mouse model fed an atherogenic diet did not 
reduce the size of the atherosclerotic plaque in comparison to mice fed the 
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diet without polyphenols. A small but significant increase in plasma LDL and 
total cholesterol was seen in the polyphenol fed mice.  
 
 The polyphenols EGCG and ellagic acid were unable to inhibit VEGF-induced 
VEGFR-2 phosphorylation in HUVECs in 2 % foetal calf serum supplemented 
media 
5.2 Do higher circulating VEGF levels increase pathological 
angiogenesis?  
It has previously been reported that a single intraperitoneal injection of VEGF at 2 
µg/kg body weight was able to significantly increase atherosclerotic plaque size in 
both a hypercholesteraemic mouse model (ApoE-/-ApoB100-/-) and a high 
cholesterol fed New Zealand white rabbit model. The repeatability of this 
observation in two different species suggests that VEGF induction of atherosclerosis 
is not dependent on genetic hypercholesterolemia or species (Celletti et al., 2001a, 
Celletti et al., 2001b). However, another study looking at the effect of adenoviral 
VEGF gene transfer in different mouse models of atherosclerosis found that only 
the mice with an ApoE-/- genotype (ApoE-/- and ApoE-/-LDLR-/-) had high plasma 
VEGF levels after gene transfer and were susceptible to VEGF induced 
atherosclerotic progression. The LDLR-/- and LDLR-/-ApoB100/100 mouse models did 
not have increased VEGF plasma levels or aortic atherosclerosis following 
adenoviral VEGF gene transfer (Heinonen et al., 2013), suggested to be due to 
ApoB100-containing lipoprotein (increased in circulation in LDLR-/- mice) 
upregulation of VEGFR-1 expression by which acts as a sink for VEGF-A thereby 
limiting its stimulatory activity (Avraham-Davidi et al., 2012). This suggests that 
while the VEGF induction effect is not species specific, that changes in lipid-
regulation can alter the VEGF response. However, the ApoE-/- model used in the 
study presented in chapter 3 was previously reported to be susceptible to VEGF-
induced atherosclerosis following adenoviral VEGF gene transfer. Taking this into 
account, the ApoE-/- mouse used in chapter 3 appears to be an appropriate model 
for this type of investigation.  
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Celletti et al. did not measure whether the VEGF was active at the time of injection 
although the increase in atherosclerotic plaque size was specific to the VEGF 
injection only which strongly suggests that it was. In the study presented in chapter 
3 it was demonstrated that the VEGF in the injection solution was active and able to 
stimulate VEGFR-2 phosphorylation in HUVECs. However, one limitation of both 
studies is that the VEGF concentration in plasma following VEGF intraperitoneal 
injection was not determined. MSA has been demonstrated to reach circulation 
following intraperitoneal injection (Kijanka et al., 2014) but as yet the same has not 
been reported for VEGF. The decision to not measure VEGF in plasma was taken as 
the time for VEGF to reach the plasma is unknown therefore a time course post 
injection would be required and considering the strong stimulatory effects of VEGF 
observed previously that this would be an excessive use of animals. However, given 
the lack of observed effect of VEGF stimulation of atherosclerosis progression in the 
study presented in chapter 3, even after including a further 2 VEGF injections 
compared to the Celletti et al. paper, it would be prudent to investigate the 
concentration of VEGF in mouse plasma over time following a single intraperitoneal 
injection of 2 µg/kg body weight to determine whether VEGF is able to pass into the 
plasma at a significant concentration.  
Another point for consideration is whether the VEGF, upon reaching the plasma, 
was active as the data presented in this thesis did not address this question. 
Previously 2 out of 7 serum proteins were found to undergo modification prior to 
absorption from the peritoneal cavity following injection (Regoeczi et al., 1989) 
however no literature to date discusses stability or activity of VEGF following 
absorption from the peritoneal cavity. Higher circulating VEGF levels positively 
correlate with increased vascularisation of the retinal epithelium in proliferative 
retinopathy (Lip et al., 2000), and therefore retinal angiogenesis may be a good 
method of quantification of systemic angiogenesis as a measure of VEGF activity in 
response to the VEGF injections (Stahl et al., 2010). The retinal tissue was fixed in 
formaldehyde at the time of animal death and therefore would be suitable for use 
in investigations into systemic angiogenesis in this study.  
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It was concluded by Celletti et al. that a single intraperitoneal injection of VEGF 
stimulated growth of the atherosclerotic plaque, at least in part, due to the 
upregulation of CD34+/Flk-1+ bone marrow cells and macrophage infiltration into 
the lesion (Celletti et al., 2001a, Celletti et al., 2001b). This was not measured in the 
study presented in chapter 3 and might provide insight into whether the VEGF was 
able to produce the same physiological response as reported previously. 
Macrophage infiltration and CD34+ cell content in the atherosclerotic plaque can 
easily be measured although increased expression of CD34+/Flk-1+ hematopoietic 
progenitor cells in bone marrow cannot be quantified and bone marrow was not 
isolated from the mice in the chapter 3 study.  
Atherosclerosis is a complex disease and the morphology of the plaque can 
contribute to the pathology of the disease without necessarily altering the size of 
the atherosclerotic plaque. For example, VEGF and blood vessel generation is 
associated with vulnerable plaque, fibrous cap thinning, and thrombosis. 
Vulnerable plaques are associated with an increased cardiovascular event risk such 
as stroke (Carter et al., 2007, Chen et al., 1999, Juan-Babot et al., 2003, Fleiner et 
al., 2004). Therefore if plaque instability is increased through rapid proliferation of 
immature blood vessels stimulated by the VEGF injections then the potential risk of 
atherosclerosis related death would be increased. To investigate this, the aortic 
plaque can be classified into disease stages as identified previously (Insull, 2009, 
Stary et al., 1995) or particular markers of unstable plaque such as high microvessel 
density, high macrophage content, large lipid core and thin fibrous cap can be 
stained for. This would provide an insight into whether the VEGF injections 
increased the cardiovascular risk without altering the plaque size.  
Given that the ApoE-/- has been shown to be an appropriate model of VEGF 
induced atherosclerosis in the right conditions previously (Heinonen et al., 2013, 
Leppanen et al., 2005), the protocol used for injection mirrored that used by Celletti 
et al. (Celletti et al., 2001a, Celletti et al., 2001b), two further VEGF injections were 
undertaken than in the Celletti et al. studies, and that the VEGF was active upon 
injection support the conclusion that VEGF intraperitoneal injection in the ApoE-/- 
does not induce progression of atherosclerosis. However, investigation into the 
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plaque morphology and systemic angiogenesis in the study presented in chapter 3 
would help interpret these results further.  
5.3 Can polyphenols that inhibit VEGF signalling by 
interacting with VEGF in vitro inhibit pathological 
angiogenesis by binding to VEGF in vivo? 
For the polyphenols capable of inhibiting VEGF-induced VEGFR-2 in vitro to be 
effective in vivo it would be expected that: 1) A dose capable of eliciting inhibition 
of VEGF-induced VEGFR-2 phosphorylation would have to be within the 
physiologically achievable range; 2) The inhibitory action would need to be effective 
under physiologically relevant conditions; and 3) it would need to be shown to 
inhibit VEGF-induced pathological angiogenesis, for example atherosclerosis, in an 
animal model.  
In chapter 2 it was reported that the primary green tea and pomegranate 
polyphenols, EGCG and punicalagin, were both potent inhibitors of VEGF-induced 
VEGFR-2 with the concentrations required to inhibit 50 % phosphorylation (IC50) 
being, 96 and 49 nM respectively. The bioavailability of the polyphenols is an 
important consideration when determining whether it is possible for the same 
inhibitory effect to occur in vivo. EGCG is found in circulation predominantly as an 
aglycone (Ullmann et al., 2003, Chow et al., 2001, Meng et al., 2002, Lee et al., 
2002) and up to concentration of 700 nM (Henning et al., 2005) demonstrating that 
EGCG has the potential to reach an effective dose in vivo. However, punicalagin is 
thought to be very poorly bioavailable and not to reach the plasma (Mertens-
Talcott et al., 2006) and is instead rapidly converted to ellagic acid early in the 
gastrointestinal tract (Gonzalez-Barrio et al., 2010). Ellagic acid is found in the 
plasma following pomegranate consumption up to 200 nM although, when given as 
an ellagic acid dose, higher plasma concentrations of over 600 nM were observed 
(Hamad et al., 2009). Under the model conditions presented in chapter 2 ellagic 
acid had an IC50 for inhibiting VEGF-induced VEGFR-2 phosphorylation of 310 nM 
suggesting that a concentration capable of inhibiting VEGF activity in vitro could be 
achieved in vivo. Considering that ellagic acid is also rapidly metabolised by the 
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microbiota to generate higher plasma concentrations of the urolithins (µM) (García-
Villalba et al., 2013) the biological activity of these compounds on VEGF-induced 
VEGFR-2 phosphorylation also needed consideration. In chapter 2 the in vitro anti-
VEGF activity of the urolithin microbial metabolites was investigated for the first 
time. The IC50 values for inhibition of VEGF-induced VEGFR-2 phosphorylation by 
urolithin D, C, A and B were 0.2, 3.7, 54.0, 251 µM respectively. This data 
demonstrates that each step of metabolism to remove a hydroxyl group from the 
urolithin compounds reduces the inhibitory capacity in this assay. Furthermore 
urolithin A and B glucuronide were unable to inhibit VEGF-induced VEGFR-2 
phosphorylation at concentrations up to 150 µM suggesting that phase-II 
metabolism can also have a negative effect on this activity. This being said, the peak 
urolithin plasma concentrations following a high dose of ellagitannins or ellagic acid 
has not been undertaken and the highest reported urolithin C plasma concentration 
was 1.8 µM (Cerda et al., 2004), close to the 2 µM concentration which caused 
significant inhibition of VEGF-induced VEGFR-2 phosphorylation in vitro. Taking all 
data into account EGCG and ellagic acid are the only compounds capable of 
inhibiting VEGF-induced VEGFR-2 phosphorylation at concentrations found in 
plasma following dietary intervention.  
The data presented in chapter 2 also reported that the polyphenols capable of 
inhibiting VEGF-induced VEGFR-2 phosphorylation did so predominantly through 
interaction with the VEGF ligand and not the cell. EGCG and urolithin C were 
completely ineffective at inhibiting VEGF-induced VEGFR-2 phosphorylation without 
coming into contact with the VEGF ligand while punicalagin, ellagic acid, and 
urolithin D were only able to elicit around 10 % phosphorylation inhibition through 
actions on the cell or receptor at the concentrations tested. Therefore for the 
compounds which reach and effective dose in vivo, EGCG and EA, to potently inhibit 
VEGF signalling in vivo the polyphenols would need to interact with the VEGF ligand 
in the blood. The in vitro work in chapter 2 was carried out in serum free basal 
media, as has been done previously (Huang et al., 2012, Lamy et al., 2006, Wen et 
al., 2008, Lamy et al., 2002, Lee et al., 2004, Liu et al., 2008, Neuhaus et al., 2004, 
Rodriguez et al., 2006, Lu et al., 2008, Shimizu et al., 2010, Pan et al., 2011, Cerezo 
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et al., 2015, Moyle et al., 2015). The addition of serum to the HUVEC model of 
VEGF-induced VEGFR-2 phosphorylation as presented in chapter 4 investigated this 
inhibition in a more physiologically relevant environment. It was found that the 
addition of 2 % FCS in the VEGF supplemented media prior to the addition of the 
polyphenol completely prevented the inhibitory action of the polyphenol. 
Furthermore, if the VEGF and polyphenol were pre-mixed in basal media before the 
addition of FCS then gradually over time the presence of the serum mediated the 
recovery of VEGF activity. In healthy human serum total protein values are 60 – 80 
g/L (Kyle and Greipp, 1978, Gahutu and Wane, 2006). Around 50 g/L total serum 
proteins are found in plasma from C57BL6 mice while in ApoE-/- strains the total 
serum protein level is slightly elevated above the standard laboratory mouse at 57 
g/L (Zaias et al., 2009). The literature suggests that both EGCG and ellagic acid have 
an affinity for serum albumin (Ozyurt et al., 2016, Zinellu et al., 2014, Tang et al., 
2013) and given that the protein content in 2 % serum supplemented media will be 
well below the protein content in the blood it can be concluded that EGCG and 
ellagic acid are unlikely to inhibit VEGF activity in vivo by interacting with the VEGF 
ligand given the presence of a high serum concentration in plasma.  
In chapter 3 it was reported that dietary intake of EGCG and ellagic acid at 3.4 and 
4.3 mg/mouse/day respectively does not reduce atherosclerosis in the ApoE-/- 
mouse fed an atherogenic diet. The equivalent dose for a 60 kg human would be 
around 770 mg EGCG and 970 mg ellagic acid daily (Reagan-Shaw et al., 2008), a 
dose only typically achievable with dietary supplements. However, considering 
there was no-stimulation of atherosclerosis progression by the VEGF injections it is 
difficult to conclude the effect of EGCG and EA dietary intervention at these doses 
on VEGF-induced atherosclerosis. However, it is known that VEGF and VEGFR-2 are 
frequently reported to be upregulated in those suffering with atherosclerosis and in 
atherosclerotic tissue (Ho-Tin-Noe et al., 2011, Kimura et al., 2007, Blann et al., 
2002, Fleisch et al., 1999, Kucukardali et al., 2008) with many morphological 
features of the atherosclerotic plaque such as macrophage uptake of oxidised LDL 
known to upregulate VEGF protein release (Riazy et al., 2009). Therefore, if it could 
be identified if VEGF and VEGFR-2 were upregulated over time in the 
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atherosclerotic tissue and mouse plasma collected from the study presented in 
chapter 3 (for example at week 3 and/or week 6 over baseline) irrelevant of 
injection type it would provide information as to whether the polyphenols were 
able to inhibit the upregulation of endogenous VEGF signalling associated with 
atherosclerosis. Unfortunately, due to time restrictions, these investigations were 
not able to be completed as part of this thesis. Therefore, the data presented in this 
thesis support the notion that it is unlikely EGCG and EA could inhibit VEGF-induced 
pathological angiogenesis through interactions with the VEGF ligand in a serum 
protein rich environment such as blood. However, it does not limit the possibilities 
for alternative methods of polyphenol treatment for example topical application or 
intravitreal injection of polyphenols.  
5.4 What are the wider implications of the influence of 
serum proteins to the field of polyphenol research?  
Polyphenol have been reported to inhibit numerous key cell signalling pathways 
through inhibiting phosphorylation events. This includes a large body of work with 
one of the main polyphenols investigated in this thesis, EGCG. Many papers report 
polyphenol effects in serum-free or low serum media experiments, primarily due to 
serum-starving to normalise the cell population or to reduce variables. In previous 
experiments delphinidin (Lamy et al., 2006, Teller et al., 2009), EGCG (Lamy et al., 
2002), and quercetin (Pratheeshkumar et al., 2012) were reported to inhibit VEGFR-
2 phosphorylation through actions on the VEGF receptor and not the ligand after 
extended incubation periods were undertaken in serum-free media. Treatment 
with ellagic acid and VEGF in serum-free media was also reported to reduce VEGFR-
2 phosphorylation, in vitro tyrosine kinase activity and microvessel generation from 
aortic rings (Wang et al., 2012). Polyphenol inhibition of other receptors is also 
investigated in serum-free media for example, in decreasing potency, delphinidin, 
quercetin and EGCG in combination with epidermal growth factor treatment 
inhibited phosphorylation of epidermal growth factor receptor (EGFR) and human 
epidermal growth factor receptor 2 (HER2/ErbB2) (Teller et al., 2009, Fridrich et al., 
2008). Similarly green and black tea polyphenols, specifically theaflavin monogallate 
and epigallocatechin digallate, were able to act as competitive inhibitors of ephrin 
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(Eph) to reduce EphA4 receptor phosphorylation in serum-free media (Noberini et 
al., 2012). Where serum is used it is typically at low concentrations. For example, 
apigenin and luteolin were also found to inhibit platelet derived growth factor 
receptor β (PDGFR-β) phosphorylation in 0.5 % BSA containing media (Lamy et al., 
2008). While serum proteins were present in this model they were at much lower 
concentrations that would be encountered in vivo (Kyle and Greipp, 1978, Gahutu 
and Wane, 2006, Zaias et al., 2009). Physiological responses to polyphenols have 
also been reported in serum-free studies. EGCG inhibition of oral epithelial cell 
growth was also markedly reduced in the presence of serum proteins in comparison 
to basal media, demonstrating others have observed this effect previously (Hong et 
al., 2009). Considering the observation in chapter 4, it is logical to hypothesise that 
the presence of serum-proteins in these models would have the potential to affect 
the previously reported actions of polyphenols. However, there are many papers in 
the published literature which do not discuss the specific content of the media used 
to conduct the experiments. The data presented in this thesis highlights that this 
should be important considerations and further importance should be given to 
undertaking more physiologically relevant cell based experiments, such as those 
with higher serum content. However, this would require a wider awareness of the 
impact of serum and biological proteins on polyphenol activities in vitro. 
Furthermore cell culture investigations into the mode of action of the polyphenol 
on VEGF-induced VEGFR-2 phosphorylation inhibition could be applied more widely 
to provide greater understanding to other inhibitory actions reported. Taking 
delphinidin, quercetin and EGCG inhibition of EGF-stimulated EGFR phosphorylation 
as an example, the study design provided the opportunity for the polyphenols to 
interact with both the receptor and ligand (Fridrich et al., 2008, Teller et al., 2009). 
Utilising a side-by-side comparison of polyphenol actions on the cell alone versus 
actions when used in combination with the ligand, as undertaken in chapter 2, 
could provide critical information as to where the polyphenols were exerting the 
most potent effects. Through the use of this side-by side approach it was identified 
in chapter 2 that for the polyphenols to potently inhibit VEGF signalling in vivo they 
would need to be able to interact with VEGF within a biological system at 
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physiological concentrations. If this approach could be taken to other signalling 
pathways to understand where and how the polyphenol may exert its effect we 
may be able to tailor the in vitro biological treatment to match the biological 
system where the in vivo effects would be predicted to occur.  
5.5 Summary of recommendations for future work 
5.5.1 Further interpretation of animal intervention in chapter 3 
A key aim outlined in chapter 1 was to determine whether the polyphenols which 
elicit potent inhibition of VEGF-induced VEGFR-2 phosphorylation could, in turn, 
inhibit VEGF-induced angiogenesis-driven atherosclerosis. This relied on the 
induction of atherosclerosis by VEGF injection as previously reported (Celletti et al., 
2001a, Celletti et al., 2001b). Below, 3 key further investigations into the tissues 
from the animal study in chapter 3 are outlined which would help to conclude 1) 
whether intraperitoneal injected VEGF is capable of inducing angiogenesis and 
atherosclerosis and 2) whether EGCG and ellagic acid dietary supplementation was 
able to alter alternative markers of atherosclerosis.  
Firstly, concluding whether systemic angiogenesis was upregulated in the VEGF 
injected animals beyond the levels observed in the MSA injected animals would 
provide information as to whether the VEGF was active upon entry in to the blood 
system. One way to measure this would be with retinal angiogenesis, which is 
highly susceptible to increased circulating VEGF, as a marker of systemic 
angiogenesis levels (Stahl et al., 2010, Kliffen et al., 1997). This is undertaken by 
dissecting the retinal epithelium from the retinal pigment epithelium under a 
microscope and preparing the retinal epithelium for flat-mounting and staining with 
a blood vessel marker, for example isolectin B4 (Stahl et al., 2010). Quantification 
can be undertaken by counting the branch points in a specified field of view 
(Stenzel et al., 2011). Retinopathy associated vascular tufts can also be quantified 
(Lamoke et al., 2011). Should an effect be observed in the VEGF injected animals 
the same measurement can be used to determine whether the polyphenols were 
able to inhibit systemic angiogenesis in the study.  
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Secondly, it would need to be determined if the VEGF injections, while they did not 
stimulate increases in plaque size, were able to alter the pathology of 
atherosclerosis as determined by morphological analysis. Increased VEGF 
expression is associated with increased plaque vulnerability and rupture (Chen et 
al., 1999), thereby increasing the risk of a cardiovascular event (Eliasziw et al., 
1994). Therefore, this analysis may provide further insight into whether the VEGF 
injections caused a more dangerous pathology in the animals. Standard 
histopathological stains such as Masson’s trichrome or Movat’s pentachrome would 
identify all connective tissues (Movat, 1955). Immunohistochemistry staining for 
macrophage infiltration and fibrinogen, including to mark any locations where 
thinning of the fibrous cap has occurred are also important to help classify the stage 
of atherosclerotic disease (Rosenfeld et al., 2000). Large acellular necrotic regions 
and immunohistochemical staining for intra-plaque vessels with a vascular 
endothelial marker such as von Willebrand’s factor (vWf) are crucial. Perivascular 
diffusion of vWf into the surrounding tissue also gives an indication to vessel 
leakage (van Lammeren et al., 2012, Virmani et al., 2005). Should a difference be 
observed between the VEGF injected mice versus the serum albumin injected mice 
this analysis can be undertaken within the aortic cryosections from the polyphenol-
fed mice to determine if the EGCG and ellagic acid supplemented diet was able to 
affect plaque stability or atherosclerotic disease classification in the ApoE-/- mouse.  
Finally, it should be determined if endogenous VEGF signalling was upregulated in 
the plaque irrelevant of injection type. This can be done by comparing the plaque 
between the time points instead of treatments. VEGF and VEGFR-2 expression in 
the plaque can be measured by immunohistochemical staining with anti-VEGF and 
anti-VEGFR-2 antibodies. Alterations to VEGF or VEGFR-2 protein or gene 
expression could also be analysed in the lung tissue as it is a rich source of VEGF 
expressing vascular endothelial cells (Berse et al., 1992). Investigating the 
circulating VEGF levels in the mouse plasma may be difficult as the limit of 
detection is 9 pg/ml (Manenti et al., 2005) however VEGF ELISA analysis (Keyes et 
al., 2003) of the mouse plasma can be undertaken to indicate whether changes to 
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circulating VEGF levels have occurred in response to any treatments within the 
animal study presented in chapter 3.  
Should these investigations into the remaining tissue from the animal study in 
chapter 3 demonstrate that VEGF was not active, did not induce morphological 
changes in the plaque and there was not an endogenous upregulation of VEGF It 
can be concluded that in this experiment VEGF injection did not induce 
atherosclerosis as has been observed previously (Celletti et al., 2001a, Celletti et al., 
2001b). However, further small-scale animal studies into VEGF concentration in 
plasma over time following a single 2 µg/kg body weight VEGF injection would also 
provide information on the pharmacokinetics of VEGF entry into the plasma while 
labelled VEGF could be injected into the animal and with the appropriate scanner 
the dissemination throughout the body could be tracked in real-time as has been 
done previously following intravenous VEGF injection (Wang et al., 2009). This 
would provide further information as to whether the VEGF can reach the target 
tissues following intraperitoneal injection. 
5.5.2 Alternative animal intervention trials to investigate hypothesis 
Given that it was previously observed that adenoviral gene transfer of human VEGF 
into the ApoE-/- mouse model resulted in induction of atherosclerosis (Heinonen et 
al., 2013) the dietary intervention study with EGCG and ellagic acid could be 
repeated using this model. However, considering the implications of the presence 
of serum on the VEGF inhibitory activities of these polyphenols perhaps 
intervention with alternative VEGF inhibitory polyphenols could be undertaken, for 
example the apple procyanidins (Moyle et al., 2015), following investigation into 
their inhibitory effects in the presence of serum proteins. Furthermore, utilising 
VEGF adenoviral gene transfer in other models of atherosclerosis where 
progression of atherosclerosis is not so accelerated, for example wild type mice or 
New Zealand white rabbits fed a high cholesterol diet, could provide a more natural 
model of VEGF induced atherosclerosis to provide insight into the morphology of 
VEGF-associated atherosclerotic disease. Retinal vascularisation could be used as a 
measure of systemic angiogenesis across the study using live imaging equipment to 
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visualise retinal angiogenesis without the need to sacrifice animals at each time 
point (Nakao et al., 2013).  
It would also be interesting to undertake further investigations into the in vivo 
effects of EGCG and ellagic acid on VEGF signalling using alternative routes of 
polyphenol delivery. For example, currently anti-VEGF monoclonal antibody 
treatments are injected into the vitreous of the eye but there are side effects such 
as increased risk of thrombotic events (Thulliez et al., 2014). The protein content in 
the eye is much lower than the plasma at around 1-4 g/L (Skeie et al., 2012) 
although are slightly raised in VEGF associated retinopathies such as proliferative 
diabetic retinopathy (Loukovaara et al., 2015). EGCG and ellagic acid could provide 
an interesting candidate for an alternative intravitreal injection therapy. EGCG 
and/or ellagic acid could be injected into the vitreous of the ischemia-induced 
retinopathy mouse model which has been used previously to demonstrate the anti-
angiogenic potential of tyrosine kinase inhibitors (Maier et al., 2005). Equally, it has 
previously been demonstrated that topical application of EGCG to mouse skin 
reduced tumour initiation and growth by up to 87 % (Huang et al., 1992) and this 
effect was reported to be due to stopping the phosphorylation events associated 
with tumour progression. Given the advances in technologies since that publication 
a similar study could be conducted which measures blood vessel density and 
VEGFR-2 expression in the tumours in vivo as well as post-mortem histology of 
tissue to provide key insights into whether inhibition of VEGF signalling is 
responsible for this observation. Ellagic acid could also be an interesting candidate 
for investigation into topical application to skin cancer to reduced pathological 
angiogenesis.  
5.5.3 Further investigation into polyphenol-protein interactions 
The data presents an interesting avenue of investigation into the interactions 
between polyphenol and biologically relevant proteins. Investigating the nature of 
these interactions would provide key information to determine whether in vitro 
observations can be translated into a physiological environment. One example of 
such an experiment would be saturation transfer difference (STD) NMR, where the 
spin polarisation of the small molecule particles (e.g. polyphenol) is altered through 
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interaction with a protein (e.g. human serum albumin) and this change can be 
detected can providing information about location and strength of the interaction. 
This has previously been used to characterise the binding of tryptophan to human 
serum albumin (Viegas et al., 2011). Another method which may be useful is high 
performance affinity chromatography (HPAC) using a column containing 
immobilised serum albumin as the stationary phase would provide information on 
the binding kinetics of the protein-polyphenol interaction. Competitive 
displacement assays can be conducted, for example running VEGF in the mobile 
phase across the polyphenol bound to the serum protein stationary phase and 
measuring the concentration of polyphenol to be eluted (Hage et al., 2011). Surface 
plasmon resonance technology can detect very small binding or interaction events 
and could be useful for investigation of polyphenol-protein interactions. Taking the 
interactions between VEGF and polyphenols as an example, the VEGF ligand can be 
bound onto a Biacore surface plasmon resonance chip and the polyphenol can be 
run across the chip in solution in the presence and absence of serum proteins to 
compare the binding parameters. Similarly the FCS can be run through before 
and/or after the addition of the polyphenol to further investigate the strength of 
interaction. This would help interpret the observation shown in Figure 4.8 that 
polyphenol bound VEGF can regain activity in the presence of FCS over time. X-ray 
crystallography of a small molecule-protein complex can also be undertaken to 
identify the binding locations of a small molecule however there are many possible 
confounding factors with this route of experimentation and care should be taken to 
consider these complications (Cooper et al., 2011).  
Finally, the data presented in this thesis and the discussion in section 5.4 suggests a 
general recommendation that future research takes into consideration the impact 
of serum or serum proteins on the biological activity of polyphenols. Comparison 
between the cellular responses to polyphenols in the presence or absence of serum 
or serum proteins will be important for understanding whether in vitro 
observations can be translated to in vivo observations. However, this would require 
the integration and appreciation of more biologically relevant cell culture 
experiments by researchers, reviewers, editors and the wider scientific community.  
References 
177 
 
AASE, K., VON EULER, G., LI, X., PONTEN, A., THOREN, P., CAO, R., CAO, Y., OLOFSSON, B., 
GEBRE-MEDHIN, S., PEKNY, M., ALITALO, K., BETSHOLTZ, C. & ERIKSSON, U. 2001. 
Vascular endothelial growth factor-B-deficient mice display an atrial conduction 
defect. Circulation, 104, 358-64. 
ACTIS-GORETTA, L., LÉVÈQUES, A., GIUFFRIDA, F., ROMANOV-MICHAILIDIS, F., VITON, F., 
BARRON, D., DUENAS-PATON, M., GONZALEZ-MANZANO, S., SANTOS-BUELGA, C., 
WILLIAMSON, G. & DIONISI, F. 2012. Elucidation of (−)-epicatechin metabolites 
after ingestion of chocolate by healthy humans. Free Radical Biology and Medicine, 
53, 787-795. 
AKHTAR, S., HARTMANN, P., KARSHOVSKA, E., RINDERKNECHT, F. A., SUBRAMANIAN, P., 
GREMSE, F., GROMMES, J., JACOBS, M., KIESSLING, F., WEBER, C., STEFFENS, S. & 
SCHOBER, A. 2015. Endothelial Hypoxia-Inducible Factor-1alpha Promotes 
Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a. 
Hypertension, 66, 1220-6. 
ALBER, H. F., FRICK, M., DULAK, J., DORLER, J., ZWICK, R. H., DICHTL, W., PACHINGER, O. & 
WEIDINGER, F. 2005. Vascular endothelial growth factor (VEGF) plasma 
concentrations in coronary artery disease. Heart, 91, 365-6. 
ANANINGSIH, V. K., SHARMA, A. & ZHOU, W. 2013. Green tea catechins during food 
processing and storage: A review on stability and detection. Food Research 
International, 50, 469-479. 
ARAI, Y., WATANABE, S., KIMIRA, M., SHIMOI, K., MOCHIZUKI, R. & KINAE, N. 2000. Dietary 
intakes of flavonols, flavones and isoflavones by Japanese women and the inverse 
correlation between quercetin intake and plasma LDL cholesterol concentration. J 
Nutr, 130, 2243-50. 
ARISATO, T., HASHIGUCHI, T., SARKER, K. P., ARIMURA, K., ASANO, M., MATSUO, K., 
OSAME, M. & MARUYAMA, I. 2003. Highly accumulated platelet vascular 
endothelial growth factor in coagulant thrombotic region. Journal of Thrombosis 
and Haemostasis, 1, 2589-2593. 
ARTS, I. C. & HOLLMAN, P. C. 2005. Polyphenols and disease risk in epidemiologic studies. 
Am J Clin Nutr, 81, 317s-325s. 
ARTS, I. C., HOLLMAN, P. C., FESKENS, E. J., BUENO DE MESQUITA, H. B. & KROMHOUT, D. 
2001a. Catechin intake and associated dietary and lifestyle factors in a 
representative sample of Dutch men and women. Eur J Clin Nutr, 55, 76-81. 
ARTS, I. C., HOLLMAN, P. C., FESKENS, E. J., BUENO DE MESQUITA, H. B. & KROMHOUT, D. 
2001b. Catechin intake might explain the inverse relation between tea 
consumption and ischemic heart disease: the Zutphen Elderly Study. Am J Clin Nutr, 
74, 227-32. 
ASHIKARI-HADA, S., HABUCHI, H., KARIYA, Y. & KIMATA, K. 2005. Heparin regulates vascular 
endothelial growth factor165-dependent mitogenic activity, tube formation, and its 
receptor phosphorylation of human endothelial cells. Comparison of the effects of 
heparin and modified heparins. J Biol Chem, 280, 31508-15. 
AUCLAIR, S., MILENKOVIC, D., BESSON, C., CHAUVET, S., GUEUX, E., MORAND, C., MAZUR, 
A. & SCALBERT, A. 2009. Catechin reduces atherosclerotic lesion development in 
apo E-deficient mice: a transcriptomic study. Atherosclerosis, 204, e21-7. 
AUGER, C., TEISSEDRE, P.-L., GERAIN, P., LEQUEUX, N., BORNET, A., SERISIER, S., 
BESANCON, P., CAPORICCIO, B., CRISTOL, J.-P. & ROUANET, J.-M. 2005. Dietary 
Wine Phenolics Catechin, Quercetin, and Resveratrol Efficiently Protect 
Hypercholesterolemic Hamsters against Aortic Fatty Streak Accumulation. Journal 
of Agricultural and Food Chemistry, 53, 2015-2021. 
AVIRAM, M., ROSENBLAT, M., GAITINI, D., NITECKI, S., HOFFMAN, A., DORNFELD, L., 
VOLKOVA, N., PRESSER, D., ATTIAS, J., LIKER, H. & HAYEK, T. 2004. Pomegranate 
References 
178 
 
juice consumption for 3 years by patients with carotid artery stenosis reduces 
common carotid intima-media thickness, blood pressure and LDL oxidation. Clinical 
Nutrition, 23, 423-433. 
AVIRAM, M., VOLKOVA, N., COLEMAN, R., DREHER, M., REDDY, M. K., FERREIRA, D. & 
ROSENBLAT, M. 2008. Pomegranate phenolics from the peels, arils, and flowers are 
antiatherogenic: studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) 
mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem, 56, 
1148-57. 
AVRAHAM-DAVIDI, I., ELY, Y., PHAM, V. N., CASTRANOVA, D., GRUNSPAN, M., MALKINSON, 
G., GIBBS-BAR, L., MAYSELESS, O., ALLMOG, G., LO, B., WARREN, C. M., CHEN, T. T., 
UNGOS, J., KIDD, K., SHAW, K., ROGACHEV, I., WAN, W., MURPHY, P. M., FARBER, S. 
A., CARMEL, L., SHELNESS, G. S., IRUELA-ARISPE, M. L., WEINSTEIN, B. M. & YANIV, 
K. 2012. ApoB-containing lipoproteins regulate angiogenesis by modulating 
expression of VEGF receptor 1. Nat Med, 18, 967-73. 
AVRAHAM, H. K., LEE, T. H., KOH, Y., KIM, T. A., JIANG, S., SUSSMAN, M., SAMAREL, A. M. & 
AVRAHAM, S. 2003. Vascular endothelial growth factor regulates focal adhesion 
assembly in human brain microvascular endothelial cells through activation of the 
focal adhesion kinase and related adhesion focal tyrosine kinase. J Biol Chem, 278, 
36661-8. 
BACHMANOV, A. A., REED, D. R., BEAUCHAMP, G. K. & TORDOFF, M. G. 2002. Food Intake, 
Water Intake, and Drinking Spout Side Preference of 28 Mouse Strains. Behavior 
genetics, 32, 435-443. 
BAE, M.-J., ISHII, T., MINODA, K., KAWADA, Y., ICHIKAWA, T., MORI, T., KAMIHIRA, M. & 
NAKAYAMA, T. 2009. Albumin stabilizes (–)-epigallocatechin gallate in human 
serum: Binding capacity and antioxidant property. Molecular Nutrition & Food 
Research, 53, 709-715. 
BAKER, M., ROBINSON, S. D., LECHERTIER, T., BARBER, P. R., TAVORA, B., D'AMICO, G., 
JONES, D. T., VOJNOVIC, B. & HODIVALA-DILKE, K. 2012. Use of the mouse aortic 
ring assay to study angiogenesis. Nat Protoc, 7, 89-104. 
BALA, I., BHARDWAJ, V., HARIHARAN, S., SITTERBERG, J., BAKOWSKY, U. & KUMAR, M. N. V. 
R. 2005. Design of biodegradable nanoparticles: a novel approach to encapsulating 
poorly soluble phytochemical ellagic acid. Nanotechnology, 16, 2819. 
BAUR, A., RESKI, R. & GORR, G. 2005. Enhanced recovery of a secreted recombinant human 
growth factor using stabilizing additives and by co-expression of human serum 
albumin in the moss Physcomitrella patens. Plant Biotechnol J, 3, 331-40. 
BELAIR, D. G., KHALIL, A. S., MILLER, M. J. & MURPHY, W. L. 2014. Serum-Dependence of 
Affinity-Mediated VEGF Release from Biomimetic Microspheres. 
Biomacromolecules, 15, 2038-2048. 
BELAIR, D. G. & MURPHY, W. L. 2013. Specific VEGF sequestering to biomaterials: Influence 
of serum stability. Acta biomaterialia, 9, 8823-8831. 
BELLOMO, D., HEADRICK, J. P., SILINS, G. U., PATERSON, C. A., THOMAS, P. S., GARTSIDE, 
M., MOULD, A., CAHILL, M. M., TONKS, I. D., GRIMMOND, S. M., TOWNSON, S., 
WELLS, C., LITTLE, M., CUMMINGS, M. C., HAYWARD, N. K. & KAY, G. F. 2000. Mice 
lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, 
dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. 
Circ Res, 86, E29-35. 
BELOTTI, D., PAGANONI, P., MANENTI, L., GAROFALO, A., MARCHINI, S., TARABOLETTI, G. & 
GIAVAZZI, R. 2003. Matrix Metalloproteinases (MMP9 and MMP2) Induce the 
Release of Vascular Endothelial Growth Factor (VEGF) by Ovarian Carcinoma Cells. 
Implications for Ascites Formation, 63, 5224-5229. 
References 
179 
 
BERBEE, J. F. P., WONG, M. C., WANG, Y. N., VAN DER HOORN, J. W. A., KHEDOE, P., VAN 
KLINKEN, J. B., MOL, I. M., HIEMSTRA, P. S., TSIKAS, D., ROMIJN, J. A., HAVEKES, L. 
M., PRINCEN, H. M. G. & RENSEN, P. C. N. 2013. Resveratrol protects against 
atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in 
APOE*3-Leiden.CETP mice. Journal of Nutritional Biochemistry, 24, 1423-1430. 
BERGH, J., BONDARENKO, I. M., LICHINITSER, M. R., LILJEGREN, A., GREIL, R., VOYTKO, N. L., 
MAKHSON, A. N., CORTES, J., LORTHOLARY, A., BISCHOFF, J., CHAN, A., DELALOGE, 
S., HUANG, X., KERN, K. A. & GIORGETTI, C. 2012. First-line treatment of advanced 
breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: 
results of a prospective, randomized phase III study. J Clin Oncol, 30, 921-9. 
BERNATCHEZ, P. N., SOKER, S. & SIROIS, M. G. 1999. Vascular endothelial growth factor 
effect on endothelial cell proliferation, migration, and platelet-activating factor 
synthesis is Flk-1-dependent. J Biol Chem, 274, 31047-54. 
BERSE, B., BROWN, L. F., VAN DE WATER, L., DVORAK, H. F. & SENGER, D. R. 1992. Vascular 
permeability factor (vascular endothelial growth factor) gene is expressed 
differentially in normal tissues, macrophages, and tumors. Mol Biol Cell, 3, 211-20. 
BHATTACHARYA, R., YE, X. C., WANG, R., LING, X., MCMANUS, M., FAN, F., BOULBES, D. & 
ELLIS, L. M. 2016. Intracrine VEGF Signaling Mediates the Activity of Prosurvival 
Pathways in Human Colorectal Cancer Cells. Cancer Research, 76, 3014-3024. 
BJORNHEDEN, T., LEVIN, M., EVALDSSON, M. & WIKLUND, O. 1999. Evidence of hypoxic 
areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol, 19, 870-6. 
BLANN, A. D., BELGORE, F. M., MCCOLLUM, C. N., SILVERMAN, S., LIP, P. L. & LIP, G. Y. 2002. 
Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients 
with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond), 102, 
187-94. 
BOKER, L. K., VAN DER SCHOUW, Y. T., DE KLEIJN, M. J., JACQUES, P. F., GROBBEE, D. E. & 
PEETERS, P. H. 2002. Intake of dietary phytoestrogens by Dutch women. J Nutr, 
132, 1319-28. 
BOURASSA, P., CÔTÉ, R., HUTCHANDANI, S., SAMSON, G. & TAJMIR-RIAHI, H.-A. 2013. The 
effect of milk alpha-casein on the antioxidant activity of tea polyphenols. Journal of 
Photochemistry and Photobiology B: Biology, 128, 43-49. 
BOURASSA, P., KANAKIS, C. D., TARANTILIS, P., POLLISSIOU, M. G. & TAJMIR-RIAHI, H. A. 
2010. Resveratrol, genistein, and curcumin bind bovine serum albumin. J Phys 
Chem B, 114, 3348-54. 
BRAKENHIELM, E., CAO, R. & CAO, Y. 2001. Suppression of angiogenesis, tumor growth, and 
wound healing by resveratrol, a natural compound in red wine and grapes. Faseb j, 
15, 1798-800. 
BRAS, N. F., GONCALVES, R., MATEUS, N., FERNANDES, P. A., RAMOS, M. J. & DO FREITAS, 
V. 2010. Inhibition of Pancreatic Elastase by Polyphenolic Compounds. Journal of 
Agricultural and Food Chemistry, 58, 10668-10676. 
BROWN, D. M., MICHELS, M., KAISER, P. K., HEIER, J. S., SY, J. P. & IANCHULEV, T. 2009. 
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related 
macular degeneration: Two-year results of the ANCHOR study. Ophthalmology, 
116, 57-65.e5. 
BRYAN, B. A., DENNSTEDT, E., MITCHELL, D. C., WALSHE, T. E., NOMA, K., LOUREIRO, R., 
SAINT-GENIEZ, M., CAMPAIGNIAC, J. P., LIAO, J. K. & D'AMORE, P. A. 2010. 
RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated 
angiogenesis. Faseb j, 24, 3186-95. 
CANTLEY, L. C. 2002. The phosphoinositide 3-kinase pathway. Science, 296, 1655-7. 
CAO, H., JIA, X., SHI, J., XIAO, J. & CHEN, X. 2016. Non-covalent interaction between dietary 
stilbenoids and human serum albumin: Structure–affinity relationship, and its 
References 
180 
 
influence on the stability, free radical scavenging activity and cell uptake of 
stilbenoids. Food Chemistry, 202, 383-388. 
CAO, R. Y., ST. AMAND, T., GRÄBNER, R., HABENICHT, A. J. R. & FUNK, C. D. 2009. Genetic 
and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in 
atherosclerotic lesion development in ApoE deficient mice. Atherosclerosis, 203, 
395-400. 
CARDONE, M. H., ROY, N., STENNICKE, H. R., SALVESEN, G. S., FRANKE, T. F., STANBRIDGE, 
E., FRISCH, S. & REED, J. C. 1998. Regulation of cell death protease caspase-9 by 
phosphorylation. Science, 282, 1318-21. 
CARMELIET, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology, 69 Suppl 
3, 4-10. 
CARMELIET, P., FERREIRA, V., BREIER, G., POLLEFEYT, S., KIECKENS, L., GERTSENSTEIN, M., 
FAHRIG, M., VANDENHOECK, A., HARPAL, K., EBERHARDT, C., DECLERCQ, C., 
PAWLING, J., MOONS, L., COLLEN, D., RISAU, W. & NAGY, A. 1996. Abnormal blood 
vessel development and lethality in embryos lacking a single VEGF allele. Nature, 
380, 435-9. 
CARTER, A., MURPHY, M. O., TURNER, N. J., HALKA, A. T., GHOSH, J., SERRACINO-INGLOTT, 
F., WALKER, M. G. & SYED, F. 2007. Intimal Neovascularisation is a Prominent 
Feature of Atherosclerotic Plaques in Diabetic Patients with Critical Limb Ischaemia. 
European Journal of Vascular and Endovascular Surgery, 33, 319-324. 
CELLETTI, F. L., HILFIKER, P. R., GHAFOURI, P. & DAKE, M. D. 2001a. Effect of human 
recombinant vascular endothelial growth factor165 on progression of 
atherosclerotic plaque. Journal of the American College of Cardiology, 37, 2126-
2130. 
CELLETTI, F. L., WAUGH, J. M., AMABILE, P. G., BRENDOLAN, A., HILFIKER, P. R. & DAKE, M. 
D. 2001b. Vascular endothelial growth factor enhances atherosclerotic plaque 
progression. Nature Medicine, 7, 425-9. 
CELLETTI, F. L., WAUGH, J. M., AMABILE, P. G., KAO, E. Y., BOROUMAND, S. & DAKE, M. D. 
2002. Inhibition of vascular endothelial growth factor-mediated neointima 
progression with angiostatin or paclitaxel. J Vasc Interv Radiol, 13, 703-7. 
CERDÁ, B., CERÓN, J. J., TOMÁS-BARBERÁN, F. A. & ESPÍN, J. C. 2003. Repeated Oral 
Administration of High Doses of the Pomegranate Ellagitannin Punicalagin to Rats 
for 37 Days Is Not Toxic. Journal of Agricultural and Food Chemistry, 51, 3493-3501. 
CERDA, B., ESPIN, J. C., PARRA, S., MARTINEZ, P. & TOMAS-BARBERAN, F. A. 2004. The 
potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised 
into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives 
by the colonic microflora of healthy humans. European Journal of Nutrition, 43, 
205-220. 
CERDA, B., LLORACH, R., CERON, J. J., ESPIN, J. C. & TOMAS-BARBERAN, F. A. 2003. 
Evaluation of the bioavailability and metabolism in the rat of punicalagin, an 
antioxidant polyphenol from pomegranate juice. Eur J Nutr, 42, 18-28. 
CERDA, B., PERIAGO, P., ESPIN, J. C. & TOMAS-BARBERAN, F. A. 2005. Identification of 
urolithin A as a metabolite produced by human colon microflora from ellagic acid 
and related compounds. Journal of Agricultural and Food Chemistry, 53, 5571-5576. 
CEREZO, A. B., WINTERBONE, M. S., MOYLE, C. W., NEEDS, P. W. & KROON, P. A. 2015. 
Molecular structure-function relationship of dietary polyphenols for inhibiting 
VEGF-induced VEGFR-2 activity. Mol Nutr Food Res, 59, 2119-31. 
CHAKRABORTY, G., JAIN, S., KALE, S., RAJA, R., KUMAR, S., MISHRA, R. & KUNDU, G. C. 
2008. Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-
induced VEGF expression. Mol Med Rep, 1, 641-6. 
References 
181 
 
CHANET, A., MILENKOVIC, D., DEVAL, C., POTIER, M., CONSTANS, J., MAZUR, A., BENNETAU-
PELISSERO, C., MORAND, C. & BÉRARD, A. M. 2012. Naringin, the major grapefruit 
flavonoid, specifically affects atherosclerosis development in diet-induced 
hypercholesterolemia in mice. The Journal of Nutritional Biochemistry, 23, 469-477. 
CHEN, C.-M., LI, S.-C., CHEN, C. Y. O., AU, H.-K., SHIH, C.-K., HSU, C.-Y. & LIU, J.-F. 2011a. 
Constituents in purple sweet potato leaves inhibit in vitro angiogenesis with 
opposite effects ex vivo. Nutrition, 27, 1177-1182. 
CHEN, P.-L. & S. EASTON, A. 2011. Anti-Angiogenic Effects of Resveratrol on Cerebral 
Angiogenesis. Current Neurovascular Research, 8, 14-24. 
CHEN, T. T., LUQUE, A., LEE, S., ANDERSON, S. M., SEGURA, T. & IRUELA-ARISPE, M. L. 2010. 
Anchorage of VEGF to the extracellular matrix conveys differential signaling 
responses to endothelial cells. The Journal of Cell Biology, 188, 595-609. 
CHEN, X. L., NAM, J. O., JEAN, C., LAWSON, C., WALSH, C. T., GOKA, E., LIM, S. T., TOMAR, 
A., TANCIONI, I., URYU, S., GUAN, J. L., ACEVEDO, L. M., WEIS, S. M., CHERESH, D. A. 
& SCHLAEPFER, D. D. 2012. VEGF-induced vascular permeability is mediated by 
FAK. Dev Cell, 22, 146-57. 
CHEN, Y.-K., CHEUNG, C., REUHL, K. R., LIU, A. B., LEE, M.-J., LU, Y.-P. & YANG, C. S. 2011b. 
Effects of Green Tea Polyphenol (−)-Epigallocatechin-3-gallate on Newly Developed 
High-Fat/Western-Style Diet-Induced Obesity and Metabolic Syndrome in Mice. 
Journal of Agricultural and Food Chemistry, 59, 11862-11871. 
CHEN, Y. X., NAKASHIMA, Y., TANAKA, K., SHIRAISHI, S., NAKAGAWA, K. & SUEISHI, K. 1999. 
Immunohistochemical expression of vascular endothelial growth factor/vascular 
permeability factor in atherosclerotic intimas of human coronary arteries. 
Arterioscler Thromb Vasc Biol, 19, 131-9. 
CHENG, A.-L., KANG, Y.-K., LIN, D.-Y., PARK, J.-W., KUDO, M., QIN, S., CHUNG, H.-C., SONG, 
X., XU, J., POGGI, G., OMATA, M., LOWENTHAL, S. P., LANZALONE, S., YANG, L., 
LECHUGA, M. J. & RAYMOND, E. 2013. Sunitinib Versus Sorafenib in Advanced 
Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical 
Oncology, 31, 4067-4075. 
CHEYNIER, V. 2005. Polyphenols in foods are more complex than often thought. Am J Clin 
Nutr, 81, 223s-229s. 
CHOW, H. H., CAI, Y., ALBERTS, D. S., HAKIM, I., DORR, R., SHAHI, F., CROWELL, J. A., YANG, 
C. S. & HARA, Y. 2001. Phase I pharmacokinetic study of tea polyphenols following 
single-dose administration of epigallocatechin gallate and polyphenon E. Cancer 
Epidemiol Biomarkers Prev, 10, 53-8. 
CHRISTOFFERSSON, G., VAGESJO, E., VANDOOREN, J., LIDEN, M., MASSENA, S., REINERT, R. 
B., BRISSOVA, M., POWERS, A. C., OPDENAKKER, G. & PHILLIPSON, M. 2012. VEGF-A 
recruits a proangiogenic MMP-9-delivering neutrophil subset that induces 
angiogenesis in transplanted hypoxic tissue. Blood, 120, 4653-62. 
CHUN, O. K., CHUNG, S. J. & SONG, W. O. 2007. Estimated dietary flavonoid intake and 
major food sources of U.S. adults. J Nutr, 137, 1244-52. 
CHUN, O. K., FLOEGEL, A., CHUNG, S. J., CHUNG, C. E., SONG, W. O. & KOO, S. I. 2010. 
Estimation of antioxidant intakes from diet and supplements in U.S. adults. J Nutr, 
140, 317-24. 
CHYU, K. Y., BABBIDGE, S. M., ZHAO, X., DANDILLAYA, R., RIETVELD, A. G., YANO, J., 
DIMAYUGA, P., CERCEK, B. & SHAH, P. K. 2004. Differential effects of green tea-
derived catechin on developing versus established atherosclerosis in 
apolipoprotein E-null mice. Circulation, 109, 2448-53. 
CISOWSKI, J., ŁOBODA, A., JÓZKOWICZ, A., CHEN, S., AGARWAL, A. & DULAK, J. 2005. Role 
of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 
knockout. Biochemical and Biophysical Research Communications, 326, 670-676. 
References 
182 
 
CLIFFORD, M. N. 1999. Chlorogenic acids and other cinnamates – nature, occurrence and 
dietary burden. Journal of the Science of Food and Agriculture, 79, 362-372. 
COLOMBO, B. M., CACCIAPAGLIA, F., PUNTONI, M., MURDACA, G., ROSSI, E., RODRIGUEZ, 
G., NOBILI, F., PISCIOTTA, L., BERTOLINI, S., MOCCETTI, T., DENTALI, F., STEIDL, L., 
CIPRANDI, G., AFELTRA, A., INDIVERI, F. & PUPPO, F. 2009. Traditional and non 
traditional risk factors in accelerated atherosclerosis in Systemic Lupus 
Erythematosus: Role of vascular endothelial growth factor (VEGATS Study). 
Autoimmunity Reviews, 8, 309-315. 
COOPER, D. R., POREBSKI, P. J., CHRUSZCZ, M. & MINOR, W. 2011. X-ray crystallography: 
Assessment and validation of protein-small molecule complexes for drug discovery. 
Expert opinion on drug discovery, 6, 771-782. 
COUFFINHAL, T., SILVER, M., KEARNEY, M., SULLIVAN, A., WITZENBICHLER, B., MAGNER, 
M., ANNEX, B., PETERS, K. & ISNER, J. M. 1999. Impaired collateral vessel 
development associated with reduced expression of vascular endothelial growth 
factor in ApoE-/- mice. Circulation, 99, 3188-98. 
CRESPY, V., MORAND, C., BESSON, C., MANACH, C., DEMIGNE, C. & REMESY, C. 2001. 
Comparison of the intestinal absorption of quercetin, phloretin and their glucosides 
in rats. J Nutr, 131, 2109-14. 
CUDMORE, M. J., HEWETT, P. W., AHMAD, S., WANG, K. Q., CAI, M., AL-ANI, B., FUJISAWA, 
T., MA, B., SISSAOUI, S., RAMMA, W., MILLER, M. R., NEWBY, D. E., GU, Y., 
BARLEON, B., WEICH, H. & AHMED, A. 2012. The role of heterodimerization 
between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis. 
Nat Commun, 3, 972. 
D'ARCHIVIO, M., FILESI, C., DI BENEDETTO, R., GARGIULO, R., GIOVANNINI, C. & MASELLA, 
R. 2007. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita, 43, 
348-61. 
D’AGOSTINO, R. B., VASAN, R. S., PENCINA, M. J., WOLF, P. A., COBAIN, M., MASSARO, J. M. 
& KANNEL, W. B. 2008. General Cardiovascular Risk Profile for Use in Primary Care. 
The Framingham Heart Study, 117, 743-753. 
DALEPRANE, J. B., SCHMID, T., DEHNE, N., RUDNICKI, M., MENRAD, H., GEIS, T., IKEGAKI, 
M., ONG, T. P., BRUNE, B. & ABDALLA, D. S. 2012. Suppression of hypoxia-inducible 
factor-1alpha contributes to the antiangiogenic activity of red propolis polyphenols 
in human endothelial cells. J Nutr, 142, 441-7. 
DANIEL, E. M., KRUPNICK, A. S., HEUR, Y.-H., BLINZLER, J. A., NIMS, R. W. & STONER, G. D. 
1989. Extraction, stability, and quantitation of ellagic acid in various fruits and nuts. 
Journal of Food Composition and Analysis, 2, 338-349. 
DANIEL, E. M., RATNAYAKE, S., KINSTLE, T. & STONER, G. D. 1991. The Effects of pH and Rat 
Intestinal Contents on the Liberation of Ellagic Acid from Purified and Crude 
Ellagitannins. Journal of Natural Products, 54, 946-952. 
DANN, J. M., SYKES, P. H., MASON, D. R. & EVANS, J. J. 2009. Regulation of Vascular 
Endothelial Growth Factor in endometrial tumour cells by resveratrol and EGCG. 
Gynecologic Oncology, 113, 374-378. 
DATTA, S. R., DUDEK, H., TAO, X., MASTERS, S., FU, H., GOTOH, Y. & GREENBERG, M. E. 
1997. Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic 
Death Machinery. Cell, 91, 231-241. 
DAWBER, T. R., MEADORS, G. F. & MOORE, F. E., JR. 1951. Epidemiological approaches to 
heart disease: the Framingham Study. Am J Public Health Nations Health, 41, 279-
81. 
DE FRANCESCO, E. M., LAPPANO, R., SANTOLLA, M. F., MARSICO, S., CARUSO, A. & 
MAGGIOLINI, M. 2013. HIF-1α/GPER signaling mediates the expression of VEGF 
References 
183 
 
induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer 
Research, 15, R64. 
DE KLEIJN, M. J., VAN DER SCHOUW, Y. T., WILSON, P. W., ADLERCREUTZ, H., MAZUR, W., 
GROBBEE, D. E. & JACQUES, P. F. 2001. Intake of dietary phytoestrogens is low in 
postmenopausal women in the United States: the Framingham study(1-4). J Nutr, 
131, 1826-32. 
DE NIGRIS, F., WILLIAMS-IGNARRO, S., SICA, V., LERMAN, L. O., D'ARMIENTO, F. P., BYRNS, 
R. E., CASAMASSIMI, A., CARPENTIERO, D., SCHIANO, C., SUMI, D., FIORITO, C., 
IGNARRO, L. J. & NAPOLI, C. 2007. Effects of a pomegranate fruit extract rich in 
punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed 
shear stress and atherogenesis. Cardiovasc Res, 73, 414-23. 
DECICCO-SKINNER, K. L., HENRY, G. H., CATAISSON, C., TABIB, T., GWILLIAM, J. C., WATSON, 
N. J., BULLWINKLE, E. M., FALKENBURG, L., O'NEILL, R. C., MORIN, A. & WIEST, J. S. 
2014. Endothelial Cell Tube Formation Assay for the In Vitro Study of Angiogenesis. 
e51312. 
DEHGHANIAN, F., HOJATI, Z. & KAY, M. 2014. New Insights into VEGF-A Alternative Splicing: 
Key Regulatory Switching in the Pathological Process. Avicenna J Med Biotechnol, 6, 
192-9. 
DEL RIO, D., COSTA, L. G., LEAN, M. E. J. & CROZIER, A. 2010. Polyphenols and health: What 
compounds are involved? Nutrition, Metabolism and Cardiovascular Diseases, 20, 
1-6. 
DEMER, L. L. & TINTUT, Y. 2008. Vascular calcification: pathobiology of a multifaceted 
disease. Circulation, 117, 2938-48. 
DENG, Y., ZHANG, X. & SIMONS, M. 2015. Molecular controls of lymphatic VEGFR3 
signaling. Arterioscler Thromb Vasc Biol, 35, 421-9. 
DILIS, V. & TRICHOPOULOU, A. 2010. Antioxidant intakes and food sources in Greek adults. 
J Nutr, 140, 1274-9. 
DING, Y., ZHANG, B., ZHOU, K., CHEN, M., WANG, M., JIA, Y., SONG, Y., LI, Y. & WEN, A. 
2014. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and 
atherosclerosis: role of Nrf2 activation. Int J Cardiol, 175, 508-14. 
DOBREVA, M. A., GREEN, R. J., MUELLER-HARVEY, I., SALMINEN, J.-P., HOWLIN, B. J. & 
FRAZIER, R. A. 2014. Size and Molecular Flexibility Affect the Binding of 
Ellagitannins to Bovine Serum Albumin. Journal of Agricultural and Food Chemistry, 
62, 9186-9194. 
DOI, Y., YASHIRO, M., YAMADA, N., AMANO, R., NODA, S. & HIRAKAWA, K. 2012. VEGF-
A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer 
cells. Ann Surg Oncol, 19, 2733-43. 
DONNINI, S., FINETTI, F., LUSINI, L., MORBIDELLI, L., CHEYNIER, V., BARRON, D., 
WILLIAMSON, G., WALTENBERGER, J. & ZICHE, M. 2006. Divergent effects of 
quercetin conjugates on angiogenesis. Br J Nutr, 95, 1016-23. 
DONOVAN, J. L., CRESPY, V., MANACH, C., MORAND, C., BESSON, C., SCALBERT, A. & 
REMESY, C. 2001. Catechin is metabolized by both the small intestine and liver of 
rats. J Nutr, 131, 1753-7. 
DOUGHER, M. & TERMAN, B. I. 1999. Autophosphorylation of KDR in the kinase domain is 
required for maximal VEGF-stimulated kinase activity and receptor internalization. 
Oncogene, 18, 1619-27. 
DOYLE, B. & CAPLICE, N. 2007. Plaque Neovascularization and Antiangiogenic Therapy for 
Atherosclerosis. Journal of the American College of Cardiology, 49, 2073-2080. 
DUBE, A., NICOLAZZO, J. A. & LARSON, I. 2011a. Assessment of plasma concentrations of 
(−)-epigallocatechin gallate in mice following administration of a dose reflecting 
consumption of a standard green tea beverage. Food Chemistry, 128, 7-13. 
References 
184 
 
DUBE, A., NICOLAZZO, J. A. & LARSON, I. 2011b. Chitosan nanoparticles enhance the plasma 
exposure of (−)-epigallocatechin gallate in mice through an enhancement in 
intestinal stability. European Journal of Pharmaceutical Sciences, 44, 422-426. 
DUMONT, D. J., JUSSILA, L., TAIPALE, J., LYMBOUSSAKI, A., MUSTONEN, T., PAJUSOLA, K., 
BREITMAN, M. & ALITALO, K. 1998. Cardiovascular failure in mouse embryos 
deficient in VEGF receptor-3. Science, 282, 946-9. 
DUQUE, J. L. F., LOUGHLIN, K. R., ADAM, R. M., KANTOFF, P. W., ZURAKOWSKI, D. & 
FREEMAN, M. R. 1999. Plasma levels of vascular endothelial growth factor are 
increased in patients with metastatic prostate cancer. Urology, 54, 523-527. 
DURAN, W. N., BRESLIN, J. W. & SANCHEZ, F. A. 2010. The NO cascade, eNOS location, and 
microvascular permeability. Cardiovasc Res, 87, 254-61. 
EBOS, J. M. L., LEE, C. R., CRUZ-MUNOZ, W., BJARNASON, G. A., CHRISTENSEN, J. G. & 
KERBEL, R. S. 2009. Accelerated Metastasis after Short-Term Treatment with a 
Potent Inhibitor of Tumor Angiogenesis. Cancer Cell, 15, 232-239. 
EL-SHAHAWI, M. S., HAMZA, A., BAHAFFI, S. O., AL-SIBAAI, A. A. & ABDULJABBAR, T. N. 
2012. Analysis of some selected catechins and caffeine in green tea by high 
performance liquid chromatography. Food Chemistry, 134, 2268-2275. 
ELIASZIW, M., STREIFLER, J. Y., FOX, A. J., HACHINSKI, V. C., FERGUSON, G. G. & BARNETT, H. 
J. 1994. Significance of plaque ulceration in symptomatic patients with high-grade 
carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial. 
Stroke, 25, 304-8. 
ENDO, A., FUKUHARA, S., MASUDA, M., OHMORI, T. & MOCHIZUKI, N. 2003. Selective 
inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a 
central role for VEGFR-2 in human aortic endothelial cell responses to VEGF. J 
Recept Signal Transduct Res, 23, 239-54. 
ENGELBERG, H. 1961. Plasma Heparin Levels. Circulation, 23, 573. 
EPPLER, S. M., COMBS, D. L., HENRY, T. D., LOPEZ, J. J., ELLIS, S. G., YI, J. H., ANNEX, B. H., 
MCCLUSKEY, E. R. & ZIONCHECK, T. F. 2002. A target-mediated model to describe 
the pharmacokinetics and hemodynamic effects of recombinant human vascular 
endothelial growth factor in humans. Clin Pharmacol Ther, 72, 20-32. 
ESCUDIER, B., EISEN, T., STADLER, W. M., SZCZYLIK, C., OUDARD, S., STAEHLER, M., 
NEGRIER, S., CHEVREAU, C., DESAI, A. A., ROLLAND, F., DEMKOW, T., HUTSON, T. E., 
GORE, M., ANDERSON, S., HOFILENA, G., SHAN, M., PENA, C., LATHIA, C. & 
BUKOWSKI, R. M. 2009. Sorafenib for Treatment of Renal Cell Carcinoma: Final 
Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer 
Global Evaluation Trial. Journal of Clinical Oncology, 27, 3312-3318. 
ESPÍN, J. C., GONZÁLEZ-BARRIO, R., CERDÁ, B., LÓPEZ-BOTE, C., REY, A. I. & TOMÁS-
BARBERÁN, F. A. 2007. Iberian Pig as a Model To Clarify Obscure Points in the 
Bioavailability and Metabolism of Ellagitannins in Humans. Journal of Agricultural 
and Food Chemistry, 55, 10476-10485. 
FANTIN, A., VIEIRA, J. M., GESTRI, G., DENTI, L., SCHWARZ, Q., PRYKHOZHIJ, S., PERI, F., 
WILSON, S. W. & RUHRBERG, C. 2010. Tissue macrophages act as cellular 
chaperones for vascular anastomosis downstream of VEGF-mediated endothelial 
tip cell induction. Blood, 116, 829-40. 
FAVOT, L., MARTIN, S., KERAVIS, T., ANDRIANTSITOHAINA, R. & LUGNIER, C. 2003. 
Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on 
angiogenesis. Cardiovasc Res, 59, 479-87. 
FEARNLEY, G. W., SMITH, G. A., ABDUL-ZANI, I., YULDASHEVA, N., MUGHAL, N. A., HOMER-
VANNIASINKAM, S., KEARNEY, M. T., ZACHARY, I. C., TOMLINSON, D. C., HARRISON, 
M. A., WHEATCROFT, S. B. & PONNAMBALAM, S. 2016. VEGF-A isoforms program 
differential VEGFR2 signal transduction, trafficking and proteolysis. Biol Open. 
References 
185 
 
FERRARA, N. 2009. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol, 29, 
789-91. 
FERRARA, N. 2010. Binding to the extracellular matrix and proteolytic processing: two key 
mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell, 21, 
687-90. 
FERRARA, N., CARVER-MOORE, K., CHEN, H., DOWD, M., LU, L., O'SHEA, K. S., POWELL-
BRAXTON, L., HILLAN, K. J. & MOORE, M. W. 1996. Heterozygous embryonic 
lethality induced by targeted inactivation of the VEGF gene. Nature, 380, 439-42. 
FERRARA, N., GERBER, H. P. & LECOUTER, J. 2003. The biology of VEGF and its receptors. 
Nat Med, 9, 669-76. 
FERRARA, N. & HENZEL, W. J. 1989. Pituitary follicular cells secrete a novel heparin-binding 
growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 
161, 851-8. 
FERRARA, N., HILLAN, K. J. & NOVOTNY, W. 2005. Bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical 
Research Communications, 333, 328-335. 
FIORANI, M., ACCORSI, A. & CANTONI, O. 2003. Human red blood cells as a natural 
flavonoid reservoir. Free Radic Res, 37, 1331-8. 
FITO, M., CLADELLAS, M., DE LA TORRE, R., MARTI, J., MUNOZ, D., SCHRODER, H., 
ALCANTARA, M., PUJADAS-BASTARDES, M., MARRUGAT, J., LOPEZ-SABATER, M. C., 
BRUGUERA, J., COVAS, M. I. & INVESTIGATORS, S. 2008. Anti-inflammatory effect of 
virgin olive oil in stable coronary disease patients: a randomized, crossover, 
controlled trial. European Journal of Clinical Nutrition, 62, 570-574. 
FLEINER, M., KUMMER, M., MIRLACHER, M., SAUTER, G., CATHOMAS, G., KRAPF, R. & 
BIEDERMANN, B. C. 2004. Arterial neovascularization and inflammation in 
vulnerable patients: early and late signs of symptomatic atherosclerosis. 
Circulation, 110, 2843-50. 
FLEISCH, M., BILLINGER, M., EBERLI, F. R., GARACHEMANI, A. R., MEIER, B. & SEILER, C. 
1999. Physiologically assessed coronary collateral flow and intracoronary growth 
factor concentrations in patients with 1- to 3-vessel coronary artery disease. 
Circulation, 100, 1945-50. 
FONG, G. H., ROSSANT, J., GERTSENSTEIN, M. & BREITMAN, M. L. 1995. Role of the Flt-1 
receptor tyrosine kinase in regulating the assembly of vascular endothelium. 
Nature, 376, 66-70. 
FONG, G. H., ZHANG, L., BRYCE, D. M. & PENG, J. 1999. Increased hemangioblast 
commitment, not vascular disorganization, is the primary defect in flt-1 knock-out 
mice. Development, 126, 3015-25. 
FRIDRICH, D., TELLER, N., ESSELEN, M., PAHLKE, G. & MARKO, D. 2008. Comparison of 
delphinidin, quercetin and (-)-epigallocatechin-3-gallate as inhibitors of the EGFR 
and the ErbB2 receptor phosphorylation. Mol Nutr Food Res, 52, 815-22. 
FRIEDLANDER, M. 2007. Fibrosis and diseases of the eye. Journal of Clinical Investigation, 
117, 576-586. 
FUH, G., LI, B., CROWLEY, C., CUNNINGHAM, B. & WELLS, J. A. 1998. Requirements for 
binding and signaling of the kinase domain receptor for vascular endothelial growth 
factor. J Biol Chem, 273, 11197-204. 
FUKUMURA, D., XAVIER, R., SUGIURA, T., CHEN, Y., PARK, E. C., LU, N., SELIG, M., NIELSEN, 
G., TAKSIR, T., JAIN, R. K. & SEED, B. 1998. Tumor induction of VEGF promoter 
activity in stromal cells. Cell, 94, 715-25. 
FULTON, D., GRATTON, J. P., MCCABE, T. J., FONTANA, J., FUJIO, Y., WALSH, K., FRANKE, T. 
F., PAPAPETROPOULOS, A. & SESSA, W. C. 1999. Regulation of endothelium-derived 
nitric oxide production by the protein kinase Akt. Nature, 399, 597-601. 
References 
186 
 
GAHUTU, J. B. & WANE, J. 2006. Reference values for serum protein and electrolyte study 
from Rwanda. East Afr Med J, 83, 64-7. 
GALATI, G., LIN, A., SULTAN, A. M. & O'BRIEN, P. J. 2006. Cellular and in vivo hepatotoxicity 
caused by green tea phenolic acids and catechins. Free Radical Biology and 
Medicine, 40, 570-580. 
GAMPEL, A., MOSS, L., JONES, M. C., BRUNTON, V., NORMAN, J. C. & MELLOR, H. 2006. 
VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial 
storage compartment. Blood, 108, 2624-31. 
GARCÍA-VILLALBA, R., BELTRÁN, D., ESPÍN, J. C., SELMA, M. V. & TOMÁS-BARBERÁN, F. A. 
2013. Time Course Production of Urolithins from Ellagic Acid by Human Gut 
Microbiota. Journal of Agricultural and Food Chemistry, 61, 8797-8806. 
GARCÍA-VILLALBA, R., ESPÍN, J. C. & TOMÁS-BARBERÁN, F. A. 2016. Chromatographic and 
spectroscopic characterization of urolithins for their determination in biological 
samples after the intake of foods containing ellagitannins and ellagic acid. Journal 
of Chromatography A, 1428, 162-175. 
GELEIJNSE, J. M., LAUNER, L. J., VAN DER KUIP, D. A., HOFMAN, A. & WITTEMAN, J. C. 2002. 
Inverse association of tea and flavonoid intakes with incident myocardial infarction: 
the Rotterdam Study. Am J Clin Nutr, 75, 880-6. 
GELEIJNSE JM, L. L. J. H. A. P. H. P. W. J. M. 1999. Tea flavonoids may protect against 
atherosclerosis: The rotterdam study. Archives of Internal Medicine, 159, 2170-
2174. 
GÉLINAS, D. S., BERNATCHEZ, P. N., ROLLIN, S., BAZAN, N. G. & SIROIS, M. G. 2002. 
Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: Role of 
PI3K, PKC and PLC pathways. British Journal of Pharmacology, 137, 1021-1030. 
GETZ, G. S. & REARDON, C. A. 2006. Diet and murine atherosclerosis. Arterioscler Thromb 
Vasc Biol, 26, 242-9. 
GIANTONIO, B. J., CATALANO, P. J., MEROPOL, N. J., O'DWYER, P. J., MITCHELL, E. P., 
ALBERTS, S. R., SCHWARTZ, M. A. & III, A. B. B. 2007. Bevacizumab in Combination 
With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated 
Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology 
Group Study E3200. Journal of Clinical Oncology, 25, 1539-1544. 
GIL, M. I., TOMAS-BARBERAN, F. A., HESS-PIERCE, B., HOLCROFT, D. M. & KADER, A. A. 
2000. Antioxidant activity of pomegranate juice and its relationship with phenolic 
composition and processing. J Agric Food Chem, 48, 4581-9. 
GILLE, H., KOWALSKI, J., YU, L., CHEN, H., PISABARRO, M. T., DAVIS-SMYTH, T. & FERRARA, 
N. 2000. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) 
constitutively inhibits vascular endothelial growth factor-dependent 
phosphatidylinositol 3'-kinase activation and endothelial cell migration. EMBO J, 
19, 4064-73. 
GIRISH, C., KONER, B. C., JAYANTHI, S., RAMACHANDRA RAO, K., RAJESH, B. & PRADHAN, S. 
C. 2009. Hepatoprotective activity of picroliv, curcumin and ellagic acid compared 
to silymarin on paracetamol induced liver toxicity in mice. Fundamental & Clinical 
Pharmacology, 23, 735-745. 
GOERGES, A. L. & NUGENT, M. A. 2004. pH regulates vascular endothelial growth factor 
binding to fibronectin: a mechanism for control of extracellular matrix storage and 
release. J Biol Chem, 279, 2307-15. 
GONCALVES, R., MATEUS, N., PIANET, I., LAGUERRE, M. & DE FREITAS, V. 2011. 
Mechanisms of Tannin-Induced Trypsin Inhibition: A Molecular Approach. 
Langmuir, 27, 13122-13129. 
References 
187 
 
GONZALEZ-BARRIO, R., BORGES, G., MULLEN, W. & CROZIER, A. 2010. Bioavailability of 
anthocyanins and ellagitannins following consumption of raspberries by healthy 
humans and subjects with an ileostomy. J Agric Food Chem, 58, 3933-9. 
GONZÁLEZ-SARRÍAS, A., GARCÍA-VILLALBA, R., NÚÑEZ-SÁNCHEZ, M. Á., TOMÉ-CARNEIRO, 
J., ZAFRILLA, P., MULERO, J., TOMÁS-BARBERÁN, F. A. & ESPÍN, J. C. 2015. 
Identifying the limits for ellagic acid bioavailability: A crossover pharmacokinetic 
study in healthy volunteers after consumption of pomegranate extracts. Journal of 
Functional Foods, 19, Part A, 225-235. 
GONZALEZ-SARRIAS, A., GARCIA-VILLALBA, R., ROMO-VAQUERO, M., ALASALVAR, C., 
OREM, A., ZAFRILLA, P., TOMAS-BARBERAN, F. A., SELMA, M. V. & ESPIN, J. C. 2016. 
Clustering according to urolithin metabotype explains the interindividual variability 
in the improvement of cardiovascular risk biomarkers in overweight-obese 
individuals consuming pomegranate: A randomised clinical trial. Mol Nutr Food Res. 
GONZÁLEZ-SARRÍAS, A., GIMÉNEZ-BASTIDA, J. A., NÚÑEZ-SÁNCHEZ, M. Á., LARROSA, M., 
GARCÍA-CONESA, M. T., TOMÁS-BARBERÁN, F. A. & ESPÍN, J. C. 2014. Phase-II 
metabolism limits the antiproliferative activity of urolithins in human colon cancer 
cells. European Journal of Nutrition, 53, 853-864. 
GONZALEZ, J., DONOSO, W., SANDOVAL, N., REYES, M., GONZALEZ, P., GAJARDO, M., 
MORALES, E., NEIRA, A., RAZMILIC, I., YURI, J. A. & MOORE-CARRASCO, R. 2015. 
Apple Peel Supplemented Diet Reduces Parameters of Metabolic Syndrome and 
Atherogenic Progression in ApoE-/- Mice. Evidence-Based Complementary and 
Alternative Medicine. 
GOODLAD, R. A., RYAN, A. J., WEDGE, S. R., PYRAH, I. T., ALFEREZ, D., POULSOM, R., SMITH, 
N. R., MANDIR, N., WATKINS, A. J. & WILKINSON, R. W. 2006. Inhibiting vascular 
endothelial growth factor receptor-2 signaling reduces tumor burden in the 
ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis, 27, 2133-9. 
GORINSTEIN, S., CASPI, A., LIBMAN, I., LERNER, H. T., HUANG, D. J., LEONTOWICZ, H., 
LEONTOWICZ, M., TASHMA, Z., KATRICH, E., FENG, S. B. & TRAKHTENBERG, S. 2006. 
Red grapefruit positively influences serum triglyceride level in patients suffering 
from coronary atherosclerosis: Studies in vitro and in humans. Journal of 
Agricultural and Food Chemistry, 54, 1887-1892. 
GROSSO, G., STEPANIAK, U., TOPOR-MĄDRY, R., SZAFRANIEC, K. & PAJĄK, A. 2014. 
Estimated dietary intake and major food sources of polyphenols in the Polish arm 
of the HAPIEE study(). Nutrition (Burbank, Los Angeles County, Calif.), 30, 1398-
1403. 
GU, L., KELM, M. A., HAMMERSTONE, J. F., BEECHER, G., HOLDEN, J., HAYTOWITZ, D., 
GEBHARDT, S. & PRIOR, R. L. 2004. Concentrations of proanthocyanidins in 
common foods and estimations of normal consumption. J Nutr, 134, 613-7. 
GUAN, H., LIN, Y., BAI, L., AN, Y. F., SHANG, J. N., WANG, Z., ZHAO, S. H., FAN, J. L. & LIU, E. 
Q. 2016. Dietary Cocoa Powder Improves Hyperlipidemia and Reduces 
Atherosclerosis in apoE Deficient Mice through the Inhibition of Hepatic 
Endoplasmic Reticulum Stress. Mediators of Inflammation. 
GURUVAYOORAPPAN, C. & KUTTAN, G. 2007. Antiangiogenic Effect of Rutin and its 
Regulatory Effect on the Production of VEGF, IL-lß and TNF-α in Tumor Associated 
Macrophages. Journal of Biological Sciences  
HAGE, D. S., ANGUIZOLA, J., BARNABY, O., JACKSON, A., YOO, M. J., PAPASTAVROS, E., 
PFAUNMILLER, E., SOBANSKY, M. & TONG, Z. 2011. Characterization of drug 
interactions with serum proteins by using high-performance affinity 
chromatography. Current drug metabolism, 12, 313-328. 
HAMAD, A.-W. R., AL-MOMANI, W. M., JANAKAT, S. & ORAN, S. A. 2009. Bioavailability of 
ellagic acid after single dose administration using HPLC. Pak J Nutr, 8, 1661-4. 
References 
188 
 
HASKELL, H., NATARAJAN, M., HECKER, T. P., DING, Q., STEWART, J., JR., GRAMMER, J. R. & 
GLADSON, C. L. 2003. Focal adhesion kinase is expressed in the angiogenic blood 
vessels of malignant astrocytic tumors in vivo and promotes capillary tube 
formation of brain microvascular endothelial cells. Clin Cancer Res, 9, 2157-65. 
HAUER, A. D., VAN PUIJVELDE, G. H., PETERSE, N., DE VOS, P., VAN WEEL, V., VAN 
WANROOIJ, E. J., BIESSEN, E. A., QUAX, P. H., NIETHAMMER, A. G., REISFELD, R. A., 
VAN BERKEL, T. J. & KUIPER, J. 2007. Vaccination against VEGFR2 attenuates 
initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol, 27, 
2050-7. 
HEINONEN, S. E., KIVELA, A. M., HUUSKO, J., DIJKSTRA, M. H., GURZELER, E., MAKINEN, P. I., 
LEPPANEN, P., OLKKONEN, V. M., ERIKSSON, U., JAUHIAINEN, M. & YLA-
HERTTUALA, S. 2013. The effects of VEGF-A on atherosclerosis, lipoprotein profile, 
and lipoprotein lipase in hyperlipidaemic mouse models. Cardiovasc Res, 99, 716-
23. 
HENNING, S. M., NIU, Y., LEE, N. H., THAMES, G. D., MINUTTI, R. R., WANG, H., GO, V. L. & 
HEBER, D. 2004. Bioavailability and antioxidant activity of tea flavanols after 
consumption of green tea, black tea, or a green tea extract supplement. Am J Clin 
Nutr, 80, 1558-64. 
HENNING, S. M., NIU, Y., LIU, Y., LEE, N. H., HARA, Y., THAMES, G. D., MINUTTI, R. R., 
CARPENTER, C. L., WANG, H. & HEBER, D. 2005. Bioavailability and antioxidant 
effect of epigallocatechin gallate administered in purified form versus as green tea 
extract in healthy individuals. The Journal of Nutritional Biochemistry, 16, 610-616. 
HERNAEZ, A., FERNANDEZ-CASTILLEJO, S., FARRAS, M., CATALAN, U., SUBIRANA, I., 
MONTES, R., SOLA, R., MUNOZ-AGUAYO, D., GELABERT-GORGUES, A., DIAZ-GIL, O., 
NYYSSONEN, K., ZUNFT, H. J. F., DE LA TORRE, R., MARTIN-PELAEZ, S., PEDRET, A., 
REMALEY, A. T., COVAS, M. I. & FITO, M. 2014. Olive Oil Polyphenols Enhance High-
Density Lipoprotein Function in Humans A Randomized Controlled Trial. 
Arteriosclerosis Thrombosis and Vascular Biology, 34, 2115-2119. 
HERTOG, M. G., FESKENS, E. J., HOLLMAN, P. C., KATAN, M. B. & KROMHOUT, D. 1993. 
Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen 
Elderly Study. Lancet, 342, 1007-11. 
HERTOG, M. G., FESKENS, E. J. & KROMHOUT, D. 1997. Antioxidant flavonols and coronary 
heart disease risk. Lancet, 349, 699. 
HIRATSUKA, S., MINOWA, O., KUNO, J., NODA, T. & SHIBUYA, M. 1998. Flt-1 lacking the 
tyrosine kinase domain is sufficient for normal development and angiogenesis in 
mice. Proc Natl Acad Sci U S A, 95, 9349-54. 
HIROTA, K. & SEMENZA, G. L. 2006. Regulation of angiogenesis by hypoxia-inducible factor 
1. Crit Rev Oncol Hematol, 59, 15-26. 
HIRVONEN, T., PIETINEN, P., VIRTANEN, M., OVASKAINEN, M. L., HAKKINEN, S., ALBANES, D. 
& VIRTAMO, J. 2001. Intake of flavonols and flavones and risk of coronary heart 
disease in male smokers. Epidemiology, 12, 62-7. 
HIRVONEN, T., VIRTAMO, J., KORHONEN, P., ALBANES, D. & PIETINEN, P. 2000. Intake of 
flavonoids, carotenoids, vitamins C and E, and risk of stroke in male smokers. 
Stroke, 31, 2301-6. 
HISHIKAWA, K., NAKAKI, T. & FUJITA, T. 2005. Oral flavonoid supplementation attenuates 
atherosclerosis development in apolipoprotein E-deficient mice. Arterioscler 
Thromb Vasc Biol, 25, 442-6. 
HIYAMA, T., TANAKA, T., ENDO, S., KOMINE, K., KUDO, T., KOBAYASHI, H. & SHIOKAWA, Y. 
2010. Angiogenesis in atherosclerotic plaque obtained from carotid 
endarterectomy: association between symptomatology and plaque morphology. 
Neurol Med Chir (Tokyo), 50, 1056-61. 
References 
189 
 
HO-TIN-NOE, B., LE DALL, J., GOMEZ, D., LOUEDEC, L., VRANCKX, R., EL-BOUCHTAOUI, M., 
LEGRES, L., MEILHAC, O. & MICHEL, J. B. 2011. Early atheroma-derived agonists of 
peroxisome proliferator-activated receptor-gamma trigger intramedial 
angiogenesis in a smooth muscle cell-dependent manner. Circ Res, 109, 1003-14. 
HOLLMAN, P. C. H., BIJSMAN, M. N. C. P., VAN GAMEREN, Y., CNOSSEN, E. P. J., DE VRIES, J. 
H. M. & KATAN, M. B. 1999. The sugar moiety is a major determinant of the 
absorption of dietary flavonoid glycosides in man. Free Radical Research, 31, 569-
573. 
HOLMQVIST, K., CROSS, M. J., ROLNY, C., HAGERKVIST, R., RAHIMI, N., MATSUMOTO, T., 
CLAESSON-WELSH, L. & WELSH, M. 2004. The adaptor protein shb binds to tyrosine 
1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-
dependent cellular migration. J Biol Chem, 279, 22267-75. 
HONG, J., KIM, M. R., LEE, N. H. & LEE, B. H. 2009. Inhibition of Oral Epithelial Cell Growth in 
vitro by Epigallocatechin-3-gallate; Its Modulation by Serum and Antioxidant 
Enzymes. Food Science and Biotechnology, 18, 971-977. 
HONG, Z., XU, Y., YIN, J. F., JIN, J., JIANG, Y. & DU, Q. 2014. Improving the effectiveness of (-
)-epigallocatechin gallate (EGCG) against rabbit atherosclerosis by EGCG-loaded 
nanoparticles prepared from chitosan and polyaspartic acid. J Agric Food Chem, 62, 
12603-9. 
HOOPER, L., KAY, C., ABDELHAMID, A., KROON, P. A., COHN, J. S., RIMM, E. B. & CASSIDY, A. 
2012. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a 
systematic review and meta-analysis of randomized trials. American Journal of 
Clinical Nutrition, 95, 740-751. 
HOROWITZ, J. R., RIVARD, A., VAN DER ZEE, R., HARIAWALA, M., SHERIFF, D. D., ESAKOF, D. 
D., CHAUDHRY, G. M., SYMES, J. F. & ISNER, J. M. 1997. Vascular endothelial growth 
factor/vascular permeability factor produces nitric oxide-dependent hypotension. 
Evidence for a maintenance role in quiescent adult endothelium. Arterioscler 
Thromb Vasc Biol, 17, 2793-800. 
HSEU, Y.-C., CHEN, S.-C., LIN, W.-H., HUNG, D.-Z., LIN, M.-K., KUO, Y.-H., WANG, M.-T., CHO, 
H.-J., WANG, L. & YANG, H.-L. 2011. Toona sinensis (leaf extracts) inhibit vascular 
endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial 
cells. Journal of Ethnopharmacology, 134, 111-121. 
HUANG, L., FAN, B., MA, A., SHAUL, P. W. & ZHU, H. 2015. Inhibition of ABCA1 protein 
degradation promotes HDL cholesterol efflux capacity and RCT and reduces 
atherosclerosis in mice. J Lipid Res, 56, 986-97. 
HUANG, M.-T., HO, C.-T., WANG, Z. Y., FERRARO, T., FINNEGAN-OLIVE, T., LOU, Y.-R., 
MITCHELL, J. M., LASKIN, J. D., NEWMARK, H., YANG, C. S. & CONNEY, A. H. 1992. 
Inhibitory effect of topical application of a green tea polyphenol fraction on tumor 
initiation and promotion in mouse skin. Carcinogenesis, 13, 947-954. 
HUANG, S., YANG, N., LIU, Y., HU, L., ZHAO, J., GAO, J., LI, Y., LI, C., ZHANG, X. & HUANG, T. 
2012. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of 
both vascular endothelial growth factor and angiopoietin signaling. Nutrition 
Research, 32, 530-536. 
HUANG, W., LI, Z., NIU, H., LI, L., LIN, W. & YANG, J. 2008. Utilization of acorn fringe for 
ellagic acid production by Aspergillus oryzae and Endomyces fibuliger. Bioresource 
Technology, 99, 3552-3558. 
HUANG, W., NIU, H., LI, Z., LIN, W., GONG, G. & WANG, W. 2007. Effect of ellagitannin acyl 
hydrolase, xylanase and cellulase on ellagic acid production from cups extract of 
valonia acorns. Process Biochemistry, 42, 1291-1295. 
References 
190 
 
HUO, Y., SCHOBER, A., FORLOW, S. B., SMITH, D. F., HYMAN, M. C., JUNG, S., LITTMAN, D. 
R., WEBER, C. & LEY, K. 2003. Circulating activated platelets exacerbate 
atherosclerosis in mice deficient in apolipoprotein E. Nat Med, 9, 61-67. 
HUTTER, R., SPEIDL, W. S., VALDIVIEZO, C., SAUTER, B., CORTI, R., FUSTER, V. & BADIMON, 
J. J. 2013. Macrophages Transmit Potent Proangiogenic Effects of oxLDL In Vitro 
and In Vivo Involving HIF-1α Activation: a Novel Aspect of Angiogenesis in 
Atherosclerosis. Journal of cardiovascular translational research, 6, 558-569. 
IACOBELLIS, G., CIPRIANI, R., GABRIELE, A., DI MARIO, U. & MORANO, S. 2004. High 
circulating vascular endothelial growth factor (VEGF) is related to a better systolic 
function in diabetic hypertensive patients. Cytokine, 27, 25-30. 
INOUE, M., ITOH, H., TANAKA, T., CHUN, T.-H., DOI, K., FUKUNAGA, Y., SAWADA, N., 
YAMSHITA, J., MASATSUGU, K., SAITO, T., SAKAGUCHI, S., SONE, M., YAMAHARA, 
K.-I., YURUGI, T. & NAKAO, K. 2001. Oxidized LDL Regulates Vascular Endothelial 
Growth Factor Expression in Human Macrophages and Endothelial Cells Through 
Activation of Peroxisome Proliferator–Activated Receptor-γ. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 21, 560. 
INOUE, M., ITOH, H., UEDA, M., NARUKO, T., KOJIMA, A., KOMATSU, R., DOI, K., OGAWA, Y., 
TAMURA, N., TAKAYA, K., IGAKI, T., YAMASHITA, J., CHUN, T. H., MASATSUGU, K., 
BECKER, A. E. & NAKAO, K. 1998. Vascular endothelial growth factor (VEGF) 
expression in human coronary atherosclerotic lesions: possible pathophysiological 
significance of VEGF in progression of atherosclerosis. Circulation, 98, 2108-16. 
INSULL, W., JR. 2009. The pathology of atherosclerosis: plaque development and plaque 
responses to medical treatment. Am J Med, 122, S3-S14. 
ISBRUCKER, R. A., EDWARDS, J. A., WOLZ, E., DAVIDOVICH, A. & BAUSCH, J. 2006. Safety 
studies on epigallocatechin gallate (EGCG) preparations. Part 2: Dermal, acute and 
short-term toxicity studies. Food and Chemical Toxicology, 44, 636-650. 
JAKOBSSON, L., BENTLEY, K. & GERHARDT, H. 2009. VEGFRs and Notch: a dynamic 
collaboration in vascular patterning. Biochem Soc Trans, 37, 1233-6. 
JENKINS, P. J., HARPER, R. W. & NESTEL, P. J. 1978. Severity of coronary atherosclerosis 
related to lipoprotein concentration. British Medical Journal, 2, 388. 
JENSEN, R. L., RAGEL, B. T., WHANG, K. & GILLESPIE, D. 2006. Inhibition of hypoxia inducible 
factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) 
secretion and tumor growth in malignant gliomas. J Neurooncol, 78, 233-47. 
JOAKIMSEN, O., BONAA, K. H., STENSLAND-BUGGE, E. & JACOBSEN, B. K. 1999. Age and sex 
differences in the distribution and ultrasound morphology of carotid 
atherosclerosis: the Tromso Study. Arterioscler Thromb Vasc Biol, 19, 3007-13. 
JOHANNOT, L. & SOMERSET, S. M. 2006. Age-related variations in flavonoid intake and 
sources in the Australian population. Public Health Nutr, 9, 1045-54. 
JOUKOV, V., SORSA, T., KUMAR, V., JELTSCH, M., CLAESSON‐WELSH, L., CAO, Y., SAKSELA, 
O., KALKKINEN, N. & ALITALO, K. 1997. Proteolytic processing regulates receptor 
specificity and activity of VEGF‐C. The EMBO Journal, 16, 3898-3911. 
JUAN-BABOT, J., MARTINEZ-GONZALEZ, J., BERROZPE, M. & BADIMON, L. 2003. 
Neovascularization in human coronary arteries with lesions of different severity. 
Rev Esp Cardiol, 56, 978 - 986. 
JUNG, M. H., LEE, S. H., AHN, E. M. & LEE, Y. M. 2009. Decursin and decursinol angelate 
inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling 
pathway. Carcinogenesis, 30, 655-61. 
JUZWIAK, S., WOJCICKI, J., MOKRZYCKI, K., MARCHLEWICZ, M., BIALECKA, M., WENDA-
ROZEWICKA, L., GAWRONSKA-SZKLARZ, B. & DROZDZIK, M. 2005. Effect of 
quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. 
Pharmacol Rep, 57, 604-9. 
References 
191 
 
KAESS, B. M., PREIS, S. R., BEISER, A., SAWYER, D. B., CHEN, T. C., SESHADRI, S. & VASAN, R. 
S. 2016. Circulating vascular endothelial growth factor and the risk of 
cardiovascular events. Heart. 
KAKOLYRIS, S., KARAKITSOS, P., TZARDI, M. & AGAPITOS, E. 1995. Immunohistochemical 
detection of fibronectin in early and advanced atherosclerosis. In vivo (Athens, 
Greece), 9, 35-40. 
KALDAS, M. I., WALLE, U. K., VAN DER WOUDE, H., MCMILLAN, J. M. & WALLE, T. 2005. 
Covalent Binding of the Flavonoid Quercetin to Human Serum Albumin. Journal of 
Agricultural and Food Chemistry, 53, 4194-4197. 
KAMBA, T. & MCDONALD, D. M. 2007. Mechanisms of adverse effects of anti-VEGF therapy 
for cancer. Br J Cancer, 96, 1788-1795. 
KANG, M.-K., LIM, S. S., LEE, J.-Y., YEO, K. M. & KANG, Y.-H. 2013. Anthocyanin-Rich Purple 
Corn Extract Inhibit Diabetes-Associated Glomerular Angiogenesis. PLoS ONE, 8, 
e79823. 
KARONEN, M., ORAVIITA, M., MUELLER-HARVEY, I., SALMINEN, J.-P. & GREEN, R. J. 2015. 
Binding of an Oligomeric Ellagitannin Series to Bovine Serum Albumin (BSA): 
Analysis by Isothermal Titration Calorimetry (ITC). Journal of Agricultural and Food 
Chemistry, 63, 10647-10654. 
KAVANTZAS, N., CHATZIIOANNOU, A., YANNI, A. E., TSAKAYANNIS, D., BALAFOUTAS, D., 
AGROGIANNIS, G. & PERREA, D. 2006. Effect of green tea on angiogenesis and 
severity of atherosclerosis in cholesterol-fed rabbit. Vascular Pharmacology, 44, 
461-463. 
KELI, S. O., HERTOG, M. G., FESKENS, E. J. & KROMHOUT, D. 1996. Dietary flavonoids, 
antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med, 
156, 637-42. 
KENDALL, R. L. & THOMAS, K. A. 1993. Inhibition of vascular endothelial cell growth factor 
activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A, 90, 
10705-9. 
KEOGH, J. B., MCINERNEY, J. & CLIFTON, P. M. 2007. The Effect of Milk Protein on the 
Bioavailability of Cocoa Polyphenols. Journal of Food Science, 72, S230-S233. 
KERIO, L. C., WACHIRA, F. N., WANYOKO, J. K. & ROTICH, M. K. 2013. Total polyphenols, 
catechin profiles and antioxidant activity of tea products from purple leaf coloured 
tea cultivars. Food Chemistry, 136, 1405-1413. 
KEUNEN, O., JOHANSSON, M., OUDIN, A., SANZEY, M., RAHIM, S. A. A., FACK, F., THORSEN, 
F., TAXT, T., BARTOS, M., JIRIK, R., MILETIC, H., WANG, J., STIEBER, D., STUHR, L., 
MOEN, I., RYGH, C. B., BJERKVIG, R. & NICLOU, S. P. 2011. Anti-VEGF treatment 
reduces blood supply and increases tumor cell invasion in glioblastoma. 
Proceedings of the National Academy of Sciences of the United States of America, 
108, 3749-3754. 
KEYES, K. A., MANN, L., COX, K., TREADWAY, P., IVERSEN, P., CHEN, Y.-F. & TEICHER, B. A. 
2003. Circulating angiogenic growth factor levels in mice bearing human tumors 
using Luminex Multiplex technology. Cancer Chemotherapy and Pharmacology, 51, 
321-327. 
KHALESI, S., SUN, J., BUYS, N., JAMSHIDI, A., NIKBAKHT-NASRABADI, E. & KHOSRAVI-
BOROUJENI, H. 2014. Green tea catechins and blood pressure: a systematic review 
and meta-analysis of randomised controlled trials. European Journal of Nutrition, 
53, 1299-1311. 
KHURANA, R., SIMONS, M., MARTIN, J. & ZACHARY, I. 2005. Role of angiogenesis in 
cardiovascular disease: a critical appraisal. Circulation, 112, 1813 - 1824. 
KHURANA, R., ZHUANG, Z., BHARDWAJ, S., MURAKAMI, M., DE MUINCK, E., YLA-
HERTTUALA, S., FERRARA, N., MARTIN, J., ZACHARY, I. & SIMONS, M. 2004. 
References 
192 
 
Angiogenesis-dependent and independent phases of intimal hyperplasia. 
Circulation, 110, 2436 - 2443. 
KIJANKA, G., PROKOPOWICZ, M., SCHELLEKENS, H. & BRINKS, V. 2014. Influence of 
Aggregation and Route of Injection on the Biodistribution of Mouse Serum 
Albumin. Plos One, 9, 9. 
KIM, H. K., SONG, K. S., PARK, Y. S., KANG, Y. H., LEE, Y. J., LEE, K. R., KIM, H. K., RYU, K. W., 
BAE, J. M. & KIM, S. 2003. Elevated levels of circulating platelet microparticles, 
VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis 
predictor. European Journal of Cancer, 39, 184-191. 
KIM, J. A., FORMOSO, G., LI, Y., POTENZA, M. A., MARASCIULO, F. L., MONTAGNANI, M. & 
QUON, M. J. 2007a. Epigallocatechin gallate, a green tea polyphenol, mediates NO-
dependent vasodilation using signaling pathways in vascular endothelium requiring 
reactive oxygen species and Fyn. J Biol Chem, 282, 13736-45. 
KIM, S.-J., JEONG, H.-J., LEE, K.-M., MYUNG, N.-Y., AN, N.-H., MO YANG, W., KYU PARK, S., 
LEE, H.-J., HONG, S.-H., KIM, H.-M. & UM, J.-Y. 2007b. Epigallocatechin-3-gallate 
suppresses NF-κB activation and phosphorylation of p38 MAPK and JNK in human 
astrocytoma U373MG cells. The Journal of Nutritional Biochemistry, 18, 587-596. 
KIMURA, K., HASHIGUCHI, T., DEGUCHI, T., HORINOUCHI, S., UTO, T., OKU, H., SETOYAMA, 
S., MARUYAMA, I., OSAME, M. & ARIMURA, K. 2007. Serum VEGF—As a prognostic 
factor of atherosclerosis. Atherosclerosis, 194, 182-188. 
KLEEMANN, R., VERSCHUREN, L., MORRISON, M., ZADELAAR, S., VAN ERK, M. J., WIELINGA, 
P. Y. & KOOISTRA, T. 2011. Anti-inflammatory, anti-proliferative and anti-
atherosclerotic effects of quercetin in human in vitro and in vivo models. 
Atherosclerosis, 218, 44-52. 
KLIFFEN, M., SHARMA, H. S., MOOY, C. M., KERKVLIET, S. & DE JONG, P. T. 1997. Increased 
expression of angiogenic growth factors in age-related maculopathy. Br J 
Ophthalmol, 81. 
KNEKT, P., JARVINEN, R., REUNANEN, A. & MAATELA, J. 1996. Flavonoid intake and 
coronary mortality in Finland: a cohort study. BMJ, 312, 478-481. 
KNEKT, P., KUMPULAINEN, J., JARVINEN, R., RISSANEN, H., HELIOVAARA, M., REUNANEN, 
A., HAKULINEN, T. & AROMAA, A. 2002. Flavonoid intake and risk of chronic 
diseases. Am J Clin Nutr, 76, 560-8. 
KOJIMA-YUASA, A., HUA, J. J., KENNEDY, D. O. & MATSUI-YUASA, I. 2003. Green tea extract 
inhibits angiogenesis of human umbilical vein endothelial cells through reduction of 
expression of VEGF receptors. Life Sciences, 73, 1299-1313. 
KOLODGIE, F. D., NARULA, J., YUAN, C., BURKE, A. P., FINN, A. V. & VIRMANI, R. 2007. 
Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug 
therapy? J Am Coll Cardiol, 49, 2093-101. 
KONDO, T., OHTA, T., IGURA, K., HARA, Y. & KAJI, K. 2002. Tea catechins inhibit 
angiogenesis in vitro, measured by human endothelial cell growth, migration and 
tube formation, through inhibition of VEGF receptor binding. Cancer Letters, 180, 
139-144. 
KONTERMANN, R. E. 2011. Strategies for extended serum half-life of protein therapeutics. 
Current Opinion in Biotechnology, 22, 868-876. 
KOPPARAPU, P. K., BOORJIAN, S. A., ROBINSON, B. D., DOWNES, M., GUDAS, L. J., 
MONGAN, N. P. & PERSSON, J. L. 2013. Expression of VEGF and its receptors 
VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res, 
33, 2381-90. 
KRILLEKE, D., NG, Y. S. & SHIMA, D. T. 2009. The heparin-binding domain confers diverse 
functions of VEGF-A in development and disease: a structure-function study. 
Biochem Soc Trans, 37, 1201-6. 
References 
193 
 
KU, D. N., GIDDENS, D. P., ZARINS, C. K. & GLAGOV, S. 1985. Pulsatile flow and 
atherosclerosis in the human carotid bifurcation. Positive correlation between 
plaque location and low oscillating shear stress. Arteriosclerosis, 5, 293-302. 
KUCUKARDALI, Y., AYDOGDU, S., OZMEN, N., YONEM, A., SOLMAZGUL, E., OZYURT, M., 
CINGOZBAY, Y. & AYDOGDU, A. 2008. The relationship between severity of 
coronary artery disease and plasma level of vascular endothelial growth factor. 
Cardiovascular Revascularization Medicine, 9, 66-70. 
KUMAR, H., DEVARAJI, V., JOSHI, R., JADHAO, M., AHIRKAR, P., PRASATH, R., BHAVANA, P. 
& GHOSH, S. K. 2015. Antihypertensive activity of a quinoline appended chalcone 
derivative and its site specific binding interaction with a relevant target carrier 
protein. Rsc Advances, 5, 65496-65513. 
KUWAHARA, F., KAI, H., TOKUDA, K., SHIBATA, R., KUSABA, K., TAHARA, N., NIIYAMA, H., 
NAGATA, T. & IMAIZUMI, T. 2002. Hypoxia-inducible factor-1alpha/vascular 
endothelial growth factor pathway for adventitial vasa vasorum formation in 
hypertensive rat aorta. Hypertension, 39, 46-50. 
KVANTA, A., ALGVERE, P. V., BERGLIN, L. & SEREGARD, S. 1996. Subfoveal fibrovascular 
membranes in age-related macular degeneration express vascular endothelial 
growth factor. Investigative Ophthalmology & Visual Science, 37, 1929-1934. 
KYLE, J. A. M., MORRICE, P. C., MCNEILL, G. & DUTHIE, G. G. 2007. Effects of Infusion Time 
and Addition of Milk on Content and Absorption of Polyphenols from Black Tea. 
Journal of Agricultural and Food Chemistry, 55, 4889-4894. 
KYLE, R. A. & GREIPP, P. R. 1978. 3. The laboratory investigation of monoclonal 
gammopathies. Mayo Clin Proc, 53, 719-39. 
LABRECQUE, L., LAMY, S., CHAPUS, A., MIHOUBI, S., DUROCHER, Y., CASS, B., BOJANOWSKI, 
M. W., GINGRAS, D. & BELIVEAU, R. 2005. Combined inhibition of PDGF and VEGF 
receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis, 26, 
821-6. 
LAGIOU, P., SAMOLI, E., LAGIOU, A., SKALKIDIS, Y., KATSOUYANNI, K., PETRIDOU, E. & 
TRICHOPOULOS, D. 2006. Flavonoid classes and risk of peripheral arterial occlusive 
disease: a case-control study in Greece. European Journal of Clinical Nutrition, 60, 
214-219. 
LAI, H. T., THREAPLETON, D. E., DAY, A. J., WILLIAMSON, G., CADE, J. E. & BURLEY, V. J. 
2015. Fruit intake and cardiovascular disease mortality in the UK Women's Cohort 
Study. Eur J Epidemiol, 30, 1035-48. 
LAMALICE, L., HOULE, F. & HUOT, J. 2006. Phosphorylation of Tyr1214 within VEGFR-2 
triggers the recruitment of Nck and activation of Fyn leading to SAPK2/p38 
activation and endothelial cell migration in response to VEGF. J Biol Chem, 281, 
34009-20. 
LAMALICE, L., HOULE, F., JOURDAN, G. & HUOT, J. 2004. Phosphorylation of tyrosine 1214 
on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of 
SAPK2/p38. Oncogene, 23, 434-45. 
LAMBERT, J. D., HONG, J., KIM, D. H., MISHIN, V. M. & YANG, C. S. 2004. Piperine enhances 
the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J 
Nutr, 134, 1948-52. 
LAMBERT, J. D., KENNETT, M. J., SANG, S., REUHL, K. R., JU, J. & YANG, C. S. 2010. 
Hepatotoxicity of high oral dose (−)-epigallocatechin-3-gallate in mice. Food and 
Chemical Toxicology, 48, 409-416. 
LAMBERT, J. D., LEE, M. J., LU, H., MENG, X., HONG, J. J., SERIL, D. N., STURGILL, M. G. & 
YANG, C. S. 2003. Epigallocatechin-3-gallate is absorbed but extensively 
glucuronidated following oral administration to mice. J Nutr, 133, 4172-7. 
References 
194 
 
LAMOKE, F., LABAZI, M., MONTEMARI, A., PARISI, G., VARANO, M. & BARTOLI, M. 2011. 
Trans-Chalcone prevents VEGF expression and retinal neovascularization in the 
ischemic retina. Experimental Eye Research, 93, 350-354. 
LAMY, S., AKLA, N., OUANOUKI, A., LORD-DUFOUR, S. & BÉLIVEAU, R. 2012. Diet-derived 
polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. 
Experimental Cell Research, 318, 1586-1596. 
LAMY, S., BÉDARD, V., LABBÉ, D., SARTELET, H., BARTHOMEUF, C., GINGRAS, D. & 
BÉLIVEAU, R. 2008. The Dietary Flavones Apigenin and Luteolin Impair Smooth 
Muscle Cell Migration and VEGF Expression through Inhibition of PDGFR-β 
Phosphorylation. Cancer Prevention Research, 1, 452-459. 
LAMY, S., BLANCHETTE, M., MICHAUD-LEVESQUE, J., LAFLEUR, R., DUROCHER, Y., 
MOGHRABI, A., BARRETTE, S., GINGRAS, D. & BELIVEAU, R. 2006. Delphinidin, a 
dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 
phosphorylation. Carcinogenesis, 27, 989-96. 
LAMY, S., GINGRAS, D. & BELIVEAU, R. 2002. Green tea catechins inhibit vascular 
endothelial growth factor receptor phosphorylation. Cancer Res, 62, 381-5. 
LARROSA, M., TOMAS-BARBERAN, F. A. & ESPIN, J. C. 2006. The dietary hydrolysable tannin 
punicalagin releases ellagic acid that induces apoptosis in human colon 
adenocarcinoma Caco-2 cells by using the mitochondrial pathway. J Nutr Biochem, 
17, 611-25. 
LAVRENCIC, A., KOSMINA, B., KEBER, I., VIDECNIK, V. & KEBER, D. 1996. Carotid intima-
media thickness in young patients with familial hypercholesterolaemia. Heart, 76, 
321-5. 
LE BOEUF, F., HOULE, F. & HUOT, J. 2004. Regulation of vascular endothelial growth factor 
receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock 
protein 90 and Src kinase activities. J Biol Chem, 279, 39175-85. 
LECKEY, L. C., GARIGE, M., VARATHARAJALU, R., GONG, M., NAGATA, T., SPURNEY, C. F. & 
LAKSHMAN, R. M. 2010. Quercetin and Ethanol Attenuate the Progression of 
Atherosclerotic Plaques With Concomitant Up Regulation of Paraoxonase1 (PON1) 
Gene Expression and PON1 Activity in LDLR−/− Mice. Alcoholism: Clinical and 
Experimental Research, 34, 1535-1542. 
LEE, C. H., JEONG, T. S., CHOI, Y. K., HYUN, B. H., OH, G. T., KIM, E. H., KIM, J. R., HAN, J. I. & 
BOK, S. H. 2001. Anti-atherogenic effect of citrus flavonoids, naringin and 
naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high 
cholesterol-fed rabbits. Biochemical and Biophysical Research Communications, 
284, 681-8. 
LEE, L. S., KIM, S. H., KIM, Y. B. & KIM, Y. C. 2014. Quantitative analysis of major 
constituents in green tea with different plucking periods and their antioxidant 
activity. Molecules, 19, 9173-86. 
LEE, M. J., MALIAKAL, P., CHEN, L., MENG, X., BONDOC, F. Y., PRABHU, S., LAMBERT, G., 
MOHR, S. & YANG, C. S. 2002. Pharmacokinetics of tea catechins after ingestion of 
green tea and (-)-epigallocatechin-3-gallate by humans: formation of different 
metabolites and individual variability. Cancer Epidemiol Biomarkers Prev, 11, 1025-
32. 
LEE, Y. K., BONE, N. D., STREGE, A. K., SHANAFELT, T. D., JELINEK, D. F. & KAY, N. E. 2004. 
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea 
component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic 
leukemia. Blood, 104, 788-94. 
LEI, F., XING, D.-M., XIANG, L., ZHAO, Y.-N., WANG, W., ZHANG, L.-J. & DU, L.-J. 2003. 
Pharmacokinetic study of ellagic acid in rat after oral administration of 
pomegranate leaf extract. Journal of Chromatography B, 796, 189-194. 
References 
195 
 
LEPPANEN, P., KOOTA, S., KHOLOVA, I., KOPONEN, J., FIEBER, C., ERIKSSON, U., ALITALO, K. 
& YLA-HERTTUALA, S. 2005. Gene transfers of vascular endothelial growth factor-A, 
vascular endothelial growth factor-B, vascular endothelial growth factor-C, and 
vascular endothelial growth factor-D have no effects on atherosclerosis in 
hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-
deficient mice. Circulation, 112, 1347-52. 
LI, N., TAYLOR, L. S. & MAUER, L. J. 2011. Degradation kinetics of catechins in green tea 
powder: effects of temperature and relative humidity. J Agric Food Chem, 59, 6082-
90. 
LI, X. Y., FENG, Y., LIU, J. H., FENG, X. W., ZHOU, K. Y. & TANG, X. D. 2013. Epigallocatechin-
3-Gallate Inhibits IGF-I-Stimulated Lung Cancer Angiogenesis through 
Downregulation of HIF-l alpha and VEGF Expression. Journal of Nutrigenetics and 
Nutrigenomics, 6, 169-178. 
LIAO, D. & JOHNSON, R. S. 2007. Hypoxia: A key regulator of angiogenesis in cancer. Cancer 
and Metastasis Reviews, 26, 281-290. 
LIN, C.-M., CHIU, J.-H., WU, I. H., WANG, B.-W., PAN, C.-M. & CHEN, Y.-H. 2010. Ferulic acid 
augments angiogenesis via VEGF, PDGF and HIF-1α. The Journal of Nutritional 
Biochemistry, 21, 627-633. 
LIN, J., REXRODE, K. M., HU, F., ALBERT, C. M., CHAE, C. U., RIMM, E. B., STAMPFER, M. J. & 
MANSON, J. E. 2007. Dietary intakes of flavonols and flavones and coronary heart 
disease in US women. Am J Epidemiol, 165, 1305-13. 
LIN, M. T., YEN, M. L., LIN, C. Y. & KUO, M. L. 2003. Inhibition of vascular endothelial growth 
factor-induced angiogenesis by resveratrol through interruption of Src-dependent 
vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol, 64, 1029-
36. 
LIP, P. L., BELGORE, F., BLANN, A. D., HOPE-ROSS, M. W., GIBSON, J. M. & LIP, G. Y. H. 2000. 
Plasma VEGF and Soluble VEGF Receptor FLT-1 in Proliferative Retinopathy: 
Relationship to Endothelial Dysfunction and Laser Treatment. Investigative 
Ophthalmology & Visual Science, 41, 2115-2119. 
LIU, L.-Z., JING, Y., JIANG, L. L., JIANG, X.-E., JIANG, Y., ROJANASAKUL, Y. & JIANG, B.-H. 
2011. Acacetin inhibits VEGF expression, tumor angiogenesis and growth through 
AKT/HIF-1α pathway. Biochemical and Biophysical Research Communications, 413, 
299-305. 
LIU, L., LAI, C. Q., NIE, L., ORDOVAS, J., BAND, M., MOSER, L. & MEYDANI, M. 2008. The 
modulation of endothelial cell gene expression by green tea polyphenol-EGCG. Mol 
Nutr Food Res, 52, 1182-92. 
LIU, Y., COX, S. R., MORITA, T. & KOUREMBANAS, S. 1995. Hypoxia regulates vascular 
endothelial growth factor gene expression in endothelial cells. Identification of a 5' 
enhancer. Circ Res, 77, 638-43. 
LIU, Y. & HU, M. 2002. Absorption and metabolism of flavonoids in the caco-2 cell culture 
model and a perused rat intestinal model. Drug Metab Dispos, 30, 370-7. 
LOKE, W. M., PROUDFOOT, J. M., HODGSON, J. M., MCKINLEY, A. J., HIME, N., MAGAT, M., 
STOCKER, R. & CROFT, K. D. 2010. Specific dietary polyphenols attenuate 
atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and 
endothelial dysfunction. Arterioscler Thromb Vasc Biol, 30, 749-57. 
LOUKOVAARA, S., NURKKALA, H., TAMENE, F., GUCCIARDO, E., LIU, X., REPO, P., LEHTI, K. & 
VARJOSALO, M. 2015. Quantitative Proteomics Analysis of Vitreous Humor from 
Diabetic Retinopathy Patients. Journal of Proteome Research, 14, 5131-5143. 
LU, H., MENG, X. & YANG, C. S. 2003. Enzymology of methylation of tea catechins and 
inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug 
Metab Dispos, 31, 572-9. 
References 
196 
 
LU, J., ZHANG, K., NAM, S., ANDERSON, R. A., JOVE, R. & WEN, W. 2010. Novel angiogenesis 
inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream 
signaling. Carcinogenesis, 31, 481-8. 
LU, N., GAO, Y., LING, Y., CHEN, Y., YANG, Y., GU, H.-Y., QI, Q., LIU, W., WANG, X.-T., YOU, 
Q.-D. & GUO, Q.-L. 2008. Wogonin suppresses tumor growth in vivo and VEGF-
induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life 
Sciences, 82, 956-963. 
LU, Z., ZHANG, Y., LIU, H., YUAN, J., ZHENG, Z. & ZOU, G. 2007. Transport of a cancer 
chemopreventive polyphenol, resveratrol: interaction with serum albumin and 
hemoglobin. J Fluoresc, 17, 580-7. 
LUO, H., RANKIN, G. O., JULIANO, N., JIANG, B.-H. & CHEN, Y. C. 2012. Kaempferol inhibits 
VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 
pathway. Food Chemistry, 130, 321-328. 
LUO, H., RANKIN, G. O., LIU, L., DADDYSMAN, M. K., JIANG, B. H. & CHEN, Y. C. 2009. 
Kaempferol inhibits angiogenesis and VEGF expression through both HIF 
dependent and independent pathways in human ovarian cancer cells. Nutr Cancer, 
61, 554-63. 
MA, L., NI, M., HAO, P., LU, H., YANG, X., XU, X., ZHANG, C., HUANG, S., ZHAO, Y., LIU, X. & 
ZHANG, Y. 2016. Tongxinluo mitigates atherogenesis by regulating angiogenic 
factors and inhibiting vasa vasorum neovascularization in apolipoprotein E-
deficient mice. Oncotarget, 7, 16194-16204. 
MAIER, P., UNSOELD, A. S., JUNKER, B., MARTIN, G., DREVS, J., HANSEN, L. L. & AGOSTINI, 
H. T. 2005. Intravitreal injection of specific receptor tyrosine kinase inhibitor 
PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefe's 
Archive for Clinical and Experimental Ophthalmology, 243, 593-600. 
MAITI, T. K., CHATTERJEE, J. & DASGUPTA, S. 2003. Effect of green tea polyphenols on 
angiogenesis induced by an angiogenin-like protein. Biochem Biophys Res Commun, 
308, 64-7. 
MAJHI, A., RAHMAN, G. M., PANCHAL, S. & DAS, J. 2010. Binding of curcumin and its long 
chain derivatives to the activator binding domain of novel protein kinase C. 
Bioorganic & Medicinal Chemistry, 18, 1591-1598. 
MANACH, C., SCALBERT, A., MORAND, C., REMESY, C. & JIMENEZ, L. 2004. Polyphenols: 
food sources and bioavailability. Am J Clin Nutr, 79, 727-47. 
MANACH, C., WILLIAMSON, G., MORAND, C., SCALBERT, A. & REMESY, C. 2005. 
Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 
bioavailability studies. Am J Clin Nutr, 81, 230S-242S. 
MANENTI, L., RICCARDI, E., MARCHINI, S., NAUMOVA, E., FLORIANI, I., GAROFALO, A., 
DOSSI, R., MARRAZZO, E., RIBATTI, D., SCANZIANI, E., BANI, M., BELOTTI, D., 
BROGGINI, M. & GIAVAZZI, R. 2005. Circulating plasma vascular endothelial growth 
factor in mice bearing human ovarian carcinoma xenograft correlates with tumor 
progression and response to therapy. Mol Cancer Ther, 4, 715-25. 
MANNI, S., KISKO, K., SCHLEIER, T., MISSIMER, J. & BALLMER-HOFER, K. 2014. Functional 
and structural characterization of the kinase insert and the carboxy terminal 
domain in VEGF receptor 2 activation. Faseb j, 28, 4914-23. 
MARNIEMI, J., ALANEN, E., IMPIVAARA, O., SEPPANEN, R., HAKALA, P., RAJALA, T. & 
RONNEMAA, T. 2005. Dietary and serum vitamins and minerals as predictors of 
myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis, 15, 
188-97. 
MARTINEZ-GONZALEZ, M. A., SALAS-SALVADO, J., ESTRUCH, R., CORELLA, D., FITO, M., ROS, 
E. & PREDIMED, I. 2015. Benefits of the Mediterranean Diet: Insights From the 
PREDIMED Study. Progress in Cardiovascular Diseases, 58, 50-60. 
References 
197 
 
MASSIN, P., BANDELLO, F., GARWEG, J. G., HANSEN, L. L., HARDING, S. P., LARSEN, M., 
MITCHELL, P., SHARP, D., WOLF-SCHNURRBUSCH, U. E., GEKKIEVA, M., 
WEICHSELBERGER, A. & WOLF, S. 2010. Safety and efficacy of ranibizumab in 
diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, 
double-masked, multicenter phase II study. Diabetes Care, 33, 2399-405. 
MATHEW, A. S., CAPEL-WILLIAMS, G. M., BERRY, S. E. & HALL, W. L. 2012. Acute effects of 
pomegranate extract on postprandial lipaemia, vascular function and blood 
pressure. Plant Foods Hum Nutr, 67, 351-7. 
MATSUBARA, K., KANEYUKI, T., MIYAKE, T. & MORI, M. 2005. Antiangiogenic Activity of 
Nasunin, an Antioxidant Anthocyanin, in Eggplant Peels. Journal of Agricultural and 
Food Chemistry, 53, 6272-6275. 
MATSUMOTO, T., BOHMAN, S., DIXELIUS, J., BERGE, T., DIMBERG, A., MAGNUSSON, P., 
WANG, L., WIKNER, C., QI, J. H., WERNSTEDT, C., WU, J., BRUHEIM, S., MUGISHIMA, 
H., MUKHOPADHYAY, D., SPURKLAND, A. & CLAESSON-WELSH, L. 2005. VEGF 
receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor 
angiogenesis. EMBO J, 24, 2342-53. 
MATTERN, J., KOOMÄGI, R. & VOLM, M. 1996. Association of vascular endothelial growth 
factor expression with intratumoral microvessel density and tumour cell 
proliferation in human epidermoid lung carcinoma. British Journal of Cancer, 73, 
931-934. 
MAYNARD, S. E., MIN, J. Y., MERCHAN, J., LIM, K. H., LI, J., MONDAL, S., LIBERMANN, T. A., 
MORGAN, J. P., SELLKE, F. W., STILLMAN, I. E., EPSTEIN, F. H., SUKHATME, V. P. & 
KARUMANCHI, S. A. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) 
may contribute to endothelial dysfunction, hypertension, and proteinuria in 
preeclampsia. J Clin Invest, 111, 649-58. 
MCCOLL, B. K., PAAVONEN, K., KARNEZIS, T., HARRIS, N. C., DAVYDOVA, N., ROTHACKER, J., 
NICE, E. C., HARDER, K. W., ROUFAIL, S., HIBBS, M. L., ROGERS, P. A., ALITALO, K., 
STACKER, S. A. & ACHEN, M. G. 2007. Proprotein convertases promote processing 
of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. Faseb j, 21, 
1088-98. 
MCLAREN, J., PRENTICE, A., CHARNOCK-JONES, D. S., MILLICAN, S. A., MULLER, K. H., 
SHARKEY, A. M. & SMITH, S. K. 1996. Vascular endothelial growth factor is 
produced by peritoneal fluid macrophages in endometriosis and is regulated by 
ovarian steroids. J Clin Invest, 98, 482-9. 
MCLAUGHLIN, A. P. & DE VRIES, G. W. 2001. Role of PLCgamma and Ca(2+) in VEGF- and 
FGF-induced choroidal endothelial cell proliferation. Am J Physiol Cell Physiol, 281, 
C1448-56. 
MEIR, K. S. & LEITERSDORF, E. 2004. Atherosclerosis in the apolipoprotein-E-deficient 
mouse: a decade of progress. Arterioscler Thromb Vasc Biol, 24, 1006-14. 
MENG, X., SANG, S., ZHU, N., LU, H., SHENG, S., LEE, M. J., HO, C. T. & YANG, C. S. 2002. 
Identification and characterization of methylated and ring-fission metabolites of 
tea catechins formed in humans, mice, and rats. Chem Res Toxicol, 15, 1042-50. 
MERTENS-TALCOTT, S. U., JILMA-STOHLAWETZ, P., RIOS, J., HINGORANI, L. & DERENDORF, 
H. 2006. Absorption, Metabolism, and Antioxidant Effects of Pomegranate (Punica 
granatum L.) Polyphenols after Ingestion of a Standardized Extract in Healthy 
Human Volunteers. Journal of Agricultural and Food Chemistry, 54, 8956-8961. 
MEYER, R. D., SACKS, D. B. & RAHIMI, N. 2008. IQGAP1-Dependent Signaling Pathway 
Regulates Endothelial Cell Proliferation and Angiogenesis. PLoS ONE, 3, e3848. 
MINATTI, J., WAZLAWIK, E., HORT, M. A., ZALESKI, F. L., RIBEIRO-DO-VALLE, R. M., 
MARASCHIN, M. & DA SILVA, E. L. 2012. Green tea extract reverses endothelial 
References 
198 
 
dysfunction and reduces atherosclerosis progression in homozygous knockout low-
density lipoprotein receptor mice. Nutrition Research, 32, 684-693. 
MINK, P. J., SCRAFFORD, C. G., BARRAJ, L. M., HARNACK, L., HONG, C. P., NETTLETON, J. A. 
& JACOBS, D. R., JR. 2007. Flavonoid intake and cardiovascular disease mortality: a 
prospective study in postmenopausal women. Am J Clin Nutr, 85, 895-909. 
MINODA, K., ICHIKAWA, T., KATSUMATA, T., ONOBORI, K., MORI, T., SUZUKI, Y., ISHII, T. & 
NAKAYAMA, T. 2010. Influence of the Galloyl Moiety in Tea Catechins on Binding 
Affinity for Human Serum Albumin. Journal of Nutritional Science and Vitaminology, 
56, 331-334. 
MIRANDA, A. M., STELUTI, J., FISBERG, R. M. & MARCHIONI, D. M. 2016. Dietary intake and 
food contributors of polyphenols in adults and elderly adults of Sao Paulo: a 
population-based study. Br J Nutr, 115, 1061-70. 
MIURA, Y., CHIBA, T., TOMITA, I., KOIZUMI, H., MIURA, S., UMEGAKI, K., HARA, Y., IKEDA, 
M. & TOMITA, T. 2001. Tea catechins prevent the development of atherosclerosis 
in apoprotein E-deficient mice. J Nutr, 131, 27-32. 
MOULTON, K., HELLER, E., KONERDING, M., FLYNN, E., PALINSKI, W. & FOLKMAN, J. 1999. 
Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization 
and plaque growth in apolipoprotein E-deficient mice. Circulation, 99, 1726 - 1732. 
MOVAT, H. Z. 1955. Demonstration of all connective tissue elements in a single section; 
pentachrome stains. AMA Arch Pathol, 60, 289-95. 
MOYLE, C. W., CEREZO, A. B., WINTERBONE, M. S., HOLLANDS, W. J., ALEXEEV, Y., NEEDS, P. 
W. & KROON, P. A. 2015. Potent inhibition of VEGFR-2 activation by tight binding of 
green tea epigallocatechin gallate and apple procyanidins to VEGF: relevance to 
angiogenesis. Mol Nutr Food Res, 59, 401-12. 
MURPHY, M. M., BARRAJ, L. M., SPUNGEN, J. H., HERMAN, D. R. & RANDOLPH, R. K. 2014. 
Global assessment of select phytonutrient intakes by level of fruit and vegetable 
consumption. Br J Nutr, 112, 1004-18. 
MURSU, J., VOUTILAINEN, S., NURMI, T., TUOMAINEN, T. P., KURL, S. & SALONEN, J. T. 
2008. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in 
middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. 
British Journal of Nutrition, 100, 890-895. 
MURUGAN, V., MUKHERJEE, K., MAITI, K. & MUKHERJEE, P. K. 2009. Enhanced oral 
bioavailability and antioxidant profile of ellagic acid by phospholipids. J Agric Food 
Chem, 57, 4559-65. 
NAKAO, S., ARITA, R., NAKAMA, T., YOSHIKAWA, H., YOSHIDA, S., ENAIDA, H., HAFEZI-
MOGHADAM, A., MATSUI, T. & ISHIBASHI, T. 2013. Wide-Field Laser 
Ophthalmoscopy for Mice: A Novel Evaluation System for Retinal/Choroidal 
Angiogenesis in MiceOptos Evaluation of Mouse Angiogenesis. Investigative 
Ophthalmology & Visual Science, 54, 5288-5293. 
NAKASHIMA, Y., PLUMP, A. S., RAINES, E. W., BRESLOW, J. L. & ROSS, R. 1994. ApoE-
deficient mice develop lesions of all phases of atherosclerosis throughout the 
arterial tree. Arterioscler Thromb, 14, 133-40. 
NAMIKI, A., BROGI, E., KEARNEY, M., KIM, E. A., WU, T., COUFFINHAL, T., VARTICOVSKI, L. & 
ISNER, J. M. 1995. Hypoxia induces vascular endothelial growth factor in cultured 
human endothelial cells. J Biol Chem, 270, 31189-95. 
NAUMOVSKI, N., BLADES, B. L. & ROACH, P. D. 2015. Food Inhibits the Oral Bioavailability of 
the Major Green Tea Antioxidant Epigallocatechin Gallate in Humans. Antioxidants, 
4, 373-393. 
NEAGOE, P. E., LEMIEUX, C. & SIROIS, M. G. 2005. Vascular endothelial growth factor 
(VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF 
receptor-1 and -2 heterodimer. J Biol Chem, 280, 9904-12. 
References 
199 
 
NEGRÃO, R., COSTA, R., DUARTE, D., GOMES, T. T., AZEVEDO, I. & SOARES, R. 2013. 
Different effects of catechin on angiogenesis and inflammation depending on VEGF 
levels. The Journal of Nutritional Biochemistry, 24, 435-444. 
NEGRÃO, R., COSTA, R., DUARTE, D., TAVEIRA GOMES, T., MENDANHA, M., MOURA, L., 
VASQUES, L., AZEVEDO, I. & SOARES, R. 2010. Angiogenesis and Inflammation 
Signaling Are Targets of Beer Polyphenols on Vascular Cells. Journal of Cellular 
Biochemistry, 111, 1270-1279. 
NÉMETH, K., PLUMB, G. W., BERRIN, J.-G., JUGE, N., JACOB, R., NAIM, H. Y., WILLIAMSON, 
G., SWALLOW, D. M. & KROON, P. A. 2003. Deglycosylation by small intestinal 
epithelial cell β-glucosidases is a critical step in the absorption and metabolism of 
dietary flavonoid glycosides in humans. European Journal of Nutrition, 42, 29-42. 
NEUHAUS, T., PABST, S., STIER, S., WEBER, A. A., SCHROR, K., SACHINIDIS, A., VETTER, H. & 
KO, Y. D. 2004. Inhibition of the vascular-endothelial growth factor-induced 
intracellular signaling and mitogenesis of human endothelial cells by 
epigallocatechin-3 gallate. Eur J Pharmacol, 483, 223-7. 
NEWBY, A. C. & ZALTSMAN, A. B. 1999. Fibrous cap formation or destruction — the critical 
importance of vascular smooth muscle cell proliferation, migration and matrix 
formation. Cardiovascular Research, 41, 345-360. 
NICHOLSON, S. K., TUCKER, G. A. & BRAMELD, J. M. 2010. Physiological concentrations of 
dietary polyphenols regulate vascular endothelial cell expression of genes 
important in cardiovascular health. Br J Nutr, 103, 1398-403. 
NILSSON, I., BAHRAM, F., LI, X., GUALANDI, L., KOCH, S., JARVIUS, M., SODERBERG, O., 
ANISIMOV, A., KHOLOVA, I., PYTOWSKI, B., BALDWIN, M., YLA-HERTTUALA, S., 
ALITALO, K., KREUGER, J. & CLAESSON-WELSH, L. 2010. VEGF receptor 2/-3 
heterodimers detected in situ by proximity ligation on angiogenic sprouts. Embo j, 
29, 1377-88. 
NISSEN, S. E. 2000. Rationale for a postintervention continuum of care: insights from 
intravascular ultrasound. The American Journal of Cardiology, 86, 12H-17H. 
NOBERINI, R., KOOLPE, M., LAMBERTO, I. & PASQUALE, E. B. 2012. Inhibition of Eph 
receptor–ephrin ligand interaction by tea polyphenols. Pharmacological Research, 
66, 363-373. 
NORATA, G. D., MARCHESI, P., PASSAMONTI, S., PIRILLO, A., VIOLI, F. & CATAPANO, A. L. 
2007. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and 
trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis, 191, 265-271. 
O'CONNELL, J. E. & FOX, P. F. 1999. Proposed mechanism for the effect of polyphenols on 
the heat stability of milk. International Dairy Journal, 9, 523-536. 
OAK, M. H., BEDOUI, J. E., MADEIRA, S. V., CHALUPSKY, K. & SCHINI-KERTH, V. B. 2006. 
Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular 
smooth muscle cells by preventing activation of p38 MAPK and JNK. Br J 
Pharmacol, 149, 283-90. 
OGAWA, S., OKU, A., SAWANO, A., YAMAGUCHI, S., YAZAKI, Y. & SHIBUYA, M. 1998. A novel 
type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially 
utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-
binding domain. J Biol Chem, 273, 31273-82. 
OH, S. J., KIM, O., LEE, J. S., KIM, J.-A., KIM, M. R., CHOI, H. S., SHIM, J.-H., KANG, K. W. & 
KIM, Y. C. 2010. Inhibition of angiogenesis by quercetin in tamoxifen-resistant 
breast cancer cells. Food and Chemical Toxicology, 48, 3227-3234. 
OHKI, K., AMANO, F., YAMAMOTO, S. & KOHASHI, O. 1999. Suppressive effects of serum on 
the LPS-induced production of nitric oxide and TNF-[agr] by a macrophage-like cell 
line, WEHI-3, are dependent on the structure of polysaccharide chains in LPS. 
Immunol Cell Biol, 77, 143-152. 
References 
200 
 
OJHA, H., MISHRA, K., HASSAN, M. I. & CHAUDHURY, N. K. 2012. Spectroscopic and 
isothermal titration calorimetry studies of binding interaction of ferulic acid with 
bovine serum albumin. Thermochimica Acta, 548, 56-64. 
OOI, K., SHIRAKI, K., SAKURAI, Y., MORISHITA, Y. & NOBORI, T. 2005. Clinical significance of 
abnormal lipoprotein patterns in liver diseases. Int J Mol Med, 15, 655-60. 
OSADA, M., IMAOKA, S. & FUNAE, Y. 2004. Apigenin suppresses the expression of VEGF, an 
important factor for angiogenesis, in endothelial cells via degradation of HIF-1α 
protein. FEBS Letters, 575, 59-63. 
OSAWA, R., KUROISO, K., GOTO, S. & SHIMIZU, A. 2000. Isolation of tannin-degrading 
lactobacilli from humans and fermented foods. Appl Environ Microbiol, 66, 3093-7. 
OTSUKA, F., KRAMER, M. C. A., WOUDSTRA, P., YAHAGI, K., LADICH, E., FINN, A. V., DE 
WINTER, R. J., KOLODGIE, F. D., WIGHT, T. N., DAVIS, H. R., JONER, M. & VIRMANI, 
R. 2015. Natural progression of atherosclerosis from pathologic intimal thickening 
to late fibroatheroma in human coronary arteries: A pathology study. 
Atherosclerosis, 241, 772-782. 
OVASKAINEN, M. L., TORRONEN, R., KOPONEN, J. M., SINKKO, H., HELLSTROM, J., 
REINIVUO, H. & MATTILA, P. 2008. Dietary intake and major food sources of 
polyphenols in Finnish adults. J Nutr, 138, 562-6. 
OZDAL, T., CAPANOGLU, E. & ALTAY, F. 2013. A review on protein–phenolic interactions 
and associated changes. Food Research International, 51, 954-970. 
OZYURT, H., LUNA, C. & ESTEVEZ, M. 2016. Redox chemistry of the molecular interactions 
between tea catechins and human serum proteins under simulated hyperglycemic 
conditions. Food & Function, 7, 1390-1400. 
PÀEZ-RIBES, M., ALLEN, E., HUDOCK, J., TAKEDA, T., OKUYAMA, H., VIÑALS, F., INOUE, M., 
BERGERS, G., HANAHAN, D. & CASANOVAS, O. 2009. Antiangiogenic Therapy Elicits 
Malignant Progression of Tumors to Increased Local Invasion and Distant 
Metastasis. Cancer Cell, 15, 220-231. 
PAN, R., DAI, Y., GAO, X.-H., LU, D. & XIA, Y.-F. 2011. Inhibition of vascular endothelial 
growth factor-induced angiogenesis by scopoletin through interrupting the 
autophosphorylation of VEGF receptor 2 and its downstream signaling pathways. 
Vascular Pharmacology, 54, 18-28. 
PANG, J., ZHANG, Z., ZHENG, T. Z., BASSIG, B. A., MAO, C., LIU, X., ZHU, Y., SHI, K., GE, J., 
YANG, Y. J., DEJIA, H., BAI, M. & PENG, Y. 2016. Green tea consumption and risk of 
cardiovascular and ischemic related diseases: A meta-analysis. Int J Cardiol, 202, 
967-74. 
PANTUSA, M., SPORTELLI, L. & BARTUCCI, R. 2012. Influence of stearic acids on resveratrol-
HSA interaction. Eur Biophys J, 41, 969-77. 
PARK, S.-H. & KANG, Y.-H. 2012. Dietary ellagic acid regulates serum cholesterol and retards 
atherosclerotic lesions in apoE knockout mice. The FASEB Journal, 26, 1026.6-
1026.6. 
PEETERS, W., MOLL, F. L., VINK, A., VAN DER SPEK, P. J., DE KLEIJN, D. P. V., DE VRIES, J.-P. P. 
M., VERHEIJEN, J. H., NEWBY, A. C. & PASTERKAMP, G. 2011. Collagenase matrix 
metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with 
systemic cardiovascular outcome. European Heart Journal. 
PENDSE, A. A., ARBONES-MAINAR, J. M., JOHNSON, L. A., ALTENBURG, M. K. & MAEDA, N. 
2009. Apolipoprotein E knock-out and knock-in mice: atherosclerosis, metabolic 
syndrome, and beyond. J Lipid Res, 50 Suppl, S178-82. 
PENG, X., WANG, X., QI, W., SU, R. & HE, Z. 2016. Affinity of rosmarinic acid to human 
serum albumin and its effect on protein conformation stability. Food Chemistry, 
192, 178-187. 
References 
201 
 
PERTOVAARA, L., KAIPAINEN, A., MUSTONEN, T., ORPANA, A., FERRARA, N., SAKSELA, O. & 
ALITALO, K. 1994. Vascular endothelial growth factor is induced in response to 
transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem, 
269, 6271-4. 
PETROVAN, R. J., KAPLAN, C. D., REISFELD, R. A. & CURTISS, L. K. 2007. DNA vaccination 
against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. 
Arterioscler Thromb Vasc Biol, 27, 1095-100. 
PFUNDSTEIN, B., HAUBNER, R., WURTELE, G., GEHRES, N., ULRICH, C. M. & OWEN, R. W. 
2014. Pilot walnut intervention study of urolithin bioavailability in human 
volunteers. J Agric Food Chem, 62, 10264-73. 
PISKULA, M. K. & TERAO, J. 1998. Accumulation of (-)-epicatechin metabolites in rat plasma 
after oral administration and distribution of conjugation enzymes in rat tissues. J 
Nutr, 128, 1172-8. 
PLET, B., DELCAMBRE, A., CHAIGNEPAIN, S. & SCHMITTER, J.-M. 2015. Affinity ranking of 
peptide–polyphenol non-covalent assemblies by mass spectrometry approaches. 
Tetrahedron, 71, 3007-3011. 
PLUMP, A. S., SMITH, J. D., HAYEK, T., AALTO-SETALA, K., WALSH, A., VERSTUYFT, J. G., 
RUBIN, E. M. & BRESLOW, J. L. 1992. Severe hypercholesterolemia and 
atherosclerosis in apolipoprotein E-deficient mice created by homologous 
recombination in ES cells. Cell, 71, 343-53. 
PONZO, V., GOITRE, I., FADDA, M., GAMBINO, R., DE FRANCESCO, A., SOLDATI, L., GENTILE, 
L., MAGISTRONI, P., CASSADER, M. & BO, S. 2015. Dietary flavonoid intake and 
cardiovascular risk: a population-based cohort study. J Transl Med, 13, 218. 
POUNIS, G., DI CASTELNUOVO, A., BONACCIO, M., COSTANZO, S., PERSICHILLO, M., KROGH, 
V., DONATI, M. B., DE GAETANO, G. & IACOVIELLO, L. 2016. Flavonoid and lignan 
intake in a Mediterranean population: proposal for a holistic approach in 
polyphenol dietary analysis, the Moli-sani Study. Eur J Clin Nutr, 70, 338-345. 
PRATHEESHKUMAR, P., BUDHRAJA, A., SON, Y.-O., WANG, X., ZHANG, Z., DING, S., WANG, 
L., HITRON, A., LEE, J.-C., XU, M., CHEN, G., LUO, J. & SHI, X. 2012. Quercetin 
Inhibits Angiogenesis Mediated Human Prostate Tumor Growth by Targeting 
VEGFR- 2 Regulated AKT/mTOR/P70S6K Signaling Pathways. PLoS ONE, 7, e47516. 
PUUPPONEN-PIMIÄ, R., SEPPÄNEN-LAAKSO, T., KANKAINEN, M., MAUKONEN, J., 
TÖRRÖNEN, R., KOLEHMAINEN, M., LEPPÄNEN, T., MOILANEN, E., NOHYNEK, L., 
AURA, A.-M., POUTANEN, K., TÓMAS-BARBERÁN, F. A., ESPÍN, J. C. & OKSMAN-
CALDENTEY, K.-M. 2013. Effects of ellagitannin-rich berries on blood lipids, gut 
microbiota, and urolithin production in human subjects with symptoms of 
metabolic syndrome. Molecular Nutrition & Food Research, 57, 2258-2263. 
QI, J. H. & CLAESSON-WELSH, L. 2001. VEGF-induced activation of phosphoinositide 3-
kinase is dependent on focal adhesion kinase. Exp Cell Res, 263, 173-82. 
RAEDERSTORFF, D. G., SCHLACHTER, M. F., ELSTE, V. & WEBER, P. 2003. Effect of EGCG on 
lipid absorption and plasma lipid levels in rats. The Journal of Nutritional 
Biochemistry, 14, 326-332. 
RAK, J., MITSUHASHI, Y., BAYKO, L., FILMUS, J., SHIRASAWA, S., SASAZUKI, T. & KERBEL, R. S. 
1995. Mutant ras Oncogenes Upregulate VEGF/VPF Expression: Implications for 
Induction and Inhibition of Tumor Angiogenesis. Cancer Research, 55, 4575-4580. 
RAMESH, E., GERALDINE, P. & THOMAS, P. A. 2010. Regulatory effect of epigallocatechin 
gallate on the expression of C-reactive protein and other inflammatory markers in 
an experimental model of atherosclerosis. Chem Biol Interact, 183, 125-32. 
RAMOS, M. A., KUZUYA, M., ESAKI, T., MIURA, S., SATAKE, S., ASAI, T., KANDA, S., HAYASHI, 
T. & IGUCHI, A. 1998. Induction of Macrophage VEGF in Response to Oxidized LDL 
References 
202 
 
and VEGF Accumulation in Human Atherosclerotic Lesions. Arteriosclerosis, 
Thrombosis, and Vascular Biology, 18, 1188. 
RANI, U. P., KESAVAN, R., GANUGULA, R., AVANEESH, T., KUMAR, U. P., REDDY, G. B. & 
DIXIT, M. 2013. Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell 
proliferation and prevents atheroma formation in streptozotocin-induced diabetic 
rats. J Nutr Biochem, 24, 1830-9. 
RANPURA, V., HAPANI, S., CHUANG, J. & WU, S. 2010. Risk of cardiac ischemia and arterial 
thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer 
patients: A meta-analysis of randomized controlled trials. Acta Oncologica, 49, 287-
297. 
RATCLIFFE, K. E., TAO, Q., YAVUZ, B., STOLETOV, K. V., SPRING, S. C. & TERMAN, B. I. 2002. 
Sck is expressed in endothelial cells and participates in vascular endothelial growth 
factor-induced signaling. Oncogene, 21, 6307-16. 
REAGAN-SHAW, S., NIHAL, M. & AHMAD, N. 2008. Dose translation from animal to human 
studies revisited. Faseb j, 22, 659-61. 
RECHNER, A. R., KUHNLE, G., BREMNER, P., HUBBARD, G. P., MOORE, K. P. & RICE-EVANS, 
C. A. 2002. The metabolic fate of dietary polyphenols in humans. Free Radical 
Biology and Medicine, 33, 220-235. 
REDDICK, R. L., ZHANG, S. H. & MAEDA, N. 1994. Atherosclerosis in mice lacking apo E. 
Evaluation of lesional development and progression. Arterioscler Thromb, 14, 141-
7. 
REDDY, V. C., VIDYA SAGAR, G. V., SREERAMULU, D., VENU, L. & RAGHUNATH, M. 2005. 
Addition of milk does not alter the antioxidant activity of black tea. Ann Nutr 
Metab, 49, 189-95. 
REGOECZI, E., ZAIMI, O., CHINDEMI, P. A. & CHARLWOOD, P. A. 1989. Absorption of plasma 
proteins from peritoneal cavity of normal rats. Am J Physiol, 256, E447-52. 
REYNOLDS, A. R., HART, I. R., WATSON, A. R., WELTI, J. C., SILVA, R. G., ROBINSON, S. D., DA 
VIOLANTE, G., GOURLAOUEN, M., SALIH, M., JONES, M. C., JONES, D. T., SAUNDERS, 
G., KOSTOUROU, V., PERRON-SIERRA, F., NORMAN, J. C., TUCKER, G. C. & 
HODIVALA-DILKE, K. M. 2009. Stimulation of tumor growth and angiogenesis by low 
concentrations of RGD-mimetic integrin inhibitors. Nat Med, 15, 392-400. 
RIAZY, M., CHEN, J. H. & STEINBRECHER, U. P. 2009. VEGF secretion by macrophages is 
stimulated by lipid and protein components of OxLDL via PI3-kinase and PKCζ 
activation and is independent of OxLDL uptake. Atherosclerosis, 204, 47-54. 
ROBINSON, E. S., KHANKIN, E. V., KARUMANCHI, S. A. & HUMPHREYS, B. D. 2010. 
Hypertension induced by vascular endothelial growth factor signaling pathway 
inhibition: mechanisms and potential use as a biomarker. Semin Nephrol, 30, 591-
601. 
ROBINSON, J. G., FOX, K. M., BULLANO, M. F. & GRANDY, S. 2009. Atherosclerosis profile 
and incidence of cardiovascular events: a population-based survey. BMC Cardiovasc 
Disord, 9, 46. 
RODRIGUEZ, S. K., GUO, W., LIU, L., BAND, M. A., PAULSON, E. K. & MEYDANI, M. 2006. 
Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth 
factor angiogenic signaling by disrupting the formation of a receptor complex. Int J 
Cancer, 118, 1635-44. 
ROMO-VAQUERO, M., GARCIA-VILLALBA, R., GONZALEZ-SARRIAS, A., BELTRAN, D., TOMAS-
BARBERAN, F. A., ESPIN, J. C. & SELMA, M. V. 2015. Interindividual variability in the 
human metabolism of ellagic acid: Contribution of Gordonibacter to urolithin 
production. Journal of Functional Foods, 17, 785-791. 
ROSENFELD, M. E., POLINSKY, P., VIRMANI, R., KAUSER, K., RUBANYI, G. & SCHWARTZ, S. M. 
2000. Advanced Atherosclerotic Lesions in the Innominate Artery of the ApoE 
References 
203 
 
Knockout Mouse. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 2587-
2592. 
ROSENFELD , P. J., BROWN , D. M., HEIER , J. S., BOYER , D. S., KAISER , P. K., CHUNG , C. Y. & 
KIM , R. Y. 2006. Ranibizumab for Neovascular Age-Related Macular Degeneration. 
New England Journal of Medicine, 355, 1419-1431. 
ROUANET, J.-M., DÉCORDÉ, K., RIO, D. D., AUGER, C., BORGES, G., CRISTOL, J.-P., LEAN, M. 
E. J. & CROZIER, A. 2010. Berry juices, teas, antioxidants and the prevention of 
atherosclerosis in hamsters. Food Chemistry, 118, 266-271. 
RUAN, G.-X. & KAZLAUSKAS, A. 2012. Axl is essential for VEGF-A-dependent activation of 
PI3K/Akt. The EMBO Journal, 31, 1692-1703. 
RUHRBERG, C., GERHARDT, H., GOLDING, M., WATSON, R., IOANNIDOU, S., FUJISAWA, H., 
BETSHOLTZ, C. & SHIMA, D. T. 2002. Spatially restricted patterning cues provided 
by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes 
Dev, 16, 2684-98. 
RUSSELL, F. D. & HAMILTON, K. D. 2014. Nutrient deprivation increases vulnerability of 
endothelial cells to proinflammatory insults. Free Radic Biol Med, 67, 408-15. 
SAHEBKAR, A., SIMENTAL-MENDIA, L. E., GIORGINI, P., FERRI, C. & GRASSI, D. 2016. Lipid 
profile changes after pomegranate consumption: A systematic review and meta-
analysis of randomized controlled trials. Phytomedicine, 23, 1103-12. 
SAKURAI, Y., OHGIMOTO, K., KATAOKA, Y., YOSHIDA, N. & SHIBUYA, M. 2005a. Essential 
role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. 
Proceedings of the National Academy of Sciences of the United States of America, 
102, 1076-1081. 
SAKURAI, Y., OHGIMOTO, K., KATAOKA, Y., YOSHIDA, N. & SHIBUYA, M. 2005b. Essential 
role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc 
Natl Acad Sci U S A, 102, 1076-81. 
SALTZ, L. B., CLARKE, S., DÍAZ-RUBIO, E., SCHEITHAUER, W., FIGER, A., WONG, R., KOSKI, S., 
LICHINITSER, M., YANG, T.-S., RIVERA, F., COUTURE, F., SIRZÉN, F. & CASSIDY, J. 
2008. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-
Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. 
Journal of Clinical Oncology, 26, 2013-2019. 
SANDHOFER, A., TATARCZYK, T., KIRCHMAIR, R., IGLSEDER, B., PAULWEBER, B., PATSCH, J. 
R. & SCHRATZBERGER, P. 2009. Are plasma VEGF and its soluble receptor sFlt-1 
atherogenic risk factors? Cross-sectional data from the SAPHIR study. 
Atherosclerosis, 206, 265-269. 
SARABIPOUR, S., BALLMER-HOFER, K. & HRISTOVA, K. 2016. VEGFR-2 conformational 
switch in response to ligand binding. Elife, 5. 
SARTIPPOUR, M. R., SEERAM, N. P., RAO, J. Y., MORO, A., HARRIS, D. M., HENNING, S. M., 
FIROUZI, A., RETTIG, M. B., ARONSON, W. J., PANTUCK, A. J. & HEBER, D. 2008. 
Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in 
vitro and in vivo. Int J Oncol, 32, 475-80. 
SASAZUKI, S., KODAMA, H., YOSHIMASU, K., LIU, Y., WASHIO, M., TANAKA, K., TOKUNAGA, 
S., KONO, S., ARAI, H., DOI, Y., KAWANO, T., NAKAGAKI, O., TAKADA, K., KOYANAGI, 
S., HIYAMUTA, K., NII, T., SHIRAI, K., IDEISHI, M., ARAKAWA, K., MOHRI, M. & 
TAKESHITA, A. 2000. Relation between Green Tea Consumption and the Severity of 
Coronary Atherosclerosis among Japanese Men and Women. Annals of 
Epidemiology, 10, 401-408. 
SATO, M., YAMADA, Y., MATSUOKA, H., NAKASHIMA, S., KAMIYA, T., IKEGUCHI, M. & 
IMAIZUMI, K. 2009. Dietary Pine Bark Extract Reduces Atherosclerotic Lesion 
Development in Male ApoE-Deficient Mice by Lowering the Serum Cholesterol 
Level. Bioscience Biotechnology and Biochemistry, 73, 1314-1317. 
References 
204 
 
SAWABE, M., ARAI, T., KASAHARA, I., HAMAMATSU, A., ESAKI, Y., NAKAHARA, K., HARADA, 
K., CHIDA, K., YAMANOUCHI, H., OZAWA, T., TAKUBO, K., MURAYAMA, S. & 
TANAKA, N. 2006. Sustained progression and loss of the gender-related difference 
in atherosclerosis in the very old: a pathological study of 1074 consecutive autopsy 
cases. Atherosclerosis, 186, 374-9. 
SAWANO, A., TAKAHASHI, T., YAMAGUCHI, S. & SHIBUYA, M. 1997. The phosphorylated 
1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for 
PLCgamma. Biochem Biophys Res Commun, 238, 487-91. 
SAWICKI, G., SALAS, E., MURAT, J., MISZTA-LANE, H. & RADOMSKI, M. W. 1997. Release of 
gelatinase A during platelet activation mediates aggregation. Nature, 386, 616-9. 
SCHANTZ, M., ERK, T. & RICHLING, E. 2010. Metabolism of green tea catechins by the 
human small intestine. Biotechnology Journal, 5, 1050-1059. 
SCODITTI, E., CALABRISO, N., MASSARO, M., PELLEGRINO, M., STORELLI, C., MARTINES, G., 
DE CATERINA, R. & CARLUCCIO, M. A. 2012. Mediterranean diet polyphenols 
reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human 
vascular endothelial cells: A potentially protective mechanism in atherosclerotic 
vascular disease and cancer. Archives of Biochemistry and Biophysics, 527, 81-89. 
SEERAM, N. P., ARONSON, W. J., ZHANG, Y., HENNING, S. M., MORO, A., LEE, R. P., 
SARTIPPOUR, M., HARRIS, D. M., RETTIG, M., SUCHARD, M. A., PANTUCK, A. J., 
BELLDEGRUN, A. & HEBER, D. 2007. Pomegranate ellagitannin-derived metabolites 
inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric 
Food Chem, 55, 7732-7. 
SEERAM, N. P., HENNING, S. M., ZHANG, Y., SUCHARD, M., LI, Z. & HEBER, D. 2006. 
Pomegranate juice ellagitannin metabolites are present in human plasma and some 
persist in urine for up to 48 hours. J Nutr, 136, 2481-5. 
SEERAM, N. P., LEE, R. & HEBER, D. 2004. Bioavailability of ellagic acid in human plasma 
after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. 
Clin Chim Acta, 348, 63-8. 
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